-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EDD8vpjvtrOVm7d9bfzUjerFx3t790f6hNZM0Cj45jPRTk6buCLaHb6lIqE5xHP6
 nF6jkrY0EUTJeSgjZ23BGA==

<SEC-DOCUMENT>0001047469-05-007027.txt : 20050318
<SEC-HEADER>0001047469-05-007027.hdr.sgml : 20050318
<ACCEPTANCE-DATETIME>20050318152531
ACCESSION NUMBER:		0001047469-05-007027
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20050422
FILED AS OF DATE:		20050318
DATE AS OF CHANGE:		20050318
EFFECTIVENESS DATE:		20050318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABBOTT LABORATORIES
		CENTRAL INDEX KEY:			0000001800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				360698440
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-02189
		FILM NUMBER:		05691569

	BUSINESS ADDRESS:	
		STREET 1:		100 ABBOTT PARK ROAD
		STREET 2:		D-322 AP6D
		CITY:			ABBOTT PARK
		STATE:			IL
		ZIP:			60064-3500
		BUSINESS PHONE:		8479376100
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2152528zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#05CHI1029_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="73%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2>Filed by the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><BR><FONT SIZE=2><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
Soliciting Material Pursuant to &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="77%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><BR><FONT SIZE=2><B>Abbott Laboratories</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><FONT SIZE=2>Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(5)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
(1)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2><BR>
Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(2)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(3)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>(4)</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="89%"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="89%"><BR><FONT SIZE=2><B>Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- ZEQ.=1,SEQ=1,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=875067,FOLIO='blank',FILE='DISK047:[05CHI9.05CHI1029]BA1029A.;3',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="684" height="889" src="coverimage001.jpg"></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>
<!-- ZEQ.=1,SEQ=2,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=633312,FOLIO='',FILE="DISK047:[05CHI9.05CHI1029.EDGAR]COVER_1029.CHC",USER="ABLIJDE",CD='Mar 10 09:41 2005' -->



<P><FONT SIZE=2>
<IMG SRC="g519019.jpg" ALT="ABBOTT LABORATORIES LOGO" WIDTH="52" HEIGHT="46">
 </FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=2>Abbott Laboratories<BR>
100 Abbott Park Road<BR>
Abbott Park, Illinois 60064-6400 U.S.A.</FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="87%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="43%" VALIGN="TOP"><FONT SIZE=2>Cover:</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="55%" VALIGN="TOP"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="43%" VALIGN="TOP"><FONT SIZE=2><BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Katrina Donnell spends hours at the beach, but only seconds checking her blood glucose levels, thanks to FreeStyle&reg; Flash, the world's smallest glucose monitor. During a routine physical nearly four
years ago, the 15-year-old from San Diego, Calif., was diagnosed with diabetes. Today, she spends time with her friends and educates others about the disease through her volunteer activities with the Juvenile Diabetes Research
Foundation.</I></FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=2><I><BR>&nbsp;</I></FONT></TD>
<TD WIDTH="55%" VALIGN="TOP"><FONT SIZE=2><I><BR>
&nbsp;</I></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- ZEQ.=1,SEQ=3,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=88856,FOLIO='blank',FILE='DISK047:[05CHI9.05CHI1029]BE1029A.;6',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=5><B>Your Vote<BR>
Is Important  </B></FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=3><B>Please sign and promptly return your<BR>
proxy in the enclosed envelope or vote<BR>
your shares by telephone or using the Internet.</B></FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=4><B>Notice of Annual Meeting<BR>
of Shareholders</B></FONT></P>

<P><FONT SIZE=2>The Annual Meeting of the Shareholders of Abbott Laboratories will be held at Abbott's headquarters, 100&nbsp;Abbott Park Road, at the intersection of Route
137 and Waukegan Road, Lake County, Illinois, on Friday, April&nbsp;22, 2005, at 9:00&nbsp;a.m. for the following purposes: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
elect 14 directors to hold office until the next Annual Meeting or until their successors are elected (Item 1 on the proxy card),
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as auditors of Abbott for 2005 (Item 2 on the proxy card), and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>To
transact such other business as may properly come before the meeting, including consideration of shareholder proposals on: executive compensation, performance-based
options, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> testing, political contributions, HIV/AIDS&#151;TB&#151;Malaria, and separating the role of Chairman and Chief Executive
Officer, if such proposals are presented at the meeting (Items 3, 4, 5, 6, 7, and 8 on the proxy card). </FONT></DD></DL>

<P><FONT SIZE=2><B>The board of directors recommends that you vote FOR Items 1 and 2 on the proxy card.</B></FONT></P>

<P><FONT SIZE=2><B>The board of directors recommends that you vote AGAINST Items 3, 4, 5, 6, 7, and 8 on the proxy
card.</B></FONT></P>

<P><FONT SIZE=2>The close of business February&nbsp;23, 2005 has been fixed as the record date for determining the shareholders entitled to receive notice of and to vote at
the Annual Meeting. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>Admission
to the meeting will be by admission card only. If you plan to attend, please complete and return the reservation form on the back cover, and an admission card will be sent to you. Due to
space limitations, reservation forms must be received before April&nbsp;15, 2005. Each admission card admits one person. A shareholder may request two admission cards. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>By
order of the board of directors. </FONT></P>

<P><FONT SIZE=2>LAURA
J. SCHUMACHER<BR></FONT> <FONT SIZE=2><I>Secretary  </I></FONT></P>

<P><FONT SIZE=2>March&nbsp;18, 2005 </FONT></P>

<HR NOSHADE>
<BR>
<!-- ZEQ.=1,SEQ=4,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=292551,FOLIO='blank',FILE='DISK047:[05CHI9.05CHI1029]DE1029A.;17',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_dg1029_1_1"> </A> </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=5>Abbott Laboratories </FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=5>Proxy
Statement </FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=2><B>Solicitation of Proxies  </B></FONT></P>

<P><FONT SIZE=2>
The accompanying proxy is solicited on behalf of the board of directors for use at the Annual Meeting of Shareholders. The meeting will be held on April&nbsp;22, 2005, at Abbott's headquarters, 100
Abbott Park Road, at the intersection of Route 137 and Waukegan Road, Lake County, Illinois. This proxy statement and the accompanying proxy card are being mailed to shareholders on or about
March&nbsp;18, 2005. </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2><B>Information about the Annual Meeting  </B></FONT></P>

<P><FONT SIZE=2>Who Can Vote </FONT></P>

<P><FONT SIZE=2>
Shareholders of record at the close of business on February&nbsp;23, 2005 will be entitled to notice of and to vote at the Annual Meeting. As of January&nbsp;31, 2005, Abbott had 1,558,939,682
outstanding common shares, which are Abbott's only outstanding voting securities. All shareholders have cumulative voting rights in the election of directors and one vote per share on all other
matters. </FONT></P>

<P><FONT SIZE=2>Cumulative Voting </FONT></P>

<P><FONT SIZE=2>
Cumulative voting allows a shareholder to multiply the number of shares owned by the number of directors to be elected and to cast the total for one nominee or distribute the votes among the nominees,
as the shareholder desires. Nominees who receive the greatest number of votes will be elected. If you wish to cumulate your votes, you must sign and mail in your proxy card or attend the Annual
Meeting. </FONT></P>

<P><FONT SIZE=2>Voting by Proxy </FONT></P>

<P><FONT SIZE=2>
All of Abbott's shareholders may vote by mail or at the Annual Meeting. The bylaws provide that a shareholder may authorize no more than two persons as proxies to attend and vote at the meeting. Most
of Abbott's shareholders may also vote their shares by telephone or the Internet. If you vote by telephone or the Internet, you do not need to return your proxy card. The instructions for voting by
telephone or the Internet can be found with your proxy card. </FONT></P>

<P><FONT SIZE=2>Revoking a Proxy </FONT></P>

<P><FONT SIZE=2>
You may revoke your proxy by voting in person at the Annual Meeting or, at any time prior to the meeting: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>by
delivering a written notice to the secretary of Abbott, </FONT></DD></DL>
<HR NOSHADE>

<P><FONT SIZE=2>1</FONT></P>

<!-- ZEQ.=1,SEQ=5,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=186845,FOLIO='1',FILE='DISK047:[05CHI9.05CHI1029]DG1029A.;37',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dg1029_1_2"> </A>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>by
delivering an authorized proxy with a later date, or
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>by
voting by telephone or the Internet after you have given your proxy. </FONT></DD></DL>

<P><FONT SIZE=2>Discretionary Voting Authority </FONT></P>

<P><FONT SIZE=2>
Unless authority is withheld in accordance with the instructions on the proxy, the persons named in the proxy will vote the shares covered by proxies they receive to elect the 14 nominees named in
Item 1 on the proxy card. Should a nominee become unavailable to serve, the shares will be voted for a substitute designated by the board of directors, or for fewer than 14 nominees if, in the
judgment of the proxy holders, such action is necessary or desirable. The persons named in the proxy may also decide to vote shares cumulatively so that one or more of the nominees may receive fewer
votes than the other nominees (or no votes at all), although they have no present intention of doing&nbsp;so. </FONT></P>

<P><FONT SIZE=2>Where
a shareholder has specified a choice for or against the ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as auditors, or the approval of a shareholder proposal, or where the
shareholder has abstained on these matters, the shares represented by the proxy will be voted (or not voted) as specified. Where no choice has been specified, the proxy will be voted FOR ratification
of Deloitte&nbsp;&amp; Touche LLP as auditors and AGAINST the shareholder proposals. </FONT></P>

<P><FONT SIZE=2>The
board of directors is not aware of any other issue which may properly be brought before the meeting. If other matters are properly brought before the meeting, the accompanying proxy will be voted
in accordance with the judgment of the proxy holders. </FONT></P>

<P><FONT SIZE=2>Quorum and Vote Required to Approve Each Item on the Proxy </FONT></P>

<P><FONT SIZE=2>
A majority of the outstanding shares entitled to vote on a matter, represented in person or by proxy, constitutes a quorum for consideration of that matter at the meeting. The affirmative vote of a
majority of the shares represented at the meeting and entitled to vote on a matter shall be the act of the shareholders with respect to that matter. </FONT></P>

<P><FONT SIZE=2>Effect of Broker Non-Votes and Abstentions </FONT></P>

<P><FONT SIZE=2>
A proxy submitted by an institution such as a broker or bank that holds shares for the account of a beneficial owner may indicate that all or a portion of the shares represented by that proxy are not
being voted with respect to a particular matter. This could occur, for example, when the broker or bank is not permitted to vote those shares in the absence of instructions from the beneficial owner
of the stock. These "non-voted shares" will be considered shares not present and, therefore, not entitled to vote on that matter, although these shares may be considered present and
entitled to vote for other purposes. Non-voted shares will not affect the determination of the outcome of the vote on any matter to be decided at the meeting. Shares represented by proxies
which are present and entitled to vote on a matter but which have elected to abstain from voting on that matter will have the effect of votes against that matter. </FONT></P>

<P><FONT SIZE=2>Inspectors of Election </FONT></P>

<P><FONT SIZE=2>
The inspectors of election and the tabulators of all proxies, ballots, and voting tabulations that identify shareholders are independent and are not Abbott employees. </FONT></P>

<P><FONT SIZE=2>Cost of Soliciting Proxies </FONT></P>


<P><FONT SIZE=2>
Abbott will bear the cost of making solicitations from its shareholders and will reimburse banks and brokerage firms for out-of-pocket expenses incurred in connection with this
solicitation. Proxies may be solicited by mail or in person by directors, officers, or employees of Abbott and its subsidiaries. </FONT></P>

<P><FONT SIZE=2>Abbott
has retained Georgeson Shareholder to aid in the solicitation of proxies, at an estimated cost of $17,500 plus reimbursement for reasonable out-of-pocket expenses. </FONT></P>

<P><FONT SIZE=2>Abbott Laboratories Stock Retirement Plan </FONT></P>

<P><FONT SIZE=2>
Participants in the Abbott Laboratories Stock Retirement Plan will receive a voting instruction card for their shares held in the Abbott Laboratories Stock Retirement Trust. The Stock Retirement Trust
is administered by both a trustee and three co-trustees. The trustee of the Trust is Putnam Fiduciary Trust Company. The co-trustees are T.&nbsp;C.&nbsp;Freyman,
G.&nbsp;W.&nbsp;Linder, and T.&nbsp;M.&nbsp;Wascoe, officers of Abbott. The voting power with respect to the shares is held by and shared between the co-trustees and the
participants. The co-trustees must solicit voting instructions from the participants and follow the voting instructions they receive. The co-trustees may use their own
discretion with respect to those shares for which no voting instructions are received. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>2</FONT></P>

<!-- ZEQ.=2,SEQ=6,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=835723,FOLIO='2',FILE='DISK047:[05CHI9.05CHI1029]DG1029A.;37',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dg1029_1_3"> </A>
<BR>

<P><FONT SIZE=2>Confidential Voting </FONT></P>

<P><FONT SIZE=2>
It is Abbott's policy that all proxies, ballots, and voting tabulations that reveal how a particular shareholder has voted be kept confidential and not be disclosed, except: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2>where disclosure may be required by law or regulation,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
where disclosure may be necessary in order for Abbott to assert or defend claims,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
where a shareholder provides comments with a proxy,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
where a shareholder expressly requests disclosure,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
to allow the inspectors of election to certify the results of a vote, or</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2><BR>
&#149;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="95%"><FONT SIZE=2><BR>
in other limited circumstances, such as a contested election or proxy solicitation not approved and recommended by the board of directors.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2><B>Information Concerning Nominees for Directors (Item 1 on Proxy Card)  </B></FONT></P>

<P><FONT SIZE=2>Fourteen
directors are to be elected to hold office until the next Annual Meeting or until their successors are elected. All of the nominees are currently serving as directors. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>3</FONT></P>

<!-- ZEQ.=3,SEQ=7,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=335925,FOLIO='3',FILE='DISK047:[05CHI9.05CHI1029]DG1029A.;37',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_di1029_1_4"> </A> </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT SIZE=4><B>Nominees for Election as Directors  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><BR><FONT SIZE=2>
<IMG SRC="g426392.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
 </FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Roxanne&nbsp;S.
Austin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;44&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 2000<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Former President and Chief Operating Officer, DIRECTV,&nbsp;Inc., El Segundo, California<BR>
(Digital Satellite Television Service Provider)<BR>
<BR> </I></FONT><FONT SIZE=2>Mrs.&nbsp;Austin served as president and chief operating officer of DIRECTV, Inc. from June 2001 to December 2003. She also served as executive vice president of Hughes Electronics Corporation and as a member of its
executive committee until December 2003. From 1997 to June 2001, Mrs.&nbsp;Austin was the corporate senior vice president and chief financial officer of Hughes Electronics Corporation. Mrs.&nbsp;Austin served as Hughes Electronics' vice president,
treasurer, chief accounting officer and controller from December 1996 to July 1997; as its vice president, treasurer, and controller from July 1996 to December 1996; and as its vice president and controller from July 1993 to July 1996. Prior to
joining Hughes, Mrs.&nbsp;Austin was a partner at the accounting firm Deloitte &amp; Touche. Mrs.&nbsp;Austin earned her B.B.A. degree in accounting from the University of Texas at San Antonio. She serves on the board of trustees of the California
Science Center. Mrs.&nbsp;Austin serves on the board of directors of Target Corporation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g173968.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>William M.
Daley&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Age&nbsp;56&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 2004<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Chairman of the Midwest, JPMorgan Chase &amp; Co., Chicago, Illinois<BR>
(Banking and Financial Services Company)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Daley has served as the senior executive of the Midwest region and on the JPMorgan Chase &amp; Co. Executive Committee and on its International Council since May 2004. He served as president, SBC Communications,
Inc. (diversified telecommunications) from December 2001 to May 2004. Mr.&nbsp;Daley was vice chairman of Evercore Capital Partners L.P. from January to November 2001. From June to December 2000, Mr.&nbsp;Daley served as chairman of Vice President
Albert Gore's 2000 presidential election campaign. Mr.&nbsp;Daley served as the U.S. Secretary of Commerce from January 1997 to June 2000. Mr.&nbsp;Daley serves on the board of directors of Boston Properties, Inc. and Loyola University of Chicago. He
also sits on the Council on Foreign Relations. Mr.&nbsp;Daley is a graduate of Loyola University in Chicago and of John Marshall Law School.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g616240.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>H.&nbsp;Laurance
Fuller&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;66&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1988<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired Co-Chairman of the Board, BP Amoco, p.l.c., London, United Kingdom<BR>
(Integrated Petroleum and Chemicals Company)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Fuller was elected president of Amoco Corporation in 1983 and chairman and chief executive officer in 1991. As the result of the merger of British Petroleum, p.l.c. and Amoco effective December 31, 1998, he
became co-chairman of BP Amoco, p.l.c. He retired from that position in April 2000. He is a director of Cabot Microelectronics Corporation, Motorola, Inc., and the Rehabilitation Institute of Chicago, and a trustee of The Orchestral Association and
Cornell University.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>4</FONT></P>

<!-- ZEQ.=1,SEQ=8,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=495718,FOLIO='4',FILE='DISK047:[05CHI9.05CHI1029]DI1029A.;21',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_di1029_1_5"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g785559.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Richard&nbsp;A.
Gonzalez&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;51&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 2001<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>President and Chief Operating Officer, Medical Products Group, Abbott Laboratories<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Gonzalez was elected Abbott's president and chief operating officer, medical products group in 2001. He served as executive vice president, medical products from 2000 to 2001, as senior vice president, hospital
products from 1998 to 2000, and as vice president, Abbott HealthSystems division from 1995 to 1998. Mr.&nbsp;Gonzalez joined Abbott in 1977. He received his bachelor's degree in biochemistry from the University of Houston and his master's degree in
biochemistry from the University of Miami.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g509192.jpg" ALT="PHOTO" WIDTH="133" HEIGHT="133">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Jack M.
Greenberg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;62&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 2000<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired Chairman and Chief Executive Officer, McDonald's Corporation, Oak Brook, Illinois (Developer, Operator, and Franchisor of a Worldwide System of Restaurants)<BR>
<BR> </I></FONT><FONT SIZE=2>At the end of 2002, Mr.&nbsp;Greenberg retired as chairman and chief executive officer of McDonald's Corporation. He had served as McDonald's chairman since May 1999 and as its chief executive officer since August 1998.
Mr.&nbsp;Greenberg served as McDonald's president from August 1998 to May 1999, and as its vice-chairman from December 1991 to 1998. Mr.&nbsp;Greenberg also served as chairman (from October 1996) and chief executive officer (from July 1997) of
McDonald's USA until August 1998. Mr.&nbsp;Greenberg is a graduate of DePaul University's School of Commerce and School of Law. He is a member of the American Institute of Certified Public Accountants, the Illinois CPA Society, and the Chicago Bar
Association. Mr.&nbsp;Greenberg is a director of The Allstate Corporation, First Data Corporation, Hasbro, Inc., Manpower Inc., and Quintiles Transnational Corp. He is also a member of the board of trustees of DePaul University, the Field Museum, the
Chicago Symphony Orchestra, and the Chicago Community Trust.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g96392.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Jeffrey&nbsp;M. Leiden,&nbsp;M.D.,
&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1999<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>President and Chief Operating Officer, Pharmaceutical Products Group, Abbott Laboratories<BR>
<BR> </I></FONT><FONT SIZE=2>Dr. Leiden was elected Abbott's president and chief operating officer, pharmaceutical products group in 2001. He served as executive vice president, pharmaceuticals and chief scientific officer from 2000 to 2001. From
July 1999 until July 2000, Dr. Leiden was Elkan R. Blout Professor of Biological Sciences, Harvard School of Public Health and Professor of Medicine, Harvard Medical School. From 1992 until July 1999, he was the Frederick H. Rawson Professor of
Medicine and Pathology and Chief of the Section of Cardiology at the University of Chicago. He is currently a member of the American Society of Clinical Investigation and the American Association of Physicians and serves on the board of directors of
the Ravinia Festival, the Museum of Science and Industry, and the Penn Medicine Board of the University of Pennsylvania. In 2001, he was elected a fellow of the American Academy of Arts and Sciences and a member of the Institute of Medicine of the
National Academy of Sciences.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>

<P><FONT SIZE=2>5</FONT></P>

<!-- ZEQ.=2,SEQ=9,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=715471,FOLIO='5',FILE='DISK047:[05CHI9.05CHI1029]DI1029A.;21',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_di1029_1_6"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g916736.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>The Rt.&nbsp;Hon. Lord Owen
CH&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1996<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Chairman of Global Natural Energy, p.l.c., London, United Kingdom<BR>
(Owner and Operator of Gasoline Retailing Sites)<BR>
<BR> </I></FONT><FONT SIZE=2>David Owen is a British subject. He has been chairman of Global Natural Energy p.l.c. since 1995. He was a neurologist and Research Fellow on the Medical Unit of St. Thomas' Hospital, London, from 1965 through 1968 and a
member of Parliament for Plymouth in the House of Commons from 1966 until he retired in May of 1992. In 1992, he was created a Life Peer and a Member of the House of Lords. In August of 1992, the European Union appointed him Co-Chairman of the
International Conference on Former Yugoslavia. He stepped down in June of 1995. Lord Owen was Secretary for Foreign and Commonwealth Affairs from 1977 to 1979 and Minister of Health from 1974 to 1976.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g993219.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Boone
Powell&nbsp;Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Age&nbsp;68&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1985<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired Chairman, Baylor Health Care System, Dallas, Texas<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Powell had been associated with Baylor University Medical Center since 1980 when he was named president and chief executive officer. In August 2001, Mr.&nbsp;Powell retired from his position as Chairman of Baylor
Health Care System. Prior to joining Baylor, he was president of Hendrick Medical Center in Abilene, Texas. He is a director of Comerica Bank-Texas, U.S.&nbsp;Oncology, and United Surgical Partners International and a fellow of the American College
of Health Care Executives. Mr.&nbsp;Powell is a graduate of Baylor University. He received a master's degree in hospital administration from the University of California.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g595336.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Addison Barry
Rand&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;60&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1992<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Chairman and Chief Executive Officer, Equitant, Stamford, Connecticut (Provider of Financial Outsourcing Solutions)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Rand has served as chairman and chief executive officer of Equitant since February 2003. Mr.&nbsp;Rand served as chairman and chief executive officer of Avis Group Holdings, Inc. from November 1999 to March 2001.
He served as executive vice president of Worldwide Operations, Xerox Corporation (a document processing, products and services company), from 1992 through 1998. Mr.&nbsp;Rand earned a bachelor's degree from American University and master's degrees in
business administration and management sciences from Stanford University. He has also been awarded several honorary doctorate degrees. Mr.&nbsp;Rand serves as a director of Agilent Technologies, Inc., and Aspect Communications, Inc. He is also a
member of the board of trustees for Howard University. Mr.&nbsp;Rand is an elected member of the National Sales/Marketing Hall of Fame.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>6</FONT></P>

<!-- ZEQ.=3,SEQ=10,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=151403,FOLIO='6',FILE='DISK047:[05CHI9.05CHI1029]DI1029A.;21',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_di1029_1_7"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g521797.jpg" ALT="PHOTO" WIDTH="133" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>W.&nbsp;Ann Reynolds,
&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;67&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1980<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired Director, Center for Community Outreach and Development, The University of Alabama at Birmingham, Birmingham, Alabama<BR>
<BR> </I></FONT><FONT SIZE=2>At the end of 2003, Dr. Reynolds retired as director, Center for Community Outreach and Development, The University of Alabama at Birmingham. She had served in that position since 2002 and as the university's president
from 1997 to 2002. From 1990 to 1997, Dr.&nbsp;Reynolds served as chancellor of The City University of New York. Prior to that, she served as chancellor of The California State University, chief academic officer of Ohio State University and associate
vice chancellor for research and dean of the graduate college of the University of Illinois Medical Center. She also held appointments as professor of anatomy, research professor of obstetrics and gynecology, and acting associate dean for academic
affairs at the University of Illinois College of Medicine. Dr. Reynolds is a graduate of Emporia State University (Kansas) and holds M.S. and Ph.D. degrees in zoology from the University of Iowa. She is also a director of Humana Inc., Maytag
Corporation, Owens-Corning, and the Champaign-Urbana News Gazette.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g633815.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Roy&nbsp;S.
Roberts&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;65&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dire
ctor since 1998<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Managing Director, Reliant Equity Investors, Chicago, Illinois (Venture Capital Firm)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Roberts has served as managing director of Reliant Equity Investors since September 2000. Mr.&nbsp;Roberts retired from General Motors in April 2000. At the time of his retirement, he was group vice president for
North American Vehicle Sales, Service and Marketing of General Motors Corporation, having been elected to that position in October 1998. Prior to that time, he was vice president and general manager in charge of Field Sales, Service and Parts for the
Vehicle Sales, Service and Marketing Group from August 1998 to October 1998, general manager of the Pontiac-GMC Division from February 1996 to October 1998, and general manager of the GMC Truck Division from October 1992 to February 1996.
Mr.&nbsp;Roberts first joined General Motors Corporation in 1977 and became a corporate officer of General Motors Corporation in April 1987. Mr.&nbsp;Roberts earned a bachelor's degree from Western Michigan University. He serves as a director of
Burlington Northern Santa Fe Corporation; as Trustee Emeritus at Western Michigan University; as immediate past president and on the National Board of Directors for the Boy Scouts of America; and on the National Board of the College
Fund/UNCF.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
<BR>
 <IMG SRC="g304005.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><FONT SIZE=2><BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2>William D.
Smithburg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;66&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since 1982<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired Chairman, President and Chief Executive Officer, The Quaker Oats Company, Chicago, Illinois (Worldwide Food Manufacturer and Marketer of Beverages and Grain-Based Products)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Smithburg retired from Quaker Oats in October 1997. Mr.&nbsp;Smithburg joined Quaker Oats in 1966 and became president and chief executive officer in 1981, and chairman and chief executive officer in 1983 and
also served as president from November 1990 to January 1993 and again from November 1995. Mr.&nbsp;Smithburg was elected to the Quaker board in 1978 and served on its executive committee until he retired. He is a director of Smurfit-Stone Container
Corporation, Northern Trust Corporation, and Corning Incorporated. He is a member of the board of trustees of Northwestern University. Mr.&nbsp;Smithburg earned a B.S. degree from DePaul University and an M.B.A. degree from Northwestern
University.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>

<P><FONT SIZE=2>7</FONT></P>

<!-- ZEQ.=4,SEQ=11,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=19841,FOLIO='7',FILE='DISK047:[05CHI9.05CHI1029]DI1029A.;21',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_di1029_1_8"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g583704.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>John&nbsp;R.
Walter&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;58&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director since
1990<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Retired President and Chief Operating Officer, AT&amp;T Corporation, Basking Ridge, New Jersey (Telecommunications Company); and Former Chairman and Chief Executive Officer, R. R. Donnelley &amp; Sons
Company, Chicago, Illinois (Printing Company)<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;Walter served as president and chief operating officer of AT&amp;T Corporation from October 1996 to July 1997. Prior to that time, he was chairman, president and chief executive officer of R. R. Donnelley &amp;
Sons Company, a printing company. He was elected chairman of the board and chief executive officer in 1989 and president in 1987. He holds a bachelor's degree from Miami University of Ohio. Mr.&nbsp;Walter serves as a director of Acceris Incorporated,
 Deere &amp; Company, Manpower Inc., SNP Corporation of Singapore, and VascoData Security International. He is a trustee of Northwestern University and a director of Evanston Northwestern Healthcare and Steppenwolf Theatre.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><BR><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="22%"><FONT SIZE=2><BR>
<BR>
 <IMG SRC="g206804.jpg" ALT="PHOTO" WIDTH="135" HEIGHT="135">
</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="75%"><BR><FONT COLOR="#2B85FF" SIZE=2>Miles&nbsp;D.
White&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director
since 1998<BR>
<BR></FONT> <FONT COLOR="#2B85FF" SIZE=2><I>Chairman of the Board and Chief Executive Officer, Abbott Laboratories<BR>
<BR> </I></FONT><FONT SIZE=2>Mr.&nbsp;White has served as Abbott's chairman of the board and chief executive officer since 1999. He served as an executive vice president of Abbott from 1998 to 1999, as senior vice president, diagnostics operations
from 1994 to 1998, and as vice president, diagnostics systems operations from 1993 to 1994. Mr.&nbsp;White joined Abbott in 1984. He received both his bachelor's degree in mechanical engineering and M.B.A. degree from Stanford University. He serves
on the board of trustees of The Culver Educational Foundation, The Field Museum in Chicago, and Northwestern University and is deputy chair of the board of directors of the Federal Reserve Bank of Chicago.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>8</FONT></P>

<!-- ZEQ.=5,SEQ=12,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=755688,FOLIO='8',FILE='DISK047:[05CHI9.05CHI1029]DI1029A.;21',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_dk1029_1_9"> </A> </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2><B>The Board of Directors and its Committees  </B></FONT></P>


<P><FONT COLOR="#2B85FF" SIZE=2>The Board of Directors </FONT></P>

<P><FONT SIZE=2>
The board of directors, which held eight meetings in 2004, currently has fourteen members. The average attendance of all directors at board and committee meetings in 2004 was 98&nbsp;percent. Abbott
encourages its board members to attend the annual shareholders meeting. Last year, all of Abbott's directors attended the annual shareholders meeting. </FONT></P>

<P><FONT SIZE=2>The
board has determined that each of the following directors, who constitute all eleven of Abbott's non-employee directors, is independent in accordance with the New York Stock Exchange
listing standards: R.&nbsp;S.&nbsp;Austin, W.&nbsp;M.&nbsp;Daley, H.&nbsp;L.&nbsp;Fuller, J.&nbsp;M.&nbsp;Greenberg, D.&nbsp;A.&nbsp;L.&nbsp;Owen, B. Powell&nbsp;Jr.,
A.&nbsp;B.&nbsp;Rand, W.&nbsp;A.&nbsp;Reynolds, R.&nbsp;S.&nbsp;Roberts, W.&nbsp;D.&nbsp;Smithburg, and J.&nbsp;R.&nbsp;Walter. To determine independence, the board applied the
categorical standards found on Exhibit&nbsp;A to this proxy statement. The board also considered whether a director has any other material relationships with Abbott or its subsidiaries and concluded
that none of these directors had a relationship that impaired the director's independence. In making its determination, the board relied on both information provided by the directors and information
developed internally by Abbott. </FONT></P>

<P><FONT SIZE=2>The
chairman of the nominations and governance committee acts as lead director to facilitate communication with the board and preside over regularly conducted executive sessions of the independent
directors or sessions where the chairman of the board is not present. The lead director, and each of the other directors, communicates regularly with
the chairman and chief executive officer regarding appropriate agenda topics and other board related matters.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Committees of the Board of Directors </FONT></P>

<P><FONT SIZE=2>The
board of directors has five committees established in Abbott's bylaws: the executive committee, audit committee, compensation committee, nominations and governance committee, and public policy
committee. Each of the members of the audit committee, compensation committee, nominations and governance committee, and public policy committee is independent. </FONT></P>

<P><FONT SIZE=2>The
executive committee, whose members are M.&nbsp;D.&nbsp;White, chairman, H.&nbsp;L.&nbsp;Fuller, J.&nbsp;M.&nbsp;Greenberg, W.&nbsp;A.&nbsp;Reynolds, and
W.&nbsp;D.&nbsp;Smithburg, did not hold any meetings in 2004. This committee may exercise all the authority of the board in the management of Abbott, except for matters expressly reserved by law
for board action. </FONT></P>

<P><FONT SIZE=2>The
audit committee, whose members are J.&nbsp;M.&nbsp;Greenberg, chairman, R.&nbsp;S.&nbsp;Austin, D.&nbsp;A.&nbsp;L.&nbsp;Owen, W.&nbsp;D. Smithburg, and J.&nbsp;R.&nbsp;Walter,
held eight meetings in 2004. The committee is governed by a written charter. This committee assists the board of directors in fulfilling its oversight responsibility with respect to Abbott's
accounting and financial reporting practices and the audit process, the quality and integrity of Abbott's financial statements, the independent auditors' qualifications, independence and performance,
the performance of Abbott's internal audit function and internal auditors, and certain areas of legal and regulatory compliance. Each of the members of the audit committee is financially literate, as
required of audit committee members by the New York Stock Exchange. The board of directors has determined that both J.&nbsp;M.&nbsp;Greenberg, the committee's chairman, and
R.&nbsp;S.&nbsp;Austin are "audit committee financial experts." A copy of the report of the audit committee is on page&nbsp;21. </FONT></P>

<P><FONT SIZE=2>The
compensation committee, whose members are W.&nbsp;D.&nbsp;Smithburg, chairman, W.&nbsp;M.&nbsp;Daley, H.&nbsp;L.&nbsp;Fuller, J.&nbsp;M.&nbsp;Greenberg,
B.&nbsp;Powell&nbsp;Jr., and A.&nbsp;B.&nbsp;Rand, held three meetings in 2004. The committee is governed by a written charter. This committee assists the board of directors in carrying out
the responsibilities of the board relating to the compensation of Abbott's executive officers and directors by discharging the responsibilities set forth in its charter. A copy of the report of the
compensation committee is on pages&nbsp;13 and 14. </FONT></P>

<P><FONT SIZE=2>The
nominations and governance committee, whose members are H.&nbsp;L.&nbsp;Fuller, chairman, D.&nbsp;A.&nbsp;L.&nbsp;Owen, A.&nbsp;B.&nbsp;Rand, W.&nbsp;A.&nbsp;Reynolds, and
R.&nbsp;S.&nbsp;Roberts, held two meetings in 2004. The committee is governed by a written charter. This committee assists the board of directors in identifying individuals qualified to become
board members and recommends to the board the nominees for election as directors at the next annual meeting of shareholders, recommends to the board the persons to be elected as executive officers of
Abbott, develops and recommends to the board the corporate governance guidelines applicable to Abbott, and serves in an advisory capacity to the board and the chairman of the board on matters of
organization, management succession plans, major changes in the organizational structure of Abbott, and the conduct of board activities. The process used by this committee to identify a nominee
depends on the qualities being sought. Board members should have backgrounds that when combined
provide a portfolio of experience and knowledge that will serve Abbott's governance and strategic needs. Board candidates will be considered on the basis of a range of </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>9</FONT></P>

<!-- ZEQ.=1,SEQ=13,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=496515,FOLIO='9',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dk1029_1_10"> </A>
<BR>

<P><FONT SIZE=2>
criteria, including broad-based business knowledge and relationships, prominence and excellent reputations in their primary fields of endeavor, as well as a global business perspective and commitment
to good corporate citizenship. Directors should have demonstrated experience and ability that is relevant to the board of directors' oversight role with respect to Abbott's business and affairs. </FONT></P>

<P><FONT SIZE=2>The
public policy committee, whose members are W.&nbsp;A.&nbsp;Reynolds, chair, R.&nbsp;S.&nbsp;Austin, W.&nbsp;M.&nbsp;Daley, B.&nbsp;Powell&nbsp;Jr., R.&nbsp;S.&nbsp;Roberts, and
J.&nbsp;R.&nbsp;Walter, held two meetings in 2004. The committee is governed by a written charter. This committee assists the board of directors in fulfilling its oversight responsibility with
respect to Abbott's public policy, certain areas of legal and regulatory compliance, and governmental affairs and healthcare compliance issues that affect Abbott by discharging the responsibilities
set forth in its charter.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Communicating with the Board of Directors </FONT></P>

<P><FONT SIZE=2>You
may communicate with the board of directors by writing a letter to the chairman of the board, to the chairman of the nominations and governance committee, who acts as the lead director at the
meetings of the independent directors, or to the independent directors c/o Abbott Laboratories, 100 Abbott Park Road, D-364, AP6D, Abbott Park, Illinois 60064-6400 Attention:
corporate secretary. The general counsel or corporate secretary will regularly forward to the addressee all letters other than mass mailings, advertisements, and other materials not relevant to
Abbott's business.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Corporate Governance Materials </FONT></P>

<P><FONT SIZE=2>Abbott's
corporate governance guidelines, outline of directorship qualifications, code of business conduct and the charters of Abbott's audit committee, compensation committee, nominations and
governance committee, and public policy committee are all available in the corporate governance section of Abbott's investor relations Web Site
(</FONT><FONT SIZE=2><I>www.abbottinvestor.com</I></FONT><FONT SIZE=2>) or by sending a request for a paper copy to: Abbott Laboratories, 100 Abbott Park Road, Dept. 383, AP6D2, Abbott Park, Illinois
60064-6400, attn. Investor Relations. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>10</FONT></P>

<!-- ZEQ.=2,SEQ=14,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=984779,FOLIO='10',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dk1029_1_11"> </A>
<BR>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Compensation of Directors </FONT></P>

<P><FONT SIZE=2>Abbott
employees are not compensated for serving on the board or board committees. Abbott's non-employee directors are compensated for their service under the Abbott Laboratories
Non-Employee Directors' Fee Plan and the Abbott Laboratories 1996 Incentive Stock Program. </FONT></P>

<P><FONT SIZE=2>Under
the Abbott Laboratories Non-Employee Directors' Fee Plan, non-employee directors earn $6,667 for each month of service as director and $1,000 for each month of service as
a chairman of a board committee. Fees earned under this Plan are paid in cash to the director, paid in the form of non-qualified stock options (based on an independent appraisal of their
fair market value), or deferred (as a non-funded obligation of Abbott or paid into a grantor trust established by the director) until payments commence (generally at age 65 or upon
retirement from the board of directors). The director may elect to have deferred fees credited to either a guaranteed interest account at the prime rate plus 2.25&nbsp;percent or to a stock
equivalent account that earns the same return as if the fees were invested in Abbott stock. If necessary, Abbott contributes funds to a director's trust so that as of year-end the stock
equivalent account balance (net of taxes) is not less than seventy-five percent of the value of Abbott common stock. Abbott pays the director for any tax owed on the income earned by the
trust or any supplemental contribution to the trust by Abbott. </FONT></P>

<P><FONT SIZE=2>The
Abbott Laboratories 1996 Incentive Stock Program previously provided that each non-employee director elected to the board of directors at the annual shareholder meeting earned a restricted stock
award with a fair market value on the date of the award closest to, but not exceeding $65,000. In 2004, this was 1,577&nbsp;shares. The non-employee directors are entitled to vote these shares and
receive all dividends paid on the shares. These shares were nontransferable prior to termination, retirement from the board, death, or a change in control of Abbott. </FONT></P>

<P><FONT SIZE=2>Since
the last annual meeting, the program has been amended to provide that instead of receiving a restricted stock award each non-employee director elected to the board of directors at the annual
shareholder meeting will, instead, receive restricted stock units covering a number of Abbott common shares having a fair market value on the date of the award closest to, but not exceeding $90,000.
The non-employee directors receive cash payments equal to the dividends paid on the Abbott shares covered by the units. Upon termination, retirement from the board, death, or a change in control of
Abbott, a non-employee director will receive one Abbott common share for each restricted stock unit. In addition, the restrictions on transfer were removed from the Abbott shares that had previously
been issued under the program and from the shares of Hospira received as a dividend with respect to those shares. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>11</FONT></P>

<!-- ZEQ.=3,SEQ=15,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=618545,FOLIO='11',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dk1029_1_12"> </A>
<BR><BR>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Security Ownership of Executive Officers and Directors </FONT></P>

<P><FONT SIZE=2>The
table below reflects the number of common shares beneficially owned by each director, by the chief executive officer and the four other most highly paid executive officers (the "named officers"),
and by all directors and executive officers of Abbott as a group as of January&nbsp;31, 2005. It also reflects the number of stock equivalent units held by non-employee directors under
the Abbott Laboratories Non-Employee Directors' Fee Plan. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="72%" ALIGN="LEFT"><FONT SIZE=1>Name</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="12%" ALIGN="CENTER"><FONT SIZE=1>Shares<BR>
Beneficially<BR>
Owned,<BR>
Excluding<BR>
Options (1)(2)</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1>Stock<BR>
Equivalent<BR>
Units</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=5 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Roxanne S. Austin</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>6,844</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>William G. Dempsey</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>143,679</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Thomas C. Freyman</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>193,729</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>William M. Daley</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>1,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>285</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>H. Laurance Fuller</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>34,634</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>44,974</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Richard A. Gonzalez</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>287,440</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Jack M. Greenberg</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>6,844</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Jeffrey M. Leiden, M.D., Ph.D.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>277,508</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>The Lord Owen CH</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>14,311</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>5,758</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Boone Powell&nbsp;Jr.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>35,357</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>76,206</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Addison Barry Rand</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>22,649</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>643</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>W. Ann Reynolds, Ph.D.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>35,291</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>70,080</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Roy S. Roberts</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>11,492</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>William D. Smithburg</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>53,316</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>107,660</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>John R. Walter</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>27,576</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>29,209</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>Miles D. White</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>562,454</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="72%"><FONT SIZE=1>All directors and executive officers as a group&nbsp;(3)(4)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>2,286,316</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>334,815</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>The
table excludes unexercised option shares which are exercisable within 60&nbsp;days after January&nbsp;31, 2005, as follows: R.&nbsp;S.&nbsp;Austin,&nbsp;6,668;
W.&nbsp;G.&nbsp;Dempsey,&nbsp;570,000; T.&nbsp;C.&nbsp;Freyman,&nbsp;444,861; H.&nbsp;L.&nbsp;Fuller,&nbsp;50,644; R.&nbsp;A.&nbsp;Gonzalez,&nbsp;1,478,989;
J.&nbsp;M.&nbsp;Greenberg,&nbsp;16,857; J.&nbsp;M.&nbsp;Leiden,&nbsp;1,315,775; D.&nbsp;A.&nbsp;L.&nbsp;Owen,&nbsp;31,243; A.&nbsp;B.&nbsp;Rand,&nbsp;12,711;
W.&nbsp;A.&nbsp;Reynolds,&nbsp;51,372; R.&nbsp;S.&nbsp;Roberts,&nbsp;35,660; W.&nbsp;D.&nbsp;Smithburg,&nbsp;35,324; J.&nbsp;R.&nbsp;Walter,&nbsp;45,860;
M.&nbsp;D.&nbsp;White, 3,197,006; and all directors and executive officers as a group,&nbsp;9,290,938.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>The
table includes the shares held in the officers' accounts in the Abbott Laboratories Stock Retirement Trust as follows: W.&nbsp;G.&nbsp;Dempsey,&nbsp;10,070;
T.&nbsp;C.&nbsp;Freyman,&nbsp;16,909; R.&nbsp;A.&nbsp;Gonzalez,&nbsp;16,977; J.&nbsp;M.&nbsp;Leiden,&nbsp;616; M.&nbsp;D.&nbsp;White,&nbsp;14,678; and, all executive officers
as a group,&nbsp;120,544. Each officer has shared voting power and sole investment power with respect to the shares held in his account.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>T.&nbsp;C.&nbsp;Freyman
and certain other executive officers of Abbott are fiduciaries of several employee benefit trusts maintained by Abbott. As such, they have shared voting
and/or investment power with respect to the common shares held by those trusts. The table does not include the shares held by the trusts. As of January&nbsp;31, 2005, these trusts owned a total of
64,645,995 (4.1%) of the outstanding shares of Abbott.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>Excluding
the shared voting and/or investment power over the shares held by the trusts described in footnote 3, the directors and executive officers as a group together own
beneficially less than one percent of the outstanding shares of Abbott. </FONT>
<BR><BR>
</DD></DL>
<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>12</FONT></P>

<!-- ZEQ.=4,SEQ=16,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=865043,FOLIO='12',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dk1029_1_13"> </A>
<HR NOSHADE SIZE=6>

<P><FONT COLOR="#2B85FF" SIZE=2>Executive Compensation </FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=2>Report of the Compensation Committee </FONT></P>

<P><FONT SIZE=2>
The Compensation Committee of the Board of Directors is composed entirely of directors who have never been employees of the corporation and who satisfy the independence requirements of the New York
Stock Exchange, Rule&nbsp;16b-3 of the Securities Exchange Act of 1934, as amended, and Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended. The Committee is
responsible for oversight of the Company's executive officer and director compensation policies and programs, setting its executive officer compensation philosophy and specifically, reviewing, setting
and administering the compensation of Abbott's Chief Executive Officer, and other executive officers and directors. The Committee reviews relative health-care and select high performing
company market data provided by an independent outside consultant when considering programs that govern director and executive officer annual compensation, long-term incentives and stock
ownership programs. </FONT></P>

<P><FONT SIZE=2>The
foundation of the executive compensation program is based on principles designed to help align the corporation's business strategy, values and management initiatives with shareholder interests.
The Committee annually reviews and approves corporate goals and objectives relevant to the compensation of the Chief Executive Officer and other executive officers. The Committee evaluates performance
in light of those goals and objectives as well as performance against certain non-financial goals including development of management talent and other strategic business objectives. </FONT></P>

<P><FONT SIZE=2>The
Committee sets the Chief Executive Officer's and other executive officers' compensation based on that evaluation, advice from the Committee's independent compensation consultant, performance
relative to its health-care and high performing company peer groups and shareholder return. </FONT></P>


<P><FONT SIZE=2>The
Company's compensation program: </FONT></P>

<UL>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Integrates
compensation programs which link total shareholder return with both the corporation's annual and long-term strategic planning and measurement
processes.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Supports
a performance-oriented environment that rewards actual performance that is related to both goals and performance of the corporation as compared to that of industry
performance levels.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>Helps
attract and retain key executives who are critical to the long-term success of the corporation. </FONT></DD></DL>
</UL>

<P><FONT SIZE=2>The
key components of the Company's total compensation program are base salary, annual incentive awards, and long-term incentive awards comprised of various forms of equity awards. These
components are administered with the goal of providing total compensation that is competitive in the marketplace, recognizes meaningful differences in individual performance, and varies the
opportunity based on individual and corporate performance. In determining the long-term incentive component of the Chief Executive Officer's and other executive officers' compensation, the
Committee considers the Company's performance and relative shareholder return, the component mix and value of similar incentive awards to executives at comparable companies, and the awards given to
the Chief Executive Officer and other executive officers in past years. </FONT></P>

<P><FONT SIZE=2>The
marketplace is defined by comparing the corporation's pay practices to a group of twenty-four major corporations with similar characteristics, including ten within the
health-care industry and eight which are also included in the Standard and Poor's Health Care-500. A select group of high-performing non-healthcare
companies, who are defined as having a five year compounded return on equity (ROE) of 18% or higher and chosen for size and comparability to the corporation, is used as a secondary source of
comparison. Using compensation survey data from the comparison groups, a range for total compensation and each of its elements&#151;base, annual incentive and long-term equity-
based compensation&#151;is established. The intent is to deliver competitive total compensation that varies with the corporation's relative performance. To achieve this objective, a substantial
portion of executive pay is delivered through performance-related variable compensation programs, which are based upon achievement of specific corporate and individual performance goals. Each year the
Committee reviews the elements of executive compensation to ensure that the total compensation program, and each of its elements, meets the overall objectives discussed above. </FONT></P>


<P><FONT SIZE=2>In
2004, total compensation was paid to executives based on individual performance and on the extent to which the business plans for the corporation and their areas of responsibility were achieved or
exceeded. Specifically, for 2004 the Company met or exceeded all of its financial goals and delivered five-year total shareholder returns that were above the seventy-fifth percentile of
the companies in Abbott's health-care peer group. </FONT></P>

<P><FONT SIZE=2>The
Abbott Performance Incentive Plan (PIP), which limits participation to Senior Officers of Abbott and its subsidiaries and complies with the performance requirements of Section&nbsp;162(m) of the
Internal Revenue </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>13</FONT></P>

<!-- ZEQ.=5,SEQ=17,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=576214,FOLIO='13',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dk1029_1_14"> </A>
<BR>

<P><FONT SIZE=2>
Code of 1986; and the Management Incentive Plan (MIP), in which the other officers of the Company participate, are annual incentive plans designed to reward executives when the Company achieves
certain financial objectives and when each executive's area of responsibility meets its predetermined goals. These goals include specific financial targets related to consolidated net earnings,
profitability, total sales and earnings per share. While many aspects of performance can be measured in these financial terms, the Committee also evaluates the success of the management team in areas
of performance that cannot be measured by traditional accounting tools, including the development and execution of strategic plans, the development of management and employees, including Abbott's
diversity initiative and the exercise of leadership within the industry and in the communities that Abbott serves. All of these factors are collectively taken into account by management and the
Committee when determining the appropriate level of annual incentive awards. </FONT></P>

<P><FONT SIZE=2>Each
year, individual base award allocations establish the maximum annual bonus awards for PIP participants as a percentage of consolidated net earnings. Actual awards paid to PIP participants have
historically been below their maximums. </FONT></P>

<P><FONT SIZE=2>Each
year, individual incentive targets are established for MIP participants based on competitive survey data from the group of companies discussed above. Under the MIP, 40% of a participant's target
incentive award is attributable to corporate performance relative to its Earnings Per Share target. The remainder of the incentive award is based on the Committee's overall assessment of each
participant's achievement of the predetermined financial and strategic performance goals discussed above. As noted above, awards are paid at levels commensurate with Company and individual performance
and relative to peer group companies. </FONT></P>

<P><FONT SIZE=2>For
2004, the corporation achieved or exceeded its predetermined financial goals. As a result, each PIP participant's final award allocation and each MIP participant's incentive award were based on
the corporation's financial goal achievement and the committee's overall assessment of each participant's achievement of the predetermined goals discussed above. </FONT></P>

<P><FONT SIZE=2>To
motivate and reward its executives and managers and to directly align key employee and shareholder interests, the corporation has provided long-term incentives in the form of equity
participation for many years. Grants of stock options, replacement stock options, restricted stock units and restricted stock awards are important parts of this relationship. To ensure this objective
is achieved, executives follow fixed stock ownership guidelines. </FONT></P>

<P><FONT SIZE=2>Targeted
ranges and form of equity awards are determined taking into account competitive practice among the comparison companies noted above. Equity participation targets are set based on established
salary ranges and may vary based on each executive's performance as determined by the Committee. As noted above, the target ranges and mix of equity awards are established such that equity awards are
appropriately delivered and scaled to the performance of the company within its peer group. Based on its analysis of the competitive equity marketplace and upon the recommendation of its independent
compensation consultant, the Committee has determined that the annual equity award should consist of both stock options and restricted stock awards. For 2004, the equity award component mix was 70%
stock options and 30% restricted stock. </FONT></P>

<P><FONT SIZE=2>The
Committee also believes it is critical to periodically award restricted stock as a vehicle to retain key management talent. These stock awards are generally restricted for a 5-year
period. The last such retention award was in 2002. Therefore, it is expected the next restricted stock retention award would be made in 2007. </FONT></P>

<P><FONT SIZE=2>The
Company's performance for 2004 as described above and as reflected in the Corporation's financial statements included strong growth in sales, earnings, stock price performance and shareholder
returns that were above the seventy-fifth percentile of the companies in Abbott's health-care peer group. Accordingly, the Committee determined that Mr.&nbsp;White met or exceeded all
strategic and financial goals for 2004. Therefore, in February&nbsp;2005, the Committee awarded Mr.&nbsp;White a bonus of $2,700,000. </FONT></P>

<P><FONT SIZE=2>Other
2004 compensation, recommended and approved as appropriate by the Committee and Board of Directors in February&nbsp;2004, included a base salary increase of 3.5% to $1,560,000, a 380,000 share
stock option grant (adjusted to 404,340 after the Hospira stock dividend) and a 55,000 share restricted stock award. </FONT></P>

<P><FONT SIZE=2>It
is the Committee's policy to establish and maintain compensation programs for executive officers, which operate, in the best interests of the corporation and its stockholders in achieving the
corporation's long-term business objectives. To that end, the committee continues to assess the impact of the Omnibus Budget Reconciliation Act of 1993 on its executive compensation
strategy and takes action to assure that appropriate levels of deductibility are maintained. </FONT></P>

<P><FONT SIZE=2><I><U>Compensation Committee</U>  </I></FONT></P>

<P><FONT SIZE=2>W.&nbsp;D.&nbsp;Smithburg,&nbsp;chairman, W.&nbsp;M.&nbsp;Daley, H.&nbsp;L.&nbsp;Fuller, J.&nbsp;M.&nbsp;Greenberg, B.&nbsp;Powell&nbsp;Jr., and
A.&nbsp;B.&nbsp;Rand. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>14</FONT></P>

<!-- ZEQ.=6,SEQ=18,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=481913,FOLIO='14',FILE='DISK047:[05CHI9.05CHI1029]DK1029A.;36',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<BR>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_dm1029_1_15"> </A> </FONT></P>

<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Summary Compensation Table </FONT></P>

<P><FONT SIZE=2>
The following table summarizes compensation earned in 2004, 2003 and 2002 by the named officers. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="18%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="4%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER"><FONT SIZE=1>Annual Compensation<BR></FONT>
<HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER"><FONT SIZE=1>Long-term Compensation</FONT><HR NOSHADE></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="18%" ALIGN="LEFT"><FONT SIZE=1>Name and<BR>
Principal Position</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1>Year</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Salary ($)(1)</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Bonus ($)</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Other<BR>
Annual<BR>
Compens-<BR>
ation ($)</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Restricted<BR>
Stock<BR>
Award(s) ($)(2)</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1>Securities<BR>
Underlying<BR>
Options/<BR>
SARs (#)(3)</FONT><BR></TH>
<TH WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>All Other<BR>
Compensa-<BR>
tion ($)(4)</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=20 ALIGN="CENTER"><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="18%"><FONT SIZE=1>Miles D. White<BR>
Chairman of the Board,<BR>
Chief Executive Officer<BR>
and Director</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>2004<BR>
<BR>
2003<BR>
<BR>
2002</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$<BR><BR><BR><BR></FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,551,846<BR>
<BR>
1,564,961<BR>
<BR>
1,497,388</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$<BR><BR><BR><BR></FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,700,000<BR>
<BR>
1,750,000<BR>
<BR>
1,250,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$<BR><BR><BR><BR></FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>87,817<BR>
<BR>
84,122<BR>
<BR>
66,068</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$<BR><BR><BR><BR></FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>2,401,300<BR>
<BR>
0<BR>
<BR>
11,468,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>404,340<BR>
<BR>
675,674<BR>
<BR>
675,674</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$<BR><BR><BR><BR></FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>77,592<BR>
<BR>
78,248<BR>
<BR>
74,869</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=20><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="18%"><FONT SIZE=1>Jeffrey M. Leiden, M.D., Ph.D.<BR>
President and Chief<BR>
Operating Officer,<BR>
Pharmaceutical Products<BR>
Group and Director</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>2004<BR>
<BR>
2003<BR>
<BR>
2002</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>875,385<BR>
<BR>
882,692<BR>
<BR>
807,408</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,100,000<BR>
<BR>
970,000<BR>
<BR>
680,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>64,752<BR>
<BR>
70,602<BR>
<BR>
65,854</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>1,746,400<BR>
<BR>
0<BR>
<BR>
8,314,300</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>287,294<BR>
26,124<BR>
478,824<BR>
<BR>
478,824</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>(5)<BR><BR><BR></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>43,769<BR>
<BR>
44,135<BR>
<BR>
40,371</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=20><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="18%"><FONT SIZE=1>Richard A. Gonzalez<BR>
President and Chief<BR>
Operating Officer,<BR>
Medical Products Group<BR>
and Director</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>2004<BR>
<BR>
2003<BR>
<BR>
2002</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>875,385<BR>
<BR>
882,692<BR>
<BR>
802,508</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,100,000<BR>
<BR>
885,000<BR>
<BR>
505,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>53,334<BR>
<BR>
50,866<BR>
<BR>
40,801</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>1,746,400<BR>
<BR>
0<BR>
<BR>
8,314,300</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>287,294<BR>
<BR>
478,824<BR>
25,298<BR>
478,824<BR>
55,365</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR><BR><BR>(5)<BR><BR>(5)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>43,769<BR>
<BR>
44,135<BR>
<BR>
40,126</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=20><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="18%"><FONT SIZE=1>Thomas C. Freyman<BR>
Executive Vice President,<BR>
Finance and Chief Financial Officer</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>2004<BR>
<BR>
2003<BR>
<BR>
2002</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>617,308<BR>
<BR>
585,577<BR>
<BR>
493,327</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>685,000<BR>
<BR>
589,000<BR>
<BR>
375,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>8,318<BR>
<BR>
8,027<BR>
<BR>
11,265</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>349,280<BR>
<BR>
0<BR>
<BR>
1,433,500</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>58,522<BR>
58,107<BR>
106,404<BR>
<BR>
95,764</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>(5)<BR><BR><BR></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>30,866<BR>
<BR>
29,279<BR>
<BR>
24,666</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=20><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="18%"><FONT SIZE=1>William G. Dempsey<BR>
Senior Vice President,<BR>
Pharmaceutical Operations</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>2004<BR>
<BR>
2003<BR>
<BR>
2002</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>565,769<BR>
<BR>
534,808<BR>
<BR>
501,619</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>567,500<BR>
<BR>
540,500<BR>
<BR>
375,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>84,594<BR>
<BR>
73,790<BR>
<BR>
79,454</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="RIGHT"><FONT SIZE=1>349,280<BR>
<BR>
0<BR>
<BR>
1,433,500</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>58,522<BR>
35,729<BR>
106,404<BR>
55,556<BR>
95,764</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=1><BR>(5)<BR><BR>(5)<BR></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1>28,289<BR>
<BR>
26,740<BR>
<BR>
25,081</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=20><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>Abbott's
U.S. salaried employees are paid on a bi-weekly pay period schedule. In typical years, such as 2004 and 2002, this results in 26 pay periods. In 2003, the
calendar included an extra pay period for Abbott's U.S. salaried employees resulting in salaries approximately 3.8&nbsp;percent higher than a typical year having 26 pay periods.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>The
number and value of Abbott restricted shares held as of December&nbsp;31, 2004, respectively, were as follows:<BR>
M. D. White - 295,000 / $13,761,750;<BR>
J. M. Leiden - 260,000 / $12,129,000;<BR>
R. A. Gonzalez - 205,000 / $9,563,250;<BR>
T.&nbsp;C. Freyman - 43,000 / $2,005,950; and<BR>
W.&nbsp;G. Dempsey - 33,000 / $1,539,450.<BR>
As the result of the spin-off of Hospira,&nbsp;Inc. to shareholders on April&nbsp;30, 2004, the named officers, along with all other Abbott shareholders, received a special dividend
distribution in the form of shares of Hospira,&nbsp;Inc. The number and value of Hospira restricted shares held as of December&nbsp;31, 2004, respectively, were as follows:<BR>
M. D. White - 29,500 / $988,250;<BR>
J. M. Leiden - 26,000 / $871,000;<BR>
R. A. Gonzalez - 20,500 / $686,750;<BR>
T.&nbsp;C. Freyman - 4,300 / $144,050; and<BR>
W.&nbsp;G. Dempsey - 3,300 / $110,550.<BR>
These Hospira shares are subject to the same restrictions as the related Abbott restricted shares held by the officer. The officers receive any dividends paid on these Abbott and Hospira restricted
shares.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>The
number of securities that were outstanding on April&nbsp;30, 2004 has been adjusted to reflect the spin-off of Hospira,&nbsp;Inc. on April&nbsp;30, 2004.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>These
amounts are employer contributions made to the Stock Retirement Plan and made or accrued with respect to the 401(k) Supplemental Plan.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD><FONT SIZE=2>These
options are replacement stock options. They are described in the table captioned "Options Granted in Last Fiscal Year" on page&nbsp;16. </FONT></DD></DL>
<HR NOSHADE>

<P><FONT SIZE=2>15</FONT></P>

<!-- ZEQ.=1,SEQ=19,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=704514,FOLIO='15',FILE='DISK047:[05CHI9.05CHI1029]DM1029A.;24',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_do1029_1_16"> </A> </FONT></P>

<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Stock Options </FONT></P>

<P><FONT SIZE=2>
The following tables summarize the named officers' stock option activity during 2004. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><U>Options Granted in Last Fiscal Year (1)</U></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER"><FONT SIZE=1><BR>
Individual Grants<BR></FONT>
<HR NOSHADE></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>Name</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="15%" ALIGN="CENTER"><FONT SIZE=1>Number of Securities<BR>
Underlying Options/<BR>
SARs Granted<BR>
(#)(2)</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="15%" ALIGN="CENTER"><FONT SIZE=1>% of Total Options/<BR>
SARs Granted to<BR>
Employees in Fiscal<BR>
Year</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Exercise or<BR>
Base<BR>
Price ($/Sh.)</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>Expiration<BR>
Date</FONT><BR></TH>
<TH WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Grant Date<BR>
Present Value(3)</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>Miles D. White</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>404,340(4)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>1.5%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.03</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/19/14</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>4,480,087</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>Jeffrey M. Leiden, M.D., Ph.D.</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>287,294(4)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>1.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.03</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/19/14</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>3,183,218</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="2%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=1>Replacement Options:</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>12,555</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.0%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.64</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/13/13</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>137,226</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>13,569</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.69</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/13/13</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>137,725</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>Richard A. Gonzalez</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>287,294(4)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>1.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.03</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/19/14</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>3,183,218</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>Thomas C. Freyman</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>58,522(4)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.2%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.03</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/19/14</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>648,424</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="2%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=1>Replacement Options:</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>24,684</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.07</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/10/10</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>210,555</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>31,131</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.64</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/13/13</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>340,262</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>2,292</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.0%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>43.61</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/12/08</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>11,850</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>William G. Dempsey</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>58,522(4)</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.2%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.03</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/19/14</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>648,424</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD WIDTH="2%"><FONT SIZE=0>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=1>Replacement Options:</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>31,172</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.1%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>41.64</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/13/13</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>340,710</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>2,278</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.0%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>43.86</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/13/07</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>7,312</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=2><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>2,279</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="15%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>0.0%</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>43.86</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>02/12/08</FONT></TD>
<TD WIDTH="4%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="TOP"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="12%" ALIGN="CENTER" VALIGN="TOP"><FONT SIZE=1>10,643</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=14><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>The
number of securities and exercise or base price have been adjusted to reflect the spin-off of Hospira,&nbsp;Inc. on April&nbsp;30, 2004.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>These
options contain a replacement feature. When the option's exercise price is paid (or, in the case of a non-qualified stock option, when the option's exercise price or
the withholding taxes resulting on exercise of that option are paid) with shares of Abbott's common stock, a replacement option is granted for the number of shares used to make that payment. The
replacement option has an exercise price equal to the fair market value of Abbott's common stock on the date the replacement option is granted, is exercisable in full six months after the date of
grant, and has a term expiring on the expiration date of the original option.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>These
values were determined using a Black-Scholes stock option valuation model. For options, other than replacement options, the model uses the following assumptions: expected
volatility of 32%, dividend yield of 2.2%, risk-free interest of 2.9%, and option life of 5.4&nbsp;years. For replacement options, the model uses the following assumptions: expected
volatility ranging between 17% and 32%, dividend yield ranging between 2.2% and 2.5%, risk-free interest ranging between 2.3% and 3.3%, and an option life equal to 54% of the option's
remaining term. Expected volatility is based on the historic volatility of Abbott stock over a period prior to the option's grant equal to the option's expected life. Dividend yield is based on the
option's exercise price and the annual dividend rate at the time of the grant. Risk-free interest is based on the rates available at the time of the grant for zero-coupon U.S.
government issues with a remaining term equal to the option's expected life.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>One-third
of the shares covered by these options are exercisable after one year; two-thirds after two years; and all after three years. </FONT>
<BR><BR>
</DD></DL>
<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>16</FONT></P>

<!-- ZEQ.=1,SEQ=20,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=198502,FOLIO='16',FILE='DISK047:[05CHI9.05CHI1029]DO1029A.;25',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_do1029_1_17"> </A>
<UL>
<P ALIGN="CENTER"><FONT SIZE=2><U>Aggregated Option/SAR Exercises in Last Fiscal Year and Year-End Option/SAR Values (1)</U></FONT></P>

</UL>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="21%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="10%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="5%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="19%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Number of Securities<BR>
Underlying Unexercised<BR>
Options/SARs at<BR>
Fiscal Year End (#)</FONT><BR></TH>
<TH WIDTH="5%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Value of Unexercised<BR>
In-the-Money Options/<BR>
SARs at<BR>
Fiscal Year End ($)</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="21%" ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH WIDTH="5%" ROWSPAN=2><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="10%" ROWSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Shares Acquired on Exercise (#)</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH WIDTH="21%" ALIGN="LEFT"><BR><FONT SIZE=1>Name</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=1><BR>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><BR>
Value Realized ($)</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=1><BR>&nbsp;</FONT></TH>
<TH WIDTH="19%" ALIGN="CENTER"><FONT SIZE=1><BR>
Exercisable/Unexercisable</FONT><BR></TH>
<TH WIDTH="5%"><FONT SIZE=1><BR>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1><BR>
Exercisable/Unexercisable</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=1>Miles D. White</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>2,611,778 / 1,080,013</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>13,134,098 / $8,316,098</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=1>Jeffrey M. Leiden, M.D., Ph.D.</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>29,774</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>251,168</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>887,225 /&nbsp;&nbsp;&nbsp;779,687</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>3,171,312 /&nbsp;&nbsp;5,964,838</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=1>Richard A. Gonzalez</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>0</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>1,064,008 /&nbsp;&nbsp;&nbsp;766,118</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>3,533,400 /&nbsp;&nbsp;5,897,536</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=1>Thomas C. Freyman</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>77,586</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>810,224</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>357,964 /&nbsp;&nbsp;&nbsp;163,670</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>766,029 /&nbsp;&nbsp;1,287,610</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="21%"><FONT SIZE=1>William G. Dempsey</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>47,202</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>406,867</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>483,103 /&nbsp;&nbsp;&nbsp;165,935</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><FONT SIZE=1>1,249,488 /&nbsp;&nbsp;1,293,357</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=11><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>The
number of shares has been adjusted for the spin-off of Hospira,&nbsp;Inc. on April&nbsp;30, 2004. </FONT></DD></DL>
<HR NOSHADE>

<P><FONT SIZE=2>17</FONT></P>

<!-- ZEQ.=2,SEQ=21,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=490449,FOLIO='17',FILE='DISK047:[05CHI9.05CHI1029]DO1029A.;25',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_dq1029_1_18"> </A> </FONT></P>

<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Pension and Retirement Arrangements </FONT></P>

<P><FONT SIZE=2>
Abbott and certain subsidiaries maintain a defined benefit pension plan known as the Abbott Laboratories Annuity Retirement Plan covering most employees in the United States, age 21 or older. Pension
benefits are generally based on service and eligible earnings for the 60 consecutive months within the final 120&nbsp;months of employment for which eligible earnings were highest. Pension benefits
are partially offset for Social Security benefits. </FONT></P>

<P><FONT SIZE=2>The
following table shows the estimated annual benefits payable to employees upon normal retirement. The amounts shown are computed on a straight life annuity basis without giving effect to Social
Security offsets and include supplemental benefits under a nonqualified supplemental pension plan. </FONT></P>

<P ALIGN="CENTER"><FONT COLOR="#2B85FF" SIZE=2>Pension Plan Table</FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TH>
<TH WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER"><FONT SIZE=1>Years of Service</FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%"><FONT SIZE=1>Remuneration</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>15</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>20</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>25</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>30</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>35</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2 ALIGN="CENTER"><HR NOSHADE></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=14 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;900,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>303,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>405,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>472,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>499,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>499,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>1,100,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>371,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>495,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>577,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>610,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>610,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>1,300,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>438,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>585,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>682,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>721,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>721,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>1,500,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>506,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>675,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>787,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>832,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>832,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>1,700,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>573,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>765,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>892,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>943,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>943,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>1,900,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>641,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>855,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>997,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,054,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,054,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>2,100,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>708,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>945,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,102,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,165,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,165,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>2,300,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>776,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,035,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,207,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,276,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,276,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>2,500,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>843,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,125,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,312,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,387,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,387,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>2,700,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>911,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,215,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,417,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,498,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,498,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>2,900,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>978,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,305,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,522,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,609,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,609,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>3,100,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,046,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,395,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,627,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,720,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,720,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>3,300,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,113,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,485,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,732,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,831,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,831,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>3,500,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,181,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,575,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,837,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,942,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,942,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>3,700,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,248,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,665,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,942,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,053,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,053,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>3,900,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,316,250</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,755,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,047,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,164,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,164,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="10%" ALIGN="CENTER"><FONT SIZE=1>4,100,000</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,383,750</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>1,845,000</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,152,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,275,500</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>2,275,500</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=2 ALIGN="CENTER"><HR NOSHADE></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=14 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>The compensation considered in determining the pensions payable to the named officers is the compensation shown in the "Salary" and "Bonus" columns of the
Summary Compensation Table on page&nbsp;15. Pensions accrued under the Annuity Retirement Plan are funded through the Abbott Laboratories Annuity Retirement Trust, established on behalf of all
participants in that plan. Pensions accrued under the nonqualified supplemental pension plan with present values exceeding $100,000 are funded through individual trusts established on behalf of the
officers who participate in that plan. </FONT></P>

<P><FONT SIZE=2>During
2004, the following amounts, less applicable tax withholdings, were deposited in such individual trusts established on behalf of the named officers: M.&nbsp;D.&nbsp;White,&nbsp;$866,651;
R.&nbsp;A.&nbsp;Gonzalez,&nbsp;$478,944; T.&nbsp;C.&nbsp;Freyman,&nbsp;$294,768; and W.&nbsp;G.&nbsp;Dempsey,&nbsp;$647,018. As of December&nbsp;31, 2004, the years of service
credited under the Plan for the named officers were as follows: M.&nbsp;D.&nbsp;White&nbsp;-&nbsp;20;
J.&nbsp;M.&nbsp;Leiden&nbsp;-&nbsp;4;&nbsp;R.&nbsp;A.&nbsp;Gonzalez&nbsp;-&nbsp;24; T.&nbsp;C.&nbsp;Freyman&nbsp;-&nbsp;25; and
W.&nbsp;G.&nbsp;Dempsey&nbsp;-&nbsp;22. </FONT></P>

<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Key Employee Retention </FONT></P>


<P><FONT SIZE=2>
Abbott has change in control arrangements with its management team, in the form of change in control agreements for Abbott officers and a change in control plan for other key management personnel. The
agreements with the named officers are described below. </FONT></P>

<P><FONT SIZE=2>The
agreements with the named officers continue in effect until December&nbsp;31, 2007, and at the end of each year will automatically be extended through the third year thereafter unless Abbott
notifies the officer that the agreement will not be extended. The agreements also automatically extend for two years following any change in control (as defined in the agreements) that occurs while
they are in effect. The agreements provide that if the officer is terminated other than for specified reasons or if the officer elects to terminate employment under certain circumstances during a
potential change in control (as defined in the agreements) or within two years following a change in control of Abbott (including termination by the officer for any reason during the
thirty-day window period which begins six months after the date of a change in control), the officer is entitled to </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>18</FONT></P>

<!-- ZEQ.=1,SEQ=22,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=339341,FOLIO='18',FILE='DISK047:[05CHI9.05CHI1029]DQ1029A.;16',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_dq1029_1_19"> </A>
<BR>

<P><FONT SIZE=2>
receive a lump sum payment equal to three times the officer's annual salary and bonus (assuming for this purpose that all target performance goals have been achieved or, if higher, based on the
average bonus for the last three years), plus any unpaid bonus owing for any completed performance period and the pro rata bonus for any current bonus period (based on the highest of the bonus
assuming achievement of target performance, the average bonus for the past three years, or in the case of the unpaid bonus for any completed performance period, the actual bonus earned). The officer
will also receive up to three years of additional employee benefits (including outplacement services and tax and financial counseling for three years and the value of three more years of pension
accruals), payment of any excise taxes and other related taxes and payments for which the officer is responsible as a result of the agreement, and reimbursement of certain legal, tax and audit fees.
The agreements also limit the conduct for which awards under Abbott's stock incentive programs can be terminated and generally permit options to remain exercisable for the remainder of their term.
Independent compensation consultants confirm that the level of payments provided under the agreements is consistent with current market practice. </FONT></P>

<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Performance Graph </FONT></P>

<P><FONT SIZE=2>
The following graph compares the change in Abbott's cumulative total shareholder return on its common shares with the Standard&nbsp;&amp; Poor's 500 Index and the Standard&nbsp;&amp; Poor's 500 Health
Care Index. Abbott's cumulative total shareholder returns have outperformed both the Standard&nbsp;&amp; Poor's 500 Index and the Standard and Poor's 500 Health Care Index over the period shown on the
following graph. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2>
<IMG SRC="g368266.jpg" ALT="PERFORMANCE CHART" WIDTH="672" HEIGHT="463">
 </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>19</FONT></P>

<!-- ZEQ.=2,SEQ=23,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=630767,FOLIO='19',FILE='DISK047:[05CHI9.05CHI1029]DQ1029A.;16',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2><A
NAME="page_du1029_1_20"> </A> </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Ratification of Independent Registered Public Accountants (Item&nbsp;2 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>Abbott's
bylaws provide that the audit committee shall appoint annually a firm of independent registered public accountants to serve as auditors. In October&nbsp;2004, the audit committee appointed
Deloitte&nbsp;&amp; Touche LLP to act as auditors for 2005. Deloitte&nbsp;&amp; Touche LLP has served as Abbott's auditors since 2002. </FONT></P>

<P><FONT SIZE=2>Although
the audit committee has sole authority to appoint auditors, it would like to know the opinion of the shareholders regarding its appointment of Deloitte&nbsp;&amp; Touche LLP as auditors for
2005. For this reason, shareholders are being asked to ratify this appointment. If the shareholders do not ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as auditors for 2005, the audit
committee will take that fact into consideration, but may, nevertheless, continue to retain Deloitte&nbsp;&amp; Touche LLP. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends a vote FOR ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as independent registered
public accountants for 2005.</FONT></P>

<P><FONT SIZE=2>Representatives of Deloitte&nbsp;&amp; Touche LLP are expected to be present at the Annual Meeting and will be given the opportunity to make a statement if they
desire to do so. They will also be available to respond to appropriate questions. </FONT></P>

<P><FONT SIZE=2>Audit Fees and Non-Audit Fees </FONT></P>

<P><FONT SIZE=2>
The following table presents fees for professional audit services by Deloitte&nbsp;&amp; Touche LLP, the member firms of Deloitte Touche Tohmatsu, and their respective affiliates ("the Deloitte
Entities") for the audit of Abbott's annual financial statements for the years ended December&nbsp;31, 2004 and December&nbsp;31, 2003, and fees billed for other services rendered by the Deloitte
Entities during these periods. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="69%" ALIGN="LEFT"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=2>2004</FONT><HR NOSHADE></TH>
<TH WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=2>2003</FONT><HR NOSHADE></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>Audit fees:(1)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>11,257,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>6,725,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>Audit related fees:(2)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>98,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>1,873,000</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>Tax fees:(3)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>2,588,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>2,032,000</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>All other fees:(4)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>&#151;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD WIDTH="69%"><FONT SIZE=2>Total</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>13,943,000</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>$</FONT></TD>
<TD WIDTH="11%" ALIGN="RIGHT"><FONT SIZE=2>10,630,000</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD><FONT SIZE=2>The
Deloitte Entities billed or will bill Abbott for professional services rendered for: the audit of Abbott's annual financial statements and the review of Abbott's financial
statements included in Abbott's quarterly reports, the 2004 Sarbanes-Oxley Section&nbsp;404 attestation, statutory and subsidiary audits, the review of documents filed with the Securities and
Exchange Commission, and certain accounting consultations in connection with the audits.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD><FONT SIZE=2>Audit
related fees include: accounting consultations and audits in connection with proposed acquisitions and divestitures, and internal control consultations related to Sarbanes-Oxley
Section&nbsp;404 compliance.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD><FONT SIZE=2>Tax
fees consist principally of professional services rendered by the Deloitte Entities for tax compliance and tax planning and advice including assistance with tax audits and
appeals, and tax advice related to mergers and acquisitions.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD><FONT SIZE=2>No
fees for other service were incurred in 2004 or 2003. </FONT></DD></DL>

<P><FONT SIZE=2>Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of the Independent Auditor </FONT></P>

<P><FONT SIZE=2>
The audit committee has established policies and procedures to pre-approve all audit and permissible non-audit services performed by the Deloitte Entities after
January&nbsp;1, 2003. </FONT></P>

<P><FONT SIZE=2>Prior
to engagement of the independent registered public accounting firm for the next year's audit, management will submit a schedule of all proposed services expected to be rendered during that year
for each of four categories of services to the audit committee for approval. </FONT></P>

<P><FONT SIZE=2>Prior
to engagement, the audit committee pre-approves these services by category of service. The fees are budgeted and the audit committee requires the independent registered public
accounting firm and management to report actual fees versus the budget periodically by category of service. During the year, circumstances may arise when it may become necessary to engage the
independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the audit committee requires specific
pre-approval before engaging the independent registered public accounting firm. </FONT></P>

<P><FONT SIZE=2>The
audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report any pre-approval decisions to
the audit committee at its next scheduled meeting. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>20</FONT></P>

<!-- ZEQ.=1,SEQ=24,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=374323,FOLIO='20',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_21"> </A>
<BR><BR>
<HR NOSHADE>

<P><FONT COLOR="#2B85FF" SIZE=2>Report of the Audit Committee </FONT></P>

<P><FONT SIZE=2>Management
is responsible for Abbott's internal controls and the financial reporting process. The independent registered public accounting firm is responsible for performing an audit of the
consolidated financial statements and expressing an opinion on the conformity of those financial statements with accounting principles generally accepted in the United States of America, as well as
expressing an opinion on (i)&nbsp;management's assessment of the effectiveness of internal control over financial reporting and (ii)&nbsp;the effectiveness of internal control over financial
reporting. The audit committee reviews these processes on behalf of the board of directors. In this context, the committee has reviewed and discussed the audited financial statements contained in the
2004 Annual Report on Form&nbsp;10-K with Abbott's management and its independent registered public accounting firm. </FONT></P>

<P><FONT SIZE=2>The
committee has discussed with the independent registered public accounting firm the matters required to be discussed by the Statement on Auditing Standards No.&nbsp;61
(</FONT><FONT SIZE=2><I>Communication with Audit Committees</I></FONT><FONT SIZE=2>), as amended. </FONT></P>

<P><FONT SIZE=2>The
committee has received the written disclosures and the letter from the independent registered public accounting firm required by Independence Standards Board Standard No.&nbsp;1
(</FONT><FONT SIZE=2><I>Independence Discussions with Audit Committees</I></FONT><FONT SIZE=2>), as amended, and has discussed with the independent registered public accounting firm their
independence. The committee has also considered whether the provision of the services described on page&nbsp;20 under the caption "Audit Fees and Non-Audit Fees" is compatible with
maintaining the independence of the independent registered public accounting firm. </FONT></P>


<P><FONT SIZE=2>Based
on the review and discussions referred to above, the committee recommended to the board of directors that the audited financial statements be included in Abbott's Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2004 filed with the Securities and Exchange Commission. </FONT></P>

<P><FONT SIZE=2><I><U>Audit Committee</U>  </I></FONT></P>


<P><FONT SIZE=2>
J.&nbsp;M. Greenberg, chairman, R.&nbsp;S. Austin, D.&nbsp;A.&nbsp;L. Owen, W.&nbsp;D.&nbsp;Smithburg and J.&nbsp;R. Walter </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </FONT></P>

<P><FONT SIZE=2>Abbott
believes that during 2004 its officers and directors complied with all filing requirements under Section&nbsp;16(a) of the Securities Exchange Act of 1934.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposals </FONT></P>

<P><FONT SIZE=2>Six
shareholder proposals have been received. Abbott is advised that the proposals will be presented for action at the Annual Meeting. The proposed resolutions and the statements made in support
thereof are presented below. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you&nbsp;vote AGAINST the proposals. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>21</FONT></P>

<!-- ZEQ.=2,SEQ=25,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=370399,FOLIO='21',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_22"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal on Executive Compensation (Item&nbsp;3 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>Ronald
M. Friedman, 5743 Theobald Road, Morton Grove, Illinois 60053-3047, owner of 303 Abbott common shares, has informed Abbott that he intends to present the following proposal at the
meeting: </FONT></P>

<P><FONT SIZE=2>Shareholders
request that the board of directors grant no bonuses, pay raises, stock options, restricted stock or any other additional benefits, other than salary, for the five highest compensated
executive officers in any year in which Abbott or any of its 50% or more owned subsidiaries pay any fines to government agencies in excess of fifteen million dollars. This applies only to compensation
agreements made in the future. </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>I
believe that Abbott's management and board of directors should conduct our company's business in such a manner so we do not incur government fines. This resolution makes it clear to our management
and directors, that operating in ways to incur government fines is unacceptable to shareholders. The following table lists the consent decrees and other settlements and corresponding bonuses, options
and restricted stock granted to the chief executive officer. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="101%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1>Year</FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Amount of<BR>
Payment to<BR>
Government</FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Bonus</FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>Options<BR>
Granted</FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER"><FONT SIZE=1>Restricted<BR>
Stock</FONT><HR NOSHADE></TH>
<TH WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH WIDTH="53%" ALIGN="CENTER"><FONT SIZE=1>Government<BR>
Action</FONT><HR NOSHADE></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=1>1999</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1>100,000,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1>800,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1>439,895</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1>0</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=1>Consent Decree - with FDA</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=1><BR>
2001</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1><BR>
437,500,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1><BR>
2,100,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1><BR>
748,302</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1><BR>
2,089,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=1><BR>
Dept. of Justice Settlement with TAP</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=1><BR>
2002</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1><BR>
129,000,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1><BR>
1,250,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1><BR>
635,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="9%" ALIGN="RIGHT"><FONT SIZE=1><BR>
11,468,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=1><BR>
Continued Payment from 1999 Consent Decree</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="4%"><FONT SIZE=1><BR>
2003</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="10%" ALIGN="RIGHT"><FONT SIZE=1><BR>
534,000,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>$</FONT></TD>
<TD WIDTH="8%" ALIGN="RIGHT"><FONT SIZE=1><BR>
1,750,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="RIGHT"><FONT SIZE=1><BR>
635,000</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><BR>
0</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="53%"><FONT SIZE=1><BR>
Ross Enteral Nutrition Investigation</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal on Executive
Compensation (Item&nbsp;3 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>As
a health care company, Abbott operates in a complex, dynamic and highly regulated environment. Abbott's management is committed to ensuring that its practices comply with applicable laws and
regulations worldwide and to promoting the highest ethical standards. </FONT></P>

<P><FONT SIZE=2>This
commitment to compliance is embodied in the company's management systems and programs. For example, Abbott's Code of Business Conduct provides guidelines to all employees on ethical and legal
issues. Furthermore, Abbott's Office of Ethics and Compliance makes available to employees a number of resources to enhance compliance, including an Ethics and Compliance Helpline, a
toll-free number available to all employees 24&nbsp;hours a day, seven days a week; division level compliance staff; and extensive in-person as well as Web-based
training programs. </FONT></P>

<P><FONT SIZE=2>Management
is charged with resolving legal or compliance issues in the long-term interests of shareholders, patients and employees. In some circumstances, these interests are best served
through settlement of disputes, regardless of fault. Such settlements minimize legal costs and risks of protracted litigation, as well as avoid disruption to the business. </FONT></P>

<P><FONT SIZE=2>Linking
executive compensation to a single dimension such as settlement decisions is inappropriate. Abbott's total compensation program is competitive and performance driven, aligning compensation
with the achievement of annual and long-term goals, and the company's values. Compensation decisions are based on multiple dimensions designed to ensure that management is furthering
shareholder interests. Management's incentive compensation reflects these multiple dimensions. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>22</FONT></P>

<!-- ZEQ.=3,SEQ=26,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=276647,FOLIO='22',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_23"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal Concerning Performance-Based Options (Item&nbsp;4 on Proxy Card) </FONT></P>


<P><FONT SIZE=2>The
United Brotherhood of Carpenters Pension Fund, 101 Constitution Avenue, N.W., Washington, D.C. 20001, owner of 25,400 Abbott common shares, has informed Abbott that it intends to present the
following proposal at the meeting: </FONT></P>

<P><FONT SIZE=2><I>Resolved</I></FONT><FONT SIZE=2>: That the shareholders of Abbott Laboratories (the "Company") request that the Compensation Committee of the Board of Directors adopt a policy
that a significant portion of future stock option grants to senior executives shall be performance-based. Performance-based options are defined as follows: (1)&nbsp;indexed options, in which the
exercise price is linked to an industry or well-defined peer group index; (2)&nbsp;premium-priced stock options, in which the exercise price is set above the market price on the grant
date; or (3)&nbsp;performance-vesting options, which vest when a performance target is met.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>As
long-term shareholders of the Company, we support executive compensation policies and practices that provide challenging performance objectives and serve to motivate executives to
enhance long-term corporate value. We believe that standard fixed-price stock option grants can and often do provide levels of compensation well beyond those merited, by reflecting stock
market value increases, not performance superior to the company's peer group. </FONT></P>

<P><FONT SIZE=2>Our
shareholder proposal advocates performance-based stock options in the form of indexed, premium-priced or performance-vesting stock options. With indexed options, the option exercise price moves
with an appropriate peer group index so as to provide compensation value only to the extent that the company's stock price performance is superior to the companies in the peer group utilized.
Premium-priced options entail the setting of an option exercise price above the exercise price used for standard fixed-priced options so as to provide value for stock price performance that exceeds
the premium option price. Performance-vesting options encourage strong corporate performance by conditioning the vesting of granted options on the achievement of demanding stock and/or operational
performance measures. </FONT></P>

<P><FONT SIZE=2>Our
shareholder proposal requests that the Company's Compensation Committee utilize one or more varieties of performance-based stock options in constructing the long-term equity portion of
the senior executives' compensation plan. The use of performance-based options, to the extent they represent a significant portion of the total options granted to senior executives, will help place a
strong emphasis on rewarding superior corporate performance and the achievement of demanding performance goals. </FONT></P>

<P><FONT SIZE=2>Leading
investors and market observers, such as Warren Buffet and Alan Greenspan, have criticized the use of fixed-price options on the grounds that they all to often reward mediocre or poor
performance. The Conference Board's Commission on Public Trust and Private Enterprise in 2002 looked at the issue of executive compensation and endorsed the use of performance-based options to help
restore public confidence in the markets and U.S. corporations. </FONT></P>

<P><FONT SIZE=2>At
present, the Company does not employ performance-based stock options as defined in this proposal, so shareholders cannot be assured that only superior performance is being rewarded.
Performance-based options can be an important component of a compensation plan designed to focus senior management on accomplishing long-term corporate strategic goals and superior
long-term corporate performance. We urge your support for this important executive compensation reform.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal Concerning
Performance-Based Options (Item&nbsp;4 on Proxy Card)</FONT></P>

<P><FONT SIZE=2>The
Abbott board of directors supports the concept of performance-based compensation for all employees. In the opinion of the board, the interests of its executive officers are already aligned with
the interests of shareholders through the grant of fixed-priced fair market value stock options. Fixed-priced stock options are inherently performance-based because the exercise price (sometimes
called grant price) equals the market price of Abbott common stock on the date of grant. Employees realize no economic benefit unless Abbott's stock price increases in value subsequent to the grant
date, thereby benefiting all shareholders. </FONT></P>

<P><FONT SIZE=2>As
stated in the Compensation Committee Report on pages 13 and 14 of this Proxy Statement, performance-based compensation is an important component of executive compensation and represents a
substantial part of Abbott's compensation program. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>23</FONT></P>

<!-- ZEQ.=4,SEQ=27,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=593011,FOLIO='23',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_24"> </A>
<BR>

<P><FONT SIZE=2>The
board opposes the specific performance-based options recommended by the proponent because they are not prevalent in the marketplace and may disadvantage the company in attracting and retaining
critical personnel. Further, given the valuation methods utilized, the use of alternative forms of incentive could require the company to grant more shares than it would otherwise award with a
traditional option grant to remain competitive. In addition, variability in accounting charges associated with some performance-based options could create volatility in earnings and performance
comparisons. </FONT></P>

<P><FONT SIZE=2>It
is in the best interests of shareholders to preserve the flexibility and discretion of the independent Compensation Committee to design a long-term incentive program that is the most
appropriate for attracting and retaining industry-leading executive talent. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>24</FONT></P>

<!-- ZEQ.=5,SEQ=28,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=738942,FOLIO='24',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_25"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal Concerning </FONT><FONT COLOR="#2B85FF" SIZE=2><I>In Vitro</I></FONT><FONT COLOR="#2B85FF" SIZE=2> Testing (Item 5 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>John
M. Carter (owner of 478 Abbott common shares), The Enid K. Dillon Trust (owner of 3,000 Abbott common shares), and Cornelia Cerf (owner of 300 Abbott common shares), through their attorney, Susan
L. Hall, 2818 Connecticut Avenue, N.W., Washington, D.C., 20008, have informed Abbott that they intend to present the following proposal at the meeting. </FONT></P>

<P><FONT SIZE=2>WHEREAS,
statistics published by research oversight bodies in North America and Europe document that the vast majority of painful and distressing animal experiments are conducted to satisfy outdated,
government-mandated testing requirements<SUP>1</SUP> and that such testing is on the rise;<SUP>2</SUP> and </FONT></P>


<P><FONT SIZE=2>WHEREAS,
nearly 60% of animals used in regulatory testing suffer pain ranging from moderate to severe, all the way to pain near, at, or above the pain tolerance threshold,<SUP>3</SUP> generally
without any pain relief; and </FONT></P>

<P><FONT SIZE=2>WHEREAS,
non-animal test methods are generally less expensive,<SUP>4</SUP> more rapid, and always more humane, than animal-based tests; and </FONT></P>

<P><FONT SIZE=2>WHEREAS,
unlike animal tests, non-animal methods have been scientifically validated and/or accepted as total replacements for the following five toxicity endpoints: skin corrosion
(irreversible tissue damage), skin irritation (milder and reversible damage), skin absorption (the rate of chemical penetration), phototoxicity (an inflammatory reaction caused by the interaction of a
chemical with sunlight), and pyrogenicity (a fever-like reaction that can occur when certain intravenous drugs interact with the immune system); </FONT></P>

<P><FONT SIZE=2>NOW
THEREFORE BE IT RESOLVED, that the shareholders request that the Board: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Commit
specifically to using only non-animal methods for assessing skin corrosion, irritation, absorption, phototoxicity and pyrogenicity.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Confirm
that it is in the Company's best interest to commit to replacing animal-based tests with non-animal methods.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Petition
the relevant regulatory agencies requiring safety testing for the Company's products to accept as total replacements for animal-based methods, those approved
non-animal methods described above, along with any others currently used and accepted by the Organization for Economic Cooperation and Development (OECD) and other developed countries. </FONT></DD></DL>
<BR>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>This
Resolution is designed to harmonize the interests of sound science with the elimination of animal-based test methods where non-animal methodologies exist. It seeks to encourage the
relevant regulatory agencies to join their peers in accepting validated </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and other non-animal test methods. It will not compromise
consumer safety or violate applicable statutes and regulations. </FONT></P>

<P><FONT SIZE=2>Further,
this Resolution commits the Company to end animal testing for five specific endpoints in favor of valid non-animal methods. These include the 3T3 Neutral Red Uptake Phototoxicity
Test, human skin equivalent tests for corrosivity, and a human blood-based test for pyrogenicity, all of which have been successfully validated through the European Centre for the Validation of
Alternate Methods.<SUP>5</SUP> Several non-animal methods have also been adopted as Test Guidelines by the OECD<SUP>6</SUP> (an alliance of 30 member countries including the US, EU,
Japan, Canada and Australia). Regulatory agencies in OECD member countries are not at liberty to reject data from non-animal tests for skin corrosion, skin absorption and phototoxicity
where such data have been generated in accordance with an OECD Test Guideline. </FONT></P>

<P><FONT SIZE=2>We
urge shareholders to support this Resolution. </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="36">
<DL compact>
<DT style='margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD><FONT SIZE=1>CCAC
Animal Use Survey - 2001: http://www.ccac.ca/english/FACTS/Facframeaus2001.htm. </FONT></DD><DT style='margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD><FONT SIZE=1>Statistics
of Scientific Procedures on Living Animals - Great Britain - 2002. http://www.official-documents.co.uk/document/cm58/5886/5886.htm. </FONT></DD><DT style='margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD><FONT SIZE=1>CCAC
Animal Use Survey - 2001. </FONT></DD><DT style='margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD><FONT SIZE=1>Derelanko
MJ and Hollinger MA (Eds.). (2002). </FONT><FONT SIZE=1><I>Handbook of Toxicology, Second Ed</I></FONT><FONT SIZE=1>, 1414 pp. Washington, DC: CRC Press. </FONT></DD><DT style='margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD><FONT SIZE=1>ECVAM
website: http://ecvam.jrc.it. </FONT></DD><DT style='margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD><FONT SIZE=1>OECD
test guidelines: http://www.oecd.org/document/22/0,2340,en_2649_34377_1916054_1_1_1_1,00.html. </FONT></DD></DL>
<HR NOSHADE>

<P><FONT SIZE=2>25</FONT></P>

<!-- ZEQ.=6,SEQ=29,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=102926,FOLIO='25',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_26"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal Concerning </FONT> <FONT COLOR="#2B85FF" SIZE=2><I>In Vitro</I></FONT><FONT COLOR="#2B85FF" SIZE=2> Testing (Item 5 on Proxy Card) </FONT></P>


<P><FONT SIZE=2>The
company uses </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> (non-animal) tests, including those mentioned in the proposal, where the methods have been proven as
scientifically valid and approved by regulatory agencies around the world. Abbott's
preference is to use </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> tests whenever appropriate, if these tests do not compromise patient safety or the effectiveness of our medicines. </FONT></P>

<P><FONT SIZE=2>The
requirement of this proposal to replace all animal-based tests with </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> tests is unfeasible. There are insufficient </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> tests approved and available to allow Abbott to discover and test new medicines. It has been scientifically proven that many </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> tests do not mimic the true biological state, and therefore, cannot be relied upon to determine safety and efficacy of medicines. To date, </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> tests can comprise but a small component of overall testing that is required by regulatory bodies. Abbott is required by national and international regulatory agencies to
use </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> (animal) testing to meet our commitment to provide patients with safe and effective medicines. </FONT></P>

<P><FONT SIZE=2>Abbott
respects the unique role animals have played in advancing medical discovery, without which millions of people would not realize the benefits of the many treatments that improve and save lives.
Abbott's animal welfare and treatment policies and practices reflect industry best standards. Our program and facilities meet regulations of the United States, European Union and other countries,
including the U.S. Animal Welfare Act and the standards established by the National Research Council's </FONT><FONT SIZE=2><I>Guide for the Care and Use of Laboratory Animals</I></FONT><FONT SIZE=2>.
Abbott's program has been accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) since 1975. In past site reviews by AAALAC, our company's
program has been noted to be exemplary. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>26</FONT></P>

<!-- ZEQ.=7,SEQ=30,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=285056,FOLIO='26',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_27"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal Concerning Political Contributions (Item 6 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>The
Mercy Investment Program, 205 Avenue C, #10E, New York, New York 10009, owner of 150 Abbott common shares, and three other proponents have informed Abbott that they intend to present the following
proposal at the meeting. </FONT></P>

<P><FONT SIZE=2>Resolved,
that the shareholders of Abbott Laboratories ("Company") hereby request that the Company provide a report updated semi-annually, disclosing the Company's: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Policies
and procedures for political contributions (both direct and indirect) made with corporate funds.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Monetary
and non-monetary contributions to political candidates, political parties, political committees and other political entities organized and operating under 26 USC
Sec. 527 of the Internal Revenue Code including the following:
<BR><BR></FONT>
<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD><FONT SIZE=2>An
accounting of the Company's funds contributed to any of the persons described above;
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD><FONT SIZE=2>The
business rationale for each of the Company's political contributions; and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>c.</FONT></DT><DD><FONT SIZE=2>Identification
of the person or persons in the Company who participated in making the decisions to contribute. </FONT></DD></DL>
</DD></DL>

<P><FONT SIZE=2>This
report shall be posted on the company's website to reduce costs to shareholders.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>As
long-term shareholders of Abbott Laboratories we support policies that apply transparency and accountability to corporate political giving. In our view, such disclosure is consistent
with public policy in regard to public company disclosure. </FONT></P>

<P><FONT SIZE=2>There
are various disclosure requirements for political contributions but they are difficult for shareholders to access and are not complete. Although the Bi-Partisan Campaign Reform Act
enacted in 2002 prohibits corporate contributions to political parties at the federal level, corporate soft money state-level contributions are legal in 49 states and disclosure standards vary widely. </FONT></P>

<P><FONT SIZE=2>Corporations
can also make unlimited contributions to "Section&nbsp;527" organizations, political committees formed for the purpose of influencing elections but not supporting or opposing specific
candidates. These do not have to be reported. </FONT></P>

<P><FONT SIZE=2>Between
January&nbsp;1, 1991 and December&nbsp;31, 2002 the Pharmaceutical Research and Manufacturers Association (PhRMA)&#151;of which the company is a dues-paying
member&#151;gave $35.5&nbsp;million in soft money political contributions. (Follow the Dollar Report, July&nbsp;1, 2003, Common Cause). </FONT></P>


<P><FONT SIZE=2>Company
executives exercise wide discretion over the use of corporate resources for political purposes. They make decisions without a stated business rationale for such donations. In
2001-02, the last fully reported election cycle, Abbott Laboratories contributed at least $335,100 (The Center for Responsive Politics, Soft Money Donors,
http://www.opensecrets.org/softmoney). </FONT></P>

<P><FONT SIZE=2>Relying
only on the limited data available from Federal Election Commission and the Internal Revenue Service, the Center for Responsive Politics, a leading campaign finance watchdog organization,
provides an incomplete picture of the Company's political donations. </FONT></P>


<P><FONT SIZE=2>Proponents
believe our company should be using its resources to win in the marketplace through superior products and services to its customers not because it has superior access to political leaders.
Political power can change, leaving companies relying on this strategy vulnerable. </FONT></P>

<P><FONT SIZE=2>Finally,
the requested report represents a minimal cost to the company, as presumably management already monitors corporate resources used for such purposes. Although lacking a business rationale for
such contributions, our peer company Pfizer discloses these contributions on an annual basis. </FONT></P>

<P><FONT SIZE=2>There
is currently no single source of information that provides the information sought by this resolution. That is why we urge your support for this critical governance reform. </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal Concerning Political
Contributions (Item 6 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>The
Abbott board of directors views Abbott's participation in the political process on issues that influence patients' access to affordable and innovative medicines and the company's
long-term success to be appropriate. For example, the company's political involvement has contributed to providing 41&nbsp;million Medicare seniors with access to discounts on their
medicines; increased funding for AIDS Drug Assistance Programs that will benefit 87,000 patients; and ensuring Medicare coverage for thousands of patients using </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>27</FONT></P>

<!-- ZEQ.=8,SEQ=31,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=807977,FOLIO='27',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_28"> </A>

<P><FONT SIZE=2>
end-stage renal care and self-injectable rheumatoid arthritis medicines. </FONT></P>

<P><FONT SIZE=2>Information
about the political contributions of Abbott and the Abbott Laboratories Employee Political Action Committee (AEPAC) is publicly available on the Federal Election Commission (FEC) Web site
(www.fec.gov) and state election Web sites. </FONT></P>


<P><FONT SIZE=2>Abbott
and its employees participate in the political process with contributions to federal and state political candidates and parties. All AEPAC funds, which represent the primary source of political
contributions to candidates in 2004, come from voluntary, personal contributions of Abbott employees. </FONT></P>

<P><FONT SIZE=2>Support
from Abbott and AEPAC for any candidate is bipartisan and based on clear criteria: policy positions that reflect Abbott's interests; representation of geographic areas where Abbott employees
and facilities are located; relevant legislative committee assignments; political track record; ability to be elected; and need for financial assistance. For example, the company has supported
political candidates from both parties who are working to expand access of health care to uninsured patients; who believe in the free market system; who value the importance of medical innovation; and
who support protection of intellectual property. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>28</FONT></P>

<!-- ZEQ.=9,SEQ=32,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=653374,FOLIO='28',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_29"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal Concerning HIV/AIDS-TB-Malaria Pandemics (Item 7 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>The
Maryland Province of the Society of Jesus, 5704 Roland Avenue, Baltimore, Maryland 21210-1399 and 28 other proponents have informed Abbott that they intend to present the following
proposal at the meeting. Abbott will provide the proponents' names and addresses to any shareholder who requests that information and, if provided by a proponent to Abbott, the number of Abbott common
shares held by that proponent. </FONT></P>

<P><FONT SIZE=2><I>Resolved</I></FONT><FONT SIZE=2>: Shareholders request that our Board review the economic effects of the HIV/AIDS, tuberculosis and malaria pandemics on the company's business
strategy, and its initiatives to date, and report to shareholders within six (6)&nbsp;months following the 2005 annual meeting. This report, developed at reasonable costs and omitting proprietary
information, will identify the impacts of these pandemics on the company.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>We
believe that HIV/AIDS, Tuberculosis (TB) and Malaria pose major risks to the long-term financial health of firms, like Abbott Laboratories that operate in emerging markets. </FONT></P>

<P><FONT SIZE=2>The
crisis of HIV/AIDS in Africa, with half of all global HIV/AIDS cases, is well known. UNAIDS&#151;the joint United Nations AIDS program&#151;reports life expectancy in much of
southern Africa has declined by over half, to barely thirty years. </FONT></P>

<P><FONT SIZE=2>New
research also shows disturbing trends in Asian markets. New infection rates in Asia are at all-time highs. 7.4&nbsp;million people there are living with HIV. India alone has more
citizens living with HIV than any country, except South Africa. ("Report on the Global AIDS Pandemic," UNAIDS 2004). </FONT></P>


<P><FONT SIZE=2>Foreign
Affairs reported in December&nbsp;2002 that even moderate HIV pandemics in India and China may reduce per capita GNP by 2025 to virtually 2000 levels&#151;wiping out a generation's
worth of economic growth. </FONT></P>

<P><FONT SIZE=2>In
China, UNAIDS projects 10&nbsp;million infections by 2010. Stephen Roach, Morgan Stanley's Chief Economist, wrote in June&nbsp;2004 that "all the economic growth in the world cannot possibly
compensate for the devastation China would face if [UNAIDS] projections were to come to pass." </FONT></P>

<P><FONT SIZE=2>Standard
Chartered Bank Group Chief Executive Mervyn Davies, in a 2004 World Economic Forum report, cautioned that "AIDS imposes a day-to-day economic 'tax' that compromises
business productivity." Firms pay in increased health and benefit costs, decreased productivity, higher turnover, and other ways. </FONT></P>


<P><FONT SIZE=2>Despite
these warnings, the same report concluded "firms are not particularly active in combating HIV/AIDS" and "businesses appear to be making decisions based on a patchy assessment of the risks they
face." </FONT></P>

<P><FONT SIZE=2>Unfortunately,
"most companies do not yet report appropriate data for investors to make informed decisions about the impact of HIV/AIDS," says a 2003 survey of corporations by UNAIDS. We believe, to
date, our company's reporting has also been inadequate. </FONT></P>

<P><FONT SIZE=2>In
contrast to our company's performance, several large-cap firms make reporting on infectious diseases best practice. The Bill&nbsp;&amp; Melinda Gates Foundation has funded an HIV/AIDS
Resource Document at the Global Reporting Initiative. </FONT></P>

<P><FONT SIZE=2>In
2004, Coca-Cola shareholders approved a resolution seeking such a report with 98% support. Coca-Cola's subsequent report notes "the moral and business imperatives are of
equal importance" in responding to HIV/AIDS. </FONT></P>

<P><FONT SIZE=2>Our
experience with Coca-Cola and other leading companies demonstrates that these reports need not be onerous. In our opinion, shareholders must fully understand the threats posed by these
diseases in order to make informed assessments of our company's value. </FONT></P>


<P><FONT SIZE=2>We
urge shareholders to vote FOR this resolution.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal Concerning
HIV/AIDS&#151;TB&#151;Malaria Pandemics (Item 7 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>This
proposal is unnecessary because the company already recognizes that HIV/AIDS poses a serious social and health threat globally. Moreover, the health, economic and social impacts of this pandemic
have been documented by many organizations including UNAIDS, WHO, World Bank, think tanks such as the Center for Strategic and International Studies, business organizations such as the Global Business
Coalition on HIV/AIDS, and several U.S. government agencies. </FONT></P>

<P><FONT SIZE=2>Abbott
is a leader among global health care companies and is already addressing this pandemic on multiple fronts. Our company's efforts include research and development of new HIV medicines and
diagnostic instruments and tests; comprehensive workplace policies; humanitarian initiatives to assist developing countries; </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>29</FONT></P>

<!-- ZEQ.=10,SEQ=33,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=892509,FOLIO='29',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_30"> </A>
<BR>

<P><FONT SIZE=2>
and encompass advocacy for U.S. and multilateral funding to address HIV/AIDS in countries hardest hit by this disease. Abbott's efforts have been documented in our Global Citizenship reports and Web
site. </FONT></P>

<P><FONT SIZE=2>The
creation of further reviews and another report as required by the proposal are not productive uses of company resources. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>30</FONT></P>

<!-- ZEQ.=11,SEQ=34,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=394641,FOLIO='30',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_31"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Shareholder Proposal on Separating the Roles of Chair and CEO (Item 8 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>Catholic
Healthcare West, 185 Berry Street, Suite 300, San Francisco, California 94107-1739, owner of 195,120 Abbott common shares, and 6 other proponents have informed Abbott that they
intend to present the following proposal at the meeting. Abbott will provide the proponents' names and addresses to any shareholder who requests that information and, if provided by a proponent to
Abbott, the number of Abbott common shares held by that proponent. </FONT></P>

<P><FONT SIZE=2><I>Resolved</I></FONT><FONT SIZE=2>: The shareholders of Abbott Laboratories (the "Company") request the Board of Directors establish a policy of, whenever possible, separating
the roles of Chairman and Chief Executive Officer, so that an independent director who has not served as an executive officer of the Company serves as Chair of the Board of Directors. </FONT></P>

<P><FONT SIZE=2>This
proposal shall not apply to the extent that complying would necessarily breach any contractual obligations in effect at the time of the 2005 shareholder meeting.  </FONT></P>

<HR NOSHADE SIZE=8>


<P><FONT COLOR="#2B85FF" SIZE=2>Proponent's Statement in Support of Shareholder Proposal </FONT></P>

<P><FONT SIZE=2>We
believe in the principle of the separation of the roles of Chairman and Chief Executive Officer. This is a basic element of sound corporate governance practice. In addition, the lack of access to
medicines has created a leadership crisis at our company which a separation of the Chair and CEO would begin to address. </FONT></P>

<P><FONT SIZE=2>We
believe an independent Board Chair&#151;separated from&nbsp;the CEO&#151;is the preferable form of corporate governance. The primary purpose of the Board of Directors is to protect
shareholder's interests by providing
independent oversight of management and the CEO. The Board gives strategic direction and guidance to our Company. </FONT></P>


<P><FONT SIZE=2>The
Board will likely accomplish both roles more effectively by separating the roles of Chair and CEO. An independent Chair will enhance investor confidence in our Company and strengthen the integrity
of the Board of Directors. </FONT></P>

<P><FONT SIZE=2>A
number of respected institutions recommend such separation. CalPERS Corporate Core Principles and Guidelines state: "the independence of a majority of the Board is not enough" and that "the
leadership of the board must embrace independence, and it must ultimately change the way in which directors interact with management." </FONT></P>

<P><FONT SIZE=2>An
independent board structure will also help the board address complex policy issues facing our company, foremost among them the crisis in access to pharmaceutical products. </FONT></P>


<P><FONT SIZE=2>Millions
of Americans and others around the world have no access to our company's life-saving medicines. This is an emergency, and our company's charitable work, while laudable, is neither
a sufficient nor strategic response. We believe an independent Chair and vigorous Board will bring greater focus to this ethical imperative, and be better able to forge solutions for shareholders and
patients to address this crisis. </FONT></P>

<P><FONT SIZE=2>The
current business model of the pharmaceutical sector is undergoing significant challenges. The industry has generated substantial revenue from American purchasers, who pay higher prices for
medicines than people in other developed countries. Pressure on drug pricing and dependence on this business model may impact our company's long-term value. </FONT></P>


<P><FONT SIZE=2>In
order to ensure that our Board can provide the proper strategic direction for our Company with independence and accountability, we urge a vote FOR this resolution.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Board of Directors' Statement in Opposition to the Shareholder Proposal on Separating the
Roles of Chair and CEO (Item 8 on Proxy Card) </FONT></P>

<P><FONT SIZE=2>In
the opinion of the Abbott board of directors, the company's governance structure ensures that the appropriate level of oversight and independence is applied to all board decisions. The board also
believes it is in the best interests of the company and its shareholders to retain flexibility to exercise its collective judgment to determine who should serve as chairman, given the circumstances at
any particular point in time. The existing structure, in which the offices of chairman and chief executive officer are held by one individual, supports the board's exercise of its oversight
responsibilities and does not compromise its independence. </FONT></P>

<P><FONT SIZE=2>The
company has a strong governance profile. The board is composed of more than a two-thirds majority of independent directors. All of the key committees, including Audit, Compensation,
Nominations and Governance and Public Policy are composed of independent directors. The company also has established governance guidelines, which are posted on its corporate Web site. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>31</FONT></P>

<!-- ZEQ.=12,SEQ=35,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=228289,FOLIO='31',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_32"> </A>

<P><FONT SIZE=2>The
board has a lead director to facilitate communication with the board and preside over regularly conducted executive sessions or sessions where the chairman is not present. The lead director, and
all other directors, communicate regularly with the chairman and CEO regarding appropriate agenda topics and other board related matters. Additionally, the company has a published procedure enabling
shareholders and other third parties to communicate directly with board members. </FONT></P>

<P><FONT SIZE=2>The
interests of the company and its shareholders are well-served by the current structure. The governance profile of the company is sufficient to ensure independence and accountability
and a rigid application of this proposal is not in the best interests of the company. It deprives the board of its exercise of business judgment to determine how best to provide oversight to the
company and eliminates the ability to consider all circumstances in determining the appropriate chairman for the board. </FONT></P>

<P><FONT SIZE=3>The board of directors recommends that you vote AGAINST the proposal. </FONT></P>

<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>32</FONT></P>

<!-- ZEQ.=13,SEQ=36,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=280069,FOLIO='32',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_33"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Other Matters </FONT></P>

<P><FONT SIZE=2>In
1999, shareholder derivative actions were filed against Abbott's then current directors and certain former directors relating to Abbott's alleged noncompliance with the United States Food and Drug
Administration's Quality System Regulation at Abbott's Diagnostic Division facilities in Lake County, Illinois. In March&nbsp;2001, the United States District Court for the Northern District of
Illinois dismissed these complaints. The plaintiffs appealed to the United States Court of Appeals for the Seventh Circuit. In March&nbsp;2003, the Seventh Circuit reversed the District Court's
dismissal. These derivative actions alleged the defendants breached their fiduciary duties by, among other things, allowing the alleged regulatory noncompliance and causing Abbott to pay
$100&nbsp;million to the federal government and withdraw certain medical diagnostic kits from the U.S. market. The plaintiffs requested unspecified monetary damages, including punitive and exemplary
damages, to be paid to Abbott, reimbursement of their legal fees and costs, and various other
forms of relief. On March&nbsp;1, 2005, the trial court approved a settlement of this matter. Under the terms of the settlement, a charter for the board's public policy committee has been adopted (a
copy of which is available in the corporate governance section of Abbott's investor relations Web Site, www.abbottinvestor.com), Abbott will fund regulatory / compliance activities in the amount of
$27&nbsp;million, and the plaintiffs' attorneys fees will be paid from proceeds of insurance maintained by Abbott for its directors. </FONT></P>

<P><FONT SIZE=2>In
2001, shareholder derivative suits were filed in the Circuit Court of Cook County, Illinois against Abbott's then current directors, with the exception of R. A. Gonzalez (who was not a director at
the time of the alleged activity), alleging that these directors breached their fiduciary duties by failing to take action to prevent certain marketing and pricing practices at TAP Pharmaceutical
Products&nbsp;Inc. TAP is a 50&nbsp;percent owned joint venture of Abbott. The plaintiffs requested a return of salaries, reimbursement of their legal fees and costs, and various other forms of
relief. On February&nbsp;25, 2005, the court approved a settlement in this matter. Under the terms of the settlement, certain provisions were included in the charter for the board's public policy
committee, and the plaintiffs' attorneys fees will be paid from proceeds of insurance maintained by Abbott for its directors. </FONT></P>

<P><FONT SIZE=2>In
2003, three shareholder derivative actions were filed in the Circuit Court of Cook County, Illinois against Abbott's then current directors alleging that these directors breached their fiduciary
duties in relation to certain business practices in the enteral nutritional business. The suits sought compensatory damages, return of salaries, attorneys fees and other forms of relief. All three
actions were consolidated and in the Circuit Court of Cook County, Illinois. In January&nbsp;2004, a related additional shareholder derivative action was filed in the United States District Court
for the Northern District of Illinois which was dismissed on July 29, 2004. On February&nbsp;28, 2005, the Circuit Court of Cook County approved a settlement in this matter. Under the terms of the
settlement, certain provisions were included in the charter for the board's public policy committee, and the plaintiffs' attorneys fees will be paid from proceeds of insurance maintained by Abbott for
its directors. </FONT></P>

<P><FONT SIZE=2>As
required by its articles of incorporation, Abbott advanced defense costs on behalf of the present and former directors named in these suits.  </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Date for Receipt of Shareholder Proposals for the 2006 Annual Meeting Proxy Statement </FONT></P>

<P><FONT SIZE=2>Shareholder
proposals for presentation at the 2006 Annual Meeting must be received by Abbott no later than November&nbsp;18, 2005 and must otherwise comply with the applicable requirements of the
Securities and Exchange Commission to be considered for inclusion in the proxy statement and proxy for the 2006 meeting. </FONT></P>

<HR NOSHADE>

<P><FONT SIZE=2>33</FONT></P>

<!-- ZEQ.=14,SEQ=37,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=313518,FOLIO='33',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<A NAME="page_du1029_1_34"> </A>
<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>Procedure for Recommendation and Nomination of Directors and Transaction of Business at Annual Meeting </FONT></P>

<P><FONT SIZE=2>A
shareholder may recommend persons as potential nominees for director by submitting the names of such persons in writing to the chairman of the nominations and governance committee or the secretary
of Abbott. Recommendations should be accompanied by a statement of qualifications and confirmation of the person's willingness to serve. A nominee who is recommended by a shareholder following these
procedures will receive the same consideration as other comparably qualified nominees. </FONT></P>

<P><FONT SIZE=2>A
shareholder entitled to vote for the election of directors at an Annual Meeting and who is a shareholder of record on: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
record date for that Annual Meeting,
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
date the shareholder provides timely notice to Abbott, and
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>the
date of the Annual Meeting, </FONT></DD></DL>

<P><FONT SIZE=2>may
directly nominate persons for director by providing proper timely written notice to the secretary of Abbott. </FONT></P>

<P><FONT SIZE=2>That
notice must include the name, age, business address, residence address and principal occupation or employment of the nominee, the class and number of shares of Abbott owned by the nominee and any
other information relating to the nominee that is required to be disclosed in solicitations for proxies pursuant to the Securities Exchange Act. In addition, the notice must include the name and
record address of the nominating shareholder and the class and number of shares of Abbott owned by the nominating shareholder. </FONT></P>


<P><FONT SIZE=2>A
shareholder of record on the record date for an Annual Meeting of Shareholders, the date the shareholder provides timely notice to Abbott and on the date of the Annual Meeting of Shareholders may
properly bring business before the Annual Meeting by providing timely written notice to the secretary of Abbott. For each matter the shareholder proposes to bring before the Annual Meeting, the notice
must include a brief description of the business to be discussed, the reasons for conducting such business at the Annual Meeting, the name and record address of the shareholder proposing such
business, the class and number of shares of Abbott owned by the shareholder and any material interest of the shareholder in such business. </FONT></P>

<P><FONT SIZE=2>To
be timely, written notice either to directly nominate persons for director or to bring business properly before the Annual Meeting must be received at Abbott's principal executive offices not less
than ninety days and not more than one hundred twenty days prior to the anniversary date of the preceding Annual Meeting. If the Annual Meeting is called for a date that is not within twenty five days
before or after such anniversary date, notice by the shareholder must be received not later than the close of business on the tenth day following the day on which such notice of the date of the Annual
Meeting was mailed or made public in a press release or in a filing with the Securities and Exchange Commission, whichever occurs first. </FONT></P>

<HR NOSHADE SIZE=8>

<P><FONT COLOR="#2B85FF" SIZE=2>General </FONT></P>

<P><FONT SIZE=2>It
is important that proxies be returned promptly. Shareholders are urged, regardless of the number of shares owned, to vote their shares. Most of Abbott's shareholders may vote their shares by
telephone or the Internet. Shareholders who wish to vote by mail should sign and return their proxy card in the enclosed business reply envelope. Shareholders who vote by telephone or the Internet do
not need to return their proxy card. </FONT></P>

<P><FONT SIZE=2>The
Annual Meeting will be held at Abbott's headquarters, 100 Abbott Park Road, located at the intersection of Route 137 and Waukegan Road, Lake County, Illinois. Admission to the meeting will be by
admission card only. A shareholder planning to attend the meeting should promptly complete and return the reservation form. Reservation forms must be received before April&nbsp;15, 2005. An
admission card admits only one person. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>By
order of the board of directors. </FONT></P>

<P><FONT SIZE=2>LAURA
J. SCHUMACHER<BR></FONT> <FONT SIZE=2>SECRETARY </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
<HR NOSHADE>
<P ALIGN="RIGHT"><FONT SIZE=2>34</FONT></P>

<!-- ZEQ.=15,SEQ=38,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=647133,FOLIO='34',FILE='DISK047:[05CHI9.05CHI1029]DU1029A.;92',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="RIGHT"><FONT SIZE=2><A
NAME="page_ea1029_1_1"> </A> </FONT> <FONT SIZE=2>EXHIBIT A </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="261" SIZE=8>


<P><FONT COLOR="#2B85FF" SIZE=2>DIRECTOR INDEPENDENCE STANDARD </FONT></P>

<P><FONT SIZE=2>No
director qualifies as "independent" unless the Board affirmatively determines that the director has no material relationship with Abbott or its subsidiaries (either directly or as a partner,
shareholder or officer of an organization that has a relationship with Abbott or any of its subsidiaries). In making this determination, the Board shall consider all relevant facts and circumstances,
including the following standards: </FONT></P>

<DL compact>
<DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if the director is, or has been within the last three years, an employee of Abbott or its subsidiaries, or an immediate family member is, or
has been within the last three years, an executive officer of Abbott or its subsidiaries.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if the director has received, or has an immediate family member who has received, during any twelve-month period within the last three years,
more than $100,000 in direct compensation from Abbott or its subsidiaries, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such
compensation is not contingent in any way on continued service), and other than amounts received by an immediate family member for service as an employee (other than an executive officer).
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if (A)&nbsp;the director or an immediate family member is a current partner of a firm that is Abbott's internal or external auditor;
(B)&nbsp;the director is a current employee of such a firm; (C)&nbsp;the director has an immediate family member who is a current employee of such a firm and who participates in the firm's audit,
assurance or tax compliance (but not tax planning) practice; or (D)&nbsp;the director or an immediate family member was within the last three years (but is no longer) a partner or employee of such a
firm and personally worked on Abbott or its subsidiaries' audit within that time.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if the director or an immediate family member is, or has been within the last three years, employed as an executive officer of another company
where any of the present executive officers of Abbott or its subsidiaries at the same time serves or served on that company's compensation committee.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if the director is a current employee, or an immediate family member is a current executive officer, of a company that has made payments to, or
received payments from, Abbott or its subsidiaries for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1&nbsp;million, or 2% of such other
company's consolidated gross revenues.
<BR><BR></FONT></DD><DT style='margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD><FONT SIZE=2>A
director is not independent if the director is an executive officer of a charitable organization that received charitable contributions (other than matching contributions)
from Abbott and its subsidiaries in the preceding fiscal year that are in excess of the greater of $1&nbsp;million or 2% of such charitable organization's consolidated gross revenues. </FONT>
<BR>
</DD></DL>
<P ALIGN="RIGHT"><FONT SIZE=2>A-1</FONT></P>

<!-- ZEQ.=1,SEQ=39,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=828963,FOLIO='1',FILE='DISK047:[05CHI9.05CHI1029]EA1029A.;5',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P><FONT SIZE=2>
<IMG SRC="g519019.jpg" ALT="logo" WIDTH="52" HEIGHT="46">
 </FONT></P>

<P><FONT COLOR="#2B85FF" SIZE=2>Abbott Laboratories<BR>
100 Abbott Park Road<BR>
Abbott Park, Illinois 60064-6400 U.S.A.</FONT></P>

<P><FONT SIZE=4>
Notice of Annual Meeting<BR>
of Shareholders<BR>
and Proxy Statement </FONT></P>

<P><FONT SIZE=4>Meeting
Date<BR>
April&nbsp;22, 2005 </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="300">

<P><FONT SIZE=2>YOUR VOTE IS IMPORTANT! <BR></FONT> <FONT SIZE=2>Please sign and promptly return your proxy <BR>
in the enclosed envelope or vote your <BR>
shares by telephone or using the Internet. </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="300">
<HR NOSHADE>

<P><FONT SIZE=2>
Reservation Form for Annual Meeting </FONT></P>

<P><FONT SIZE=2>I am a shareholder of Abbott Laboratories and plan to attend the Annual <BR>
Meeting to be held at Abbott's headquarters, 100 Abbott Park Road, <BR>
located at the intersection of Route 137 and Waukegan Road, Lake <BR>
County, Illinois at 9:00 a.m. on Friday, April 22, 2005. </FONT></P>

<P><FONT SIZE=2>Please
send me an admission card for each of the following persons. </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="29%"><FONT SIZE=2>Name</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2>Name</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><FONT SIZE=1>Please print name of shareholder</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="CENTER"><FONT SIZE=1>Please print name of guest</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="29%"><BR><FONT SIZE=2>Address</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2><BR>
Address</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="29%"><FONT SIZE=2><BR>
City</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2><BR>
City</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="29%"><FONT SIZE=2><BR>
State</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
Zip Code</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2><BR>
State</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
Zip Code</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="29%" ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="29%" ALIGN="RIGHT"><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="19%" ALIGN="RIGHT"><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=2><BR>
Phone Number (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=2><BR>
Phone Number (<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="29%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="29%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="19%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<HR NOSHADE>

<P><FONT SIZE=2>If you plan to attend the meeting, please complete and return the Reservation Form directly to Abbott Laboratories, Annual Meeting Ticket Requests,
D-0383 AP6D, 100&nbsp;Abbott Park Road, Abbott Park, Illinois 60064-6048. Due to space limitations, Reservation Forms must be received before April&nbsp;15, 2005. An
admission card, along with a form of personal identification, admits one person. A shareholder may request two admission cards.<BR>
<BR>
To avoid a delay in the receipt of your admission card, do not return this form with your proxy card or mail it in the enclosed business envelope.</FONT></P>

<HR NOSHADE>
<P ALIGN="CENTER"><FONT SIZE=2>
<IMG SRC="g674535.jpg" ALT="logo" WIDTH="144" HEIGHT="87">
 </FONT></P>

<!-- ZEQ.=1,SEQ=40,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=269873,FOLIO='blank',FILE='DISK047:[05CHI9.05CHI1029]MA1029A.;13',USER='SLYUBOM',CD='18-MAR-2005;11:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER"><FONT SIZE=2><B>PROXY  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=3><B>ABBOTT LABORATORIES  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned, revoking previous proxies, acknowledges receipt of the Notice and Proxy Statement dated March&nbsp;18, 2005, in connection with the Annual
Meeting of Shareholders of Abbott Laboratories to be held at 9:00&nbsp;a.m. on April&nbsp;22, 2005, at the corporation's headquarters, and hereby appoints MILES&nbsp;D. WHITE and LAURA&nbsp;J.
SCHUMACHER, or either of them, proxy for the undersigned, with power of substitution, to represent and vote all shares of the undersigned upon all matters properly coming before the Annual Meeting or
any adjournments thereof. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the undersigned is a participant in the Abbott Laboratories Stock Retirement Plan, then this card also instructs the plan's co-trustees to vote as specified at the 2005 Annual Meeting
of Shareholders, and any adjournments thereof, all shares of Abbott Laboratories held in the undersigned's plan account upon the matters indicated and in their discretion upon such other matters as
may properly come before the meeting. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>INSTRUCTIONS: This proxy when properly executed will be voted in the manner directed herein by the undersigned shareholder. If no direction is made, this proxy
will be voted FOR Items&nbsp;1 and 2 and AGAINST Items&nbsp;3, 4, 5, 6, 7 and 8 and in accordance with the judgment of the proxy holders on any other matters that are properly brought before the
meeting.  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="14%" ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> SEE REVERSE<BR>
SIDE</FONT><HR NOSHADE></TD>
<TD WIDTH="71%" ALIGN="CENTER"><FONT SIZE=2><B>&nbsp;&nbsp;<BR>
(Important - Please sign and date on other side.)</B></FONT></TD>
<TD WIDTH="14%" ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2> SEE REVERSE<BR>
SIDE</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=179106,FOLIO='blank',FILE='DISK023:[05CHI0.05CHI1510]MA1510A.;10',USER='DINGRAM',CD='10-MAR-2005;13:12' -->
<P ALIGN="CENTER"><FONT SIZE=3><B>ABBOTT LABORATORIES  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Your vote is important. Please vote immediately.  </B></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="120%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=4><B>Vote-by-Internet</B></FONT><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;<BR>
OR</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=4><B>Vote-by-Telephone</B></FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>1.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>Log on to the Internet and go to http://www.eproxyvote.com/abt</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>1.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>Call toll-free 1-877-779-8683 (within the U.S. and Canada) or 1-201-536-8073 (outside the U.S. and Canada).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=2>2.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>Follow the easy steps outlined on the secured internet site.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>2.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="43%"><FONT SIZE=2>Follow the easy recorded instructions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3><FONT SIZE=3><B>Your vote is important!</B></FONT><FONT SIZE=2><B><BR>
Go to http://www.eproxyvote.com/abt by 11:59&nbsp;p.m. 4/21/05</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="5%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3><FONT SIZE=3><B>Your vote is important!</B></FONT><FONT SIZE=2><B><BR>
Call 1-877-PRX-VOTE by 11:59&nbsp;p.m. 4/21/05</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER"><FONT SIZE=4><B>Do not return your Proxy Card if you are voting by Telephone or Internet.  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=1>DETACH HERE </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="3%"><FONT SIZE=5><B><FONT FACE="WINGDINGS">&#253;</FONT></B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD WIDTH="90%"><FONT SIZE=1><B>Please mark<BR>
votes as in this<BR>
example.</B></FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="3%"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TD WIDTH="100%" ALIGN="CENTER"><BR><HR NOSHADE><FONT SIZE=2><B>The Board of Directors recommends that you vote FOR Items&nbsp;1 and 2.</B></FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1><BR>
1.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1><BR>
Election of 14&nbsp;Directors.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD WIDTH="7%"><FONT SIZE=1><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1><B>Nominees:</B></FONT><FONT SIZE=1> (01)&nbsp;R.S.&nbsp;Austin, (02)&nbsp;W.M. Daley, (03)&nbsp;H.L.&nbsp;Fuller,<BR>
(04)&nbsp;R.A.&nbsp;Gonzalez, (05)&nbsp;J.M.&nbsp;Greenberg, (06)&nbsp;J.M.&nbsp;Leiden,<BR>
(07)&nbsp;D.A.L.&nbsp;Owen, (08)&nbsp;B.&nbsp;Powell&nbsp;Jr., (09)&nbsp;A.B.&nbsp;Rand, (10)&nbsp;W.A.&nbsp;Reynolds, (11)&nbsp;R.S.&nbsp;Roberts, (12)&nbsp;W.D.&nbsp;Smithburg, (13)&nbsp;J.R.&nbsp;Walter, and (14)&nbsp;M.D.&nbsp;White.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7 ALIGN="CENTER"><HR NOSHADE><FONT SIZE=2><B> The Board of Directors recommends that<BR>
you vote AGAINST Items&nbsp;3, 4, 5, 6, 7 and 8.</B></FONT><HR NOSHADE></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><B>FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></B></FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1><B>WITHHELD</B></FONT><FONT SIZE=1><BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1>FOR</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>AGAINST</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1>ABSTAIN</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1>For, except vote withheld from the above nominee(s).</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>3.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal -<BR>
Executive Compensation</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><HR NOSHADE></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>4.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal -<BR>
Performance Based Options</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>2.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1>Ratification of Deloitte &amp; Touche LLP as auditors.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>5.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal - In Vitro Testing</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="RIGHT"><FONT SIZE=1>FOR<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%" ALIGN="CENTER"><FONT SIZE=1>AGAINST<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="14%" ALIGN="CENTER"><FONT SIZE=1>ABSTAIN<BR>
<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>6.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal -<BR>
Political Contributions</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="9%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>7.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal -<BR>
HIV/AIDS-TB-Malaria Pandemics</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1><B>
<IMG SRC="g560613.jpg" ALT="GRAPHIC" WIDTH="136" HEIGHT="28">
</B></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1>8.</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="28%"><FONT SIZE=1>Shareholder Proposal - Separating the<BR>
Roles of Chair and CEO</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="7%" ALIGN="CENTER"><FONT SIZE=1><FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="2%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=1><BR>
<BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD WIDTH="4%" ALIGN="CENTER"><FONT SIZE=1>&nbsp;&nbsp;<BR>
&nbsp;&nbsp;<BR>
&nbsp;&nbsp;<BR>
&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD WIDTH="14%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=5 ALIGN="CENTER"><FONT SIZE=1>MARK HERE FOR<BR>
ADDRESS CHANGE <FONT FACE="WINGDINGS">&#111;</FONT><BR>
AND NOTE AT&nbsp;LEFT</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD COLSPAN=7><FONT SIZE=1>Each joint tenant should sign; executors, administrators, trustees, etc. should give full title and, where more than one is named, a majority should sign.<BR></FONT> <FONT SIZE=1><B>Please read other side before
signing.</B></FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="8%"><FONT SIZE=2>Signature:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="22%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>Date:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="8%"><FONT SIZE=2>Signature:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="22%" ALIGN="CENTER"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE><FONT SIZE=1>(If held jointly)</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>Date:</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="11%"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT><HR NOSHADE></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE>
<P style='page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=42,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1",CHK=474859,FOLIO='blank',FILE='DISK023:[05CHI0.05CHI1510]MA1510A.;10',USER='DINGRAM',CD='10-MAR-2005;13:12' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="05CHI1029_1">QuickLinks</A><br></P>
<!-- SEQ=,FILE='QUICKLINK',USER=ABLIJDE,SEQ=,EFW="2152528",CP="ABBOTT LABORATORIES",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>coverimage001.jpg
<DESCRIPTION>COVERIMAGE001.JPG
<TEXT>
begin 644 coverimage001.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]1$E32S`T-SI;,#5#2$DY+C`U0TA)
M,3`R.2Y/5510551=,3`R.5]/5513241%7T923TY47T-/5BY%4%/_VP!#``<%
M!@8&!0<&!@8("`<)"Q(,"PH*"Q<0$0T2&Q<<'!H7&AD=(2HD'1\H(!D:)3(E
M*"PM+S`O'2,T.#0N-RHN+R[_VP!#`0@("`L*"Q8,#!8N'AH>+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+B[_P``1
M"`-Y`JP#`2(``A$!`Q$!_\0`'````@(#`0$```````````````(!`P0%!@<(
M_\0`4!```0,"!`0#!`8%"0<#`@<!`0`"$0,$!1(A,09!46$3(G$4,H&1!R-"
M4J'1%18SD[$74U158G*"DL$D-D-S=++A)93P-&,F-59DA*+QXO_$`!<!`0$!
M`0`````````````````!`@/_Q``:$0$!`0`#`0``````````````$0$2(3%!
M_]H`#`,!``(1`Q$`/P#QZM^V?ZI$];]J_P!4B(B2I1W0@C=3ZH0@$1HA"`*$
M!"`0A"`0A"`0CF@H"$(0$`4(0@$*%*`1ZH0@$(E')`(0A%&Z$(1!S1HB4(!"
M$>J`0$=T(!"$2@-$(0@.J.2/5"`1V04(!"-T(#LA"$`A!W0@.>R$(]$`A"$`
MA"-D`@(0@B%*$(!"$(H04(1`$(0@$<D("`0A"`0A$H!"$(#9'-"$`A"$!U1"
M-@A`(YH"$`CJCDA`*RGL?55JQFH/J@BM^U?ZJM65OVK_`%5?1!/9$HA')`(]
M5"E`(4*4`A'-0@F4*.:DH!"A2@.2$:*$$[:(1"C9!)1*A3S0'/=0I4(!3"$(
M"$(1J@"B5!_%!02A0A!*$>B)0'JCNB=4<T`@HYJ#L@E"$'4(#FA`1RU0"$(0
M'+=0I*A!/)!04<D`HE&R/@@E""@((4H*A!*"A0@%/)"$`B5')2@"C91W0@GT
M4*4(#LCF@]E$()0HY(02C10I(0!0H/-2@$<U"DH#XH[J%*`0HV1S03*!LCLC
M9`(1_%"`0C9"`0A0@F4].(/JD3T]CZH"MK5?ZI"GK?M7^J1%`0C9&Z(CFI1U
M1U0!0$(0"A2A`(0A`(0A`(0A`(0A%"$(0!0.J$(@0A'Q0"$=D(H4*4(@*/X*
M.:GJ@$(0BA'=![("($(0BCHA"$`A"$0=4'9"$4(0@H@A'JA"*$(0@$<T<E"(
ME'5!0BA')"$0%&Z$(#5"/BA`(04%%"$(0"$(1`A"$`A""BA'-!0B!'-"$`A&
MR-T4'=!0A$`0CNC5`(4<U/)`(0@\D`HYJ2H0"LI['U2)V;'U0%;]J_U2)ZW[
M5^G-(B@A`0A`(0A`:(0A$2E3*$4;\D(0@/5'Q0@H!""A`(0I00A"$`A"$!S1
MT0I00A"E!!0A2@A2HY(0'JB=$(0"$(0"$(*`0I4(`H1HA`(*E1')`(YH0@$;
M(0@$(0@$(0@$*5"`1SW4J$`A"-4`B`A"($<D(10A')"(A24(0"$(11\4(0@.
M:$(0')"$(@0A'-%".:.:$0'JA".2"%,H1\$`CT4:J4$<T;*5"`5C-CHJ]$[-
MB@WM7A3B8U7D8%>G7[@_-)^J?$W]17O^0?FOH%WO'U4(KY__`%3XF_J*^_R#
M\T?JGQ-_45]_D'YKZ`0@^?\`]4^)OZBOO\@_-'ZI\3?U#>_Y!^:^@$(/G_\`
M5/B;^HK[_(/S1^J?$W]17W^0?FOH!"#Y_P#U3XF_J*]_R#\T?JGQ-_45[_D'
MYKZ`0@^?_P!4^)OZAO?\@_-'ZI\3_P!17O[L?FOH!"#Y_P#U3XF_J*]_R#\T
M?JGQ-_4-]_D'YKZ`0@^?_P!4^)OZAOO\@_-'ZI\3?U#??Y!^:^@$(/G_`/5/
MB;^HK[_(/S1^J?$W]0WW^0?FOH!"#Y]J<+<24VES\#O@!S\.?X%:BK3J4JCJ
M=5CF5&[M>((]05],K3\0\/8;CULZE=T0*T?5W#1YV'UYCL4'SXA;'&\)NL%Q
M*M878&=FK7#9[3LX=EK_`%00A3'9""$*41T00A2B$$(4PB$$(4HA!"%,(A!"
M%("`@A"E$((0B$0@A2A$%!"E"(0"A2I0*A2Z0#'1>PWW!^!5G<)7%A;,;48R
MQ.+6NL5J=<P*N_W@6GU"#QY"[.\X8L#>XU?7F+V^#871Q6K8V^:@^J7N!)@-
M;J&M$22LNZX/PW#>%.)+C$L0`Q?#;VE0IFE3<ZFX.:2T`[$/$$.^SS0<!"E=
MYCG"=&GB>(5[R\LL)PNRH6GB5J-"I4::E6F"UK627%QU),PL*AP7FK8E5J8U
M:G"K(TA[?:T7W(K&H):UK&>:8DD':-4'(*%M\?P.[P7&ZF#U7,K51D--],$-
MJM>`6.$ZB9&A6ZQ/@NG8LQ*BSB&TN,1PI@J8A:4Z#YH,D!Y:XZ5"R1("#CU"
M[;Z3,-P7![_"\-P842*=C3J5JC:3V/JN>T$.>7$@SJ0!$;%;7A7AK";KA)M&
M_M#4QK'67-3"ZNOU(H-D?YW`A!YHA=CA/!]M>X5@N(WO$5KAYQ:N^WMZ-2W?
M4=XC7!L'+L)(U.RMI\#TJ-.U.+\16N'5;F]K6+*1MWU2:E-X83+=FR1J=I0<
M2A=+C?"=U@S+'VJZINJW6(5[`L8T_5NI/#2Z>8,RME9\"LKXO>856Q^WHW-&
M_-A28RVJ5GU7#[;FL_9L_M%!Q*A=9B>#4L.X/N'W%"G^DK;':EE4JM,^5M*<
MH[3JN@P#AS",3^BJ^N_96?IT5Z[[:OKF<VBUKW,_RYOD@\S0O4<:X2L*/`.`
MT;&Q:_B.XOJ%&O5V<75F%[:?H`6K18EP)>4*1=AM\S$JE.\IV-PQEO4H^'5>
M8;E+Q#VD@C,$'%A"]!I<`4Z-]:NKXPRXL:6)4;'$2RUJL-)SW0`W-&=KC+<X
MV.J0<,65;$N*,-PVO0JT+:^M;:E7K47A]$U+@LANNL;$G<#2$'`\T+LL5X)%
MK;8H_#\<ML2N<+NF6UU;TJ+V%I>_(TM<[1VNAC96U^!:--F-TJ?$EG6Q#!;=
MU:]M&V[P6N;`+6N.CH)@D;%!Q"%O,"P.GB-E?XG?8E3P[#+(L95N'TG52:CR
M<K&L;J28)[`+L<"X4P?"CQ%<8W=6=\VTPVG>63C0J/HU*=0@-K0T@[^7+N#J
M@\R"%T/`]O@=UQ)0H<05:5.S<QY8*U0TZ;ZL>1CW#4-)W*[^UX9L*W$^#V.,
M<)T,*N;BE<FH;>L:EA<-;2)8]CI)!:8)1'CZ%U;^$[9]##;JPXDL;FSNKIUG
M5N:E)]!EO4#<Q)S:EI&Q&ZSA]']6M>8+3LL7IUK7%7UJ5*XJVE2AD?3;F,L?
MKE(V=LBN&1\%V5GP9;W3;B[9Q%0=A=*LRV;>T[.K4%6NX26M8!.5O-YT6PN>
M#['#N'ZM''\0ML*OK;&7VK[DT7UC59X32T-:W[.N:3L"B//?1`785>"O8:N+
M.QO&[;#[+#[P67M/@OJ^/5+<PR,;K&4@DG99+N$ZECA_$V'W%&C<XG;W6'T[
M.M3)AS:SC!:>C@6[H.&0O1:/".$6&'\8,JXM9XKB&&6!S4:=%[3;5_$:"6DZ
M/C5LCFL*O]'M[3H7+6XA3?B-G3IU;RS]FJ-\%CRT$MJ$97EN8$@(KASJH7?5
M?H^:S'KW!6<16UQ<6%&K6O&V]K4J.I-:0``T:O<<P,#;FN3QW#Z6%X@ZUH8A
M1OZ0:UPK4F.9N/=<UVK7#F"B-;"%*$$*RGL?55JRGMJ@^FG>\?50O/:GTG63
M7N'Z)N-#_.-2_P`I]E_5-S^\:BO1$+SO^4^R_JFY_>-1_*?9?U3<_O&H/1$+
MSO\`E/LOZIN?WC4?RG67]4W/[QJ#T1"\[_E.LOZHN?WC4?RGV7]47/[QJ#T1
M"\[_`)3K+^J+G]XU'\I]E_5-S^\:@]$0O._Y3[+^J;G]XU'\IUE_5-S^\:@]
M$0O._P"4ZR_JFY_>-1_*=9?U3<_O&H/1$+SO^4ZR_JFY_>-1_*=9?U3<_O&H
M/1$+SP?2=93KA-S^\:NDX=XJPK'GFC:OJ4KEK<QH51#HZ@[%!OT(0@X#Z6,.
MIUL(M\3#?K;>H*9/5CO_`"O)5[=])?\`N?=_\VE_WA>)0@A"D!$((0I`00@A
M"F$0@A"F%$(!"F$0@A"F$0@A"F$0@A"DA$((0B$0@$(A$(!"(0=T`A"(001(
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MQ[27TPUQ!>:=./*7$"9)C6%R"$&YXJQK]/XFR^%N;?):T;?*79OV;`V9[Q*W
MS/I%QRSNL+9@]>K8X7A]*C299!P<VH&:N+C&[C,^JXA"#K<6XKM;NK@WL>%N
MMK?#,0K7C*9JAV8/JBIDF-(@B4F.\6#%;BQK"Q-+V7$;B^CQ)S>)4#\NW*(E
M<JA!W&(<:X?BCWOQ3`:E<TL3K8C9^'=FGD-1P<YC_*<PD#:%DVOTB"A<7]?]
M%UVNKXJ[$F>SWAHEQ,?5U2!+V"-!HO/EFX1A]7%+^G94JUO0+@YQJW-44Z;&
M@222>W+<\D&XXAXEI8M97UI1L'V[;K%GXE+JN?+F8&EFPYR961@7&#\'PW![
M*G9>(;#$:EX]SGZ5F/9D=3(Y2)U[HH<#XA=7EM1L\1P^XM[JTK7="[:]S:3V
MTM'@YF@M([B%0>#<1JUL);A]W8XA0Q,U&T+FWJGPVNIB:@<7`$91J3&R#-N>
M.[RI3J5*5JVG=_IMN+4JA=+69696T\O,``#T5F*<?7%P^E7L*%Y2N!>,O'&[
MOWW#&/:<P9388#63R,G82J;_`(=P^RX%N<6I7]EB-<8K2MZ5U:5'%HIFFXN:
M6N`@R`=O19G#>&6'ZD/QE_";\?OCB9MLC:E5OAT_#S3%.>>FO5!3BW'C[UU*
MI0L[MK_;:5[5%UB#Z[`YCP\4Z;=`UA(YR530XPM+7%<9O;7"ZS:6)7EM=FE4
MN`XTW4JWBN$QJ'$P.G=;/B'@-@OKZYP^XML+L+6WM:]U1OZYFR=6:3D+HDP1
MMOJ%I+;@K$J]&V:+RP9B%W0-S:X<^J17KT@"<P$91(!(!()""*7%;J9XD=2M
MC3J8Q=4[AE3-/LY96\0:?:7:XI?X#9V?%6,-JX:Z\QJS=3:^VQ`UC7JO<"2R
MCE!I-F2<Q)Y+B+3A"]NL';CE.]LAA;:+ZE>Y<X@6[VF/!<V)\0R(`$&4K.#L
M1==LHBO;"B_#/TK[42?#\")UTF9\L=4&-@>-6UGAU_@V)6-2\PN]?3JO91K>
M#4949.5S701L2""-5L;SC$W+,7HC#FT;:[PREAEM294)]FITWY@23JXG6=M2
ML?@'#,,Q;&W6^*!KP+:I4M[9]<4!=5A&6D7GW9U^2ZNEPC@V(<6X1A-]AEWP
MW<UZ55UW85:CGM<6@ECJ-2#(/,<H*#A.'<7I81=UWW.'4,0M+F@ZWKT*NA+'
M<VNW:X<BNGL./+;"QAMEAF#5*6%6)N'MI5KHU:M2I5IEA)?```!V`6IPWA)^
M(U<E#',);XMRZVM`^H[-=O'W6AI+6G:70)615X7MJ?!%/%_;&'%SBCK(V@+B
M9`CPXB,\ZS,01S04<-<5?H*TP^B,/IW1M,2]N^L=Y7?5Y,L1H=9!Y%;P_2'0
M#L,(PR^JG#KBO5I5+K$#6J/%6F6.#B6\B9$:`!::XX'Q.DYS&7EA7K4+BE;7
MM*C4+G63ZC@UH?H`1)@ELP=%D7/`5U;"Y?6Q_!64;.Z]CNZAK/BWJGW6D99)
M/]F8Y[(,?A?BZI@V$5L'KT[Q]F^N+EKK*\-M5:\"""X`RPC<1Z+&QWB:IC.'
M/M*MJ*3W8D^^S"HYP:"QK`SS23`;N2G_`%/Q&C?XK:XA=6=A1PNJVC=7==Y-
M)KW>XT902XN&N@T&ZOJ\#XA:4;NXQ7$<-PVWM;AE!]:XJN+79V9V.;E!S-(Z
M(,G$.,K+%JV+4<8P6I7PV]O6WU.E1NO"JT*H8&&'P06D#40JKKCB\N*N*W`M
M*=&XNZ]E4M_#=++9ML98V#J[2!*RJ7!-O;X/Q15Q7%;6C?X2:/A!KW%CFOU#
MM&ZAX(#>^\+G>&S@=.M=W6.TW5Z="W+Z%FUY8;JL2`UA<-0!))]$&^N.,<+=
M1XA?:<//ML0QRB67%?VLO;3>7AQ--I&C21,2=5D8C](=>^HU:M2UO#?7`IMK
MEU^\V[0TMDTZ(C*7!NLD@2=%L+KAC`;2YJXQ=87<4+.WP5F(U\(=<',RN^H6
M,I%_O!I][K"H'#N`-\?B9V'U78*W!V8C3P[QR)K.J&EX1J;Y0X$SO"#0.XGM
MJW&&*<0W&'5BR^?4>&4+IU&M;EQ!#F5&[.$<Q!E8G%_$#N),3I7CK<T12MV6
M[34J>)5J!OVJCX&9QG>%UU#A/`[G&A>4K6L[!KC`QBM*T]K%)S'EP9X?BNT@
M.G4\ER/%^'-PS%_9Z>$W&&TS28]E*M=-N,X/VVU&Z.:>4(-"A2A!">G$'U2*
MRGL?5!96'UK_`%2*VL!XK_5)"!(4PFA$(%A$)H1"!4)H1"!8*$ZB$"QJ@!-"
M(0*IA-"(0+"(30B$"PMQPE5J4.)L+J4W0?:&M/<'0A:E;/AK_>+"_P#J6?Q0
M?0*$'<H0<I])7^Y]W_S:7_>%XI"]L^DG_="[_P";2_[PO%80+"(*:$(%A$)D
M(%`1&B9"!81":$($B%,)E"!5,)D(%A1"=0@B%"9"!40F0@B$0I4P@6"HCFG4
M(%0F0@5$)D0@6$)H"-$"H30A`D(A/"B$"E$)X"B$"PB$\*(0+"W?"&*VF"8]
M0Q&]M'7-%C'MRL#2YA<T@/;FTS-)D2M-"(0>DU^/<->VUS4\8NJUO8WEEX]Y
M4IN?4%8#*XY8`@\AR6FP+BZCA.&\/VOL=2L[#[BZ=<#,`*M*NP,+6G<&)U/9
M<>`B"@ZK$\9X>9P?4X<P2SQ-I??T[QUQ>O82X-8YN6&[1(]=519<47.'\(?H
M3#[B]M+LXB;IU>A5R!S/#RY=#.^O1<Y"(0;RVQQK>%\?PFZ%>O=XG<6]85W.
MS?LRZ<Q)DDRM_9\9813N<+QRYPV^?C^&68M:.2HP6U4M:6TZCA[P(!V&\+@X
M0@[K#.+L%M.'/U9K836K8==47OOZT-%9UV3+*C-8#6P``5FXCBQP[Z*+'"KA
MUL[%+TFC2=2JA[V6.85(?'NR[2#JO.%``&P"#;\.WV$VE6[HXWAKKVRNJ/A$
MTBUM:@Z9#Z9=H#_$+J+?C;#;'$^&?8[3$:V&X*:TNO*S77%7Q1#H(T:!R"X'
M=1"#T/AKC3!<!MJ-"VH8Q2]FOWW(?;OHL=>4R1#*Q(G2#HW1:ROQ1A_Z,NK:
MVM[QM=F.'%K)[RS+K$LJ#X<EQ\(@(/2L6^D2VO7NK4QC+C<7E&XJV]>X8:-!
MK'A[F4PT`NDC3/LM!B7$]K=V'$%LRVKM=B6,T\1IDD0QC2Z6G7?7EHN4(1"#
MT=OT@V[L7XCJAN)V=EBUQ2N&5;-U,7%%S&AL0Z6D$`S\%IN*N+*6.X1?V+:%
MVQ]>]IUZ3Z];Q"VFRB:<.=]XDSH("Y$A1"#N+KBW#+UG$=O<VEZVABEK:TZ3
MJ3F9J=2BT`9@="TD<M86KX&QC"<"Q.M?XG;7-6J*!;:OMVTW&A5/_$A^A(&T
M[%<VA!V=#B+!;?%,3<X8WB&'8O:.H7[[RK3]ISYLS7L(\ND#?NK!Q=A9N:^'
MOP^\/#M3"V86*0J-]H:QKLXJS[N?.28V@PN(0@["_P"(L`Q/$O!Q#![K]#4<
M/IV-F*=1OM-N&&14D^4N)F1MJM5Q5C%MB]>QI6%M5M\/P^T9:6S*SPZH6@DE
MSB-)))T&@6D4!!"%,(CL@A/3V/JEUZ)V;(,MMO6N;SV>VI/JUGNAK&"2XKT7
M`_HYI>$RMC5P_P`0B30HF`WL7<_@MC]'6!LM;1^,5V`W%T3X4C5E/_RNV0<M
M^HG#/]"J?OG?FC]1.&?Z#4_?._-=2A!RWZB<,_T*I^_=^:/U$X9_H-3]\[\U
MU*$'+?J)PS_0JG[]WYH_43AG^@U/WSOS74H0<N.!>&09]A>?6L[\TWZC\,?U
M<?WS_P`UTR$',_J/PQ_5Q_?/_-'ZC\,?U<?WS_S73(0<S^H_#']7']\_\T?J
M/PQ_5Q_?/_-=,A!S0X&X8)'_`*<=_P">?^:\;Q&BRCB-W1I-BG3K/:T3L`3"
M^BF^\/5?/>,?_FU]_P!14_[B@P(6TX:'_P"(<,_ZEG\5KEL^&_\`>##/^I9_
M%![X=RA!W*$'+?21KPC=_P#-I?\`>%XOE7M'TC_[I77_`#:7_>%XR@3*B$\(
M0)E*(3PB$"0C*G0@2$0G1"!(1">$($@HRIT($C11"L0@K(1"L1""N$0K(0@K
MA$*Q$(*X1"L@(05PB$\(A`D*(5D(A!7"%80B$%:(5D*(0(B%9"B$"(3Y494"
M(3Y5$(%0FA$($4IH1"!$)H1"!4)H1"!4*40@B$0I1"!2$0FA"!81":$($1"9
M"!4)D(%A00GA1"!840GA$($0FA$!`J>GLEA6,&A]4'TE3I,HTVT:3<M-@RM'
M0)E+O>/JH0"D`G8$I7$-:7'8"2O#\9XAQ7$KZK6=>5Z5/,13I4ZA:UC9T&B#
MW+*[[I^2,KONGY+Y]_2&(?T^[_?N_-'Z0Q#^GW?[]WYH/H+*[[I^2,KONGY+
MY]_2&(?T^[_?N_-'Z0Q#^GW?[]WYH/H+*[[I^2(/0_)?/OZ0Q#^GW?[]WYH-
M]?'>^NCZUG?F@^@H/0H@]"OGSVV]_IMS^^=^:/;;W^FW/[YWYH/H.#T*(/0K
MY\]MO?Z;<_OG?FCVV]_IMS^^=^:#Z#:#F&AW7S]BX_\`5K[_`*BI_P!Q4>VW
MW]-N?WSOS6.9<2YQ))U).Y0)"V?#@_\`Q!AG_4L_BM="V7#@_P#7\-_ZEG\4
M'O!W*$'<H0<O](O^Z=U_S*7_`'A>-QV7LOTB:\)W7_,I?]X7CL($A$)H*(0+
M"(30B$"PB$P"(0+",J:$0@6.RB$\(A`F5&5/"(0+"B$Z(0)E1">$($A$)T($
MC1$)T0@2$0GA"!(40G4H*X1">$($A$)X1"!(4*R$0@K1"LA1"!$)X1"!$)X1
M"!$)HU00@5":$0@51":$0@6$0F@HA`L(A-"A`H:C*F0@2$0G0@KA!'9/"(U0
M)"(3PB$%:(3PB$"0A-"(0*H30B$"HA2B$$1T3L&A]4JLI['U0?2+O>/JH4N]
MX^JA`E;]C4_N'^"^>G#S.]2OH6M^QJ?W#_!?/KAYG>I_B@KA$)X1"!(4PFA$
M(%A!">$$($A$=4\:(RH%A$)X1'9`D(A60B$%<+9<.C_U_#?^H9_%8$+9</#_
M`->PW_J&?Q0>Y'<H0=RA!S/TA?[J77_,I?\`>%X_"]A^D'_=:Y_YE+_N"\A(
M0)"([)X1"!(40K(1`05PIA/&J(05PB%9"(05PB$\*805PB%9`40$"(A/`1"!
M(4$*R.R(0)"(395,($A$)X1""N$$)X004"0B$^51"!840GA$($CHB$\(A`D:
MHA/"B$"PHA.B$"0B$Z(0)"$\*(0*B.2:$0@12FA1"!40FA"!81":%"!80F0@
M2$0G0@2%$)T($A$'HG0@2$0FA$($0FA$(%0FA1"!8T1"8A$(%A1"9"!(5C!H
M?51">GM\4'T:[WCZJ%+O>/JH0)5_95/[I_@O`'#S'U*]_K?LJG]T_P`%X$X>
M9WJ4"0B$T*80)"(3PB$"PB$T(A`L(A-"F$"PB$T*8"!(1">$0@2%L>'A_P"N
MX=_U#/XK!A;'AYI..X<`)/M#/XH/;3N4(.Y0@YKC_7A:Y_YE+_N"\DA>N<??
M[KW/_,I?]P7DT(*X*(5D*(0)"(3@(A`D(A/"(0)"(3PB$"0B$\(B$"0B$\(A
M`D*(5D(@(*X1">$0@2$0GA$:H$A$)X1"!(1">$0@2$0GA00@2$$)H0@6$0FA
M$(%CHHC=/"(0)"(30B$"PB$T(A`L*(3J(0+"B%9"B$"0B$Y40@2$0GA$($0F
MA$($A$:)X40@6%$)X40@6$0F40@6$0FA$(%0FA$(%0IA$((4$)H4(((40F0@
M6%!"=0@2$],:'U1"=@T0?1+O>/JH6/87=.^LZ-W2,MJMS>BR$`N$QK@3Q[I]
MQAES3I,>2YU*J##2>A'+LN[0@\Q/`.+`Z7-H?B[\E'ZA8O\`TBT_S'\EZ>A!
MYA^H6+_TBT_S'\D?J%B_](M/\Q_)>GH0>7_J)C/\Y:?O#^2C]1,9_G+3]X?R
M7J*$'EWZB8U_.VG[P_D@\"8T!H^T)_YA_)>HH0>6?J+CG6T_??\`A3^HN.=;
M3]]_X7J2$'EOZC8YUM/WW_A*>!\=!VM3Z5O_``O5$(/*_P!1\=^[;?O?_"W_
M``MPC6P^^9?XA4IFI3GPZ=,R`>I*[5"`0A"#G./?]V+G_F4_^X+R>%ZC](5P
MVG@0MR?/7K-`'8:G_1>80@6$1HFA$($A3":$0@6$0FA$($A3":$0@2$0GA$(
M$A$)H4P@2$0GA1"!81":$0@6%$)X1"!(1">.BD"?5`D(A-"(0)"(31*(0+"B
M$\(A`D(A/"(05QT4D)X4($A$)X1"!(1"9$($(1">%$(%A1">$($A$)X41J@2
M$)X1"!(1">%!"!"$0GA1"!840GA$($@*(3H0)"(30B$"0B$\*"$"(A/"(0)"
M$T3R40@6$0FA1"!81"9$($A6,!@^J4A.P:'U0>@\%X_2LJE3#+VIEHO?-*HX
MZ,<=P>Q7HB\+JCZQWJMMAO$F,8=2;2H76:BW:G5;G`].80>O(7FGZ\XO_,6G
M^4_FI_7C%OYBU_RG\T'I2%YK^O&+?S%K_E/YH_7C%OYBU_RG\T'I2%YJ..,6
M_F+7_*?S1^O&+?S%K_E/YH/2D+S7]>,6_F+7_*?S1^O&+?S%K_E/YH/2D+S7
M]>,6_F+7_*?S4'C?&"=*=J/\!_-!Z6A>:?KMC'\W:_NS^:/UVQC^;M?W9_-!
MZ6A>:?KMC'\W:_NS^:/UVQC^;M?W9_-!Z6A>:?KMC'\W:_NS^:/UVQC^;M?W
M9_-!Z6J[BM2MZ+Z]>HVG28)<YQT`7F[N-L9(@,M0>OA_^5IL2Q;$<3(-[<NJ
M-&H8/*T?`(,CB?&#C.(>*P%MM3&6DT[QS)[E:8A-"(0*HA/"(0)"(3PB$"0B
M$\(A`D(A/"B$"PB$\*$"PB$T*80)"(E-"(*!81":$0@6%$)X4M:7$`"2=D%9
MT6+6NV,?D8UQ?&D!;&]P>_J>#1:XTWU=Z;?>`[]^RZ'`^&K##@VI<4_;+PR<
M@J0UG4N/\4'"TAB]T\^R652J0=A*@U[^A4<RZLW4XTS1(![KT'$;S!@XT:M"
MYOJH'[.T/AT6=NKO4KEL4J7%<Q;X1X=$[`M.<=/-S0:AF)415=3J$,,Q#OS6
MP86O;F:97/7MI7N&NIU:194SB#$%+0N;O#JXH5R:K!I`WCU1'20A+0J,K4VU
M&&00K(12P@A-"(0)"(3PHA`J(3PHA`D(A/"B$"D(A-"(0)"(3PHA`JB$\(A`
MD(A.B$"0HA/"(0)"(30B$"1JB$T(A`D(A/"B$"0B$\(A`D(30$%`D(30B$"$
M(A-"/@@0A$)H0@0A00K"%$($A.P:'U40G8-#ZH,^J/K'>J2%=5'UC_5)$($A
M3":$0@4!$)X1"!(1">%,($A$)X40@6.R(3P@!`L(A/$HC5`D(A/""$"\E$)X
M1"!(4PFA$(%A$)X1"!(404\2B$"PHA/"$"0@A/!1"!(1">$`($A$=$\((0)"
M(T3PB$"0B$T*805PIA-"(0*!JNGP&T%G1-Z^@:EV\Y:#8T8/O'_1:G![%U]=
M!N5QI,(+\O/LO0,)KV[:-W<,#7T[7R4]-*E4[`=FH.9O*CV7%2DT%]8F'N'O
M%W2>G8++PK";W&:E2QMB;>Q80*]S'[0C=K3T&RRK6R=4O:5.DX.N+E\-='N_
M><?02?5P7I-C:4+6VI6]!@;3IC*T#H@P<,X?P[#;=M&TM6`<W$2YQZDJC$\-
MI5`Z:+/4!=*S0;+%O0"TE!X]Q+A-,`R`1RTU"X7%;8-I%M:D#4;L0-8ZA>N<
M2TVNS$KSG&"UC7M>T.@>7L@Y+"JU2WOG6]1TTZ@S4RN@'=<[4\M4`1+'![/3
MFNAHO%2FUW)!,(A/'1$($A$)X40@6$0FA$($A$)X40@2$0GA$($A$)H1"!(1
M":$0@6%!">$0@2$0G40@2$0GA$($4$)X40@2%,)H1"!(0FA$($A!":$0@4J(
M3J(0)"(3PB$"$*(3PHA`L*$\((05IV;%$)F#0^J#85!]8[7FEA75!]8[U20@
M2.4(`3QV1"!8T1"=$($RJ830A`L(@IH0@2(4@)H4P@6$0F1"!81":$0@6$0F
MA$(%A$)H1"!84PFA$'H@2$0GA1"!84PFA$($@2B$T*80)"(YIX40@4A$)X40
M@6$0$T(A`L(A-"(0)"AT=%9$Z+*PRV-Q>T@6S3:<SO0:H-E0J5L-PTTV^6K7
M:#'0';\$]#$!8V#0-13=Y1/OO.Y^"KOSXPJ/SANL9AR/8*C#[-^,XO;X?2;D
M8`!EWRM&[C_\W0=U]']G<5;=^-7#"7U`:=NWHV?,?B?X+L*M>[IL=X-!CBT:
M-S22KK.E2M;)E*DP-ITVAC0.0"Y''[OB.T-Q<VE>W?;M,TV4P,[A&VND[?B@
MZ'#^)+:I6%I?VU>QN"0&BLWRO/9VRV5X!$\BN&X,N<3Q-@.+MHUP6![G-!AC
MI]TSS6[XWQRA@V$MKU'0YV@`YH-!Q+2S-?K$:KR?'ZCB73(`7<C%\<Q"DRM;
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M%<*<J>$0@2$0K(40@0!3&J:%,(%A$)H*(0+""$\(A`D(A/"(0)"(3PB-4"0B
M$\(C1`D*830B$"0B$\(RH$(1">$04"0B$\(RH$(4959"B$"PB$T*805PIA,0
MA!9:414JEO\`9/\`!=,S#!;X72%.7UZPDM&DCE/Q7.8=)N:;R-)T!&ZW5_B-
M2BYKF.\P]STV""BZLJ]1_LP;2IMIDYW#4DM$F/P"Z'Z-,&J6U&KB]8YJEX"V
MG.[6@Z_P6AX<N:=>MB+KAQ\.A2`G<R3)_`+U#A^]L,4L[>YPLDV8;DIDMB8T
M)CU0;NWHEP:P:R-5I<0MC2NR&Y,A,%KMBMGB5^,-H>(02XZ-`6NM;*XNZHN\
M1S,`,MI3$>J#);2919D93ITF[D,YKR'Z8+LW-[8V@<[(#J)[KV*M4?0-2K=,
MH-M`/>S$'X\EX'QUBMCBO$#18DFC0J!A>3[QGD@V&*T<3HVMO5L[ZJVQ93,4
MPXG4[`@F(';JN*X@OJM[:-=7!%:F[*XE>T,MFV^#LJ`D'PYVT*\5XWQ07#W!
MK6-#)'E;$E!E<&7=2CA=6E2F:KW57'L!`'XK+K/<RZI9@=6ZZ*/HTM1=433(
MDOIO:/6)A3Q+_L5]1+MB<OX!!EH@GDEH.\2DT[F/FK8E`B(3941V0)"(3QJB
M$"0B$T(A`D(@:IH0@6-$1U3(A`A&J(30A`F5$0$\*(0)&R"$\((0)'91"LA1
M""M$)X1&B!"%$)X00@2%$)R.2(0)"B-%9"@A`D(A-"(0)"B-4\<T$($(40GA
M$($A1">$0@KA.P:%$%.P:'U0;*H/K'>J6%;4'UCO5+""N%(">%,($A$*R$0@
MKA3">$0@2$0GA$($A$*R$0@2$0GA3""N$0K(1"!(40K(1""O*B%9"(05Y5,)
MX1"!(1">$0@0A$:)XZHA`D(A/"(0)"(3PB$%<*8[)X1""N$0K(1""N$KF]=U
M;'*$U)K35:'(,C#*)+'U2#OE"R[NU<^WJ5BTZ0!V"Z+!\*H7.&^U-=E;FD]E
M?B%M18:5(`!O,]9T"#S/#;AU"WOAGRN<7S\H7KWT7`-X1PL?_;<3ZYBO(<1M
M*EOB&(T&20UY$#N)_P!5['P%3-#A?#R-0QI#OF@Z3%K(7XMZ;G.:QK\SG-T(
M_P#AA8V'X90<UEK=8Q?4[MA(\U:`_70CD5MZ3FN;,RBI2MW,<;BDVH`-)Y?%
M!H^*<.QNVPM[J`HXK1#274ZP@Y1U(T*\`NO9?TVVH_#_`&2H:@<:/(#LO;L?
MOL8LJ%4V-=U6D[[),D#^!7E6$TV8QQ:VIBK20UX+RXP`)[(.RXDQ"E3X;I5&
M.\I9`.TKYVQ^KXMXVF#H3F/Q7L7TL<1V5>X=A]CD;;VS<KG-VGG"\3JU67.(
M"HPDMC<HCU?Z*ZUO;V=85C%;1]/YZK2<?UJ=7':M)I.5@:T#IIJLSA6G_LE*
MZ$MI6U$O>[J2=!ZKF,4K/OL5J/<3XCWAQ0=%@1+K%F;EH"ME!6/AM'P;5K.8
M69"*K`1">$0@KA$*R%$($A1"LA$(*X40K,JB$"0B$\(A!7"(3PB$%<((5D*(
M05PA/"(0)"B$\(CH$"((305$:H(A1":$0@6%$)T(*X1!3PB$"0HA60HA`D*(
M5D*(YH*X40K"%$=D"$*(5A"@A`D;IF#0HA,T:&4&UJ#ZQWJD`5U0>=WJDA`D
M*830IA`L(A/"(0)"(3PB$"PHA60B$"0B$\*<J!(1"<!$($B$0GA3""N$$*R$
M0@KA$)X1"!(1">%,(*X1"<A$($(1"LA1"!(1">$0@2$0GA$($A$)R$94%<(A
M60DJN;387O(#1N2@KJ.-)^5PB=EC5RYSJ<3E!DP=2>2W##87-FWVMM1E1ON5
M&;D=P=UJ;AMO2=-*ZK.'(E@;_$H.@P?$J]O:BW?6\*D79WN/;DK6XI5Q7$<M
M$%MG;C-+MW1]HG^`7$W6(,!`RG-L,S\Q^6RNHW]Q[%5;3#J5)PAVNK^J#IK.
M@R^Q,W9\U.X>6DQSW:?]%Z=P@P4</J6+P/JGEJ\DMKE^'X,QXEI<&U8/(S`7
M3<&\2L%[%Q4R4JQ\KG'2>DH/0GWAP^N&UI%`F`[HMK<5:;[6&3)UD%8]:E1O
M+8M>T/IN&XU7FO$AQOAUYKV=Q4K60/[-SMD&[XEK&C;U!F($;SLO$L:Q5MK=
MU*-E4V,U*D[GU3<4\<8IB0-.J"RFW<4VQ/J5Y[?7M2N2V"UN^^I07XMBC[PF
MFTGPYDD[N*KP>U?<W36!I.;303NK,&L[&[?%S>NMW-UCP\TCMJNSLZUI94Z=
M+!J'A/<(-U5`-2H>H^Z/1!NL0K6^"8.S#Z/[:HSS-)V,;D<EQN&TW.Q2G6=J
MT_Z:K(JLJ5ZU4RZH!,N.Y/5;?#,.?%-X;HP:^J#<6DFEF(][57PB@&Y<H.W1
M6$:Z(*X1">$0@KA$)X1""N$959"B$%<(A60HA!7"(5A'91"!(40K(1""J$1J
MK(40@K(1"LA1""N$0K([*"$"0H(5D*(Z($C11">$0@KA!">$0@KA$*R%$(*X
M0GA!"!(40GA01"!5$:IX40@6.2@CFG40@2$S!HI3-&B#:U6^=WJDA7U!YW>J
M0!`D*0$T!,`@KRZ(A6PB$%>5&560B$%<:(A6PB$%>53">$0@2$958`B$%<(A
M61",O)`F5!:K(1""J$0K81""N-$1U5F71&5!7E40K<J(050@A6PHRH*X1"LA
M$(*\J(5F7FC*@KRRC+V5H&NR]'X&X(H7MM3Q/%6EU.IYJ5&8!'5WKT0>=VUC
M=7;@RVMZM9W2FPE=)AO`6.WT/K6@MZ(,DUC!(]-U[E:V=M:TQ3MZ%.DP;-8T
M`*XP$'E-?@&WI4:EW?W9+0)#*3,H^97F'$F%.IUGT[5S#1:=73.7U/,A?0/'
MME>7_#%W;V$BN0#IO$ZKQ2XK-K-%E5SLI6SLE*DRG+JF7=SO4_((.`=A;:=-
ME6L7,8=14<-7>BQ;F[.E.D"VDPQ3ZN/;J2NRQW!<<Q0LK"QK.C1H<R/3LO.;
M^E>4+P>`UKWAY8'C4`C0P@[Z_%,<.-;XC/%.6F&@\YEWP"?#</RV;'5G9&^]
MKH2N5P1I-VS])7)`8^'!VTKNKUIO+:+8MK,(^PZ4&ON>+KK"268??5H&@#7^
M5:7$>.>(,0I.IU*V9AZM!5M'AFM5JO?=M<RB#Y6@ZE9=7#:5O0#G^RVS&_:J
M>8_)!Y[B3;R[+JE:J0.D0M0S#ZU3.0'#+U&Y7:W]:T-4>S9Z]1VGBU0`"?[+
M>7J5@65V+2IEK4?'MS4SY9@F.AZ(BOA/`WW5RYQ9+&P".;B3``[[GX+<WM6F
MS$KAM!C13H_54PW8&-2%N.#266UU=$-!:RXKB-@^&@#X2M'PO2=?8A<V[VEU
M6G4SY>H&Z*Z?A[`Q7L/$<`"?(=-IV_%;7#K(MM;IK1+VB2V.06YH@88QC&1X
M-9D.G4!PU!_A^*U]:]90J5:N@%1I!;M,\T'.X=2:RFX-F,SHUF-=EF0N?P*L
M^O?WEOX[@&N+\L:S.NJZ,-@1O""O*C+W5L;PHA!7"B%;'11""N$0K([*,I05
MPB%9"B$%<*(5N51""LA$)\J,J"N$$)X1""N$0GA1"!(40K(40@KA$)X1""N$
M0GA1"!(41V5D(A!7"@A60B$%<(A/"@A`D*(5D*(05Q"(3QHH0)"(3D=E!"!(
M3,&BF%+=CH@W#Q+W>J6%=4'G=ZI805@*83PI`YH%A1"LA&5`D(RIX4@($RJ(
MZ*V%$(*P%,)X[*80)"(U3Q"F$%>53">%,(*X1E5D(CL@KRHRJR%,(*\J,JLA
M$%!7"(5F5$(*X40K`$0@KA&56940@KRJ,JMRHA!D839F^Q*UM`/VU5K3Z3K^
M"^B;6DRC;LITVAK&-#6@<@%XIP!;&MQ);U,LMHM<\GX0/XKW!NF@VW""3JW1
M*TYQ'70IAHE;Y:I'75`,'E@ZG98[<.L&UG5VV=$57;OR"2LJ/-ZKE_I"XE;P
MSP_4NV0;NL?"MQT<1[WP_)!QWTN\84L/HGA_#'M]IJ@BY>S>FW[@/(GGV7DF
M#6=CB#7656HVC<3]48]X\P.^QCFM)B%U7N;VK4KU'/JO)<XN,DE(*SVF"9[]
M$&7B^$7N%5S3N*4@^[5:<S7CJ#_H=5KFUJE+]D]S7<RTPLNXQ*\K#ZVX>^=\
MQU/YK"$-!>[8(+:^,XC;46N]MK9G&&M+IGYK'K5[JYJ#VBN2UK<SW$#R]EC4
M@Z[NS6(D-T8/]4MZXW%=N%VSM7:UGCD$%)J`4JMX"0TS2MY^T3NY=`,$K4["
MC6=2AL0TGK$GY+FK][:^(T+2B(H6P&@7JF,8S87.&X?AC6?5U)JU'CFTD0T(
M..PF_997)LWU/J;L.IN/=PT/I,+,LV.LKZG>VY-*]HD>(TZ$$?Q!6LQZTIVE
MWKE?=U1/A4_-X/8_VMM.2S:-SXE%M3$F5:%1@@5]I[$'=!V3L7HW-#ZUH94)
M@L&T]1T'9<KCF*906YI!G0A;#!\+&*,=4L:HKEHESALN3QZWN*3Z_C`APJ93
M(B$&PX0R.-_>570&!ID\I='^JZXMCX+AK:D^WX6Q2N?*VL64@>Y*Z[!;GVW"
MK6X)E[F0_P#O#0H,HA1"MA1""N$0K(49905P@A6$(A!60HA60@A!60HRJR)1
M""J-T$*R$0@JA$*R%$(*X]41S5D:RHA!60EC570HA!5"B%;"C*>J"N%$*V%$
M(*HT1"LA1""N%$*R$1H@KA1&BLA1&R!"%$*R%$(*R%!"LA1'-!7"@A6$(A!6
MF8-%)"EH@(-U4'G=ZI85SP<[O5)'9`L<U,)H3!J!(1"L@(A!6`I#4\*0$%<(
MC160B$%<*83Y5,(*P"IRIP%,(*\O93E5D(#4%<=E.7560C*@JCLIA61R1E05
MP@@*R.R(05PB%9"(*"N$0K(00@KRJ(5N5$=T%65&56Y494'=_1=1::][5(U&
M5OPU7J+/=CFW1>??1?2RV=W5C5]4#Y!>A;&1\4#;K68SC&'8.RE7Q&Z90:XY
M1FY]=%LIC7DO-OIJMS^@[/$6-EUO7AW=IW_U09][])>`47O]F;7NJ3'935I@
M!OPGEJO'/I-XL=Q/BU.I1%2G86P#:--^AS'<G_YT6IP\&E97U,G2E6>W7F(T
M_P!%SUPXO>QLS))04U'9[\2="V2G>=9C1(&3=B?N@*^ON1T04`29Y+&O:A=%
M%FY5]5^2F3^"6RH>]<U]!RE`5:C,.L#4)AT0!U6#;_\`IV&U;ZM^WK:ZI'%V
M+8D2=+6@=>A*Q\9K^VWU*RIGR,,N`1$893>6.K5/?JNDE;0.NGBD*-0-=3T:
M2-E739E9`;HMA:,#6E[@BDRU;4"H*[FUHESF:?%:1GM>+WU=UQ=5:C6&!F=*
MV]X\ECCV6+P^R!4<>;B41F8<T8=</MK>K49+`Y^5Q&8<PFN[JXJ4;JUJO%:W
M8\.!<)<).A!W6'2J>)BUV0?=8!*05LMGB)<1F&6!\45Z*[!J-WP]AM@ZG-.J
MRO>UH^[39I__`&(6'PLQE/"64FYPYA&9KQ!!+05T?#M8W'`V,XB6^=MG3PVV
MZDO/FCU<[\%S4_HSCO$\%<?**3&M_O-:/])0;F$0K(494"0HA60B$%9"(T5F
M50@KA1"LA$(*X40K(1""HA$*PA1"!(41V5D*(0(0H@*R%$(*X4$*R-5!""N$
M1T5A"B$%<:J("MA1'9!7"B-5:1HHA!7E4$*R%$(*XA01\U9"(ZH*BWD%$=5;
M'9*1*"N%$*TA1`YA!5"B%;&J@CU05PI:-$Q"EHT*#>5&^=WJERJ^HWSN]4N5
M!4&J0%8&J<J!`U1$JZ.2C*@K#4`=%9"8-05PC*K<NBG*@IRH#5;EU4Y0@JRZ
M(RE795$:H*X4PK,L*<J"J$92K0$%J"J$`*W*IRH*81"MRHRH*H1"MRHRH*H1
ME5N7D@A!5"G+LG`U1'9`D(`3PI`0>H?1RSP\(ID[57O/QG_PNV"Y+@BG/#5F
M6^]J0>\DKJZ;L[`[J@G;?8KBOI4IBIPA<4W:S4;'XA=L=ESO&V'U,3X<O+6G
M4:VHUOC,+AH[+K'9!\QLJPW$63^T%*I\V@'\0M);2^HP^I_%;2[^JO&-.@JV
MPD>CC"UEF)(UY'^*"ZB![0]W1)4DN)[JRG`=4/=8]5^OQ0*VEXCI=[HW6'BU
MR^HT6EK[SM)')9-:J_PBUFY5%O2;3$DR\ZDH*WEF&X;D9[P&IZE:[!K8R^ZJ
MF7/UU5U^YUU7%NSW1[Q6:P"G3#1MLB'H@U*L#8+85(93#!\5C6;0-0GJNS5#
MV16-<GZMRC"AX5L\G<RFJB00534J>#9U3MH808F$.\2\O:FX+UC7%;+=WM,;
M.#2GX;)-.LX[ERP<1).)U@S<@`JH]V^B]CL2M,'PH":`N/;KCIE9[H/JX_@N
M4QJC6Q#Z1\5Q.T#JC:=TYP(^T!H?P72?1M>/PSAB[K6[<^(7(;:VS>KB/X#4
ME=1PW@MGAMG=-HD7%TRD]US<_9!C4!17.0#L=.2B-%8UGD;Z!3`0595!"MRH
M(050HA6D*(050H*MA1""LA1"LA1""LA$)R$$(*X1'9/"(05P@A/"@A`D=40F
M(00@2%!"LA1"!(41!3PB$"0HA.H0)&J"$T(A`A"B$Y"B-$"0HA.HA`A'500G
M@*$"0EC16$*"$"0I:-$T)F@P@W[V^8QU2QV5[V^<^J4-05!O.$V5695.7YH*
M\JC*K@U&5!3E3!JLRJ0.:"O*B%;EZJ(05Y41JK81E05@*8T3Y5,0@KA3'9/E
M00@3*@M5D((05Y4958`B$%4*2W160H+4%<*(ZJR$94"$*(5D(A!7"(5D(B$%
M<*(U5D(A!ZI]'KYP"G3.X)(])*ZD-+7$MV.X7'<!U"W!J+\L!I<TZS.J[0$$
M9@9!0$K7XDX"UN0X2/">2/\`"?P6>X2%J\6DVEP#H30J`'_"4'R3<:T,/K:Z
MT:C?DXK%L@/"S<]EET@:N$T3'[%]5OSU6%;/U`Y%!:\P3`W6)4DDK)K$@Z+'
M`S9NL(*'N@=U#3(*KN'9`K:`E@,;H,5[!2S$#7>4HJFH6L&Y*MO-&K&PUN>L
MZH>6R#<,\E,=4K!(>_E.BAY+B&M5]4>%1;3&^Y08KEKL1=_L]0#:"LFXN&T:
M3ZAV:%J:M5]>R>\Z"))06<.0&UV\@96"]_B8A6>W4E\-"S\*;[)A5>Y?[SP2
M/]%K\*!=6!.Y,D]`JCVG@BQ=<65-IJ.IV]NT3D,.>X\IY!=Y](>(TN%N!&8?
M:-:V_P`0;X3&-&H;NYWR_BM)]&%JVLVGG\M&F15J$\R!I\ED<=O%UA>)<17+
M`]]P/8\)HD:Y`=7CU@GT"BM8(+6N&Q`/X(A8V$5O:,)LJQ,EU%L_*%EH$(A1
ME3P@:H*R.2(3*"@0CT4$*PB2HA!7"B%80HA`D*(5D<U!"!"%!'9-"$"0H(3Q
M*A`A"A.0H0)NB(30@A`D(3%$($40GA1"!"HA.5!E`D*(E/"@A`A1":%"!84)
MB%!"!2H3$*(01"EHT00I;$%!TKQYCZI8[*QWO$=U`Z((`4QV4C=2$!`40F04
M"QNICDI1H@CELB%*$$0ICLI0@B.:(3(T0+"F%(04$1V4$)I4(!$*5""(1"E"
M""%$)E""(00I4C5`L=40F*A`I"([ID(/0/H\K1A[Z<#*VJX&>7-=PQH`EFQY
M+S[@"Y<VA<47L#J3:LR-VR!^"]!IY<H+#IT0,XZ:K58NYK;*\<9+6V]0G33W
M2MJ[9:/B0NIX)BCVN\PM*I`Z^4H/E'`ZYN*=S8N($!SZ?^H_%:YDMT.D&$8:
MRJR+RBX9F.VZ]1\E;=1XCWL]RI#VH&K$98YJFF)S'LGK'6G_`&@1^"JH.@N"
M#7XB8RZ[E9E#]DWT6!C&F37[2V-O^Q'H@Q+^/#*KPOW"GQ(Q2)2X=Y:<<^:)
M];:TI@OSG8*B_J^8]2LNW$4BX[+GL8NA3F#YG:!%8-_7==5V6=(Z`RXK*J6X
M<ZC8MG*1FJ'L$F#6I:#<U&G,X>65LFAMO3JW%3WG:D]D1J\?KMITJ=G2T&Y`
MY!48*W/7HYHR9MNI6$X5<1O*I:1G+7/`/0"8^06VX3HBMB%%L%Q!G+"H^A>!
MK1]SAPM2[PK>H,U>IL<GW1Z_P5_&X-3"JN(E@:US3:850`C*V(=4CT_!;O@G
M"WNPUE.JPBFZ"\=>RV7$F!/Q"H7N>P0T4Z+"0!3;S/JHKQO@^MFP<6I$.M7N
MI'N)D%;U8-M;MM<8Q6E2;EH9F^$(CRB6S\5G((&NZ/@A$H(ZRH*E0@@H4R5&
MB"$0B42@B$0A"!2$0I4((A1"E"!8[J(YIBH0+"B$Y4?P0+"@A2HYH(A00F4(
M%4%,H01"A2A`L*"F2GL@4^B$Q2E`J@J4?!`J9O-*F;L4'3/]X^J7^*9Y\Q]4
MNB`[J04*`@:4>B("A!(/=2$J.2!D2H")0,"IE)*F4#2I2`J90,H*642@9$A+
M*)0-NA*B4$H42B4$RA*2B4#*0DE$H&0E)1F0,H2RC,@[#@)SO:+M@]WRNU^(
M7I=+W1U7DW!55C<5JM<TN+J0R@"28*]5H!Q8-2T(+G:"20!U*Y[B.ZP]N$8H
MVM=,##:U,^09LH@ZZ+>FA3/O-SG^T96EXIIEG#>+AA93_P!DJ93E$>Z4'R5P
M\UE2K<4*FM-X!!Y@\B%9?VM2W<ZC4'FIF1&Q!YK%P(NI8AD(&K!I,@KI,18*
M]M+A];2Y_>8?R0<W6TH-?]QP/P5`\M:HWLLVHR:3Z?)P*P<TU:+S]H"4&'C8
MFE2?U(*V5N#X`CHM=B@FQIGFUT'X%;2A/L[3/)!JL6<&TB3L$^#4GOI![Q!>
M9`[+&O6F\Q!EH#]6SS5"M]:@-V``&@[(AKVJVWMH)`TDE<8QK\3Q`NCZMI_!
M;'B.]?5JBUI&7.WCHLK#+-MK0`^T=245ETV!C0!$!:'B&\G+;,.F[EM[^Y%M
M;OJ'D-%QM:HZM5<]QDN*#8\.AQQ>V#:9J.>XL#`8S9FD1^*WO`5*M^F'V[RZ
MF:?O-`AT@ZK3X6RI:U+:_;H:55KV_`@KJ;RA<8-QK7N+(FBRK]=2.CI#M?XR
MJCZCX2LJ+;.G%.I5=`ESB8_%;O$[6W%!QJ4J`T^U"\4P3$>(KNDUUS?W(IP-
M'/+1\A"R\7O*KJ):ZJ7&.>JBN>O;=M#CFJX4PUKZ#P"QTM)!'*5M.JXVR--O
M%5O5@!SVO;IIJ0NOS('4%)F4%R!^<HW29D%R!E!.LI<RC-W0-,HT2$HE`TJ)
M2RB4#2@GJDS(+D#2HGJES*,R!I42D+E$H')U42EE1F0-*B4I<H+D#2A5ERC,
M@L*A5ER@N06*.79)F55:NRDPN>Z`@OE02M+3QZTJ77LXJ-+NDK:A\B0="@L)
MZI9"4N2YD#E02DS*)0/*EI$*HN4M<80=.]WG/JDSJI[CG/JES(+PY,'+&#NZ
M8/09&9&=49NZC,@OS*0]4!R`Y!D9M$!RI#D9HW079D9N<JG-W4AR"T.1*JS*
M<R"S,5,JK/U1FZ(+91F*JS=T%R"S,HS*K/JHSH+<Q1G569&8%!;F49E42B4%
MV9&=4RC,@MS=U.<JF5$]T%V=+F5<J)0=-P5?6]GC?B756G2INHN'B5'!H:9'
M,KTUN/X4`,ER:G_+82/FO"*I+0U_W'-=^*[S#G9Z##,Z<T'>G'+8B64JKO6`
MM-C?$+VVE9E+"6W`<PM+'U1Y@1MLL2D);"=S!$`>J#Y:R7-CQ`:-U0=0=F,-
M(T@GD>:Z\M\:B0T@.C3\E[56PRUN!]=;TJG]]@*U%WPOAM62VV%,]6:(/"JH
MRN+2((Y+4U_+M]BH#\"O6L<^CZH^J^M978!.N6HV?Q"\_P`>X=Q;#B]U>S>Y
MF6"^F,PTU!0:+%&_[-6;TJ`CXPLOQ!1L@]Q@-;*KQ%N>BX]6@I*S/&%*C]C1
MS_0<OF@JPZB64G5GCZVL<[NW0+)OKEMI9N>3KL!U*M`YQH%J:P_2%Y_^UH&/
M[SD%.$VCWO==W`E[S(GDMTZ&ME/2I0S.1#1LM;?5GU7FVH&#'G>=F#\T&GQ:
MX==UQ;T/,`=86L;3#JS6,\VL3U6;E&:K2MQE:=#4)UCI\5LN'\#OK^_I"VLZ
M]5C3)+&$CYJI69<T6LLZ%M3$U"2(&^L0O:++`K<5:-[>4FFYIT@Q@=]@?FN,
MPGA/$;/%Z>*8D*3:--^=E$F72-IY;ZKJ:^+/S&72[K*BMO=UA29Y2`%RV+7[
M<IERHOL8!!ERXW&<6`S`.UZ2@5^(1C]B6NDBLW^,+T@NU/JO'^&*57$N)+4F
M<K'>([L!JO6R3N@LS(S]U5*)069D9U5*B4%N9&=4RB4%N=1G54J)079T9E3F
M49D%V91F51<H+D%N91F5691F06YE!<JBY1F06YE!=W5>9*7``DZ(+<R@O6JO
M,8L[2?$J`?%:C];K`UA3#])WY(.J+D%RQ+6ZIW-(5*9D%7%P&Y069DCJ@:)<
M8"IJUZ=)A>YP`"XCB+B?5UO:.EVQ<-@@Z+%>(K2R:1X@+N@.JX3%N([J^S,8
M338>^I6CJU:E5Y?4<7.)DDI$%MO5J4J[*C"<X,KU[!KBI5L:3J@(<0-"O,.'
M6TGXG3;5$CDO5:(8RDT,$"$&27<E&94.J`"28"AM5KO=<"@OS*,RJS=U!<@M
MS*6NT6.7<TS7:(.AJ5FA[M>:05V_>7-5;]WB.\W-5^W'<._%!U/C-&Y4^.WJ
MN4-^[[RCVY_WD'6BNT\U)K-^\N2%^X?:*;V]WWD'4^TLYE,+AI^TN4]M)YJ?
M;3]Y!UGCMZH\4$;KE/;G?>*=M^[[R#J!5',IO$'5<P,0/WDXQ$C[2#I0_NC.
MN;_21^\F&)G[R#H\Z,ZYT8IW3?I0=4'09T9^ZY_]*C[RC]*C[R#H"]&9:`8J
MWJI_2S>J#?9D9UH?TJWJH_2K?O(-_G1G6@.*CJE_2HZH.ASHSA<_^E!]Y2,5
M'5!O\X1G6A&*-/-3^E&?>0;S.C.M#^E&_>4'%!]Y!O7D/8YO40NIX8OFU;-C
M'F'M`!7F_P"E!]Y;3A[%F,KO8\RPF>_P0>OT7R!'Q5X<?@N>L<4MRP'Q@1UE
M;*EB-NXQXC9]4&T8X$"5.5JP:5S2!/G$;[[+(;<TXG,/F@:I2!&TK7W5C1J@
MAS)D0MHVO2/V@K`*+AH0@\[QG@?![\/+J'AO=]NF<I7&WOT=7M%S_8;EM4'8
M5!!`]0O=#1I$\DIMZ6T!!Q-GPOPI>X9:T\2P@6]S3I-94\-[F$D"#J-_5-_)
MKP4ZF&V[*U)@UAEP?]5U[K9CC`4EEK9TS4J%C>Y0<A5X(X7MJ`%/#:UUR#JE
M5T?(0L1G"&`TFD4\'M&`F2,D_P`5Z%+7T@7#3D(6FOW_`%OAL:"(F4'.6_#V
M#TJGEPRS`&WU+=_DMXVG;T*.2FQE-H^RT`!:U]1[7%I?!Y+!O+MP`;XAGF@H
MQ^"'9?Q7FN-7#[9[BZ0)T7?8M>6[,,J.J51G#="2O'N,L;I7=.G3I51FB"4&
M#B6,G,0UTE:5@NL1N&TJ;2][S`:.:C#K=E]="B*S6F)EW/T7=830M<,I_4,!
MJD>:HX:G\E4;GAS!*&"V_)]T\?65/]!V6ZSCJN=_2+^JC]).'-171YPHSKFS
MBC@E_2[N<H.ES*,XZKGABW.4WZ4[H-\7]2H+PM%^DU'Z30;W.$N<+1_I0=4?
MI,=4&\SJ,ZT9Q0=5'Z4'5!O<Z@O[K1'%!U4'%!U0;TN4%ZTGZ3;S*/TFW:4&
MZS(S+2'%&-:27"`M7=\56M(.#'ASAR"#JJUQ3I,+GN``7&8_Q3D)HVI!=UY!
M<UB6.WEZ2!4+*9Y`K4$R9*"ZZNJ]U4-2M4+B52A"#K^%,>;:M]FN'P/LDK(X
M@XEJ4JK66C@9W/1<0@DG<R@VUUCV(7-,TW5,H.\+4DDF3NA"`0A"#9\/AGZ2
MIN>[*&KTEU[0I40XU!`'5>1@EID$@]E:ZYN'-R.K/+>A<@ZC&N)7OFE:._Q*
MC`N(*U*MDNZA<T[%<RA!ZW;WU"NT.8\&>ZM?6:UI<2("\EH75Q0(-*JYL<@5
MF'&;]U,L-8P4'88AQ);VSBQIS.'(+5-XIKODM9`GFN3<2XDDR3S5]#W#ZH.[
MK5QXKQFYJOVEHW*T=>N\5Z@G[2J\5_WD2XZ$7+?O(-TT?:7.^*_[Q0:KS]I$
MY.A]K9]Y0;Q@^TN>\1_WB@O<>:')T(O6_>4B]:=`5SH>[J5(>X;$H<G1^V-!
MW4B\!V*YSQ'$[E2VJ\?:1:Z470ZJ?:>ZYT5GC64PN:FTH5T/M/=!N>ZY_P!I
M?*@W%0\T*Z'VKNH]IZ%:`7#P-RI]I?U16]-R?O*#<]UHQ<NZJ#<//-!O/:NZ
MGVKNM#X[^J9MP[F@WGM/=3[4>JTGM*DW10;GVI-[3W6D%R2I]H*#="YGFI]H
M/5:47";VDH-Q[0>J/:.ZTOM)4BO.I0;CQSU0*\\UJ!7/Q6SP6@ZYKYWCZMF_
M<]$&VM;1]1@?4)`.P66RT#'9F$M<.<K(&@A,$%/ME];3EJDCF`K:>/7C1J'(
M+0=T>&SH$&92XIOF\G'UE9]+BR]+M:#CZ+3!K1R"9!U%'C"Y$%UL\@<I64>.
M&6](OK!](#FXKDF.$&5JL>I>+AE=@W`D(.^I?2-9//O_`(KJ>&N)+?&!7>RI
MEI48S.)7R+0]I?<&DRJX$'JNOL,7QNPP2MA=%S#3?5\4/U#@2((GF--D'T6S
MBFEB&(.PK`Z1N;@'SU3I2I-^\X_P'-;FG2H8>/'O*YN+@;U7Z`?W1R"^>>%?
MI!&`</5\/JT&B\=5<]U2-7]"3V79\#8W1XH94Q/BG%`;9C\E&T#\H<0)E\<N
M@YH/4+?$3BM1S;.D^I0:8?7V8#T!YGT6149;V]-Y+0ZH1OOJN:?Q6;VN,+X:
MLC=/8`W+1;%.F.YV:%MZ=J^PH&]QO$VNK1)8SRTF=A.I]4&DO+>I;T17KZ3N
M2N)XBQFC;G-F``&TJKZ1_I`MZK&V=C5864W3F;S*\9QC&[N^J$N>8/-!LN(N
M*;B\J5:-$EM,F-URCG.<9<23W4(0769>+NB6.RNSB#,<UW7M!ZK@6M=.8#9=
M%;W3JE%KB9,0?5!NO:.Z/:.ZU/BNZJ!4=U0;?QPH\8+5>*[JI\9W5!L_&"/'
M6L\5T*?%)0;'VA!N`M9XCBD=6:#!=J@VOCA'C]UK!4,:%/XI0;#QE'BCJM8Z
M[:UV4NU3>+.H*#/-:5!K=U@AY'-3XA&Z#+-8H-8]5A>(5.?F@C$[IS+=T<US
M!,F2MOBM2:8;/P6H0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"$(0"R*'N'U6.LB
MA[A]4&VN/V]3^\JU9<?MZG]XJM5ST(0@"=D`A,UA<83&DX=$6*T)Q3).X4FD
MX:R$)JM"8M*D,<40J;YH#2`I^&J*B94J(YJ44(4@=U.4H%1R393T01R0*A3!
M*D`H(0I+3*`T]$(A2"B#T0`>B`S*9]5.70*(TB449M/S4C3NH#=>J8#HH+*#
M#5J-8T$N<8"[FPMFVUNRDWD-3U*T?#MG+C=/&@T9ZKI!H$4P4A0%*!E(2J4#
M!"$#=`[-PJ;MGB4JK#]II"M9[P459S:C24'D-0NM,4?Y2?-LNEM:[:E(%S7-
M]0M#Q/2%#&*HCG*R<,O*3*8!J$=LWYH,V[M*-:3IKV6#;LKV%PRK2)?3:\%U
M,D@/`Y&%L?TA:NT+P?\`#^2JJW%%\Y7#X`_DB/:N'N/:V+4VX7PE@-.C7;2#
MJE/1K6\I[Z\U?B7!O$.,VIN,<QAS:AU]GI>ZWXKQOA7&ZW#?$%KBM'.6M.6J
MS;.P[A?5%"[H7V'4[NB\/I56!['=01*&/&+_`.CNTM[-E5I=4=,.T7&\2<(M
MM`6M``<):0%]`W!I5;>HVFYIC5PG9</CS+3$,"N[AE1F:V<6SS,=$5\XUJ+Z
M-9U)[8>TP0K[6WE[75&DL^T0=EN^(Z-*K[)>TX::K8?'4)</MO:,GEFF/=8W
M=QZGLJC-IX7;U+5F5P=3>):^%K+BBZV!\)A+F$YXY1U78VMF#2R57M!IF13!
MG0Z3\U@XA0HTW70JSD<T.;3:-7D_B=0H1Q]6_EOD13O]/.L"HTL>YI!!!V/)
M*A&X9?4W&"EN;L-;Y#)6I023N4(V3+_3S*3B&\`+6(0C/_2#NBQ:E9[GYIA5
M(1692OGL`!U5YOVEIY%:Q")#OJN<_/*R*5[49NL1"*S_`-(.Z!)4OJCA`$+#
M0B1E,O*@(E9K[M@IR'>:%J$*D65JKJCI),*M"%%"$(0"$(0"$(0"$(0"$(0"
M$(0"$(0"$(0"R*'N'U6.LBA[A]4&_KL9X]0P-RJRU@47(/C5/[Q6/)V59W60
M`SE"D!@.RQQOO"<`[;H9J\93L@P53E)1E<`9!46KH;LC3:=52W2?]4I=)F-%
M2KX84WE:-%CE_,!'B>J%Q<2R>2F&[*EA!.J<%AV4*L#6(AFRI<^.6JD`N0JW
MR=$>5(UA";+U13>11+4F70F?@@99Y('\J/*"ECNJ'7-.FZ'&4&5`E&BH9=47
M#W@$.N*`=!>A5YA02`JW7-NULYY2TKNV=[QCU0J\04>771+[1:D$AX^:UMS=
MDN(8?*D2L]]>DPP2LFS:+FJQE/7,87-A[GNF-.J[3@VS<*3[NH#KY63^*HZ:
MWI-H464F;-$*\)0F"BF"D*%*"0I"$<D$J0E3()&\IZPYQ'-5C99%8>1KN1:$
M'E_&](#%B1N=T_#F`5KTAWC6E-O6J^/P65QC3!Q0EPWI@A3PC3J/JG(*9C0Y
MCLJCT3"OH\M*C6>/Q!:-+CE#:-NYVL3&L+IK3Z,N'GL#JN*WUP8G+38VG\.:
M?AW`;B[H4WBI0`B06U'?_)74MX9JF!5O_(V(:YY(]8E17D?TH<%81@5+#;["
MJ-P&.<65?'JYY<-1I\UZ3ASFW'#=O5PU[*=O6HAS&T]J1C5OP*HX[X=LSPG>
M.9=&K<6X%6FT`1`.L1V)7.?1U6JW/#U]AEH"^O0JE_AAWF+7C<3WA!7;G$'8
M7BKJ=5P93J^&7SJYQ$E:6A9UG<*7MP<W@M<]H/WB-UT-*I7P;A'$Z=W2-.[?
M>/!I5/>;H!JK:[O8?HMM#4:0^LQSXC[SB@\TNN'75."FX@03E\[3Z<ES^`W!
M)R^Z#H`-X[+VGAJC2Q'Z,:UL]N0LSL.;2#NO%<*J/HW3[:U:"_,1GW1'8VU)
MU.C5J&@XN<T!K&N`<=9Y_P#^K8V6$7=P[QKAM.DT,,-8)+`?[1W*?A^QRO;4
MK.SO.\F=%V-(T2S+]@:$#_7_`,HKPGC7#&6MRRO0IY:9\KHZKE5],WW#M'&L
M(O,+K,93\5N:@"WS9AJ"/SA?.&)6=:PO:MK786U*;BT@H,5"$(!"$(!"$(!"
M$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!"$(!9%#W#ZK'6
M10]P^J#HZU("K4D#=5AM,Z$!%:Y^NJ`F/,J203GDHC)%&B3N%E4Z%")E:^G5
M8XP9"<U`SW245G^%0!Y!-X-!P6JJ7#@)RE4>U59T!"1*VU2WI;@B$K:%#8PM
M0;FY<3H8[I?:;C[A5A6[=:6YV<!\514M*+?^(M2ZO<;PX)17KNW!*0K9.HTQ
M]K1)D8#(*Q6U:I$%AT4E]3;*42LF&DZ%6%A.H<L)GCS[JO`K[D1*%6-8\'WD
MS@Z.2J)K-,E!=5(F-E%JNHY\D!&5XU.B&LN"XNA2]E=P\P590YKZ@\KH6,^T
MU,NE7L97&RL#:I]X(K7&@X`]$-I:2[1;%U(;%*+<QIL4IVU[V"!E!E2RB7:;
M%;#P&@;B5`:)U*4[88MG';51[)4/(+8L`;SW5@@<TJXP;3#ZE:NRD![QA>D6
ME!EM;TZ#!HP0M#P[;%U=UPX2&"!ZKI%%2$P[I1NF"!E(4!8E?$K.A<MM:E8"
MJ[2!R]4&<%*4*4$A2=E`4\T`LNY$4Z>OV0L30N'JLO$/+4:V(`8$'GG&K\M^
M.]$!:7!;RK;76:D7!Q=R&BW'&8<[$JHY,I-7/X88NV@B=5?B/:N#\5O:N1F<
MTQ)DB71W7HEF^I5TJ5GN<X:Q``Z?!>=\'&FYU)AI#4#G"]<PRW%)HRTF-<1K
M`45#+:E<VU>T<P&E68ZDZ)=HX0O$^!KB[X?X\=8O:36#W6[FG3,`8U]0OH:B
M71'9<+Q!]'-+%.+J/$%G=NMWO>'W$F=1`\H[P@?B_ARGBUK7KUV/80QSZ8=Y
M3H/M$>\=-N:X3BB^K'#J>&W-[XE&V:QH:VGE),"&_`&5['C=-UGA@I,J$N8<
MWB5()`F#^!*\5QI[/;L0M1#C3NGU,Q.S2P:D\]0@MJ5W6'T75:KR:3KFHXAN
MQ,E>/6E8VE5II"7O=H#N>Z[KBO$*F.T+&PPVJ_P:+`'M+8#2!O/.5SU+!#2J
M,H5`72<S3T/,(CLN'ZE1[`]]1V@\U.F)GU)W6VQ*_NL&N;;$;5PJ6C],M9FC
M0-Q.P*UV`5:=FU[*CFT13@9WQI\]%L+K'[`T'BB*M\YKI`:/(T^KO+\@45V8
MNV%].[I-,-<T%[])88(CF?@%Y!].&%V=#'Z-]8O:3=4P^I2!&:DXD^\!M,3\
M4<9\1<3UGU;9E>E0I.`+VVY.>.CGG4_@%HL#P.ZO+6K>U27M(DM.NG5!Q3FE
MI@J%W5;`+2IJ1KV5'ZMVTZDQZH.,0NV?P]:9"`-?5:"[P6O2J.#-6SH@U"%D
MNLKAN["JC1J#=J"M"?PW]%!8X<D"H1LA`(0I#2=@4$(4Y'="IR.Z(%0I+'#<
M*$`A"$`A"$`A"$`A"$`A"$`A"$`A"$`A"$`LBA[A]5CK(H>X?5!N[FG1=7J:
MC?JJW>$V&R%@73WBYJB?M%4YG?>/S59;NGX($YA\T_BV_-P6@D\T2>J170^+
M:.$$MT[I'5+1LD%JT*$@VYN;?-]F%(N;8'DM.H),Z#\4@W7MEM.S4E6]MMVM
M!6F)?H0U5E[CH2@W#+VG,Y85K;^B/L3\%HAG,1R5OF+2#N@W/Z2HS[D?!0[$
MV;!GX+32YHB)4@%P\WX(-G4Q$.V:D]O=]U:YU1HVU4MBIH@SO;ZG*%)OZA24
M,-JN,BH`"LD80]N]5J#$&(O!/Y*?TBXCDLL86SG7"M&#T,L^./D@UGM=1^LI
MS>U,NZV#,)M9UKJX8;8-WJR4I&D=6J.,EQ4>*_JM^RQP\'<'U60+3#`.7R2D
M<SXM3JGI/KU*C6MDDF%TK:.%MTT6?AMM9U:X-%@AFNR4C;89;"TLZ=+[0$N]
M5EH"%%2$P4!2U!3?75.RM*EQ4,91H.IY+SJWJ5+S%:3LQ+WU=3,SJN[Q.C2O
MA6M:GNTZ1,]''9:W`.'385A<7!:7M]UH_BB.E;LF4*45*$(G1!-/6HT#J%E8
MF2;QX/(`#Y*FQ;FNZ0_M2K[\%]T\C[3D'FW%=<?I*_:?>+6-7/V=1S;EK_,-
M=2`L[B6J:V)WE4D>:K'XK66\^T-@ZDJH]IX%O*WM%+,RJ6Z;M'4+U?!<9J7E
MM2>;:H]T92\0`2#'P7D?`-1IOJ#&G(7L`(,P"(/P75<,XVRTPESX<YHJ.#8U
M+O-HHKU$7(:'.>`T1.IT7&<2_2-AV&.J6]K4;7N6Z>5WE"P+BSXFXK:6MJ?H
MRPV)?[[QZ+5<0\+X'PYA37-:;B]J.#`Y_,\R@5_%=[=876Q#%Z]-E.Y#*5M1
M9H^JP/#GU(Y-`;`)W)7!4WWG$N-7KK;Q&4JM4%V7[8Y#T"[0<&VV)8G5]KN*
MC&,8USWO);38T&(](V`6_P`$M*+`^SX*PNE5R'*_$[C]BQW]D?:/H@U;\&PC
MAS"65L0?2MZCAM4W/H-RN#N[ZYN*]0X?A5:I3`/UE491KI/HO8[7@.V;='$<
M;O*F+8D[7Q*HAC3_`&6\@HN^'VN;5(AA<'-AC=>R#Q:A@5_<UR_$JQ9)G*S\
MRNPP?`<.99BI<,#V4W9BUSC+C&FRWC<,HOJ-I-S"NTPYKSF,=8&PCJ47E"C:
MVUP^HUQ\)P:!.4%X,:?,(.3XTL[&SM[FHRG3=>W(8QC:;8#&\S"Z3@C"6,X6
M95<ULU&%ID<BN0XWJ,.)4Z0)K7'@@ESCI2$ZP`O3^%Q'"MO;@2\TF_.$'C]Q
M;AM5[,Q&5Q'R*K-)H'OK-XQJ&RQRX!\P>[,("T7M[7?9<@V3:38WE#Z--PU`
M6N]O`&C3\E6<1),!KA\$%]>SIG8!:NMAP+MEFF]!$&4CKMAUU*#`?A@^ZJ'X
M5T"VQO*8Y&/1*;RGME/R1(T;L(?,A(["J@.T_!;TW;"8RGY)7W#3H&F/16D:
MBGA+X/Y)V849U6U%P`#Y3\E#+EH)!!2D:XX7V4-PT3LMOX[#U4.JL&L*4C57
M=@!0)`U"Y]])S7$0NON:P>PM.@6GJLI2=95/&FR.Z(R.Z+9&E2WE5O92&Q_%
M(5KT+)>QD[RE\-O=(M4(60QC0>BL=39'O#5(E8:%<ZFWD4OA_P!I(JM"EP@[
M@J%`(4@2=P$P8WF\($0G+6C[:4@<C*"$(0@%D4/</JL=9%#W#ZH+;IP]IK2?
MM%4&HWN5L;G";RI<57"F8+BAF!7;MVPK4:WQ1T*@U>@6X'#MV4_ZMW2#2>(3
MR`]4-J;R-5TEOPQ5=J]Q"S6<+TV[DE%<=G<3H%.9Y^RNZI\.4&C5OX++HX':
ML_X0^2#SUK*SMFD_!7-L[APTHNGK"]&9AU!GNTA\E>RTI@:4V_)*/-VX=?$?
ML2592PB_<8\,_%>C^`!]D*?`/(`)1P3.'[UT2(^"R&<,W+AJ^/1=N*+XW2FC
M4^\E''LX6/-ZM;PNP;U#\UU)MGG[95-3#JCS/C.`]5!J*>`T6`?7'YJT8+0<
M=:I(]5E_H<SK<.^:R:6'-IB/$)]2@U[<"LQ]K\4XP6T',_-;)MDP#WS\TXM6
M#=Q0:QN#642=_52,'L1]D?-9%^^G:T7.F7<FA<JVIBUY=``.HTR>:#I!AEB#
M[H4?HZQGW%EV=LVC1:'NS.C4E7EK`=@@UWZ.LY\M)95I;TJ&;PV!LJ\D`:!2
MP0$#(0I02(4A0$XW0:NW)JWUV#MXH'P`6U6LPD2ZO5^\];0(!2B$()2G925"
M#-PIN:YS1[K47=0"H]WW9/R$K(PAH;0KUG#RC1:K$JWAV-_<&1EHOB.IT'\4
M'DV)N+ZN>=:CR[\5C,S>*V'.'>47#S4K@$:-$)[9H-=@CFJCM\`PFZNV-!Q*
MX8UXC*VH?DO9N#L&M</LJ5N1XSZ6K2[DO,>&W-#:(IY9$;NA=9BG$=?#<-#K
M=C15JRRFUKLQ<=/DHKO^(.*L+X>M<]W<,%0CRT@?,?@O".)OI#J8EB(N*=L7
MMI.'AYC#05L;+@C&,><_$L7KNHTC+WOJNV;NN.QJULAB5.G8D#"Z-4,-9P@/
M)YE$>E<+T>*.-JH=>AU&PJ$&H6,,.C8:GNO6C@]U0MJ=M1QC$+:G3;#6TF,:
MT".7E6FX`O<"M<(MZ-'&,--7[3?':#KR79MK6]P2^A7I/$90:=8'XZ%%<I7P
M3&_^#Q7?R3/G#?R6(++BZD_R8[;7(WBM2$_A"[;P[CR%I<[4R"^9[@JGP*WM
M-9ISEI'D).R#A;EO$5LRHZIA5I<Y]7&W?!)]"#JN<Q&IB%6@YAPNXH/-0/=F
MMC5C:8^2]6K4:AM]7/94,ZE_ND+6W[[2A1K&XO:%.6A[34K@1IMN@\:OL.Q#
M&,;\1UG=^&0UDNI>&&L!DKT^Q?6I4J5M0;1H@LC-4>-#V`U6OQ3'^&:=\6OQ
MFSUITR0Q^;4:$:?!45>+>':-TY]"Z=48R[+FBE3.M,@29('-!I^*N&J/^TXJ
MZI6N+D9<YRY*;6;:-,DF8U7'&VH_S;?DNRQOC:E="XH6%H!2JYV%]4RXM=V&
MW5<=G$02@CV:C_-A*;:A_-M^2;Q6R@U$"&VHQ^S"I-M1GW`LCQ`HS!!CFWI?
MS82&WH_<"RR0E,`(,0VU'[@2NMJ?)H644ITT04"WIQ[H0+>G]P*\;*#,R@QW
M6]/?*$O@,CW=%DNG=5RZ=D&%>46>&<K8*YRO0.9T%=/>Y@PP.2YJX-4//D^*
MN)K`?3+9UV53@2-#!680YV[?P2NIN&U/7T52L`M>>_Q49']/Q68:=29R1V2G
M.W=H'P4BU0RF_OZ)W-J`=%:VH9\QT5CZM&!H252L%SGC0E(23NK:SVO/E$*I
M94(0A`(0A`(0A`(0A`+(H>X?58ZR*'N'U0>J5*;/$?Y>:`UG(*ZL6BH[U5;2
M"-$!#1K"`6GDC,$%S1J@8&.2,QG95^,Q(ZX:.2#)#^H1G[*EM4$3"D/!U079
M^@2^([D%7XK6G5)[0TG0(,D/)W39R=%B>T"5/B-)]Y!D9W!1XCE3X@Y;(\8#
M[*"\O,;*&OJ%8XN3MD0ZY<!HQ!>35G1*/'YPL?VBK.K=%+ZSSL@M/M'4(BXC
MWA*Q'7#V3FDI#=O`&AU01<TWMKMJ5CF:$GCTS78!`'96575'MF9[+`?3<7SE
M/R0="V'`%I4Y>^BU-&M4$-`='=6^/6DB#ZH,^/-$R-U8%3;@Y`7'4J\(!,`H
M"8(&`5==WAV]5_1A/X*T+%Q4D6%4#=T-^90582W_`&5AZR5L.:Q,,;EM:;>C
M0LT0@(1LI"C[2"':#NE&X3.W3V]-U6JRFP2YS@`@WM2B;3`:)(AU8YO@N+XL
MN!0P*J/M5GAOP&J]$XV:VT=:V#-11I`'UA>1_2%<9*5K:@[-+S\4'"-.9[W:
M;K(MX%9A/5440,A)($E9M@VFZL`X%^NPT6D>@X)5):P.#?+R<)D?FNTL;:VH
M5VXSC+Q3H4&Y;>G6,D#[Q'5<KP]3JD-#',H@"9:W,[\=%UUCAMI4/M%RU]W7
MIG05W>(!Z-V'R658V*7F+<8-=;8<#98*T_6W-7R^)^8[!9M#A'#WV8L'T`:'
MA$9W,^LJ$F"X#[/+O'1;V]JV=C1-SB-W3M:#J?E-1P#AU#6_D%YWQ7](%Q5M
M[FWP$.M[?(0;AX^L?I!@?9'XH*L$X>MO:*]C7:RI4MZKJ3G-U!(*ZRVX,PS.
M'.J/:#KY3$+@?HSNZAN7-J/)S@DDGGU7KM)[2V23!&Z#4UN$[$-#:5[=M`U$
M5G?FN=Q#AZNS.*.)7D$\ZSOS7;U7@SYH`6LJ/#W$F3'1!YM?8!=M:2;NLX#8
M&H[\UQ>+T:UN_*][G>IE>P8W4#&$#2%Y?B@]IQBA0,0^H)]$Q-;'#*3J%K2:
MV@W.&B71J2LE[:YURR5G@-'0!3+1LBL)HJAH\FJN8U\0X:K($;H)U04&F^!"
M<,/-62$F<R1E0&5+'9-XA)B$I>>B"8[(,=%`J$B2U1XDB80!GHD.J=SP!JHW
MU01!`2@R8A,[,`L:I4J-/E_@@R'`=%$"-5BBL_-#S`62UK'00Y!3<@%NRTU9
ME.22MY<#*R`M-6`DR$&$^I1IK&J7E(:!IE9;V,<=0%C5;>GE]U5&-4OV[9(]
M5@5*F=^;,%E5:0:?*QQ50HO)T8J5C0YQW3,86F3"SJ5LX^]`]5:^W8!&<*%:
MUS`>Q5)$&)E;%].FT>]*QGAIG1(9K'0F+=?*#"@@C=14)@QQ$@*&C,86RM[4
MELN=HJ-:6D;A0MJ^A1;N?Q6.649T2)6$A9AHM.T?)(:+9`,!(5C+(H>X?56>
MS,C=6T;<93'5(5Z=69-1TGFJRP-$B4SR[Q7#?51F.DA12AO,J'3L&DJR6A1X
MK`8)0`IM(G+"AU)A,PI+N8.BENVJ!")@!NBES!(`4F`/>E.P2)0*6`#:5`8-
MR`G<8&BQ;BL]@V)]$%QI-<9$)A2`W"PZ=S4(_9'U60RK4.[$%P#1Z*'M;$A0
M'QH6J6F>6B!6N:ULF/BISTSJ!JH>UI.D*``T:""@(#I=)A*US)(C3NK!+@6M
M&J@,(T*!7^&`#ED*,M-WF#5D9`&JL@]?D@26#=FJ--PR/5,T.&X^*:)W"!'Y
M8D0H#OL@`RGR``]$-$N&FR"UH@)PE&R<(!.$K=TX0,-5AXH?J&`_?!^0)68%
MK<7S%UM3;]MY![:(,NQ&6V9/19,#F$E)N6FT=E8@!(0-R@[E!.A0)O*WW!-J
M+OB2Q8X$L:_Q'1T;JM!J/BNOX(:;:ABF)[>#0+&GN4&%Q'=>WX]>UIEOB$-7
MC''MQXV/5F`^6GY0/1>H-J@5O$JO(;)<]W0#4KQ;%:YN\3N*Y)/B5"=>Y05,
M!R@1JMGA%(&K-0Y!W6(`1IMW&BVN$L&:8DJZR[W"+FG3#0RBZJ<L>8Y6KHGX
MGB-6GD;7;;-@:4&P[_,=5S.$L/E@:+?Y'99C0*--3>6]$O+W@U*A'OU'%SOF
M5R6-@-I5P`/=*[&_:?>'-<=C6M*O/W"@S.`W&G5IN;T7KMM5<:;"YP;HO(."
M'M#F>B]/MZH-,"1\D,;5Y#AH`>ZPJSPQK@T;[JYI.4005@W4L8X@SW0<[C]2
M`XSNN!L0*^/EYU%-I=\=EUG$-;*PZSHN;X:8'/N[EV[GA@^"#>'*!LI:WLF=
M'-&9J!1TT"C*Z?>3:$R%,@G9!#6G[R;+U*@/Y*"Z4#$")2P%`=R1,DZH&`2D
M=E!.NA*DGN@1[)YI7-.D)RY1H@JBJ<P(]$,94+=1JK@4P<!H@Q30<XF6K'K6
M]1H)8#*V9>#HE+M-D&J;XWAF9TZK`U+W9@"MU<N`81,2M0RDVF7.+R9*"A[9
M.C82.8\#RN"RBYI\JIJ^$P$SJ@P*K;@$PV1Z+#J4[HG1I"V=*J]Q(#@!U5=7
M-)FK\@JD8=*SK/=#GEJRSA]-K0'/D]RK;=HD3)[K-J4Z67W94I&L-O08TDM!
M6KN`T/\`*V`MU6I"#ET6MKM=$>57$UK7.AL`$)1EC4F5D/U=R/P5+V`"935*
MP><+=6M%SZ0(.D+3T2`Z#S76X9:TGT&D.Y(:TU6A`@@JEM(9H#2NJJ6]`"")
M6+X=,/\`+3E*1JV6[G,@,/R51L:CCJ(71^&_*,C6A8]2TKU#[X"4C5T[)K1Y
MB$-H,$PX1*W+,-$?6U9^*=F'VP!$\U*1T50>=\&-4@!^]*FL69WZ\T@J-`&7
M4(JP@%5&B)D@(\5TZ-3>(2-6H':&M;H@U.@57B1N%`J-DH+VD.W"'$C8*IM4
M3$*073,Z()\2-"$I#7'5R#)$E0',!07!@#=$!V70B.Z4U!L$AJMG<%`\@G2"
MF<T'JJ34ICS$IF7%%VST#!@F9A.#3&FZH-9I=`V1G9KE@E!?G8#IHG!#ANL)
M^9NN64]*N7Z9"$&2[NH$#DJR]QT.BD:G=!87`#90US3K"5Q:&^8E(QYGRM,(
M+B4M/77J94.>?=C4IV]D#MZIDH3!!("<)0F"!H2N:UT%S9@R.R:>Z@=D#)DJ
M;D@%63JF.@*0H)U)"ZYY%CP729,5+RMG/=H7)T6E]1K!NX@!=#Q76#:M"P8X
MFG;4VL^,:H./XAN?9L'NJOVBW*T]RO)J0+ZT]Y7?\?W'A8=;VX=K4<7$>F@_
MU7"6C?>=\%4UDK>8.S:-5I&R2(72X.P2$U,=C@](RTA;LM,&#H`L3!J,L:2W
MDMIX9#7.`4::*^]S;1<5C7NUO[I_@N[OV^4Z0%PN,;U>X/\`!!5P=5A[1*]1
MM:OU8$B%X[PU5R5AK$%>JX?4%2FP#IJAC>T:DL@CR]5B7]P!3(:(T3L=%,$C
MX+68K7:&.RZ&$'%<3W)`<)2X!1;3PNB3N^7GXK4<35C4?D!F5O+5IIV]-@,!
MK0$&8'-!U4&)5(!YILW*4#N>UB!4[*EVI@PIS$#8(+2X[PE+Q"4D`22H<X-&
MZ"P/`")!F"J6N#MX39@-T#SINC-INJRZ>:5YTT.J"S.H+]95!=$-B2FS:H+?
M$UA'B=U47"5!<T;!!:ZH0)2-JYNRK=4&Q(49VC4P@*K<^I<L0TV23"O?5&P5
M+G@(**X:UIRC5:>T>^M>%KAY>BS[ZZ;3ID")5&$4JI>ZL]D`JHSW"BP:,E5&
MHPZ"@5EEH)]U(:9ZPHJFFQ[CI1@+(\$P,VB:F'??*N#21K)08%2@V=7Z+&?:
MT'3J5M2W^P%34#=BP(--4P\$DL`^*PJ]FZF-2"%O'TF'7,1\50^G2)]\%6I&
MC93IAT&9[!=)AS@VB`UC@L1M.@'3(^`6UM',+!`*"*KZD:4U2W.XZ@M]%G/+
M@(#`54/&GW6PHIF@D>\4&D3J:A"LIM>=X0:$[DH*_#8!/B$_%#/#`.IW5@MV
M`;JQE%L:0@6K<L%1X<X[IZ=S2RZ3IW55>SI/JO).L]52ZFS+D'X(,FI=-RZ$
M@^JJ]M>2!F.J6G1I[F2G%M3+I`=""35)B:A/93XNGES!,ZVI#8F>ZAI8PZE!
M;XH+?VA!3MJAH$UI*0"E4\Q29&%TM9(098K-,`/E.!.NBQY:QLFF%7[6X`P`
M$&:6N(WA)X+HF=0M?4NJ[FZ'Y)?:*P9JX_-!L6MWSD0E:RAOX@`Z+5>/5U`/
MS4L\2/,X'L$&XB@YL->H:*+#I.G-:^C5\-XS$%93KADB$&<VM2B"5#KBBS4&
M%@FL!/)8S[EH?F)DCL@W(K,>)!CU49P#)<U:<WX(T89'964;O/H]H"#:&NQP
MCRD>JGQ6#_PM=X]LPP2T%(74Z@.5\$H-JRH*ID#96A8UDS)0:)DG65E-&J!T
MP2@)@@D*0A2@E2%"D=4!NI1S4.00[4@*-4$1LB=$&SX?I-J8E1<_W*9-1WH-
M5C7U=US=U:SIE[B=>2S+`BWPZYKDD/J?5M,?$K4U*@IM?5>=&`N)]$'GO'=T
M*V*^"TRVD,JUE2T?:,HM?O4IBI\TE7/B6-9=S5JQ^.JZ3B.@76U*L*<>$<LC
MHKB;XYZB":@A=7@C9>U<M;?M0NOP-LU&IICT7!Z0-+>#$+/J40&P-MU7@U(>
MSMG25L+BF<KL@T`45RN(,\IG4=5P6.-#7/C:"O1,1:0TR(TV7!X_3@/*#DL%
MJ9;F`5ZG@M0.I"3R7DF'OR70^17I.`5B6M"NICKA6#:4`SZKG\8K$-<2=2MH
M]Q(D<ESF,.,.E17%WY\?$Z%.)!J`'YKJ2YIY"%R]M]9CU*=FRY=,2(EK$0P?
MT(2F2Z=%5F+08;KT3LJ9AW13O)@98)2%SX\P$]DOF)(<=.R5QTCF$$FI)T"?
M,20UT0DSCDS5(70[75!?[I,#1(Z3K*3/!`(T0Y^\('!@\U6]QY!0QQ&LJ'OD
M(#,2()4%YCR_BE)!@RFS,B900*A$R"E+G;R2@U61`*J-Q3;NX(',[I"^.:QZ
MN(4F[$$+7U,1S.RTVET]`A6SJ5@-RM=<7P;Y6ZGDHIVE]=OC*6-ZE;6TP:C1
MRNJG.\;RJC78?9U+I_BUVD,&H!6\%-K`&C8+(#0!#6@!5N:XD^516.2T3Y24
MF8?=5^30SHERCG$(%9F.T!7!CXU<D:0#U3EQZ($>P_>5#V#<DE7N<=H`2.[E
M!ANILZ%4FDWD%F.#=\Q53F4R=SH@QQ3AWV5L+>`!J/@L0TP72&E9=OH/=09#
MB.B4.UD`IB3TT4-)!0."[[I4D'YH:XS!*DB4`UNAD)VB`?+S5>W-,QQ(/J@T
M5;&'"YJ4Q1,9C)44\4HL),Y3S!"U%:^?2N:H;3!.8ZK%K79JF7-`]%4[="['
M*+)(:25COX@)D-!`6A\62!&BN#F@00)0;<8T\ME+^EZCS#8!ZK5%[!O2E-2J
M4&MD@RD&YI5:[FYJER`.@6PMJU%K9\>7>JY=]SG;D8(:JV@D^^6]T@ZBYNGM
M!<'@]I6#4N;BH/)3CXK`92MS&>X/=.\4*1!I7))Z)"LQAO8G+$]UFM>UK`:]
M23T6H=>UP/(\1W5+[FY<V#4;KT2#>&\L8\[BU5B_H`EK'DM6@>RJ72[=/2J/
M;(R@QS2%;=SFU:DMK%OJ5D4:5;-I4%0>JT%-U3/.T]5DMOZUOHP"4A6[<^Y;
MY<L#U3AKB07:%<X[$KMQ))34;ZKGFI4("0KJ&5:%('Q&$]U6;NB_1K86G=BM
M*`,A?W*87]#)(IN:>RD*V?L]-S\Q>LFWHAU1K`29*YUN(@.DN='1=%P\\73W
MW`)+6>43U16_:(``3!0F"!QLI"@)@@D;I@E"D(&4\H4*4`$.B/BIV"/LH$<9
M*`)*A76K/$KL:=B=?1!EWSO#MZ%N&Q#<Q]2N7XHN?9L'JD&"\A@70W]45KJH
M\;$P/1<%QW=@NHV@/NC,X=R@TO"](/OJE=YTI,D$]2NINVBK:5*9B'-(W6@X
M?HBG9NJN+9J.T!Z!;-[K<-\QU]4&@M015@[@PNPP31[87,/8QEZ2P^1VH73X
M-HX%-3'J."35IL`/);>Y9E8<Q(A:?AK5@:#YN06]N&.(<"BN2Q5K1MJ2N"XA
M$,<O0\6D2(7!8_3):\P@\YHDMNHYAR]#X<<26]%YZ\!M\X=Y7=\.5,I:9TA7
M4QV55X8S0@Z:KF,7J#(XRMS6KM+"3T7)XW<-%)Y[**T>$$OQ:M4B<K2M\:SH
MA<Q@X+[BJX5"TQ\UO`RJW7Q0>LIJ8R'5WAL^'/Q44ZI@DL<)5(-62`\%*^K4
MID!Z*RQ7ZM2&O3;H"95!JOTD%*YX)!(]4&0:[7;F4KZ[>JQJCZ0UT`]515N*
M(U+A"#.-4'690:S=1J"M+5OFM;E81JL5][5.@?KV5B5T#KH-F2%2^[9]X!:B
MA0OKMP#00#]I;&GP_6+AXU?R\X0%3$J;![P*QW8JYQBG3+CT6XM\"LJ9\[7/
M/=;"WL[:@!X=NWY(.3+\1KCR6[QWA74<(Q&Y$O.0+KA($!@"/-]YH2D:6CP[
M;A@\5Q<[GJMC0PZUH`!K&Z+)CJ]!:SF25%0`P;0E<>@E/#.DI'#H$"DOC94N
M<\""5<XNWA502@I(),;HR.F!";+!F0E($S.J"0Q\:0$VL:D2D^*:&DH%<#\5
M6?357'+*@D:Z?%!0<PV:JGBJ>0"R-]%62>B"@-J$P2LJDT@CHJAFS:-60PD0
M@>3T40[>$29@%07$<T#D'<A!)')(';:H+IW027%.QVAU5$GH593F#Y>:#FZ^
M$YZM6KXA`S$K7OLZ;71XCHZPMY="]9</::@#2[8+&?[3GRN#2JC3U*%-NC7E
MQ3T;4UC[Q!"V9\5KH<ZDT+,M:ULTR2S,@UCL+J&GF:X_)8E/#ZKWY0UWR76^
MUL:"($=94LJTFC/GI^DHKF/T3<"(F3R0<(N_M2/BNG%VS-_PR.LJT7-.2#4I
M:_%0<I^B+DG8^JBKA=VR):2#T77-+'^0@>H3-M27$->XCJ5:./&%W>2<I4?H
MN]B<I`7;M:RB?.6_%,#1>"0X0E'$,PN]</=)]2H_1EZ)AA(Z+NJ;J3`8>V%:
MW(07M<T)1YU[#>@QD?(4_H^]B33>N^/A3F?`/6$S6T'F`\'NI1Y\VQNC'U;E
M<W#KQQ@4BNY%%DF"V$[`P2<HE6HX3]&7HF:24V%V-Z97>C*3HYH[*)83KE^2
M57`C#[HNCPG+NN'[7V7#:;'"'N\SE<`R2`T#HLQ@@`#DH&"8!0$P0,%/)0%*
M!AV3*`I02A05(024$P-80=TKQJ$"A95N<C*E28<!`6.>05K_`"TFMYG5!2X[
MD[;E>6<071O,1K5-Y=`]%Z)C5R+7#*]68);E'J5YY@MN+O%6!XEC`7N04,-P
MQC6M#P`(B$WB7/,./J%VHH4@/+2E.VVHN!FF/B%:D<9;UJKJK,X(`V,+LL#@
MU&R57<65)]-[*;/,1IIS1@+H>`[<&%#'JG#GE+3`CLNJK,EA(C4+D^'"/+.P
MA=HYH=1`:V-$5QN,-@.\OYK@\;:?#>#"]'Q6F"ZH'`D<EP./L'G]$'E%WY;Y
MRZS!:H;3!E<MBK<M\8',K<855^J`)51TUQ=$,)E<EC5RY\LG0K:7%;R'7DM!
M6!JU3I*8:Q[6M4HEQILS$CHKS?W72!TA;'!Z0+ZX+9@#=;)]LQS2#3`^"#GJ
M5Y=9LV0F>85_M-RZ":+C'=;9MJUL[`'96BDV/=0:5]S>CRMHF#U6.^[N@(=3
M(GLN@-)O1*ZGF(T!A".=IT+RX=EITW:K96F!5ZI_VE^1O0+84KAE&I#:C0>B
MVU&KG'F@%*1J1P]:`"7O/Q672PJQIM`%$&.96QT'-'EZJ*2E393;#*8`3I=,
MWO*)')`^O93ZN51.G=+(.Z"XAI.KDIR=951>V=Y2^*U!=+>349B3HU4^*2%'
MB/($(,B7]`E.?FX!4%U0ZI?/S.Z"QQ(U+MU6Y[8T)T2EI,R491U002WDETS:
M*=`-_P`%&Q0,0V=4>7X)23$`3\%(F$$$3L$OP3:=84:=4"D:H.\(<==TIUYR
M@B9,JP#G*KF"G#@@;3E*`>RB941/H@<$=%$A+"(`0-F&\IF/$'U5?EZ)V.$;
M(,#$@'5'9:K)DK#H4VM,U"'=PKKB@PU'^'=`>;8[K'KL=0'FJ/=VC1$7S:.>
M06`GJKJ=M3>[,W*!T`6MHU<Q_8.]0%L!28:8=XSV$\I07U[=KF@-:3'98;K:
MB3#J+@5G,+&-CQ:CCZJW*]S)S?@BL1C+:GE8:15C[:VJ$.IM<'+)-.F(+F.?
MW5U-U!H\E-TGL@HMZ+FG7?U6=+FLDTB?0I&.<YWN%OHLB"YOON"##<7/=I0/
MQ5S&5H,VXRJ[*9!\0M[IF^77QRXGN@Q0U[3_`/33KU5SA4R_LP#ZH?F<V,Y!
M[%%-S(RE[G'GJ@E@>(+J33WE3FB8HSU2ED^Z_3N4_AMC6H^>R!`]P_X0'J4Q
M!/V6A,*8#2<[C"3R1+BX_%`S,X!&5A1]9,Y6A2UC.;W3R0UK!)<24#4<Y<`Z
M"-]%E!4V[1!<V8/57A!(3!*FY(&"D=5`V33""0=DP*1NZ9!(3!*%*"=R4CCY
MO1,-`D=J4#,\SM4U0R?113$`E*3U0<CQQ>!K*5HT_P!IRP>$;>*%>[>8+SD'
MH-UJ>([LWF*UBTRW-`788;9MM;*C0D9FLU$\^:"^2'>5LJ<SB)(@CD%.O40$
MCLV8G*([("FTDR0Y8]F!1OJC1,$R)[J]KJ@G21W59#O:Z3G")$(/0N'ZQ#6`
M1*]`PYP?1`)G1>9X(XM:V#JN_P`+K$D-!DD(,'&QE+@T02O/\=9I4)(,KT?'
MV#*7=MUYKC6@<)E!Y5CK<M[F18UG-&7HK,=(-V1V6/8SXF@51N&4ZE9I+O*U
M)2MFLD]2LRA)IZJJJ[S.B=%`V%AIN;@2!`;_`*K:0.I*U6!N::MTY\$^4:_%
M;8U&@>5L(8C(-RS1*]@D%K2`ASW'95.\<O:6U,K>8A%6.T$9%B7KRRC(+FG^
MR%DEU1HY=Y4.<"-6YNR#%H>'X;7NU)UEP60UX(EKI2UF,JM#13;'0IJ5-E,!
MK0`.B#(;</`$ZJUE4NZ+!JUJ=/1SVMGNHIU`3G:X.'9!L?.=4I:?O0JFU@6@
MYBI-0G76$#Y0-ZAE1#>I2AQ.P*D,>9Z%`P:P=2@9=LJ7([FZ!ZH+`#JZ?B@8
MD;0IS>BK+&[S^*CR>OQ0/G;&ZK+Z?=`+>3/Q1Y9]Q`IJ,'*5!J#[+832-PP*
M<Y&S1\D%<N/V2H.8G8A6>(](YSB9D(#*1S(0X$1YC""7QJY+YHU<@#ZI8YHC
M35R@D<B@6H2T9LI*I%:1JT@JT@'[1A(:=/<DP@3Q3!D@>JPJV,,I5`T,+M=2
MLXTJ>\2.Z5UG1>032;IV0/0NVU6AP$2L@.]%6VC&@``3!@C=`V?3=&;NHRM0
M2T<D$R%93(@Z<U3F:$]-X@^J#1U@]US4>VFU@S;K+H5&-$U'9^RRVT*3:E3/
M2D$]$SV6[1(MR0B0S;BW8R&Y9/4JRGX+V$N%,NY=E1X5%S0?!:.Q34J08[-3
M8/@BKVTA.<0(Y0K2W,T$/^`53W7+G@Y0&^FZ<.J4Q[K`>X0+-2FX#KU5KJ3Z
MH!T,=-$A]HJB?*>^R,MRW>I\`@M@4VQI/4)@YK(#G-$]5CFE6(U:2H\-^;4'
M3D@SW^%Y2YK#T,I/(#Y,GK"Q'4ZAV8)3!E:FSW/F4&87-:-`T^B&5*9)!#6G
MN%BBE5]YSFA3X3S,Y4&1XH!EV6.P4FLUXT,0L84('F>"F\%@U$(+!6S-,MVZ
MI!5<T$AC8]4!ICW04KF@DC*1V"!V5P3YFM!3^(0X:@3L(5`#V"`TD=RK:`<^
MJV6$#N4&PIB&A.$H3()&Z8*`F02I4(0.U2H"D;()'93N(4*>B""8!5?-.Z#Z
M)6CS(+"8:`M;C5T+3#:]68.7*WU*SWF2N-XZN\K*-HTZD9B@YK":!O<5I@^[
MFSN/8+O#IK`)ZPN<X2M2*56[(]XY&^G-=%)!U='9`"H!]C7T3.KL]T@CT"0U
M`-W$E07L(G,0?5!8*]-IUS'U"JK5FO?3R@B'*2\1!JD]ME61-1@$[SJ90=A@
M]8!C=>2[#"J\.'FV7`8<XTX!U"Z"RO<E1NH$'42@Z_'7YJ#8,:+S'B%P;F<%
MUF+XHVI3#&O]=5P7$%XP4:@)F`@\\Q.H*EX\@Z#1-8%N98=0YGN=U*R+)P%7
M:5I&_I/\D-&J9S"VD7'WE%L`1LKKLQ1<.RRK#P%S0;K-!&8+;E],@@+3\/D-
M9<AS9.<;^BW1+(]S5#"EPRP!\5`<8.B8EAY`(V&S4%3G'K*5KQ,$*T/;.3P]
M1S2@ELEY!Z"$%%T7EGD(;&\JR@&5*;7!PVU@JBO<M`<SPGDG2855@RL`<Y(!
MY(,NI:T:D%[0X]T.I!C(8T-'92YAVE5O;4((#OB@OMGT6,#9ERM-=NS0M3X=
M5KFG6`M@S*0(;/=!::YY`I?$>=FF$:<M%!=RE!/G)U!1#N>Z4O'(R4I?ZH+-
M>942J_$$PHSSI""S-WU42=\RKS'LHE!;F[J,W9)*B3S*"PNT2EVJ4N*4DH'E
M1,\]$A('/X*)UCF@LT)U/HH,;PEGD`@9D$DCHH.HU&B(/-3$"4"Z0-#`4R91
M(A&;31!/F.Y1!ZZI<YZ(S%`WQ4%+/.=5*`3T]CZJO3JG9$'7F@V%9Y%2H9$R
MD\>6PXMGJ`DK4YJOD$P4HISL$$>+#I=JWJY6"NUT9"`/[(1X+"/,TH;0!]V8
M^"!S6=IY/B4CG['RN/2%/LY!F8CN@4J9/F<[T02ZM4@#(T#L4OBO^RYH/8)R
MVB.90:EN!)J`$=$%;*EV'>9SG-Y:0F=5KMAQ<UI*D5J)$^([T(4"I;G4MS'T
M0.'71U;5:I(N"/-7#?@JS5I$B`X=D_BTQ]B?B@"TNT=6+CV4@0.H'5(:_)M(
M>JCQ:O.F806M+S(#``IEXV`"JSN=N0/52V>H'H@>'SI\P4I@&7.>'*2V1[P'
M>5+`X#WFN'1!`+]P7#\5EV;3!>XR3VA8VQF'#T6PHC*P`[H+0I4!2@8)@E:F
M02I"A"!P@*!LI02I)0%!.B!7=5;39]6]Y(@*HZPF<8`"!'$;G0!>6\0W9O<4
MJOF0##?1=_Q!=BSPNO4F'.&5OQ7GN"T/:\3IAT%K3G=/9!UV&T66UC1HAS@Y
MK9/2=RLC-F,$Z*7!H[]@B=-&#XA`9'D2!/HE+!]IL^JC2=?*?D@>&3#G_@4!
ME8""=8VDIJ64W+<O(*/#;'E?*KM?-5>1R,(.GLVRT;HN&U:8\2F?4*JUJQ3`
M.XV5SKD!I!'R08%S<O#?,_DN/QV[=4>ZFUT@K<8I4JU'.R`M9U7.7;&@$S)Z
MIB:U#I!@[JZTTK!5/ASB5;:_M0M#I+9T-"+UWU15=N=$MVZ6$+*DP`9FW,G7
M.#^"VI@'WUJ,#(FYS'[0_@MN'-:-!*)B,SN1",[OM"49V?=4%S>A13%Q/*`E
M+YW!'JD)#AS^*44Q,EQ/J4!<TQ68!G<V/NG=+;T32!`J/^)E,]P!`@%!<&B=
MO4H+#XHV?(]$OB.^U^`2>).Q*,W+D@<U.NR05B'&!#2HS]TKB2-2$%IJ$[;>
MJ7.>RJ]W7\$PU$@H'S'LB>Z2&\S"(;.Y0/F;T"D.'9(,HUY*9:-8@()+_DC.
M[HH#@!HU&;33=!,F-4$=TO>1/JH]2@:!&IDH\H.HU59=K_\``@.DE!;+1`_!
M1F&P@*H&3OIT4SZ('S?)1F23ZHS=P@?-T1*K+B9$:*,P'5!8#S)1(.LJK.._
MQ49_[*"[,#Z(S3K$!59G'DA!83IR2R>L*!VT4Z]([H">I5E/8^JKB=4[`8/J
M@V%;(*K_`*T'54YI=Y7B>@,IZS*7BODG?FJHIM,MA`TU2",T-[J&@-ZSV*D&
ME]H%WQ3-=1_M!!$D[`CN7((>=/$"?/1&S9^*AU2F=,L#EJ@!2C_B!2:=,'4@
MI"^CSS(#J1T!0611!&@*GZF1(*3ZOD5&=H)!F$%H\'J?DC/0;LW5(WPW<]?1
M,6CL/@@;Q:8^P5!KLCRTR@::@`HS,,YVGX()%<=&_)*;H@P`/DI^IC1I^:`Q
MAU`/Q0)[6>=($^B<71.U(-4Y)Y1\$IHR>:"VA4=5K!L:+:!85E2#"X@'INLX
M!`RD*%*!@F"4;)D$J5"$$A-R2\E,Z()"@_P4[!*4$L!)4.,E,QQ:">JIJO%-
MCGN,!H)*#C>.;W,^E9M.C?,[U6+PQ;?45;A[#YSE:8Y!:;$:[[[$*E0ZN>^`
MNTLF-M;6E;L879&P?7F@!3`,1'JF-/F7@?XBI<:9&V0H:UA/[1I^*""!R?*D
M2-<P4.%.='-4$D;$?`((J$M:YQ$0-U9A+9$G=8UVYPMW?6$@Z0LW""!`(0;H
M4*AIYV:0L>KF(,P'#KS6SH.(ICF%A7HD.(@(.:Q"HX3)([2N=O:DR5O,2@DD
MF87.WI\I5Q-80F9Z\EDVHFI*Q:>T]5G63?-LJ:V]$P$MP982GIC15W4-I.60
MF"G2X)'VA_!;,$<H6KP>11JD$:OV*S7'D:32.VB+C)S:;3V59.I'F'8JJ6;E
MCV^A3-<P;5"$$SI[Q2G/KEJM"?/.U0?()2YP!)(</1`-:]HCQ&%)6I&LT!Y:
MZ#U4%S2=6I'.8.007-^K:&`"!T*,TSY0J1DGWOR2U<^0BF]H=U.J!JM44W`.
M<`AM8.,L(+.P6*USJ+"ZXJ9Y.D-E6LJMJ,#FB!W$(BVI5S`A5TZM1FL:$QNH
M)'W2H<\MT#?S166US:A(!U&_9-E!W=F]%K!<%ITDGGV64'ES1!*)5^1HU)D=
MD>69+I'14>;[R(=U^2*N=4;LE\9H$1HJH*G(.<GT0-XPZ?-`?S(E+#`-0?0(
M\G,GT03G).NJ"1S@(TT@0I!`^R403IM_HB3&Q*DP3[OXJ2.WXH%S1RGT1F,[
M)IY0!Z(EHU@2@7*XZDJ<A^]";,W<-^*`]IV!149.Z;(!KS[J,XF=U!=.IWZ`
M(&@$2=#W4[['*D+I][9&I&ITZ('!!.FZCRZ@G5*2Z(V;V0<T0T?%`W*7';DK
M:;CET'-8Q!&\DJVFUQ!WW09=4/-5YR.B>B@!K?>GT(37%>EXKP'$ZE4FKKY6
M?-!87M`\L(#V[$0JO$C6`"I\5SMT%N7-MKZ!,VFW^;/R6."[E5CT"::PT\<B
M>Z#)\$?S9^(3&B\C2DL*7?:NCZ2B*?.Y>@S/#K#_`(0^*8>,W>DU84T?Y]_Q
M4AU$_P#%>Y!EG,[_`(305+65S]E@'=8GB41L'_-0YP</>?"#.RUA[Q9'J%/B
M`;U*0*U\-G=WQ"8-I$1+4&6;A@/FIM=W"@W(=[E.#ZPL=OAM.CA*G,V9`83V
M07BM6/0>JD5*G-S2L8N<=/#"LMZ3WU6M,P4&WMFD4VD[G4J\=4K=`G""0I4!
M2@8)@E";F@E"@*4$H0%.TR@'<@H1W34AK)Y(%>>2T'%E[[+ACJ8=#ZNGP6_J
MF7Z+SGB^]]HQ)U%I\E+RH,/A^W-:_#RTEM,9CI.O)=6ZG4.L._@M9P[3;;V?
MB$P^J9/E.W);<EKCFSM/:3_!!6*;^FO=2&N.DM/6`F\36!'H`A[SL:1^4($#
M&-DY91F;RJ9?P0XDZ>4#H%!+!IE@]T%-['@B*@<2X:!9>&.B%K[L-#6D=>BR
M[%T`%!U%O6A@!6->O:`=24E*I+!*P[ZI+80:/$GYB0`%S]U$.6YOG`Z+3W+8
M:X]0KC.^L-@`VV*VMDSFM?2&9X"WEG2AH359%-A`6'B#@*96Q+2!JM3B1T@;
MJ&LK#"&V;)#9<23(65F)T#F!8U"H&464VN]T`:A6YY&KQ_E13ECB/?E*:3!J
M2922`??(3>*P:&JWXH%-.E&I=/9031;N7JR6.$Y_DJRQHT!;\D$9Z>H`<?4J
M,[>5(?--D_N_.$N0]!\T!$_9_%&7II\$9`-!_%(\EH,2?B@ES'$ZI'T6N'FD
MCU5#ZQ:07L</B$CZ\`^5P<=M81*RM&B!\ECUW@N+6^>IT!T"Q36+G14)`CEI
M^*R*5%SVYB!39VUE5!18Y\-:01S)6P8T,`:`"J6D`0PD#T4R8\I)47,79HT@
M2HS`G=4DN'+\42[?DBK2[^T2HGN4H)W(3`_)`0?O%&I4YM(D(S!$3KT1)Z)"
M[7:43\D4\]B`I!/(0JB2C,]!<'.&PA&9TZ*F7(\W0E!=+G3HH$D1,)!FZ%3!
M]$0V4G3,F`C8JO4#1$.G5!<`!N?BI\JK$QJI`[E%/`V4&#HHT[H!`Z^J"=.Z
M=@$'4[I)"LIE@;N?F@LK6K36?#7$2AMN1_PW)*]U=FJ^7NB>20>/4U#G$])0
M7Y6#0Y@[N-$>$29+1"1M)X]^G43%U%H\PK-^*!LD>[3!^"@,JDZ,:>Q:JC6:
MT_5BH?BK!6NW":;3\4%HI5N5O'PE,*%UOX+#^"KRXB\:NRCU"3P*L_67F0]W
MH,D6]0_\$`^JGP*C?>;2'JY8XI4QO>TZG;,I!IM,"FQX[N07@6P_:&G/9R/$
MM08#6N]$@?3W]EHCU<F\2=&MH-]-4$^-1;JVDX*?%:_7V8'X*#6RZ&LP?X$:
MU!^TJ1_9""3E&HM6B.I4"M)(%LR4I8P;LJD]24PI%V[7?%!8U]6-*=$=BLFU
MSN>2\B!R"P_9WCDW+W,K86E,,I`#GJ@R0F"4;I@@D)@H"D()"8!0`FA`*0A2
M`@A23L@!04!SA23E0T<U-4B(`08.(W3;6SK7!.K6Z>O)>7-%2]O@T:OJO76<
M;7F6G2LV.U/F<`M'P]1::S[A[9#!#9ZH.ERNIL;3!`8T0!ILE\,NV$I#5H_<
M'Q2FHP[-GXD(+"UU/UZRDSW)=Y:KO@$D/.H#O@Y,&U3S=\T#%UP2)(/J$A?4
MDPT'O"5X(W=\%47N8#_J@FY<?#&8C<++LCH%K:M1[F$`-(YF-5GV)D(-RQT-
M"PKNHKP[R[K`N9,A!JKD%SM#*U]YHPK95!YC`6MO]`UO,E7$W%=BPNJ;+HK:
MG`U6IPNE+MIC1=+0I`M!`33&+5;#5I+L-=<TV.,`N$E=%<LAI,+GW^:\)RYL
MHZPIAK,\5KMGM/\`A4&''1X'P6*9/_`^1E'AGFUS90JXD#=X`4&FQ^HK-])5
M):[D:A[*/#/-M1!9X+QL9]%)\<<S'<*L4C$AM8?X4$5.1?\`)5%F>IS:/@C.
M3H0X)1XVTN^(4@U]B&E13`ND?6#3J$/>YPB,P]5$D:NI%&=OW'#O"!"VFX@N
MIF1_90:=$Y8IN<>I,*P5*8B7P5.>F3[X/8H*31F9<`T]=57YJ!$/S$]-%D'4
MZ-!'JJ*E-SI.D]RJD79@[:<P4#,-YGLJ*><'/E<0#N0LT!KAO'P47-4#-U32
M9TA7>&3L4&B-PZ3V154NVE$D]$_AQO*(`00!T"G+W3!S>D*<X`W0*&]_P4AH
M"">I42\\T0P:$$!+YM@?P4P8W$H)R]BI``G11JI$GG\@@--X1,IM=H^*G*?B
M@7-TU4@GG*D-/0!26\]2@B"I+5'*9*,T3**;*>JC+/H@.C4A3X@C0((R1K`5
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MQ)W+X6Z:($#8+7V(>ZIF+8`'W,JV*!@F"7DF"!DS4J9H0,%*`I""0%/*$#1!
MC3J@"=$B8P5#1)0.-`%15<&YB3#0)/8*USM"M#Q/>>RX74@P^IY1_J@X;'+L
MWN)5:O*8;Z+H,-M10LZ3"XAQ&9PRG<KF</IBK>4\[@&@YB3V73ONBXZUY_NH
M,O*T;O;\0E=D&[Z8]0L!]5SO=EQ]4F:XG1C6CN@S'56#;([T<JWOJN]QA;Z/
M6,YSX\U2B/55^)_;I'XPB5<YM=WOO`]3*@"LT:7#85)N&MW##_==*D56O]VC
M4^6B"UWB.!S7%,Z=5EX<[R@K7^<_\)OQ*S,.)U!W!V0;H&!MJL.N))<2LEI`
M;JL6X>8**U[Y+B)6IO\`S7#6SL%MXW)6IK#Q+H0#KR5Q-;G!:$@$\UT]*WA@
M)@!8&!VLAJZ(TFTV1SA17/8B`RF97,4@QQ?4?3+B7::\ET./5,E-YY@+F6.<
M&0V1']F4365Y3J&%HZ!!=2&XU'65BYZL>_KRUA$U0<TLGN95B5DM?3)@%H^9
M4G35KQ\BL7QZ\@"G2=\(2.N*LQ4H-C^RD*S9J.V<2/4J!O!J@'NL0737<BTC
M:6IA6D1YC\``BUF!H=LT/CF"E(;]J6GH5B>9QW#8^Z4V=S8\N:-SEU2%9!8'
M;9O4!#21HVJ?BV55X]2-9CI*L;5!&H_RZE0.2]WV6N_!1X;!N!/1HE+`<9R?
M%Q_T"<$@#(YP_NMC^*!#2S#W/B94&B&B7N/S5S=O/XGQ5C0T29;\4&.:!,%S
MCEY!64Z9&@V5TR="/@K:8T.;9%4AKNNG=,`KX;`(G5-X8B4&.6SW"K?2W.OR
M68&LY?@@SMH@UAID?:*7*[F2M@]HZJHAIVV]$&,`1U3`'J5:6CE_!1E(.R!6
MLD[E/X9ZN^*`#T!4@B=00@@4NQ3"ER_U4@@[%RL;'(_-`GA]?XIL@Z!6M:`)
MTE29YH$:QO,?,HR`\]$VG750X1J2@,C2H\,<G?,(UWV]4`D#2$$&GIR2&GW5
MN901WE!5D',Z)Z;6P8G=0Z4K<T'?=!?4M*PK/=5J!FO,J`:+-,K:I3UQ1\9^
M>X?4UV"AK>=.B(ZN$H$=3=5VMVTQ_>0VTHYO,^2>0U5F0^]4J-/8:(S0/JG`
M?$H)-.G3$BD[3F6JHU'O.5@(^,)?#>YWG=OU)5C6!FH,]<K@@<42UN:J2/6I
M"!6I,(#!3/<`N*6H*``<6M<_HYQ,*&NJ`2QP:/\`[;906.KOF`*A]&PEIFHY
MQ<+5Q/WGC16Q7J`975_B`"F-&&_7&J?[SH04/K5FG]K2ICHUJK+_`!-*E:O4
M/1@A6&E2:2:=9K#W,IVLN'#WG/'5H05MI,&HHU_\3T%K9^PWU,E9`I4P1XSW
M:<G)@]@GP:(=Z0@I&8`92!W#0$V6J[4UG_(J?%:8STZGPA,*H:X"G3?F/WG(
M,^R9EI3)).LE9"A@ANJD(&'9.-D@ZIT$A.$H3!`P4J%*">:DE`TYI24`2I!R
MB>J5%3H@1QDKS_C"]\>_\!CI92$?'FNVO[AMK9UJ[C[C21Z\EY;4<^YN2XF7
M/<@V&$MI,I.J/#B]QTCHM@;@B,OAL']H25CM8RFT-!T:(D*LE@=HXDSLJS65
MXKW$P\G^ZQ*][A]EQ/<K'-:![ICT0*H.],#T"%9&KQ^V#!T:R2E=3:=3G<>K
MF@*N6O\`MEO=,"UNAKD^I02&M:?V;?0$)'U6@P!ECGF*:`=6M\1#G,:/-;D?
MB@5CWEQ\U0]@LVQ<<YD$:_:W6'[2"(IU&T_40LFR+C4\[P\GF"AC>,DLT5%<
M:;*VE.402JJ^T"?BHTP+EV2BZ!)6'8L-6[$M_"%?=U,I`F!STE9W#=N+B^\H
M,:3*)]=Q@%C%.2R-)GHLJ_HY`2(.G);S#Z#*-#5IV6HQAX8UQ!T'1%>=<1O)
M<*8W)U6A--D^:H1\5GX]6#[TM+`Z.4PM=HT:TFM'=TJXSJ/#I;!V90*=,&`Q
MWS*>G4YEQ_PD*X7%/;-\R?\`1$8[:#G'2G5([%6"W`W%8'U5WC4CLW,?4H%2
MDX[%I[$HJDVX=]FJ[\$WLK\LACP.Y"R&B@1)J$_X24[&T"(#VF.K2$(P\A;I
M!!3!M2?*"!ZK.!8!E%(//92"XZ"D&]B)4(QFTZD;D=R)3-HNG4DK*:7#E(]%
M.;F-NPD(L4MHM!VU]2K/!V^K>?BK6E\'SB/52'-'VR.Z*5M!_.G`]58VW=`)
M8/FF:YG-V8=0KF5*8CS.CT05MH@:Y6:=T[0T'0-/QE--`[@_%,&"!D(([$()
M`(;H8'J$CB-R/75*\-!\S&D]256:@$@,$>B"SR9O_P#I*<N;?NJR`WS9B)[A
M3F%39X.B!W-I$M&<`[JHTAF+1,]D_@2!(,S\E:VF7O(!?+=)(C5!C!KALZ5!
M#N8654:X-=+<W+-EU24F.=Y2P`]]$&-!!]V/100`)_BL[P`-7"/Q2F@TZSIZ
M(,&1O_JIS1,D!97@CK^"1]$\RY!4UT\Y5D_><JGL(T\P]55E<#N/F@R@9]T&
M$;+'#ZG(`I@\C>!\$%\Z:F$!S=DH=(V31W/P01Z*,O5!#N1A2`_O\T!'9,P"
M#LH]?XIVC3:/B@>L:3JKPS1T_=`"K!=[LZSH=_P63<50:CQX;':\EC!\.EMM
MIUS%`X\6"(='H`F:`(#LY',#5(ZJXZ.IM9WE.SS#]N&^A0,YE,ZMMZWQ:F:*
MD@BFQHY9F@)'.IL,/?4?Z%#7YW9643ZN*"SQ7-T)H-/I*1S03+JCC_=IH=3>
M#+@&^@A(&M)/ON]2@NU;J!4^,!$TSJX`GHYZJ:QQ/F+&M]4^1@,M`<?F@@N+
M3Y*='X"2F%9X&I<!V:`I8ZL-FL`Z")25W&-6O)Z(&\9A]XYO[Q"1]6B-?!!]
M%2P5'NV:!WT5@>YL#PZ<()%Q!RTVO9\0LFV:^K6:]XT;W5(;XGNM:#V6?:4R
MP&73*#*4J%(0,`F`4-4A`P"8*`F02%*CDA!*A2=`E.I0,U5O,E.=&JA[@QKG
M.,-`DE!RW&M[DHLLF'5WF<N3LA%0U"V0W^*MQFZ-YB-:M,@NT]$]`"G2:&CS
M'4E5-7ZOU:PCXI"P#WG1Z*,Q&I<WT)1XP$AH8JRGR_8#G'Y(S$:9`/0I<Y(U
M<T#L4IJ,&HW^:!RX;N>1\$S*NOD+/B%4'TW>\/B@P/=+AZ!!8XU")<01U"D.
M:T?:GT*H'BNT#GQW5S6QHYSC\$$^,`?K*8^#5E6+V>-#-!T5+<VS,T>@61;L
M>'M<XG?G'^BBXZ"A[D]E55$RKK>?#`A#F:$PHTYN\+G7!`(`'==?P!;9Z[GD
M2)`7&WY<+ES0-%Z9]'=H[V%CR(+M56<]=W6I^';@G0+C.(ZHITW`%=KBE1M.
MV8QQ$@:A>5\97X:QS0=3H%&G%7;F5:]2H]X$NZ2L=O@@G*9/HE+J@]W5,!6.
MX9\UIA(%,C4$GT06T^KQ\`F8RH>4=PKV47GJ3Z*#&%(G9Q*M92J#0$F?59C+
M<\VF5:*#FB3("58QZ5$\\_S66V@")C7T4M`&@!^!5K`7;#YE1HHHB-0/BF\&
MG'DS`]RK`T#1P!]"K6LI:96CYH,;PB'0(U[RI\/30GY+-;2:>0`]93>SMT\P
M^2#7^#IJ0-9WU3"D-@1NMDVW81$-CJ.:=EJP:@'UA!ABWB(8?FI%H2[73XK8
M"D.1A3X<?:]$&(VT@:DE3X#8A91$;E(X]"@QS1(/E>052ZE6!F0>NRRCG)(G
M18]1E0SE>08YD0@I-,?::#_C2AC6'RC_`/M,)_`>1+BR?1`MB#,MGL@@>)H?
M$;Z!R</J#RYVGXRI;;D\VPKFVXC[/:`@&.).9S6[05:#XC&M>1D&H`&RK-+6
M8UVT4EH:!E9J=]4"DY3J00=,P$*74W3-,ZC<<BK',`M':YG<AT3T6BE1SU"`
MZ-!S08Q:#[H2%G0%.SQ'279@"4P9U)^:#&=2+N4>JJ-"/L`_!9Q:>Y06\@/Q
M0:YU!YUR0E\(C3S+8.IB-C/JD-,?='Q08@8\=4PS3"L+(.E,'L@C>`&GG*!1
M/(((G29^*:!V1E,["$"@1L$[&B-PB.A3TQ(,'F@*S\M6IEH/&N^BK%1Y'[9[
M.RSJ@-.H^+EF^Q59JO=I-!WJT(,4LSZ>,QW4'<J1;=7,'3S+)%*J^2!2/9H`
M4&UJ`9C1<[T*"&T*C1Y(CL94&DXN&:BX=X*9K8T-$_YH5@-N1&5S3U%0E`C:
M--AU%;X(S46DQXD]X3?5SI7>.Q)4YW1/BSZME!6]X,#R_P"+=`<6[Y"T]58:
M@?HZFUWH$!M(F,KFA!664G>9U&1_8J*/"H$PT7#?357Y*$0TP5+6AH(\5!3X
M3&D>=Y]6J?"8\:AGQ:4Y-0'WQ'<*E]R\2&G9!)HNID$56`=!(6PI"&B5@TOK
M()`6Q;L@92%"D('&R8)1LF"!@F2A,@E"$(`E`U*4CYJREI+CR05U#R6@XJO?
M9<-=3:?/6\H].:WKW2XE>=\67OM6(FFQTTZ7E'KS0::BW/4$^I6<&U#]IK?5
M56;S2IN((!=\U::Q=TGJ5<9TIIN/VYZPU.*%;[+7GX!`J902TDGL%(>\_:=Z
M9M%1(M*A]]L>KDWLC1[SV@=$LP/-4`2ES3(#LR%6.I4F]7>B`ZF##:30>KN2
M0$1I3=/HB';Y0W\2B+?%=J,S1V#4GB.Y._!06$CRBJ?1FB3PZDP&5#KU06:N
MT=FGLMW:6S!;,U.;>.:U5M1N`\'(]G0D+I,/HYX\0G,-YYJ:N,RTHO?E;E63
M<VQI`AP@K-M@RD,Q:#&RPK^Y;J7NT4:<;>M)OBP-)S&)"]EX/MV6]G382!E:
M%Y/1SNO?$-/ZL.D9M_5>MX%=T&VE/3*X03/-$QD<6UQ3J91(T$!>.\6/<^X:
MTGJO6>*ZU.[>ZK2,Z"/DO+L3I%UQXM6F7$`P#LAKF6M>Z`'$GLL^VL*KXU6Q
MLK>J6BH[6>4+;46D^7RMCE"M(U=&P%,>:"?[JS:=LT#2/DL\-(C3XJ13``<X
M@1U45AB@T[?P5G@-.PA9(`<=U9D.D9H[H-97L@^"WRG\%B&FZF_)&O7=;IT<
MY6)<T2XRR0>P08C06R'$D^BD$\G"0H\)X,&>ZL\%N4ZP@AK6[O+_`$!5[,GV
M6GYK'=1`$\^4%95"G5`U=IT07L$"!(3@;PI:TZ`ZIC`G2$"92=RE(CFAU020
M(E5N=4.QCU05U23,'7U5&9X<&EYU'59'A9QYG`J6T6M&PE!4`-3)^:0TQR<?
MB5>YU-IU<!ZJIU9FP+#/1!2]K1N\#T5;W-'VG0%:]Q=R561YU(D>B!15I@:N
M)[$*RE58`[73Y)!1)'/?9.RW<XZ-_!!<VNWD?DG;5:=HD\R5#;43Y@K!0:#L
M"@&0="\QV3`.J.S1H.6Z8,Z`?%26^?0Q&FG-!$$=0E/>4Y$<Y40V==$"R>6@
M40=SJK"S7;3J$!J"J3$*'#<ZJRHP'?\`!5N9ZH$<PQ.BK-,\I5Q]4<ICT04$
M.G4%0`#I)!61VU2/83$"$%.0C8E,P.@Z<U%2F8_\I6BHV0-4&;5<XU72*9UY
MA(0TG6W:>X45:;S5?Y3OS49:@'DS#L@M:UG\P1Z%-&60QSV_%5@5@(+4V5P`
MF4$NS.]Y[C\DH93W(=\"GR@;@CT51K4YAH<>Y06M#6G1KBFFG,FG'Q58?(T+
MAVA(,[C$:#J$%YK48@4H'5013<HC>2E:\#D@DTV@Z9?@C*1R$'FI:)]V$.#I
MUB.Q0*X&#E:W7GF_T6,ZD0XN=H-RLH@>OQ2/+B`T!L=]4%="I3;4;#I'5;%C
MPX2#*Q&-8VG&5A[1"/#<V'-('8(,\&4X6$RNYL!X^(64QX<)!06^JD)`4P*!
MQLF"K3M*!T'HH""4$3)4N,!#()'115<"[38(-;C5V++#JU:?-&5OJ5YBXNJU
M23)<X^JZ?C.^SUF6;':,U='5<_9-,EX#YV!:B)`(@!CM.1:LBFVDX@.K-;US
M,*L+;EHS>(\#K$I#4KMU%<'U6D-DH$__`%=-HZAA4>%;G>^$?W2E%P]QAU,/
M^";RN\W@N'>$"&C0W%T'?`IVTP-JS1\(3M82/*)'HK6T9W:%#U4/%F`0X*P/
MK-/[-@'HLIE&G]QTK+9;LB?#,=2$I&%2<]T>0?X=%DTZ3CYGZ3U.RRJ=)IT:
MP?%7MMW$^Y)ZA1I33:UOE`GN2LNW)95'G(:3KK,)F6[8@L=/P3^`T.@3'<(-
MF^JQK895#M.06%5I-<XN)#B?P3,:`V#"9Q$<C^*#%IT22XP(!UU73X+78:0:
M]_NC75:*G2U.H:(G59MC]4-W`'7RM&B#;W5;Q9#JC6,W$ZE<[B=.FXZ$N_!;
MF&U&%VNO-Q_):ZO0\Q@,GK$H,&C;L:T1F)_NJYMNZ<P8X*YA.K2'3ZJQK.@@
M=T",!:!+2X=REJ4P[5K?160=03IZI0P3)>$"TZ<&'>7X*PM$:D^N56-@;D.]
M2E>V=CE/+5!BO#9]XGX*HG=IU[JVJRJTF7`*H9IU)*#%JC*X.:71.Q4!SAR#
M>Y5U9H<X?_(2FFW*0#`[H+:?AZ&,Q[)S7IMV6$&-:-))[*VDQCAYG%!:;G6`
MCQ&F,S@F%M2/-0;&D3H->Q0!J4QS!5;ZQ`D9?BF=91`_BH;;Y?>:U!C/K5B8
M!;\E5GKG=WR6P:QC=,JDTZ9[>B#79W"<SW$]T9@>;9]%F.H,G23\%4ZDUI)R
M&.L(*6N+?=`E.U[H\U-I4^2-&CXH!83!CX(%=5C4%K3_`&@AEP^/VE,H<RD=
MV`_-#6TQKD8@OIUG.YM)/0J\M?`),=R%B``^Z"!T:5:`1'FJ=Y,H+LI$'YJ0
MW=1GYNDHSM)YCF@"(2QS$IBYL;*1'1!7E(/,?%3)YM^(3^4Z0H.@V05NS$]D
MA!G<JX[[?BHTW(""H2=T#L$\-E1L-OF@C0">:@.!,%!(([]BD=OJ#\D#%K2-
MDS&$`Q,2JP_3?1.QXC<H+ZQ;XKO+S2SIHV93.>?%<<LZJQH<=<DH*3FC8*"\
M@:A9)T!!I?-8[R)\M(:(*GG-L2`H:P`R-_56LJ/`GV5I`ZE/FSC2@`>Q0();
M!@'XIFR`3R*D>;0T]`587.8/)E^*#'K-<*9<#NJV',1EWY!9@>\C5R1]%K_,
MY\'T05M:\SF=HI-+K`'65'AAI]X$*9IQ!:"@0AAT+VI`VFS[1^"8Y?L-:%,/
M$9JK0.Z"APICFY7L<W+H2FEG-[7?%,V"="`$"2"-9*&N+3(*M+"=B%&0@P'`
M_!!93KS`=MU62UP=L=%@ECMT2]A_)!L5(6#3NA/O2LIE5KN8E!>%#BH!4C4H
M&!RM/=8EY<-MK>I7=LQI*R'E<EQE?9:3;-CM3JX(.2NJS[FY?5<9<]RS:3&M
M:&P!E&X$K!M@<^;*#"SAXY'E+VCH%<9U<?9LNIJ./<F$-\(:MHL]3JEHVQJ$
M2*A/9;&WP^H3IF:.[4&*UCG:-AH/316T[.H=?%$#^TMK2PX$@/<XC^ZLQF'T
MA):#\0HL:>G:-&[I^"SZ-J.31ZPMM;V](:`"5;DRR/DBM=3LFDF09^:O;84]
M\DE9P:R?-E;U5S&C[+AV08;;3*/=CT:F-MECS'3D%DOGR@NA2&,RR'G;5!C"
MVG4-$]25#J%1I`&W0%9!#3U*@P=FD]$"-IZ:F/5*\-:),`]E+FO.@@#LJC3J
M3[L^J":1<Z?#;(652-0.RES0WJ=EATJ50.,[=%FTFN)G+'4%!FBH<F5[F.`V
M\/18U>DUP#BR>W,+.%%V4.-%H<-H,@JFI3<X0[RF="-$&&&L:W*01"K+LI\K
M@0LEU.XIGS,J.;UZK&J/8)(D.[H%S%Q\P(([(:0-7.#?AND-PV-#4C^RJG5L
MV]1\[:H,IX9'E-./58[F@P9^12@U2?=S-ZPI+:I&C0.R`-7+Y&MGJ92&LYQ$
M-@`<TV2HUI+MAS4.H5R1E88=K+M`$%;WL'O3\E68?[LJUU(L.4@'7?=!HQKG
M$Q]TZ($8QV4GQ(]0G:,NI<UW>%6:3I`\1YE+D<V1GG_$0@RG5/#$EL2I;<::
MM:/4K#+?M.ICU)E4FK29LP!!LS6!&PCKF39Z9`DZ^JU1K..C:83-=6.A:W1!
MLBRD9)S?!06@:-+_`(K&;6(T<T`]BLAE8.T\0#U*""Z-W`#N"D<]L$S3A96=
MO-X(0#1=LYH^"#"'@D^]3GU3>$(G+IU"RG4Z;A,L*AU,1M"#"<T<@[_*H%-L
M26;]E:^FX?;^820_9SP8Z`H(BF/LA3(G2?F@-=K,^HE'B`>]^(0`.NH=\4[6
MZ2`D\:!R^2>E7>TYFO/Q""2S324H&4B3JKA5<=2&G_"@N#QYJ?\`E*"N0(DJ
M0!"<5*5,&*?:29*6G4HN)\K^P)0&1(YAU60US-)>6^H4U`P^X]L=T&''=1J#
MH5:]HG<)<LDH*XG7*/@D(&X!60&I'-#03)]$%`&L$G7KJK6-$'S,W]$H]\Z3
MWE`<==MT&55+W5'Y<NZK/C<M"IJ3XC_JP->JB3]J?@4"BM7;_P`0_-6LKOB'
M/GT2Y:1VGXI2T-V<@N+GD0'3ZJMU,_>,]DH<-2285C<IY./Q0%,/;[I(ZZIP
M7ZSE/J4I#9U;^*B*4^Z@?S\O#")<WG3G^ZH#6R(:B&Q[J`<[KX9/]U*"9T;3
M*80!HW\%&GW3/H@4@DR6-^`03I^Q:4^1SIAJ0M<"`1'=!4\`C6DV>DI6T1S:
MYJOTYO\`P0()^T0@K<-`!4<`.R=ATC.X^H3@.)\K1\5<TD;N#4%)R\W%`#3U
M*R`0="0?@G\-T"3`.NR#"=29]V4!A!\K7?-9S:4F()^"L%*-9_!!A"J]AAWX
MJ]E=A'=6NMPX\S\%+*#"Z/#_`!08M>XI,:7%W+8<UYQC%6K=XC4?$EQT`Y=E
MZD[#K:H<PIEQZ2L:\PFC1.86P8>>B#S_``[#ZU1F1S'C6=`MY;80T$&H]WH5
MO:-&F':,/S5^1D>6F[U)1(UM.SHTLN6?@%D>')D,/Q*S!INR/@@![B1L.Z*Q
M@P@1&O9.`X:$B`L@,8",SCE_LE(ZGF)R`E!4'C;5.PMT#OPW4MI-F3E"EH:0
M1(`Z0@4%L:,GNHF#&H/8*W)2!W<3Z)BQNG/XH%8][_>8(ZH+F&`&D*="='#N
MH(:")U]`@:01[P42T02Z>A)4M(.S8)ZA*:9,$P?1`X<"/>"@G02`>ZD!HT<)
MZ&%'ERZ!`-(G3174W-+I<[3T6,'P-21KIHIS#8N!0;6B0UNE3X;2HKO<2"#'
MJL%F9T0[GS.RM(?$FH/@@;Q*I/[9H^)075"(=6I.GJ%54>6[:_@D%0N&K20@
MFI082)-,GLJ:EOF'O-`Z"5D-+)B"/5/GH@^9Q)0:UK7,JG+,=0)!0VM5;4@T
M7.UW`G1;(.:[[8TUWW3M>:;"`YH+MR(08=O=T0Y_CVK'N<=(,%H[<I3FIG)A
MKR.I<G\%CI)@B.FZ=M*F=`QL1!"#'>YK1+LS9T!(T6/4\1P<YA8]H^T%M":C
M@6YI;&C>0]`J"PCRMIM#3KMK\T&DJM>1^T;_`(5BMIM:2YSJN^\2%T1IM&A8
MP_!0ZFT:-8T#L@TAITW,!;)[$;I/"DQX<GH%N?#&8B".A"K=1=KH'#N$&%0M
MVL,D1V63X&?[4=D[6@&#3'KT5[64X!`/S0>MVOT*6U6WI5OUAKC.QKH]G:8D
M3U5Y^A.V_P#U%7_]LW\URH^D_BJA3929?6K6L:&@&V;L`I_E2XO(TO[3_P!N
MU!U)^A*A_P#J2X_]LW\TH^A&WY\1W!__`(S?S7+?RI\7QK?VO_MFH'TI<7_U
MA9_^V:@ZO^1.@-!Q)<`=!;-_-8&,_0[B%K9OKX3C0NZK&EW@5Z09GCD".?JM
M"/I3XR+B!?6A]+9J]J^C[&;S'N%+/$K_`,,W+RYKRQN4.(<1,<D'RR*PS%M1
MC@X:$'DF#Z52<KXUCDLKB%C!CV)MB&^U5?\`O*HPK"W8GB-K84,QJ7-5M(?$
M[_)!Z=PG]%3,<P"TQ:OB]6V=<M+A2;1#H;)`,D\XE>?\1X/6P3'+S"JQSNMZ
MF0/B,S=P[Y&5]!^+BN&\88+A%AA]S^@*%F:%2HVG]6'D>4D]LO\`_9<+].N%
MBVQ&QQNFSRW##1JF/M-U:?D3\D%%C]%F#XIA%3%<-XJJ7-NUKR'-M@!F:-1N
MO(<L@Z\E]&_0\:57Z/7BJ2*;JU</(Y#FM/P+8\#\98=B.'TN&Z=K[&X,;4SS
M5<PSE?GWS:%!H>%?HQP;B'#&7MCQ34J.`:*[66X^J>0"6ZGE*\WO+;V:\N;4
M.S>#5=3!C4P2)_!>_P#T0X<_"*?$>%/?G-IB1I!T>\,C2#\B%JN%*/!/$..8
MW@+>':6:@][Q<U'YGUO.0XSNW7:.2#PTL]?DD+&G2#,KUW!OHXM[CCW%<,NG
MU3A-@&5&@.AU1KQ+&EW:#)W,+;VS>#KWC:XX-'"EFVA3:Y@N08>7M;)[_&>2
M#Q+#K&K?8C;65$$U;BJVDP1.I,+?\:\,.X6QH89[7[3-%M7Q`S+N2(B>R]9X
M=P'"N%?I";A-/#Q<&\HNN;2[JNS/MV@$.9WUY]"L'Z4,9X;L.)&T<5X6I8E<
M>SL<*[ZY8<LF&P@\[PO@^M?<&8GQ0ZZ-*G9DAE+)/BQ$ZSIJ?P7(O9![KZ:N
M+["F_1<[$#@M+]&FS%0X>UV5N4D>61_%?/7$%UA]]B-2XPO#F8=:EK0+=K\X
M:0-3/=!J&O(TF>Q3$@Z$$?B%4]NL`J6DS!^10,YO?Y*&LTU"9.T:('=2>VHX
M9V1/,)#;@R26?`+/J@^*_P`IW4$-&["4&`;1A@BF#\4S:!!)#&_-9<4Y]PA2
M/#&[!\2@I92/4".R?(=B\JT.:-FM'Q1G';X!!46"-R?\*CPY,_Z*\5R._P`$
M&OK'AD]X040=LVO]U3D?&Y^("N\4<J9^(2NJL`U)!Z`(*PRIH-9[!26N(B7C
MU"L%60(GXJ15=S\H[H*?">8ASOB$>S.)$S\ED"IM!GXJ<U0B79@.J#%%$-'F
M8\_%+ED$-I@#U67FI=)*CQ6@PUC1\$&$VC5S$AI:.:9C2TZYI[K,#P7ZO^`5
M@>R(+!H@P0UH=HV)[JW.`(@2LHEA:3E;\4P8P-#LI_T088+R-&RWG"9KA\5E
M0YT98R]"@TWQ.7+\$%#07:9P!T0!5$`:3INLAM)QW#2.RD4V%WF:X'D6H*Z.
M9D^:"?BIN:U<@2P.;V*M-)S0)S$=3&R'/8&PQ]-KAUU0:O*28\%S.X:?XHRD
MF>7=9M:M=:M9<!P=NVF?]%0/":"VI1J!QV)<@I<RKFB`-X2,)#\KAMU67E+C
MI!_Q;!*^FUSM!!Z2@1DD[#1,\.?`EH`$?_ZI\`-UG7U4Y*I;+7M<WI*"D,.S
M#([;((+2`X9>\J7-J-&L@=$V0$?M(]4"!S1K*DEA(C21J(3"@[))#7#KU0UF
M406$A`IG6-1&Z!3<9,@(`:9&OS3@L+HR$H$+6M,N<(]-E8TM(EL:]`I(;D(\
M)T]4["00(<$"D'+K&O906-#=B1ZIH<9+B?B@M,$-,'N@J/E`+0]HG<:I74P7
M9B]KCZ1*L^L:9:X$I23)SG7F6Z(+6/IM(!IAI/.%<W(X<C^"J;3:^G()!&IS
M'DH8UH\HJMGN@BHX@D1'8JL`NVT]%D.+'#(XDGJ-E1X#PZ0X$<D$.;4C7;KU
M2AH.Y/R5V1Q^T-E6X`$#9`K6F=`FRN=IMZI@(&IW01J0-3T0)!;IF1XA!`U_
M)/G<-LH"1A(<1F,>B"UM1P$P1W0'R-'A5Y2.4]U'F`]SS(+7.!YJ#E)U<DG2
M9U'()2[0EP]4%A=!C+(ZA3G#HTW50>.\'E*5\-U!._79!<&M<="&N_O(R2""
MX2--?S6-.=T`CI`YIZ9S`:Z3R0?2O!?!V#8+@ENZM:6]>[J4@^O<5F!Q)(D@
M3L`L\W_!C3!N<$!_O4DO$A(X"OX)!_1YU']Q?,.490``1Z(/I_\`2'!?]*P3
M_-21^D."_P"E8)_FI+Y>#6G[(0`!H&#Y(/2OIGKX-7KX/^B*MD]H;5\0VI:0
M-6Q.7XKT/Z'Q'`=@/[=3_O*^<R!R:!/1?1OT0B.!;'^_4_[R@^=>(FN_3^*9
M3)]KJG7^^5Z5]#/#N>]I<3WEU;-MZ8>RC1+H?XFTD'81*X+'6#].XG('_P!5
M5_[RL#*9D.T[(/7,;=QM^NPL;;B2E3I7;GW%NQM>*3*;3[ITT,+N>/,(H<3\
M-5,-9>VE.Z#FU:3GO&4/'XP02%\U$.&C29]4"F2T9G&?5![S]&SK'".![NSQ
M.^MJ+*-U7I57FH`T>;+/HJ_HPX7?P7;XQ?XM?VG@UBT4ZC:@+?";)S$]YV7A
M7A`/#B`>W(IZCZKJ?AR_(-F`G*/0(/>/HYQVPN7<6XS5N:="UJXB:K75'!L4
MQ3:`?D)6+]'W"U3!N)L:XBJW]I5PRY:XVE6G5!#V.=GS'I&R\$J!LZM,J!4>
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MQ-*JZF2-<KB)^2QJCM3(DG?N@I<9,[*`-)3_``1RV01_!.R6@B>:6(Z*Q@!&
MP0951S'5'^;GS5+G$'=34<T5'>7FJY#N2!\YR[$P@$G04_FE'<0F`(T`03-0
M#1C2FE\#R@>BK<U[NWJI%,#0E`'QC]K?D`E/C';-\=$YTT;/S5>4@R3KZH':
MUQ@$O)/0HRP8RQZE,&@^;.Z.@"AX8#K3)[DH'!:T"*FO8*'U&D:AY^"K+0W7
M,!VA-F\OF!/>$$#*UN;PW?.%'B.>/(!\22H>0X^5Z(,2,Q^$(&:RH22YX';9
M2,@)S$E(`=W?,E6,&FX02#KHWR]E:T1KI'=*).C2`4Y+IC*$%PRY=5?3:8!$
MB>NRQ@7`>8`1LKK>H]Q@CRG;L@L--VPV[(;3`,N!/J4U7.V0"(YJ&B1.A/24
M$EH+<PT^"7*Y_E#C'7HF:8.XUY)VY6GF@IIL>V!!.L0KG4*3V2#D?S#F@@JX
M5#Y<D1T02YP+13S.Z(-;4K5J1`ANG,-4/O75FQ6RF-M-5LJ9K!Q;X8#3IJX0
MH?;TZY.=M.F^-,L!!J7,!U:(!Z.0"9$D]-1*RZMHUD%P](.ZK%%@DBHYL%`'
MV<L@AI/5HA4Y6S#!E'(GFLQC:A80UK7]R%<+>J`T-I,GD<T_@@P?#>6$N#2.
M6FJCPZ1'FI1\5FW%2K3+6NH@#[IV*HJWD`#P*8Z`$R@QW,IG1E/;F2I92=R,
M=RK'W#7.:30<.L&5#\KB,E)X'<@H$\.J\D%K3Z"$HI5FN$CT!"<.@ZL(CX):
MCM)SGXE`TNYF/0J"=/?5;:C]Y!'=2*SMO":?1!+03N\0F,;2)[E2QM0^8T(!
MZH>TZG+""MQ8&P/>53?O3/P3AX!C2?13,-.H`W00QQ+H(CI*L!=!!:%CT"YS
MBZ20LDL<7>[,=T`!/N@"$@<860U@;,1)VD\E+B01M`04^(TB,D=-$,+3JYHG
MOLK2<P$'7HJ7N#701J@8A@<""TCLD--A=(=!3T@UQ,<RK"QDPYZ#%-(YB!4@
M'<)"US72-NJS"&'01\4KFL+>?P08C7[@"#SE-G,B<Q/9.^DR"T[I1`$`Y80+
MD<=0-4Q;(V!ZJ/$=XN5K=8W5L5':EFG4(*A2<WS=/BE\.2<S9[J_S:G0?%2U
MQ/NMDCG*#&:U@)=E(U4N:T:T]8Y`*]Y/,-`CJL<D%T-:#/,%!]64J%KCG"S+
M;Q2;:\LPS.PZPYL2%YR/H9I#0<058Y?[,/S7GG#_`!GQ)@%(VV&W9]FG2C5:
M*C&^D[?!;C^5;C+8.M)_Z<?F@ZT?0Y2^UC]0_P#\8?FC^1RD)C'W_P#MA^:Y
M'^5CC`#WK0G_`*?_`,J6?2OQB\2!:Z__`&!^:#K/Y&Z4R.(*D_\`3#\UZ-PQ
M@M'AS`K?"Z==U5E$$NJO$9B3),<EXB/I.XU,$UK!H/\`^WU_BL3&./>*,6M'
M6E>^;2HO$/%!GAEXZ$[P@YC&'BXQ>_K4S-.I<U'M=.X+C!6YX/PQE7VO$KC#
M_;J%ODHBB3HYSS!.I'NLS'UA:$AP'(J:U6ZJV3+)SF"A3J.J!F7[1`!)ZZ`!
M!L!A[;#B^EA->'MHWS*1S"0]A<(GU!'S6];0M+ZXJ89<XC@M2I<5A2MS86\/
MI.SZN)#6^4-!D3KHN6;=79N;:[J5`:UN*;:;X^Y[L]8V^"+6L^UO67M!V6X8
M_P`0..L'T^*#;VV#6%P^U'Z0N&^W574;)SK<:EI`E\.\H+C`B3S*M9@>'-M7
M/N<3KTZU*T;=UV-MPX!I=ER-,ZNGX+`L,7N[&@VE0-'R.<^D^I2#G4'$:EA/
MNDJEU_=EE2FZH"VI0;;.TW8TR!\^:#='AFB:GLE6[I!C;Q])M44P*CP*(J-`
M+B!)D``\^:BGPG0)N7U:UU2HTZK*(::#6U<SFYB7!S@(`Y@F>2U[L=OBYSJC
MJ-5KJAJ.95HM>QQ+`PR#RR@?Q2GB*^+GFHRSK4W9(HU;=KJ=/((;E:=H&G\4
M%W#N'V5/C*CAU]4;6I4:[F@TFBHRH6@QH3!:8E([#*%:F"+YYQ&XM7WU*EX`
M:PTX+@"0?*XM!,`0-EJZ6)7%#$1B-*HWVIKR\.R",QF3&W-2,;OFV`L6FCD;
M1-!E8T@:K*1W8'[AI078U;6F&W].RH73[A[6L-9SJ>0`N`,#4SH=UG8W0HCC
M:ZL+>G2ITO;!3:S++6@QI'379<W>75>]O'75=S75G$9G`1L`!^`"WEQQ+B5U
M4-:M0P_QR]KS6;:,;4+@00<V\Z(-Y3PJRO\`",/M[>N]A:VXN;EWLS`YV5X9
M`<7:ZD``D"-5S./8:W#;NG2IUA6IU*0JM)C,V9EK@"0'`CJHML7OJ!I97TG,
MIMJ,\.I3#F.:\RYK@=P2L>]O*M]5%6I3HLRM#&,HTQ38QHY`!!AQIR41V5A'
MS2QW0(6]U;3'EV41HG9,(&J&7OS1NE[@$2GJTW-JN]TP4GUATA`./,M,]D%V
MFQGN4#-]I2&SJ>:!?,2-'1V3AOFY_%2T@0`(*;-FWT00&LD;RF$;[*);T$]2
MB2#HZ#V0&5[M`-.^B0,=._R5K8!\PS?%.0"[RB(04D`:3\5&7E.97D4Y/EU/
M)1EUT!/H@K#8W(^"8@`1FD)R&P1`E1D\I,ZCD.:"&T@=R`/1,*;=8.OHH!Y`
M'XIMG0=)0&8NTT$::J6MD^9X@;%`/(#526@-DO$(+/#=&D1U497C[0VB0H%:
M6;`COHLBFX.T@CX;H*F.R#S-<3SG9/ES:L>`#R*M`\P)`E&6=X""@M((UT5@
M:YQG7T5H:T2W4R@4ZG6!W066](N<`2'-&X*RBQ@A[7%H'+LL,!\RP%R9SZI@
MO!!A`X:`/*3!V5%1M1SHS-^(1E:X>]4:Z-#.BQW4:TZ7'S,('?;U`V?$D]@J
M3<-MIDM!ZD2F%.\:T@/#FG25AW=K=P"ZE`['=!E,Q"9@B"=2F->0WSN'4K#H
MMJL#9HRT=EE4KIH:]E2COM$;H&?7H'7QW9E5#2XEK@>Y5;_9R3$">25[+?,/
M#K';[2"PFFTZP3_!!KTP#`#9[K#JO+21(RCH554J`4]"9.FVR#*K7%5L%K`\
M>JJ\=KFM-0%KIURK`\9S=I/=,!4J.GQ"P=@@S@^@]Q`J.F5F4,S?=/>2M=["
M`P56U<[B-)$%7-9=.IQE>X1N&Z#XH,RM7N#Y<VJQ6W%P*@:9/71)2I50[+YI
M[E9=,5F.]PDCH$"U;QU/046D^BQVNJ7-0`@-!U\JRGL<]P<^DX1V4AC_`+#2
M-4%<"BV`".Y"R&&6YR?7113HU3/GC^\G`>T934;`Y!`N=H.OPT39@X20U.&/
M&Q!C8JL@`$N;))V05@^<;`)@VF23F,]2%9Y(!;3@=TCF%VC6P!L2@,V721V4
M!X;,N'P5%2UJ.//O!5?A/:="T0@R?%C405CU:KS[A,GF$K@_8D$#H567!K>:
M!G/(T<\D\TCJYB&M,\NBK+Q.C23V532\O#H?IR&R#/HA[I<^?0K(:T1J8^"Q
MF5*O-IA.*QYR@M<&B/R2N#2"!"4.C?-\5)()(T08QMVDSMKJ"XIO9J;3(:PD
M=95K2W/N#\4\@F-$%3:6GNB>Q*`V209GL5<QCHDJQM,D`]$%`&OE$'HG:-8=
M(5F4;F4S6>4$'4G;H@KAP]T%W=3KKU4\N:"X@$Y=>L((^('J@QU!2OJY1W]%
MCU*VL`'X(,B8Z0@Q$S\E@NK&8SD*IU1SG>_'Q0;+,(,$?-*:D#<+6@ND@$E'
MFB(,H,Q]8>[NJ29YI&4:A(S#17B@!S"!`TN.A1X;N9^`5V7+T2.)U01DCDI`
MB=%!=VTY*,Y0,3NB?*ES3S0=4$'ELH,S^2#,GF@;SN$$\E:W;=5M3L!`06/R
M^(_0G507/`RM:LO[;O5*>:#&(J:$D#35*T]6@_%%QN573V^""]NFA`"&EFQU
M4-W3.Y(#RQ$`%3#>GR3!,/>*"GR3`D.3$NC4PK![_P`%+O=*"MNL*0"#H83M
M]T>J#N/4($),G4)`3(G4CDKW>^%`W<@2"=X!C35`\0:#*?B@;)F;-0*6OU!'
MXJ6TQ,%I([*\(.Z!&-HDAKGQT!5^4:%ACHJ*?O#XK,_X34%)-4=C\T>)5YLD
M[2LD;%6'W3ZH,?Q0(#I!ZPKF.&8!Y)"A_NCU3,][XH+:=0,!#<PZZ(JD5'`E
MIS=258-W*M_O(*"'R1E$#NDJN#&_6,("S6['T6)6]]_J$%?BG*(:Z/12;AQ;
MEB6STU62[]DU4CWV^J"@5M',=2&NSI(`2M%*8?1+@>8TU6<_W3_=4_:/P08A
MPYE1F9E5A`^SS5;<.;N2=-!`6VM?VZFX_;#XH--5MZ#);G;F_M:0JA[&QA+G
MAW*`B^_:N]52[WP@L+;)[?*T@G7W5;3MJ+]!5;MKJ`E=[I]$E+W@@;PVE[@7
MD`;$E7NRAH:*^8#E*A*=CZH,AC@\$!M/XJ,M=HD.:WIW5#5-7D@=[[N):\.`
MZ*L5KCF2#VT3VGOJVI[X^*#&%6L='DJ,WFDD*P;E*[?XH!K6F#G'5/E9)@@D
MJ'[#X*&\O4H+6M@`%S20K(I9!)AQ50W*C[J`?29.KR!V.RHJ`,D!TA/4Y)6[
M(,-]4-=!B/1!N*6V3Y+(JJ6[A!6TL+`643,)!3<03DCU6P;L$E3W2@PRQP:)
MRZ\I4L:3OE!'=)<?LAZJBAS]4&;`YZE1#C]F$S/=/JLBGM\$&&6.D:1\-U:T
M`#,X1ZJT>^$5/=<@5H!$D@3LK1ET_-0-QZ)A[Z!?-N(*L(:6ZCU[IA[KD?9"
M"D@3(V]4I&\ZA6G8INOH@P'-<.D="J"TET9!Z@K9/W"K;N@Q&T6$RYFL<TXH
MTQR`*R>1]$O((*89M`1E:![HT5J=!C&!Z)'.Z`E9159Y>J#&)+M#H5&2.JR1
M[Q4G;X(,0,)'-2&`=5DMYJ.108Y`&D_@HR\P0LH[)3S08A#N@*`8Y!9;DI08
.._P`(3MB-2GYE2-D'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g519019.jpg
<DESCRIPTION>G519019.JPG
<TEXT>
begin 644 g519019.jpg
M_]C_X``02D9)1@`!`0$`2`!(``#__@!'35),3%]&3TY44SI;1D].5%-?3$]'
M3UU+34524DE,3$Q/1T\N4%-4"D9O;G0@4VEZ93H@-#8@("`@(%-T<FEN9SH@
M*&@I_]L`0P`'!08&!@4'!@8&"`@'"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J
M)!T?*"`9&B4R)2@L+2\P+QTC-#@T+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:
M'BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN
M+BXN+BXN_\``$0@`)0`P`P$B``(1`0,1`?_$`!@``0`#`0``````````````
M```$!@<%_\0`-A```0($`0D%!@<``````````0(#``0%$082%A<A56&2D]('
M%$%1T14C,3)4D24T-G%S=;/_Q``:`0`!!0$````````````````%``(#!`8!
M_\0`)A$``0,#`P,%`0```````````0`"`P0%$1,441)!D2$Q4^'PT?_:``P#
M`0`"$0,1`#\`GYM8@V-.\DPS:Q!L:=Y)C4<0X[IM(G%R3<N[-3#9LYD$)2D^
M5S\3^PCCZ3V-C.<\=,:R.NN$C0YL0P?W*Q<EOMD;BQTQR/W"HV;6(-C3W),,
MVL0;&GN28O.D]C8SG/'3#2>QL9SGCIA^ZN7PCS]IFTM?S'Q]*BJPY7TI*E4:
M>`&L^Y,2\(5R=H]7ED-NJ[JZZE#S)^4@FU[>8C7L+5M.(*:J>3+%@)=+>059
M7P`-[VWQC=2`3C"9"0`!438#^2.053ZO4@G8!@)5%&RCTJBG>3U%0J7+*JE8
ME91QTI,R\E"G+7(N=9C41V:T2WYN?XT],9C0)IJ1K<A./DAEE]"UD"]@#KC:
MAB[#=A^,2WW/I$=VDJF/:(,XQV"ELL5')&XU&,Y[E</1K1/JY_C3TPT:T3ZN
M?XT],=S.[#>V);B/I#.[#>V);B/I`G<7'EW@HUM;7PWR/ZI.'J)+4&15)2CC
MJVE.%R[I!-R`/`#RC%ZI^LIK^Q/^D:^<78;`O[8EON?2,;F'VYS%"YEBZFWI
M[+1<6)!<N-47[2R;4D?*#ZCNAUY?#IQ1PD8!]@5WNT/#\O3)_ODJYDMS)*RS
MDZD'QL?+=%,MOA""5LE>^F:7'*$W:%D=6X,&`EM\+;X0B_U%#>D);?%U[.*$
HQ4:EW^8<)3)J2M+63\RO`D[CKM"$4+G*]E,XM.$2M,+'U;`X97__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g426392.jpg
<DESCRIPTION>G426392.JPG
<TEXT>
begin 644 g426392.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`]35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU23UA!3DY%7T%54U1)3E]02$]43RY%4%/_VP!#``<%
M!@8&!0<&!@8("`<)"Q(,"PH*"Q<0$0T2&Q<<'!H7&AD=(2HD'1\H(!D:)3(E
M*"PM+S`O'2,T.#0N-RHN+R[_VP!#`0@("`L*"Q8,#!8N'AH>+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+B[_P``1
M"`"'`(<#`2(``A$!`Q$!_\0`'`````<!`0````````````````(#!08'"`$$
M_\0`/!```@$#`@,%!@()`P4``````0(#``01!2$&$C$'$T%182(R<8&1L13!
M%2-"4F*AT>'P)#-#%E-R@O'_Q``6`0$!`0```````````````````0+_Q``7
M$0$!`0$``````````````````3$1_]H`#`,!``(1`Q$`/P"X?*ABCXS7>7_[
M0$`P?3UKG44?!S_6N8PN*`H&-J!VW.U"62.")I97"HHRS$["J6X\[0+B],NG
MZ07AM`>5I`<--YX\EH)QQ'Q[HNC%X4D%U<+L51O94^1-5]J7:7JUTY6W<01G
M]B)=_J:@\=M$JBZU%R"WN+XGX#PI&2X9R8[:$1I^ZN_U-!(9N.>(&;"ZA<HO
MCR,`33E9]H_$-HZ%Y/Q<>PPRX^1VJ`.LH.?:7X?UI(W+P-A)&=OCTH-%<)\?
MZ?K=RME<PFRNW_VU<Y60^0/GZ&IN!64+2]9XEE5RDR'*L-C\<U<G9WQ^NI]W
MI6K2_P"M&T<Q_P"7T/\`%]Z"S#TP37/,'?XT88/ECJ*&,=!F@+TSB@,4?&VU
M`#SH"8_PT*,1G;R\J%`J.N<YHV-JX!BC`>)H"E<T7EI;&13'Q9JJ:1I$DH.)
MI?8C]#XGY"@@/:%Q`;N5M,M),0(<.0?>/^?:JU6WCB62\FCR`<(I\_*I%W1N
M!WA7+S/T]/+[4A<VW/=1P8S'%N1USB@8%M9IG[R<YF<>/1%I29(K>!1$@P>C
M$;M\!7MU1TMVC27(63,K@=6`.%7YG/TJ0\*<+W6KS"^NHBJ'W01LHH(+'I-_
M?.6=2J$]!7J_Z3FY20F<^=7@G#T%M&%"#/PKS7.G1HI`4"@H#4-+N;)B0K*>
MFXIML[N2"=65RCJ<AE/0U</$.G12HRE1\:J/7K%K*[<`8WR-O"@T=V:<4CB#
M21!<R#](6_LN#U<>#5-@-NGTK*G`^N2Z-JUGJ08]VCA9U_>0G<_*M60NLT22
M1L&1U#*0=B#0<P=LB@12O*:X10)8&^U"E!]Z%`;&WE71BE"#0`]*`HR,54':
M3J@OM=73XGS%`.1ONWY5;US(EO;RS.W*D:%V/E@9K-JW;7EU=W\@)+LQ'PSF
M@>K62/\`$-M_M(3\,_X*Y;JH<R,=RP7\C3!'=&.&XD8^W)CKZFO5)?A`AYA[
MV?G0%F@34.+["W?>)(5)'_L36AM-MH;6RB6*-54+CI6=^$[VS;B>WN+V<1(%
M4%B"1UK0D>H64T""TNHI5(ZJV:#DX#$M3%J"L1MXT\2RJD;,34>U?6=.L8"U
MS,`V,\HW-!&=37+-S8VJLN-(>8=X!T\:F-_K,U^SMI]C(5S[S[9J-ZN6N8)X
M9X&BD*$@'H?@:"%Z3O'.FQVSCUK1G8SKK:MPTUE.Y:?3W[O?J8R,J?N/E6;]
M&?DN6'\/VJU.Q:^_1_%<UH6Q%=(4.?'&X^]$C0/RHI!Z4;'G0Q11,8]*%*8\
MJ%`?&=J`6CX\,?.C<M!&^/)FMN#M9E7WA;,!Z9VK.D$A2W6-=V_/^U7?VPZQ
M'IW#+V'><LU[['KRCK5$1%RAY<`GQSX>7]Z!._N0G,H.=P2?A3?=7KDHH;P4
M?:DM4?DYESD],CQ)I33=-N]4ODM[*%I)"```,X]:!WT35+*&,QS6O?E02Q$?
M-@>._A4]X=N=/N)8[JWDEB9",CF(Q\CX4XZ1V4B'1.2>9EDDW=>G-GJ,CPV&
MQI^X<X.2"_3F7OA&`"S=%&<_.@?-8BDCT<7,>Z\O/D>-4UJ=^+NZ=G4O("%1
M1U)\!6@=?5%TAX%4`<A`%4[I.F6TEZXD@1\-D%EZ&@AD]_JT%RUK";="J@NN
M&]D[^R3YC&^,]:Y!=7%[;EKF,JU6G></6LH[X6]N'_>"U%-7T]+7F5=R:"G[
M=3!J4R?N%A4JX9OOP'$.EW><*)5#'T.Q^]1_4$Y->NU`_:Q]<5Z9&,30N#[F
M_P`\YHD;'P!MU]:!'AFBVCF6TMY=B6B1OJHI7'2BDG9%&6('Q-"E2/'&:%`J
M!UH_+7!Z[4H-]_M047VS-*G$]H"S=VUL.7;8'F/RJ"L7,3<T,1QX@D#[5I3B
M+A^PUV&-+HR))'GDEB.&7/QV(]#6=>+-*O\`3M6NM-O+IF$3%5*CE5QX''P-
M!"M3>(S^U*KGP"#85I+LJT'3M.X<TZ^MXU:XNX5EEE;<Y/A\!69+R`0WK`$L
MK=&/D15[]DFN3MP0L85I#9S/#CJ0.H^YH+BOQ"X!>7EC`W"TTV6MVL^I#3+*
M->1`2[^51#5-8NI\6T*/WD@V'3`\S3YP5HRPV4TEUAI)R>8YWQ^5`[Z^\:VS
MLQV&00*I:^U"6PU":>-AA6'L_O"I]QAID\,7=66H.2>O>3`\HJJ+F&"WG83W
ML3MXD/F@GD&M)<6P<9&1N#3#K%RD@+4U07:E>[MV$G_B<TE=][S-WFW+U%!7
MVH.LW$5SR=.?&?4#%>ZUM9+S4[2SC4EI940#XM3/II[S49)2207))^=6'V6Z
M>^I\<V+"/F2U7O7/@#C^]$C2MK"(K6&-1[J`?04J5\>E*@44BBB8Z8Q0HW+X
M\N:%`<#/6C#/0^%=*CQWQ7<>E`4^54=VTVOX?7;:YY<)/$3S>H(!^U7DWNDX
M.U45VUZ]IVHV]@EG+WG=%PS8QOCI04W,.^LUEQS,GLGY';^7VJP.PO5XX-5O
M]'F;`N@)HP>A9>H^A_E4'T:+\5;WZ8W54DQY#<'[TV+<76DZE%=6SF*>!@R,
M/`B@UI?V4#ABHPS#EYAX#-,JZ#^#E[Z\O]0O-.8>U;&<J(VSU&/#T->;@SBV
MRXFTR.5'"7*`+/$?V6]/0^%3<)S0X1@=OK00;5-)X9[ABNGWH8A>7+['SWSC
M>H'K'X""9DTVPA&3[)<\Q&Q'Y^=6;K'#IF+,H5`WD>45$;[08[8$AE!'7%!%
M](MH;`F5D7O96YG..M>'B._6VTZXF)]MAA?B:]VI2+`6P?=VJ$:Q=)?3`3/_
M`*=#T!]XT#=I2=W;R3N,+TSYUH_L.T`V7#[ZW/'RSWYRF?",=*S==W"NT<48
M"P+C"C\ZT]V0<4:=J'"MEI\EW%'=VJ]UW;-@D#QH+%Z]:YCSH,\:@,TBJK;`
MD[&C#?H1\J`N!FA1^7Z4*`X&^]#!S1\#PH8\J"-\<7LNG\/SW,3JNX5L^(-9
M2XFO%NKPQPC;))&<Y)K5/:)`)^$[V,PM*N`2%&2!GJ*R_)I]MWS,UQ'G.&Y0
M0?GF@]_`-EE[NYE7$3)W>_[7G49XMMA!>G!!P`#C[_.I5^E8+2T$,.(XT'^&
MH)JVH/?79FR1X`9Z"B5->QNXQK=W;-NLL(.,^(;^]7O#+>V)S&6GA.X4]1_6
ML^=D^W%(.<?J3]Q6D;<<\:L-R*$PS:KQ1&D?*R,CCJ&!%0G6=?[\'N]SBIOQ
M!9)*N\8W]*KS5K/NV;E7`%%1+4A+=Y5F95SN`>M175[<VZIRY"\V*L0668RY
M%0GC!E#Q0J/'-$J..Q88'05[M*U">RE$D;$$>M>`9(]?O7HMG(.R!OX#U^55
M)J7MQ?K4YC[R\D58SE%#$[YZXJ[>QKB35M5BDTVYMU-K`I?OG8\X)/0^9)R?
M2L\V,]J90)(WB'BV!M6G.QO28;+ALW:SP32W3\Q$3!BBCH"?.HTL'8;T*/\`
M>A0&/G]*&*9>)N)]$X7LUNM9O5@5]HT`YGD/DJC<U6O$O;?IUOS0\/:<]Y)_
MW[G,<8^"CVC_`"H+CQDXQGTJINU+3NS:.-IM6G2TU/'LKIQ!F;XH-OFV/C52
M<0]I'%^N\T<^JR6T#=8;/]4N/4C<_6H8S%F/4Y]X^)-!Y]2<R2R"`R=QS'D#
MD<V/#.-J\:1$`LU.;1@CIM2$H`&<;>`HG#GP7J2:3Q'9W4NT.>1_13MFM/Z1
M,LD:LK!D89!%9*A3.6/6KP[*]=>;3X;:=BQ3"@DT58NJ][C(7(\Q4'U:SE<G
MG&!_.K`O(V9,TR7UE)*0%7)-!!+U5CA6(#!Q50Z_="\U"62,YB7V5]1YU9O:
M#,^E6\L8)$LH[I/3;VC]/O53$9'2@\>X.*7A5G*JJ\Q\*3Y"7Y0"3G``\:F^
ME:;;VML6:XCY&1B3)$P9G4#]6"-QYCS`;RJLR&2'1+ZZ[U%'ZY"%$>"2Q)``
M'U'7:EOT;K.CWC_@)[J.>`9F[IFB:-M\CKOC!WJ32Z[9IJ4MK>)>7$\]NL)D
M#%RLA`!;).6/EUQX4\ZMI.F)IS7&GRF2RDF$1%V.4HQ3>0NHR$!.`#U8[C>H
MT8-+[5N.["(1IKC7$8&WXJ)93]2,_P`Z%1O6([<+%=)/#WK'NWBCB*>T.K8^
M.V?&A0/?'O$,_$O%ESJ$C/W)<K!&W_'&HV'Y_&H^:%"@*>GQKL8H4*#KML0.
MGC7D;+OO0H4"ZKA=JG/9=(?Q+("?9DQ^="A0:)@B[T*&;]D4[0:;#&"Y4$^%
M"A09<[8=1%YQA>VT61#9MW`]6ZL?KM\J@('LT*%`6Q9XM0@D0\KI(&4^1!J?
MQ7AOH#;QVZAX@99+B60^VQD)[U%&RMRL$Z=!0H42%[J*UM=3M]1LCW-X'=2N
M<HK;`N`5V)W\_3%)7-_';VWX=)I)K909KIH4`9\>[N_P&1TV^5"A14;X@<O;
:6Z+/'*DLA<D0A"K8R0#UY06(W\A0H4*(_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g173968.jpg
<DESCRIPTION>G173968.JPG
<TEXT>
begin 644 g173968.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`\35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU724Q,24%-7T1!3$597U!(3U1/+D504__;`$,`!P4&
M!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H
M+"TO,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_``!$(
M`(<`AP,!(@`"$0$#$0'_Q``=```"`@,!`0$``````````````P4&!`<(`0()
M_\0`.A```0,#`@,&`P8%!`,``````0`"`P01$@4&(3%!!Q,B46%Q%(&1"",R
M0J&Q,V)RP=$6)422HN'P_\0`%`$!`````````````````````/_$`!01`0``
M``````````````````#_V@`,`P$``A$#$0`_`-Q8HQ3+(L@7BC%,Q19`O%&*
M998]550TS"7N!</R@\;H/MUF@N<0`.9*CJK4X(;A@+SY\@HVKK9)W7<>`Y-'
M(+!>,KWN2@D#K^)XQ,`]UF4FM450<7/[MQY7/!5&KB=Q`%E$39Q._$;(-LM`
M<`6D$'J%[BM<Z3N&IH2UA=WD75I/[*]Z7J=-J++Q.`?:^-T&7BC%,LBR!>*,
M4RR+(%XH3+(0-Q1BFV]$8H%8HQ3;(L@@MR:F=*HFNA9G53O[N%O\WG\E7V,<
MQN#I'/<.+WN/%SCS*=N*=E9N:"G8Z[:&(N</YS_C@F0L`%B+E`IL9XK[<P6O
MBLTQ-[OD+I;VV'#)P*",FA#KV^2A=0A&'$$'CQLK*]K21X;^7%0VI@!I!R:?
M,"Z"IEQ:\C_XK[BUJ?31\13R8N8;@\U[7AK6O>PAW#Q-(L;^RK55(7T\PO>[
M39!N[96YH-RT4KP&MJ82!(T=0>1"LV*Y^[$JUPW5#&UQM-%)%(V_ID#_`.*Z
M&Q0*Q19-Q1B@5BA-Q0@?BC%-Q1B4"L4!O$)N*,4&L8HRW7-0>\EQ>]W$]?$I
M6-F5C?GR4;J\KJ;6M0G>PXLN;-\R>2PZ34ZQP$S[1M)_#;(CZ(+$62M`M:R4
MZ[G%CAQLL0ZO,9`TM`B//)ANL^&1DI$A')OD@QV0ES"23<'A91.HLLPY/+1_
M4I*OU!E/2W81D7&RIFI1ZMJ[\&4\,45[ESG"Z".UF5K'/:9`X'UXCU"J]7.U
MD4CS8`-)61K^D:Y1R,D:R`TL9N\B0EV/IPX_5156YKJ4R-=X1R<@L?8^P1[N
MT^3$G)SFD=07-/Z+I+%<V=F5>VDW%3ROA?@)F<`.G(?NNF2VQ(\D"<48IMD8
MH%8H3<4('X^B,4[$(Q"!.*,4[$(Q""A[BI(SJ-0R1I(E&7)5Z7X]CY(*8QT\
M38R8Y,<G.?T!)X`*T;K)&J\.C6\O913PX6+`+>B"GT$FKNK'R5%4_`RAK&/:
M/$WJ2!R(]%<8GB.F?D.(;S"6*2)[N]>T%PY72*SA`XWL`@J=+7/EU*IBE!?B
M3W;!QXWM_P"T_<;M2I(:=M":>1DO%]LKL%C<'CSO;H!:_DJ[WA&L2/!(M)P(
M5ZCB?41-ROR%['@@I&E5-=/45.GUP!:0"WK91.J4`IG.IR.!'(J_5M%34L4D
ML3,97'+/K=436YS)4![C=UN*#)VG7:9%N?1:".0.G96QF1I'X`'#@?/FNF\>
M*Y5T6B%1O739H;"43Q@D<R,FV_<KK%S?$[W*!&*,4[%&*!.*$[!"!V/HC%.L
MBR!./HC%-LBR"@[N&&JN('.)I43`X.:;GBK=O6D:^BCJFM&<;L7$#CB1_E4B
M(N[HAO/H@=WQ.8AZ'&Y\TFLC!I'/<1QOP2VMPC[JYM>Y(ZE8];#.^`012`%_
M++B@U[J5XM1EGB-@P7]"5L+0JIE7IL52P8AS02T]%29M%DI9914SOF<XW-Q8
M?13>@UX@<:=_\.UN"#[W)4X12&]AR6N*IY?+<GF;A7C?#3$R)D9OWSPT*C3,
MPFL?-!;.S6DDJM\Z9;Q!KVR.'D&@F_Z!=+XJF=E.C4E%M6AK_A8FUE2PN=,&
M#,L)X"_.UE><0@3BC%.Q1B@1BA/Q0@]0A"`0A"#$U2G^+T^HI^KV&WOT6K(_
M"\@\#;BMO+6FZ:0T.K2AHM%+]XSY\Q]4%<U"&OL9J29C7GDUS+A+,]8UK7U(
M<7@>$QV/UN%,M`+!=8U3&2VQDMP\[(*5K<]=+*X1NX<\W@?V^:R]LT`+\I97
M.=*[B2+"RRZVD9)(&AXL!Y\TM]5'0-+G.#>[:2`@QMP.CK=P.A'&"@CR/O:P
M"H51)WU86,L3>W#]%8GUHI=NU>ISO'Q%:XO/H.@^BING5K*6*?5YQ>"F&?'\
M\A_`T?/C[!!UQL+4M-U3:FG2Z5*'P11-@<.K'L`#FGUO^ZL:XL[&NTN?9.L2
M4]<'3:-72`U#&B[HW<N\;Z^8ZA=FT=33UM+#5TLS9J>9@?'(PW#FD7!"!R$(
M0"$(0""0`238!:YWOVL;;VPQ\,$K=2K@/X4#Q@S^I_(>PN5SGO?M<W+N1TD#
MJPTU&[_CTY+&$>1/-WS0=3:QVA;.TB1T57KM,9FFQCA)E</?&]E3]5[=MH4;
M;4T%=5/Z>!L;?J3_`&7(<U?42NOWCF^@*QGO<\W<2?=!TEJOVC7MR&FZ%`#T
M,TSG_H`/W41LW?\`NC?.Z#3UTD<L?PTTH@8P,;"U@!N`.IY<2M!+>'V7:3OM
MXZG.;$0Z>1_V>T?V0;1I*ALC,'&QY63'B*..V0]KIFX-)-!J<L47@8?'$?Y3
M_CDJY6QU0X=Z2@7J$L<$W?.(P:";76M]Q:]\;4_"4Y<[,V<6\K*YR:-5:D[N
MK2RWY-%^/T4[HW929'B:O:(8NL;>9]R@U++3ZGN>H@TRB8Z.@IS>HJ2/`/0>
M952W;J5--.S2],/^VTA(8;_Q7_F>?/T6W>V3<>E[8T]VSMOM8RMD9C4OC%A3
MQG\O]3NOD/=<_H!;G['NV.7:%/'H.N0OJ=&S)9*PWDI[\[#JWK;W6F$(/T,V
M[N30MRT?QFAZG3UL/YNZ=XF>CF\VGW"EU^=VA:YJVW]0CU'1Z^:DJF'@^)UK
M^A'4>A7479[V\Z%J\<%#N>VEZC8--01]Q(?._P"3Y\/5!N]"7!-#41,F@E9+
M$\9->QP<UP\P1S0@_.RJK'S@!SN'4+$)!]T$W7B`0A"`71_V3Z#Q[BU,\K14
MX^I<?[+G!=7?9GTV:/8-;.R0Q/KJUY#QS#&M#;CUO=!L3=.J:)/+\"]CZFJA
M=9QA<`8;\[D\#YXI6A[?TC4(W3FJEJ6M=B6%O=D>XYJFU%/%2[FUF&GC+(89
MK-NZ_-H)O[GBHG_5U9HNOT$U!]Y&\X30M-VR@FUO0CSZ(-Y4>FT-$S"FIHXQ
MZ!:U[<.T5FRM&90Z<]IUVM:>X%KB!G(R$?H!U/LM@ZSKM!H^WZK7:V7NZ2FA
M,KR>?+@WW)L/<K@S>&XJ_=>XJW7-1>3-4/NUE[B-@_"P>@'!!$5,\U3/)45$
MKY9I7%[Y'F[G./$DGJ4M"$`A"$`A"$%JVIO[=FU/#HNL30PV/W#[21?]77`^
M2%54(!"$(!"$(!=E_9Z@-+V9TD[^(>YY;QY#(G]W%"$&#N&LI-.W5J\%7+B^
MH<V9GA)O=@'3R*KNQ=.96;[I8JJ,/A!+VAW(V!/^$(01OVG]V/$]%LJBO'!&
AUM55V%@]QO@WV`N?<CR7.R$(!"$(!"$(!"$(!"$(/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g616240.jpg
<DESCRIPTION>G616240.JPG
<TEXT>
begin 644 g616240.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!`35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU(7TQ!55)!3D-%7T953$Q%4E]02$]43RY%4%/_VP!#
M``<%!@8&!0<&!@8("`<)"Q(,"PH*"Q<0$0T2&Q<<'!H7&AD=(2HD'1\H(!D:
M)3(E*"PM+S`O'2,T.#0N-RHN+R[_VP!#`0@("`L*"Q8,#!8N'AH>+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+B[_
MP``1"`"'`(<#`2(``A$!`Q$!_\0`'`````<!`0````````````````$"`P0%
M!@<(_\0`.A```0,#`@0$`P8$!@,``````0`"`P0%$1(A!C%!41,B87$'@9$4
M,D)2H;%#P='P"!4C8H*2)'+A_\0`%@$!`0$```````````````````$"_\0`
M%A$!`0$```````````````````$1_]H`#`,!``(1`Q$`/P#L(SN2@!T2P.R,
MCL@;&?T0QUW2])SS1EOR0(P0<818Z[I>DE'A`C&#Z(B-T)7LB:7R/:UHZE09
M:]ATMCF:SW&H_3D@G$$#8($<@JBIN,T?W!K'N!G]$B#B"#4&U,;F`_B&X""Z
MQUZH8V1L<R1H?&]KVGJ#D)8:@0!Z<D70E+(/1&!_80-@=,(QG?*60BP>Z!&.
MNZ"<TXZ800+`V2L(#*,`($@<T>$#S*/&$"<;JHJ;W!',88(C.0<$@X&?3NK"
MZ'105$AR&M9@X/?HLU;J8F,2N;@N^Z.P0/3F:NE\6?RC\+!R:$ET;8@6Q,PX
M]<95C'#C<#..:C5.1GIE!GJ]\N<`GWV5+4U;V;'<=QS5_6$@.QME9BXM+03C
MV*"TM%ZJ*.3Q(R2W\37<G#U_JN@6BZ4EU@,E,_SLP)(R?,P^OIZKC5-6.BE'
M;D1W5A3W&6S7:"ZTI+H3M(S\S#S']/5!V7'/9$`BIIHJB&.>!X?%(T.:X'F"
ME#F@&/1$`E@!)/WD`Q[((]@@@&-]T8&?1+`W2@![(&B""@!D<DLCW1AOI@H(
M-UA=/0M@U8:^4$_^H"CT\33LT#`V"E53M-+%ODZ<`!%2`%NK(0.MB`4*MBC(
MQC?HITCB`<]`JRL+FX=JR,?1!GZV+#G`_)9RXQAP(ZK4UK'.!.505,9,NXY`
MDE!C:QCHGZL<RI\+FS4)CQY@,^Z*\-&P`ZJM@J70/VZ%!U3X:U1FM$U$Y^32
MR>7)_"[<?KE;$]<KF?PNES>*Z/.-5/G'LX?U73\'/=`G&?1$1@IT-&VV$G&_
M5`@`'H@G`WT00++<C=&`4L#.3C&>B,-[(&B,HV@]`EX\RI^+!5LL51-1.`EA
MQ)CHYH.XV01:RI#FPM'(=<^J6*A\49$<>L@<LJ@H:V.KM\+M)8XMSI<<X^?4
M)4MX^P.;$*>6>5W1C<^P_OEU064M^@PUO@S%Y&""WD?55\E>]\<CW;!KAMV6
M7N'%KZFJ?3FRU#"S=SR1@'MC',+0<*@UD-4ZKCD:W`T9VU;(&JN[1-;(#^%W
MU"S53<9ZI\C*:G?CJ_&RB<32/@N4<<;"]FH9;GF,INN;Q+441=0R-@R<,A9I
M&!^8D_MS01*YSVO#9#N.8*IGN<3\^:EU4%QC`;42&9^,NR-P?=0:@.8,9&XR
M@O>'N*IN')ZB>FH8JE\K`TNE>0&M!R<8W)*[U1S"JHZ>J#=(FC;)CMD97EI\
M[9XY(H\ZV@@YZE>J+=#X-OI8B,:(6-(]F@('0"B(SE.AJ(#?*!`!Z()P-[`%
M!`Z!V1X&,(-QOU2\(&\;HI(HY(WQ2-#F/:6N:>H2]@Y*QL@YA5T3K7=OL^"*
M=@+8QW'3]%=4T9\1[HH@\.`)R=^73*L>(Z:*2H<`T>(^$Y//?H53VRJ'A,U<
MR`2@756J>MF:^0""%O,ZRXG'MLGYO"IHQ3TS,-8T\_W53>N(7NJH+=2NP^5^
M"X#.@=3]$])5TL43]<FKR8#LY)08&_'%U$DAPWNKBBKI7TSFPF,D#!RLYQ/5
M1SSL;&[<<R%$LM<^"HDA:=3"`02>2"SND,KP9:APY[-9NLM6.#2`!@#HM/<*
MC5%OL5EJ[).KH4#W!EL?=.+[?`69BEG8'`?E;NX_0%>I,9)]=UQCX)VZ::[U
MMU<&_9J>'P6G_>[!V^0_5=I';F@+2.2+&Z<PD[`GJ@+2$$O&R"`@,#(2@"C#
M1[H8]$",<SU2ADH\;[[H8]$%==;?]OB`9,8)F[-D#=6!U&.JP-1#+2SS48<=
M<3BS/<+IY;U(^2P_%40@N[IL$"1K7_R/[(,?:&!EYJZN1VI\6(VD]#C)_DI=
M\ML-7&ZHBC/B8_AG&ZAMMU8Y]1X$S(WRS%X<6Z@!@;8^2136N^Y.NN=4-&<F
M(A@]-B@QUSL[XRU[BXN.Q!.5'A_\?((QZA65WI+P)I!*V1H!PW5*W]<!4LM'
M6:O]6L=I)/E:-_3<H+5DQJ8R,;M'/"@-@=5S0TC/ORS-B'N2!_-3H964M!*2
M<G(;D]@KCX;4L=5QG:V3-R6"2I(/<-)'[CZ(.\4=%34,/@TE/#"S/F$;`T$]
MSCJG@,#(2\;H!H'3*`@$G',]4O'HAI&<[E`0WYX01X]$$"\;;(`>N<I>.:+&
MR!('9`#?.4O'HBQT0)`PL?\`$.NM5!14;[A4B*IEF$4#>K\\]ORC;?IMW5AQ
M-QEP[PU&?\SKV"?&6TT7GE=_Q'+W.%YEXZXDJ^+;_)7R:XHW'13PZL^%&.0]
M^I/=!V&DUASR'`Z>7<IFL9-K+PYT,G=IQ]4W545=8HJ$53WR&6ECD9)C&HEH
MU-/J"I5-<*4:II`-;1R=N0@QMW^T:LOJG/)/NJAD3W%S_,X-YN<MI<KMXC7/
M>[2UVS1G)PLG77!K6F*+?)RY!5U+P961./D:=3@JJZ5]TH(VWVV5#Z>>CJ(W
M-D;S!.?J.X[%3F1RU,NB-I=)*[2T=_\`XKOB"U10<'5U)D.+83(YW=PWS^B#
MLWPRXXH^-[%]I:&PW&GPRKI@?N.Z.;_M/3MN%M,;;+PAPUQ%=^&;FRY6:L?3
M5#=G8W:]OY7#DX>A7<.'O\0<9:R+B*Q.#M@Z>A?D>^AW\BKB2N_ANR,<MEC;
M)\3>!KUH;3<04T4KOX55F%V>WFP/H5L8I(IHQ)$]LD9'WF.#@?F%%`#KE!*Q
ML@@7C?"@7:[VJSP&>ZW"FHXP.<\@;GV',_)>:>)?B_Q=>2Z&ADCM-,=M-+O(
M1ZO._P!,+`3/J*J9U35SRU$SCN^5Y>XGW.Z#TA?/C5PM0AS+9%5724<BQOA1
M_P#9V_T"Y5Q-\5^+KVV2"&H9;*1XQX5(,.(]9#YOIA8/2/IS2F-R_)Q@;H%L
M:1JD<2Z1YRYQ.2?=2[7&Z2[4\;6[^JC^^59<.@"^TQQODH/7%9:Z.^6.&FJ&
M^5T371O'-AT[$+CO%'#M?9I'_:03%OHE;]UP_OHNL0WJ@LW#=/5UTI;&UH:T
M-&ISNH`'LLG>.,[C?*5]'PY:Z77)ENNY#4W_`*#(S[E!QFXSPN<!'*^1P&/*
M"<*O@,]35,I6^&R1Y\K'/&2FN([9?;5<IZ&]R21U9:)=,<@T:79((T[`<]EB
M*Z!XJ&D.>7D['.3E$=OM%M@M^99I/$J7#!.-FCL%$XUJ?#X<K=((,K1$W/4N
M/],JIX+BN,%&/$JIYI7;N\9Y>UH[`%3^-8I)[C1VY[=.AK9)&#\+B,X^G[HK
MB]5$8*B2%W-IPFE><34I@OM:PC`U`_5H*I'`M.ZTP`5Q9K]>[+)XMHNM71.!
M_@2EH/N.1^BIVG!4@#;'7H@ZG:/CAQM1-#:M]#<6@8'VB#2[ZL(07+0/38H*
M&U?Z!DCJ2C.!OTZ((*-DY`.GH$ZW#6\]SZ(((`<;\]E:<,2!O$5M+FAP>\M(
M/J,(((/5`L-#=K3!!4!P;$#H+3RR,'W3W#MH@H8I:3PXM43L:XVZ=0.XS\D$
M$'"/CM41Q<<.PPD14432!W\Q_8KEMB?'5WND?(SRO#C&#OYAW_5!!$=KLM((
M8?$CC;EC2X>XY*RL'"L=TNDLM7(YT@&IQSODH((KC?Q1I64W%UTB8,!A8`/^
?`6'(U#&>B""K-,'&<*1`=3>>[4$%0Z`.?0H((*#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g785559.jpg
<DESCRIPTION>G785559.JPG
<TEXT>
begin 644 g785559.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`R35),3%]'4D%02$E#4SI;04)"3U14
M75))0TA!4D1?1T].6D%,15I?4$A/5$\N15!3_]L`0P`'!08&!@4'!@8&"`@'
M"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9&B4R)2@L+2\P+QTC-#@T
M+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN+BXN+BXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN_\``$0@`AP"'`P$B``(1
M`0,1`?_$`!T```$$`P$!```````````````!!08'`@0(`PG_Q``_$``!`P,"
M`P8$`P8""P`````!`@,$``41!B$2,4$'$R)187$4@9&Q(S)""!4D4J'!,]$6
M-$-B8X*BLL+A\/_$`!8!`0$!```````````````````!`O_$`!81`0$!````
M```````````````!$?_:``P#`0`"$0,1`#\`O:BBDH"BDS10&:2FS4%]M.G;
M>JX7B8W&CC8%1W6K^5(YD^E4+K/MINMQ6N!IACX&.H%)DK'$_P`N@Y(_J:"Y
M-5:\TQI<+3=+DCXE(S\,UXW3GEX1R^>*KUSM^LN5B/I^X.$;#B<0D'RKGQIN
M1*DJ?DEUTO.#O5N94HDJ&2?,UZJM[ZE'NT$)4<)V]`55478G]H%1</%I<%K.
MQ3+WQ\TT[6[M[L3SJ43K-/CH/-QLI<`^QJCA:\9XO$7"%)&#L#DDGUVY>E;I
MM"<A(8XW3DA!&=^I5]@-N6345T_8>T/1U^<2U;K['+ZN3+V6EGY*QGY5+,Y&
M:X:OEL1$?;3WP4^L9X4D%7IL-AFI7H/M2U'I)UIB8X[<;03@L/*)4@=>[4>1
M].5!UU13%I75%EU5;_CK-+2\@'#C9V6V?)2>E/E`M%)10+1244&9I#124!6M
M<IK-N@2)TC/=,H*U8&2?05LU%NT-U;>GE)2XA`<<"5%7+&#_`'WZ^U!S]KR\
MW;6=R2N=EF*V2&&D9(;&>H&Y/F>=,,.R267DI6HMG(`).,[\C_[%3!Z+(+Y2
M$%"2"HJX2E2O8#G]*F&B=$KNW\;<N^:C?H:4L+XA_:@@T2U-KD*=4T`#E#J5
M(.SF0,_,?8'K3I^X%I?&6UJ'"O\`*.($9RG^AJ]8VFK:S'0PAH$(PD$[G`Y5
MO_N6(DH4TRD8\AO04@_:H[*([SS*>\;2EI*",`E*,`GR&<_0CK3/.BM1G%M-
ME/>J"@5G;A'ETVV/SJ[[KIEN2XEQ!">#=(J*W31K!)6"%$'/BWR?7-!0-TBB
M-Q/O)!<=W(.^WKY9\N9]!FHA/DE]PE8)(P$D]!Z#I5WZHTR&`XXX0I1R>615
M:W6TI4#L$J!V.*#2T1JJYZ3O35SM[F4CPO,G/"ZCJD_YUV1I:^P]26*)>()/
M=2$9X5<T*&Q2?4&N-8,)M!_%"`H?SCG5Y]A-U<8FR["MU!86V7V4`$<*@?%C
MW'VH+NS1244"T4E%!E1110%1W78*=-RGT,AU;&%I221ORZ;\C4AIMU&DKL4\
M!03ADG)Z8WH*OC,J1%R^XRMUX!7=,-^%(SS4I65*.=AY]!UJTK*T&+=&;P0>
M`$Y.^:KYEM+LIN,AP)9(4Z258XAYGY#'I5AVMQ+L5E8&$D>&@=6QM@UZ*7@8
MKR3T-([G&?+>@PDK_")'.F&62XAP\6%8Y4\J4%$H/,BFB8WW25@\E9/M0075
M`RE0(RE7(>55+>8Y;)!'ZJMG4#G?*#39XB#GERJMM1I.>(CD=Z"'&1P.EOB`
M'D3L?>IMV69':%:.X7C/><0"L^'@.=CO5<3'`'WRHX*0",U:G[/%O<G:DG7A
M:"6(,;NFUGHMP\A[)!^M$=%T44444444&5%%)0%->IF),K3]QC1$I4^ZPI"0
M3C.:=*Q6D+0I!)`4,9',4%$6ZZ%,^X-O%U#K"%DH7S22K!R>A'"1CS)JXK,2
MW;H8<'"M325*3Y$@'%0#4NEIB);-S)<F.OI^'=6D8PKBYD#TWSYDU/;B`F`K
M@4$J"0$D[8V\Z#9F:AM4`J3(DI21S\@:UHNH[7<U.MQ):%+2C/#U%0UZ]S1"
M<-@TN[<TY(,A2DH0M7^Z%$%8R,;8'J:A$!O4DZX,/RK3$A3GUD%M@E)9\BK!
M(P>5!=K\YMIQM97X20G/OM4?U)?H<!M2Y,A*`D';J:>K59$,VE*;AE;Q0`I)
M5D(]!Y^]47KZ!+E:M>MS3J>Z1@^-6VZ<@$]-^M![.:R=F27(UJ@*?R3Q*".+
M;U-1N]7)\)<;F,=RXHC"<8VJ5.Z6O$.Q,*L][0P^4A4D!SC"2"<\"4C&",#?
M?;UVKR]":J<(KCYED#)=[O@.?4#;%!'+V%!QMQ)(*LIVZ]15W?LV.2(Z[U;%
M+):#;;ZD]$K)Q]L54<UAO*._1^18.,\JO7L`AMIMUYN2-UOO(9]@E.?_`"H+
MAHI<4E`4444"T4E%`4444#1<T.=YP\:NZ"5.#'(J'0_7-;D(=XE0(!2>AZUZ
M2&RM"VOTN@I]B1SIMBW!F'&#CZTI&PR?.@]IUF1(2I/?O-)5T8/":U[1IZT6
MA_OF6RJ0>3CZ^-0SY=`?EFO.XZH9:@N26CQ)`V*1S/3%8Z?8N2V'+M<>)R0Z
M,MQ`0`VCR]5'K]*"025_@.;9PG:N?K]_!ZS=?F.$=Z>(<(R<"KAG:J@18CBY
M\23$*.29#12H_3(_K7/.I]1N76^NRV&%H`XDH!'(&@M^+:K-<8S;JXC;H4G.
M<$'^E,NKH%KMUJ<$.(TV3DXWQ42T/?9%K!:><6MM:L\!)./:MK6]^8DL%MM1
MR1UH*XN9R_CGE0KH/L(MI@Z'2XK.9,A;F_D,)_L:H>SVB=?[M&MT%I3CSBLD
M@;(3U4?("NM;);F+3:8=MC##49I+:?7`Y_,[T&]1BEI*!**6B@QHI<4N*!,4
MN*7%&*#$I!&#4>D1F7'78[S84D*X@%;YZY^M2(FFB]M.I:,UE)464DK0!DE'
M4CVYT&C,@P"!+,;ODQT_A,)&R2.N/.O:R7SXF"W(?MLJ"V<A(=;))`VY)R1R
MY'!KSB.E;8=;/&@C.1U'0BGAM*'64J3G?<'&]`WW:7;)3*6WX\UQ&<^&*HC/
MTWJH];18;,A<AFQ3FDG<*6VE(_[JMV[I>[C>0ZVA/+N\_:JMU3$<DMA+*9"N
M?$IPDDGYT%>V)J?.OK;3#*4M;E7$K=(QSVVK=U<W;&'F&(_XCJ?$MS.<@\A_
M?YUDMU5CCR2G*7G,)</4)_E]ZCT:/<;U-8A1&B]-E+PA&?N>@`ZT%J=@-J2O
M]ZWMQ.Y6F,T?3\RL?]-7=BH]HC3S&F]/P[8R>(MIXG%_SN'=1]L\O2I'B@QQ
M12T4&.**6B@,48K+%'*@2L37G,EQH;)?ER&F&D[E;JPD#ZU6^I^U_3%K0ZS;
M7_WG-"3PI9_PP?57E[4%ASID2!&7*FR6H\=L94XXK`%1/2/:'9=4:MDZ=M[;
MBF!$6M,E?A#I!`(2GGC!SD^5<Y:EU=?-5.][=9JEM`Y1'0.%I'LD?<[UZ]F]
M\1I[7%HN;B^%E+X:>/0-K\"OIG/RHCI*4'++)4X$9BK40Z@#_"7U('D>?I3C
M"N<9TD(=3@[\\4^7V`'V%.A/$0,+&.8'7_[I4`EVX(4L(&$GR.**>[K>(T<$
M+D)2!S)Y"JWU5JIE2Q&MRVP5#QK3SQZ4SZJ@R6EGBE/J3ZJ-0B>R&&CPDA2N
M>#0:^H[G\4_W*592WS(ZG.33MV:ZEAZ:U%&N=U2GX!]1AN.D94P%#(6/3(P?
M2HDZ@)&!S/\`6O.ZMJ_T9[PC"3,\/J`D@GZD_2@[?:+:VD+:4E;:DA25).0H
M$9!!ZBLB*Y`[/.UW4&D&F[?(`NEH0,)C/+PID?\`#7N0/0Y'M5]:8[8]#WX(
M;=GJM4I7^QG#A3GT<'A/SQ06)BC%9M*;>;2ZTXAQM7Y5H4%)/L1M67#0>.**
M]>&B@@FJNU#1VFBMF1<A+F)'^K0_Q59\B1L/F:IS47;Q?YO>M6*W1[<TH82Z
MX>]='K_*#]:IQ+7ASR]*]T->6.0^]7$ULWB]7J]OJD7:Y2ICGFZX2/D.0K6:
M3PA?Z3P\Q621X32NY0PI65`D@;'%5'NPL*2$\1/N:]"G'/;.V>1%:4-63GO%
M8]Q_G6Z>`8SOGUS]J@[2[+]0(U+H>TW'CXGTM!B1ODAU'A5GWQGYTXW:RAT*
M>BI'$?S-\L^H\CZ51W[-.H4Q[G=-+O*"4R0)4<'.ZTC"P/=.#_RFNCZC2E-3
M6\.)7X/$D\*DGF/>JHU#%*5X`/+:NK+W9(=V9(=XFGA^5YO'$/?.Q'H:JM6B
M95UN<R$Q)MJTQUE"Y`65<)Z@MC<$9&V?G043"M,NY3TPXR?'PE:UG\K+8YK/
MMT\R0*SU\TQ$LK$6.DI90XE"`>9`!.3ZU=>H=-0-'V!,&&HOS)C@5*E*3A3Q
M'(8_2@=$_,Y-41VER/QH44'8)4X?GL/L:""T444$ATOK'4FE7P]8[L_&3GQ,
MYXFE^Z#E)^E7IHS]H*$^$1=76\Q7-A\9#25(/JIOF/D3[5S510?0&R7JSW^*
MF59;E&G,D9RPX%$>Z>8/N!17`D65)B.AZ+(=8=`QQM+*5?444#MP#@Y8Y?>E
MP`-^N/O1158($^`[;UK3=TH`SMN=Z**+&$<\*A^+CT(K=<(*T$ND@;["BBBT
M[:6NDC3E\M]]C*R[&>#Q'+B3R4GYIR/G7=$"4U-A1YC!)9?;2X@D8\*AD?>B
MBH1HZIO#=AL$Z[.(*_AV\H0/U+.R1\R17+";Q+MU^3?H\_X>XA:GOB.`E+BC
MS2I(_2K<'WHHHJWKA=(NL-/VF^QVRAJ2T7`VKFA6X4GUP01FN=NTQC@N*%=4
4(`'MDT44$$HHHH"BBB@****#_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g509192.jpg
<DESCRIPTION>G509192.JPG
<TEXT>
begin 644 g509192.jpg
M_]C_X``02D9)1@`!`0$!J0&I``#__@`_35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU*04-+7TU?1U)%14Y"15)'7U!(3U1/+D504__;`$,`
M!P4&!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE
M,B4H+"TO,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_`
M`!$(`(4`A0,!(@`"$0$#$0'_Q``<```!!`,!```````````````"``4&!P$#
M!`C_Q``Z$``!`P($!`0#!P,#!0`````!``(#!!$%!A(A,4%181,B<8$'D:$4
M(S)BL<'10E+Q%7+P,S6BLN'_Q``6`0$!`0```````````````````0+_Q``7
M$0$!`0$``````````````````1%!_]H`#`,!``(1`Q$`/P"XNBQ;=':_;V6=
M/-`%K'@L<D>GC?ZK!X60`!8)NQ?%Z/"H#+4R#7;:.^Y_A%C.*1X;#L/$J'@Z
M&<O4]E6]125V+5<M372@-D?L#_4>P_8('6ISW/*\MH:8`==.I<,N;L:;YG2Z
M/R$#]$YT67RR$,L(6'BYH\Q_A=`P6BAL&Q:W?W.W*!C&>L59M(UKSR)8/X4E
MR_G3#<0:(:^5E'5`VM(=+7^AX#T*:JJAA=MX+;>BCN)X;!<^4#J@N-CF/8'L
M<'-<+AP-P?19`-]ME15'B6,9>E\7#:MQAO<PN\S'>W_"K4RGFFCS%`0T>!6,
M;>2`F_NWJ/T02$\MTK=D0'5*W3@@'E8<$MO=&04@`@``?Y21$7WW^:2#:-S?
MBBMLL`(AU*`2V^RU3.;#"^60>1C2XKIM<)JS(\1X5(T?BD<UC;=;H*^QVOJJ
MB=W@1EU14/TL'(#HI+E[!6TD(?-][5.'F>?T'0+5@]!']H?4EMRS[N._#N5*
M*:+2[2#YB-ST"`&TS#OH-CSZ+EK*-I%Q\D^QPD--KKAKAHC+K7ZA!&:F%I?:
M,BW91[%86AIZVY%2BK($AZ64=Q3S,-Q>_(((36$@D<EPT-?58+B<5?0O#'BX
M)(N-^H3G7,N]R9ZJ/4PL(-B$%YY4QR/'\,^TAHCJ(G>'/'R:[MV(W"?+=E3O
MPJK719@%.XG150.8X7VULW!^5U<X%R@U6ZI6]RMNE"=N5D&NW8I+;8I("L?\
M+(MT1D;+-N/!``%K)@S<\,I:3<;S[`];%2.UCQV47SVW3AD$K1YV2W!MV0:<
M%>UT+6AE@WJI-%9HU$#@H=EJH9-'(]IO=U^*D[:HMC(;$9G`_A!`0.)D(!N+
M-Z!-N(2LU,8;D.W)Y!:Y,:IHK>(QT9.Q#AP3968G#,[1'NXD`(.>H#W/?8&P
MX=TP8FQP=8;FQ4D%5&VJ#7<W$"_H4P8Q)&USBV1@ORN@B-2RU]29:T:7@!/E
M7+'I):\./#8J/5,FMQ+MB-D#Q\.PYF;L,:#L9G\?]CE?@%@O/>0)I)<UX2V$
M:GB>Y'Y;&_TNO0Y'(H,6Y(;7/!%;99MU0:^'^4ELM?H$D!@7V2`LMEK[<D6F
M_#B@U@'FHOG$%\E'`Z,/A?J#P;C;L>14L(L;\;)HQZ!CXZ=Y;<LDL#ZH('ER
M5T<LL=-#+]D;*8G^)N]GEXGW/LI+BF*MPEI:VA?5RO`,<;6@W[D\@F^D8:>>
M:9D>ED\KG-!X'E?YA2&)T=0USS&`0T#S[7].R"K,:QW'ZC%/LC\%IH&VU.+6
M'RCE9W/;>Z=LO,E,T%0^%XB=MYC;<]RI%BN'-F?IAB<7]```/4KOH,.C!IZ0
M'6`"Z1QYH(?FJLDH:N)[M)C%W@Q@[[=U%ZRHEJ8YJQU(^:.%MW@D@-^6ZEV?
MFL:\,TC\5@.@4>PZH>(',,EP!:SN2".#%&U$+":!U)J;M8W'HN>ICD-.9"?,
M'`#T-_X3U6-U:F:0;\+<DWUP\.!L(==SGZG#H`+`7]R@ZOA/2D9QI'Q2.8Z[
MR[?BT--Q[KT*!U^BI#X3TPDS=%,SA%!*YWJ;#]U>8"#7;E:R5KK9;IP2`L4`
M6/HDCM;ND@V`+8`A&UKK9ZH-;AS7%B46NAFL-VC6.Q&Z<'#9<U7&Z6FF8S\;
MV.:/6R"(U#1]IB877:&@MMR!W3U2EKJ=VJVGA8[IAE>XSGQ(GQR-LUS7"QX(
MI,4BI*22:5Q$8W.R!5\P9)H9:U^`">,+:Z&$25%HW.:+DG<+EPJ.-[14U,>F
M:1MPTC\`/[KEK<%CB=/5TM7*V5X)+2\ECO4';9!&<_OB,0+7ZG$[*+85.TDQ
M2`:]B.X6O,--BU0[[V=C6&Y&D^:W[)OPV-]*X.D>2\"PN;H)#5-$,;G`WO\`
M11*M>7S'4=[I\JZS7%M[J.O=K>7=4%E_!>D=]HQ:L<.#&1W[DEQ_0*V0-E7G
MP<IYX\+Q)\L4C(Y)F%A>TB]F[V^BL<`]$`EJ$BQ6TBW)"18@(`]TD>_(!)`8
M_P"760/DCTV)L$B+(`(W6"$=OGZ+("")9G;X6(4\MO)*RQ/<'_ZFN6FIYX3'
M,T$,=J`Y&VZDV:J0SX89&CSP.UBW3@?Y]E$VRAX:UYMR(0#14^*PT'C13B4F
M1Q`D.]B>%UP8S68FR`B6GJFM<+78W6/HI;$YH@#0-K6V4=Q=^)\*47B[\0@A
M%=6,=MHJ)'B^WAFWS4>GJ9`\D02>XL`IC6SXN^,QNA))ZG9,%53R1-+Y[:B-
M^@0<WAN91NEEV+^`Z+ACC,TS8F[N>X,'J3;]ULJZDRAK+^5O).V1Z5M9FW"(
M'VTFH#W`GB&^;]D'HF"(0Q1P@6$;`T>PLMED9!)+C9(`(`XA(!$`$@.J`=NB
M2,-"2`@+):1=';LE9`/+@L`;\D7`7/`;WZ*`9P^)^`8"R2"AF9B6(#810NNQ
MA_,_A[#=`[9_S+1Y9R]4U$KV.JYF.CI82=Y'D6O;H+W*@M%)45N&4%5(##)4
M4\<Q:?S-XA5#F7'\3S)B,V)8G-XDSFEK&MV9&WDUHY!>G:S`&U.7<.;2,`J:
M2EC9&W@'M#1Y?X01:GKGTL8$^[!P?;]4-1BT+H#I(/:Z;*FJEB+X7L((V+'#
MZ*/U;FN):PEI/$`VN@=<8Q6.(G2YM[6%BH;BU>:IVW`<UBIA.O22XA<<C';`
M-0<VD@$N0UHJ8\-J<2I9713T19-%(S8M>'`W'LN^DH9JR80Q-[N<>`"<LU14
MV&Y4K81L#$6@GBYQ06_\,,\4V=,$\5VB+%::S:N`'GRD:/[3OZ'938#8V*\+
M8#CF*9?Q*/$L)K)*:ICX.9S',$<"#T*]`Y.^.>$UC&4^:*<T%1:QJ8&E\3CW
M;Q;]0B2KH`Z)67+A6*8=B]**O"ZV"KISPDA>'`>MN"[+=D4._()(C=)`P9AS
MCEK+S3_JF+4\4MKB%AUR'T:-_FJJS!\<GDOCR]A``MM/6'?U#&_N51P;<DG<
M\^ZV,;J-N7-!)\=SQFO,33#B6+S?9C^*&`")A[$-X^Z86C8`"P6``!862)Y#
MYH#C:7O:T<2;+VCA+A)A5$\?U01G_P`0O'&"1";%:*$\'S-;\RO8673?`<.Z
MBG8/D+(.7'<MT.+!TCF^'46VD;S]0JNS+EM^$#Q*YC_"<ZS)F'4PGH3R]U=J
MX<8J,/IL/FEQ-T0I--GB07#NUN=^B#SC-3MU:VGR^J=<(RU4XJTS@^'1M-G2
MVO<]!U*>*23),F*Z:O#JRDHS)]V/%U1@?G'$#L"5:51#2&BB%&(OLP8/"$5M
M&GE:W)!5_P!@IL/C,5/'I',G<GU*K/XH59,$%(T^75=WJK=Q.,OFD`'!4I\2
M["MIHB?,0YY';@/W00!P6`MSF70$6V*K..["<8Q7!Z@5&%XA4T<P_J@D++^M
MN/NK0RU\<<RX?:+&8(<6A_N=]U*!_N:+'W"I\+:W<(L>K<*^-.2*VF$E745.
M'RBVJ*:$NW[%MP4EY4LDHIV.PVY(H';EMN]TDD&]VUNZ$[!))`XX`XLQS#GC
MB*F/_P!@O8&7_P#L]*`+#0DD@<51F>\PUF(9CK:)XTTU#*88XP;@D<7'N;^P
M2201/&9#&UNG^H'GP3C\/<TXG0XY!@SG^/A]6[3X+S_TG$_B:>7<<#]4DD%E
MU].QLDCN>Z\Y?$:0R9HJFGA$UC&CM8']24DD$4YH2`0DD@TEMN:*(7N[Z))*
)IUM`22245__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g96392.jpg
<DESCRIPTION>G96392.JPG
<TEXT>
begin 644 g96392.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`R35),3%]'4D%02$E#4SI;04)"3U14
M74I%1D9215E?35],14E$14Y?4$A/5$\N15!3_]L`0P`'!08&!@4'!@8&"`@'
M"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9&B4R)2@L+2\P+QTC-#@T
M+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN+BXN+BXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN_\``$0@`AP"'`P$B``(1
M`0,1`?_$`!T```$$`P$!```````````````!!08'`@,(!`G_Q``^$``!`P,"
M`P8"!P<"!P`````!`@,$``41!B$2,4$'$R)187$R@0@4(U*1H;$5)$)#8L'1
MDO$S-$1R@N'P_\0`%0$!`0````````````````````'_Q``6$0$!`0``````
M`````````````1'_V@`,`P$``A$#$0`_`+OH^='M2T!24O/G1CI0'2EQ135(
MU!:&):X7UQ#DE">)QMKQEL?U$;)]`=Z!U%>)^ZVYAPMNS&@X.:`H$BHS<)LZ
MXJ4DJ4Q&)V;0<%0]>M-#]MCI;RMH#%!+UZKT^A80Y<VD*Y>(''XXIWCR&)+0
M>CO-O-*&RT*"@?F*I"ZV]I7$>[4DCEBF!F=<[%)[^W3'8[B3N$G90]0=C0=)
MXH^55%;>V*''B@7ZWO=Z@I"GHH"DJ&<*44GECG@9JR-.W^TZBMR+A:9K<EE7
M/A/B0?)0Y@^]`Z\J.M&.5+C;%!C@48WK*D%`F,FBE^=%`F*,48I1SH$I32\Z
M,9.!UH*\[4M32[9'BV*S$F[W-7=IX?B;0=LCR)\^F">E:-*Z>8MD%$5![Q7%
MQ.NG^:YU5_8>E,5D6+_KB]7YSQ(8=5#C$CD,[D?+`_\`(U8\5L-\*<C/I08+
MB;9"#[5J>CI[O!!!QMFG=;B2.'(\C7F?X"G8C(YT$1GQT`*'=G(&^U5YJ1H$
ME0!&/SJR[KQ<17\*1G(Q5=Z@RMX\B%#E00"5OQ`IS3;:KO=-'WA%ULT@L\6R
MD'="A]U0ZC]*?KNR&N'`Y[U&KJ4K84A709%!UOH+54/6&G6+M%!;7_PWVCS;
M<',>W4&I+7,/T;K\N'JF58W',1Y[)6E)Y!Q&X_$9KI^@3%&*7K28Z4"44M%`
MF*6CY4N*``K5)=2Q'=>5LEM!4<^0&:W`=*9=9N+8TE>W6_C1!>(_T&@J7LHE
M(DVV0\@?'+=<(SYD$5:[&%$'J-]O*J,[&Y(,B;#;04H2D+2".>3C_P!5:H3&
M3%<F7.YN1DK!/A<[L)'EF@DZT(&-L&O&X$I[]9.P2#GTW/\`FJY8N]IC7A<:
M'J66DA0XVI*N)&>?/F-CG/*IS='BG3LJ0#E895R.0=J!LN*T.1&AE*>-)5D^
M634"O"8X2X4R6EJ0=@%`D4P1;I(U*ZW%FSG`VDAI,9E125X\R`3OR``)-;;M
M+TS:@('[.2)10E7&>+B'%N-SR)P=MCM01N[O\:AOD#.*AMS?([P9]*DLP![B
M+&2DY4#YC_>HA<PI)(/WMZ)3YV73?J':!8)&^/K:&U#S"O"?UKML`]:X,TPL
M-:BM3JLA#<MI:B.@"P2:[R:<0\TEUMQ*T*&4J2<@CSR**4^U)BLB#FB@Q/XT
M4OK10&*4"LL4#G0(,9KP7YAB39+A'DDAAR.M#A&V$E)S3B!Z8KR77:WR,C(X
M#D9H*0[-M-*LFH)JLOJAR&6E1U/-E"RG))R/<"I[<;!"E/./2XXE)<3W26R?
M"A)&"`#MOOO0ZX%W%GN5J64LD*)/(\6^/+G3]&<!1P+'$1^5!!EZ-C&3WL.W
MEM*B%..R'2XM9&,9).>@Z]!3Y=>[%KE,<+89;9.4IY?">5/LKC0RM0\\^U-B
MVB8TAL)XDJ2021SH.=M*2'(=X"V$-A?&5)*]B#[]/>K#N-MDW-E2HT*'%6X/
M&Z@#(\R<`;FJ]NH:MVIEH;.$=YL0>56=`?(MZ%I4G!&^>9'2@B#EDBVMON3A
MY0R2L\@3Y"JQO[2/K+J```3D8JT[Q+22M*C@[X]?2JJOJLR%58E806U-<+;(
M&5?&KJ*Z`^CY>)BTW"PON%R.PCOVN(Y*"5`*2/3<''^:Y^:0HS6S'25*"!WF
M^P]ZZ"^CW;'BN]WU0'<.*3%:5]\IP5$>G*H1=AZ4AY5E28-%)\J*4T4"TN*6
MEQ0)6F8WWL1YLISE"MOE6^B@K@L,1Y3+K"U)^LI4M2"K(0H$9QZ>E/D)U*<*
M5BM&IK>W$EQYC:E!+JE)*.B2<$X]\5X&4'Q/*60A.,)SM\Z!R7)<?[Y944M#
M9`5MQ'_%1B1JN;!M=Q<DV>2TA*E)!4D*R,;'(Y`^=>1O5D*>^\PA?=I97W?$
MK*03^G^]9W$1)3;;7[492@NA;B-QE(&XR=L4'/5QN,FXW!]U;7"7#D$;8.:L
M;3ES<-O0Q()*TIPD^8IHU;!M;%R>=BSXSC><C@--UHF)EI7%BJ*I`4"@CE[T
M#I?7`IP@'G4$O:1WQ/IFK#NS:<QU%'"XM`*T^2LX(_$576H5@2UI2>0JQ*<=
M/PY=YE1[9:V?K,R0KA;;3Y^:CT`YDGD*Z_T9I]G3&FH%E94%EA'VC@_F.'=:
MOF?RQ6G0=DAV;2]G:8AQVI`@LI==0TE*UG@!/$1N=SUJ25%8TG2LJ,9H,:*R
MZ44&0H(Q2XZTN*!!O1BLL4`4#9?;?^T;<XPDX='C;/\`4*KAN4LL.1%@MK(*
M%!7,'EO5M5$]56-+A7<H[)4K'VR$\SC^(>M!&F($2/!;BML([I&24E((43S)
M]2::)DV+"CEA=J@K!..)3(V.>1]*?(3Z76@G=2DGA/M_]BO+<8D:2D+4V6U<
MLDT%4:D<A..K2Q;XJ%J.?`V-JT:<81"EIEN@=RDX6H\A[5,+I;H,9:EN$KR.
M8_2H!JJ[-HAK;9'"DJX4I'6@6^WAM^Y2)#:N)&3P"J_FO&3(6L]=A7M?E\$0
M)&[J^9^Z*;F6U.O-M(25*6H``;YJQ'?D!`1`BH&,)90D8]$BM_XU&]#ZMM.J
MX#QMZE)?A*#,AAP84@X\*O5*@,@_+F*D]16&*3'E6>*3%!CCTHK+%%!E@448
M]:6@3&]&_E2^U+MYT"8I".(8(R#7CNMVM=GC&3=KC%A,C?CD.A`^6>=5!KCM
MVT_$@RXFEUR)MQ4@I9E!O@9:5][Q;JQ[8H,;Y(DVB_2@D'N5+*F@>2D'EO3>
M]JQ#8X7$<2AT4.=3:X64KTUIN5(3WBA;V67B1N5\`5D^Y)J'7O3D<M=Y&'"!
MS!H(5J74<B8O*$X015>W!#\AT%0.$\JLY.GITA2A'C\8!P58P!\Z9KC89"'T
M1BA3DEQ7"VRTG*EGR%!7;K*U*``)/+`&Y-3G3&F7(;8FRT?O*T^%!_E@_P!Z
MG6E^SEV&4S[HT@RL9;9YAK_)KR=I,Y&F[0H(($V3EMD=1YJ^7^*NI(@-@UK)
MT?KYR\6_[6,%=Q)8!V?;V"A[Y&0?,"NQK+=8%[M<:ZVR2F1#DH"VW$_F#Y$<
MB.AKY]DDG).34^[*^T6=H2Z**DN2K1(_YF(%XWZ+3G8*'YC8U%=J45&=(:YT
MQJYD+LMS;6_C*XCIX'D>Z#S]QD5)]QM0)12XHH"@D`%1.$@9)\O>H)VH]HMN
MT%;FRIM,NZR1^[Q.+&1U6L]$_F?SKEC6':-JS5CSAN-S<;B*/AAQE%ME(\N$
M'?YYH.G=8=K^C=-%R.)AN<Y'_3PL*`/DI?PC\S5&:G[=M9792V[6IBS1E;`1
MT\;N/5Q6^?8"JDHH/3/GS;C(5*GRWY3ZOB<><*U'YFB!'5+F1XR!E;KJ&P/,
MDXKS>E3_`+$['^W.T>SLJ3Q,Q7/KCO\`VM^(?BKA%!VE)@)?M3D%`2,("6R>
M0('A_2H`VS'DHPZP$*"BEQ#G-"@<%)]B/T-2K4^KK5IAEE$M2GY\@$QX3)!=
M>QS(!.P]35=6G5\>9>5W*]VA$.*\YPR'&I![M`&`DN(4!XLD)*@<*QZ;A+8=
MIDW.-F`EN-#R4H>6CXL<U!/4>7+//.*<[9I>UV@K=8;4]+<&')3QXG%>@Z)'
MH,"I.A399262DMD#A*>6/2M"]\T$?N`C0XS\J0XAIAE"G''%\D)`R2?85QCV
MAZG5JK4LBX("D0T?9Q6U?PMCD2/,\S[^E6W](O7J7'%:*M+QPA05<74G8J&X
M:^6Q5ZX'0USW0%%%'0T&33CC3B7&EJ0M!RE23@@^8-6GH[MMU=8"U'N+J;S`
M3L6Y1^U"?Z7>?^K-55THZ"@[1TMVNZ'U"VD&Z)MLHC*F)Y#6/9?PG\?E17%U
M%!(-<:DE:MU/.ODH%)?7]FWG(:;&R4CT`_O4?HHH"CI110*D<SY#-=%_1X@Q
MK!I6]ZWFH+BG5B*PA/Q*`(R!Y<2B!D^5%%!NU1;9YUNU*U'*07K@VR$(X0XT
M%*6K@8Q@X&$GQ<AG.":BMRU!<6IJX=K*8A8"&G>[\2F#C);4\L<;B%*.>6U%
M%!8O8K>;^)4BU+[V;:D.<*E/O97&<.Y"222I/7'D=M\BIEVO:U&B=*.3&!Q7
M.4HL0@4Y`7C)6>F$C?'4X]:**#B60^[(?=?><4X\ZHK<6HY*E$Y))]ZU?.BB
6@7YT?PT44`>0%!Z444`KGBBBB@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g916736.jpg
<DESCRIPTION>G916736.JPG
<TEXT>
begin 644 g916736.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`Y35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU$059)1%]/5T5.7U!(3U1/+D504__;`$,`!P4&!@8%
M!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H+"TO
M,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_``!$(`(<`
MAP,!(@`"$0$#$0'_Q``<````!P$!`````````````````0(#!08'!`C_Q``Y
M$``!`P,"!`0#!0@"`P`````!``(#!`41$B$&,4%1$R)A<0>!D10R4J'!(T)#
M4V)RL?`6DJ+1X?_$`!0!`0````````````````````#_Q``4$0$`````````
M````````````_]H`#`,!``(1`Q$`/P#81G<E`#HE@=D9'9`V,_DACKNEZ3GF
MC+?D@;P0<+AJ;I;J67PYZN-L@_=!R1]%'5]?5U53)249\-C"6ND',KDI;#')
M*<>;;47G_>J`5W%C6/<R@HC,T'>25VAOT&ZCQQC7AQU45,X#LYP4A<;(8(6E
MH&^X';LJE>**2/[K2>ND(+#%QPP./VFC:&]XY<G\PI>BXML%8]L0KF12']R;
MR_F=EC592UKLAY<!V!T__5'FDF`P-`^>3^:#TFPAS0]A#@>1!RCQLO/UIXAO
MMB=BDK7^%_*>`YA^71:?P?QU27R9E#5PFEKW##1GR2'T/?T07,#TY(NA*61V
M1@?Z$#8'3",9WRED(L'N@1CKN@G-..F$$"P-DK"`RC`"!('-15=+-/5-H:8D
M8WD</\*5>=.7'INH:DD<(JJL<T$Y(!/<\D#4S(J>7[-"-\^<D\TO,\;=$1(:
M<9]4BGA+R';EQW)4JSR-WP?1!7KA550(DF)V[#8*JW2NJ'DMAA$>>9YD*_7-
ML<L3-31W5:K:5CLN:T<\904"M?5S.TN&&#H/U4/40S$DM?\`+"O-93-#79`5
M?GA&O;D@KL<<P)#RTM]EW04X#FR0N<Q[""US#NTIX,#92UPV*>8`TYQ^>$&J
M<"\0R7:F?1UQ;]N@&=0V\5OXO?NK:`L'HJV6UW*EN,!\T,@+AW;U!]QE;O$]
MLC&/:?*\`CV*!6/1$`E@!)/WD`Q[((]@@@&-]T8&?1+`W2@![(.2LRVGD_M*
MK]/+JH_"'(R-5DJF%U/*!DDL/^%3J.0AN_X@4$]3X:>W0)Z1P:!ZE-4_F`VY
M?FEU#M(S@\T')52%[@W'E`ZJ,JF$-&!MS7?*<-SGS9PFZ^,-B))05"XG!<,8
M]%7IP`XNZ!3UU`+R03L-^RK]6<$C!&0@C)<ZB[KE.O!CB;)I!;R(/1,R'?V4
MA"&RTV@]00$'+4`.I?&CY8P1^BVOA&I-7PS:YW')-.T$]R-OT6(T3L.EISU&
M<'H5N?"=*VDX<MU.PY#80<]\[_J@E<9]$1&"G0T;;82<;]4"``>B"<#?1!`L
MMR-T8!2P,Y.,9Z(PWL@9>W4TCN,*C$?9<1R@C!(.W8J_8W5)KX75%Q>'DZ,.
MR.YSR0/07BD#</)8WD"1A":X0Z"Z.5KP>6"JG76^H;-)%!"]^C^(92QF>V>9
M57IG7UT\C)Z?P(]>&@9S_O-!H%3</V/BDZ0XD#)]<)NY7(R!FIX;EHSD]4Q;
M[>^:QR"X-`DC.D'GJ',%4*NGN,MR+()7!C'%NY^@06:LD\./+HW'U=LH&MF9
M(XX?SY$\DJ:V75EN\<$FJ<[;Q,N8UOICJHR>&H9@2,9J//&?U0(>=SN#D]%V
M6EY,#XSS:<A<)B<QOFV[975;,`2$]T'6(!45,7V=FJ=[M+0.I*W>VTII;=2T
MSCDQ1-83[!8CP<#5<96V*-VS)R7CV!*WP-[CGT0(`*(C.4Z&H@-\H$`'H@G`
MWL`4$#H'9'@8P@W&_5+P@;QNJW>Z`Q53:MF[)#I<.Q5FV#DS7,#J*<.`QH)W
M'+&Z"JSL<8],>GS#!'0J,-D?/+XM6]C(_P`$(W(4FV5A;JSTW7#)>&"L92MD
M;'&`7/<X]`/_`&@1=?V5N>(1@`Z0WTPLUIVN97DNT[N.<GFM'O%73"V`MG:[
M4"X8.05E,U=2FK?)+,T$'9J"^P4S9XVLUO82.0=C*C+G:J6%Q=EY=_45'<.W
MB7+F3$F-KCH=Z+ONE:UVHDA!6[B2&G887#%4&-A#6Y/3U/1.5DWB%P!V7"\D
M,)Z@(-!^#=I>^^U5P=DMIXCJ<?QOY#Z96U@+,/@FZ;P+M&X_L0Z-P_NP?TPM
M1';F@+2.2+&Z<PD[`GJ@+2$$O&R"`@,#(2@"C#1[H8]$",<SU3=5":FEF@U:
M3*PMSVRG\;[[H8[!!D5PGK*$RQ2M)#"1D>BZ>%H"8I*^L83)4-PUKAR9T^JF
M;Y`V&[5(E:`QQU;]6E0>FX/J2VDJF>$P8#-/3IN@C>*;7&RE+Z69T9&0R(;M
M.?1466R/@>))3JU;\L*_U$=VE#G/%(QC>KW.<?IA0-R@JYFESZUF!MAD.!]2
M@A&O9!&<D-'4Y1PN=6R1QTDID802XG?``[KG%"V60ZGN>T<R=@I>DDCH;?.V
M-H!=L$$*^(MEF!W#<+KX9HC<>([=0B,/;+4M#FD9!;G)SZ8!7,YSO#>YW-QR
M5>_@Q;(ZF]5ET>[)HXPUC?ZGY!/R`/U0:W:K3;K13N@ME'%2PN<7%L8YGN5V
M`8&0EXW0#0.F4!`)..9ZI>/1#2,YW*`AOSP@CQZ((%XVV0`]<Y2\<T6-D"0.
MR`&^<I>/1%C;T05SBZ@=-1BKA;F2#.L`;EAY_3G]53K>#'*X`8SR*TZKGIJ6
MEEGK)8XJ=C2Z1\APT-ZY*Q9E\I:N2LK+0RHDMT%1X+99&8!R,CZCEE!8JJD,
MP.=B>H.%7[E;W`'4X8QU*DX[W3R1M=K`/4'JH.]WJ)X(#P/9!%2T@8T@.&&\
M\*&KIAXOAM/EV3L]R\CVL))<=R5#N>]\H(^J#HJ7@[#NKK\)KW26>\U45=.(
M::K9'$'N^Z)-6&`GIG)&>Y"H3CYL#<J:GLSCPQ613#1-,PO]6Z=V_P"$'IO'
M0H8VV6+?"?XKP5T5-8.)IQ'6@".GK9#Y9NS7GH[UY'W6UC#FAP(+7<CT*!(;
MLC'+9*PACT0(`ZY02L=$$"\;X060W?XW6J$.9:K14U+QL'3N$;?RR5G]]^*W
M%UU#HX:J.VPG]VC;AW_<Y/TP@]&7B]VFR0>-=;A!2,Z"1WF/L.96:<0_&>UT
MP,5BHI*V3^;.#&P?+F?R6"U-34U<SIZNHEGF=SDE>7./S*;:,G*"S\4<9W_B
M;#+E6$TX=J%/&-,8/L.?N5KOP,HJ:HX*N#:B)LL=36O;(QPR"`QH7GT%>B_@
M+C_A4P!W%;(3_P!6H([B[A*2TS&>D#I*"0[$[F,_A/Z%4*ZT+VC7D8.XP,+T
MS-%%/"^&:-KXWC#FN&00LRX[X5;1VZ:MI)!]F;]YKSYF9.-N^_S08NYF_-+C
MB<XAD;2YSM@`-R5VV^B?<;@VWT>)ZEV2&-/(#F2M!M/"\5LB\:<!]2!N[HWT
M""MV2P"G+:NM:#,-VQ]&>I[E=/$+]%GKGC8B%^/HIV4;D*O\3Q/?:IX6CS2C
M2$&%C885EL'''%?#X8RUWNJBA;R@>[Q(QZ:'9`^2K9YH80;EP]\>JR/3%Q!9
MXZAH&\U&[0[/?2[;Z$+2[#\5."KRYL;+J*.=W\.M;X7_`)'R_FO(8"5Z(/>,
M$L-1$V:GE9-&[</C<'`^Q""\-T%UNEM)-ON-729Y^!.YF?H4$':_`>[W2,H(
M(!E*"""`\X&5Z.^`XQP<\X^].XH((--61\:\0FZ<2S66/4*2A!!Z:Y>I^0.!
M\SU0009U?*M]JJ*>HIG^'41.,D;VMQ@C_0M1H;HV\6:CN,;=`J8@\M_"[DX?
M4%!!!PNC!E*C+C3^.VX.SY:2D>X?W%IW^B""#SV\8Q[)(000&$H(((%80000
#?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g993219.jpg
<DESCRIPTION>G993219.JPG
<TEXT>
begin 644 g993219.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`^35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU"3T].15]03U=%3$Q?2E)?4$A/5$\N15!3_]L`0P`'
M!08&!@4'!@8&"`@'"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9&B4R
M)2@L+2\P+QTC-#@T+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN_\``
M$0@`AP"'`P$B``(1`0,1`?_$`!P````'`0$````````````````"`P0%!@<!
M"/_$`#H0``$#`P,"!`,&!`4%``````$"`Q$`!`42(3$&01-187$'(H$4,D*1
MH;%2DL'1"!6"X?`6(V)D\?_$`!8!`0$!```````````````````!`O_$`!<1
M`0$!`0`````````````````!$0+_V@`,`P$``A$#$0`_`-A\J$4>)KNG_P"T
M!`(/IZUSD4>#/]Z$0F*`@$;>=$=4AM.MQQ*`.ZCM4)U=U"U@+#6D!V[<V;;G
M]3Z5C>2R69S+Y=N[AUP$[(3.E/L*#7LCUAT_8*\-=\'7>-#(U?[4TM^MK6Y)
M2Q9/1S+BDI%9*BT*-WW$-CO)C].:GL/EL/C02W:*O;D<*6(;2?;O0:>C.RE*
MU6YTJC[A)^G%)N]48]A6FY2XP`))7M`J@?Y_FKQQ2FO":2H0/E4=/UXGV%+6
M^`OGT&Y<47U<B`2!0:A97]E?-AVTN6W4G@I53D"L:NF+NW65)=6TL#9+:P#^
ME2F"ZRR-FX&;U*KFW'*E*^=/]Z#4CQ!-<\QS[TWL+VVR%JBZM'$N-J[^1\CZ
MTZ`'830%XF*`CTH\;;4`/.@)'_#0HQ$[>7E0H%1S,S1HVK@$48#N:`I3-).J
M;8;+KRPAM(DJ4=A3F)%9Q\1\DMR]M\,PH@`:W8/<\"@HG6M\N]S[[C;WB(*C
MX?MV]JBD6EP^K0M]PI_A"B!5DO,*VTPBY`B=P!Y>=-K1)#A2>30$L>GVUQKW
M]*G6<`VVT"AL`]C3G'I&H)_*K$PC4V(WGTH*RYTVZ_!"EF/6CVF&R-@O6PX^
MDCLVX15XL$:0)$5)-MI484G:>PH*.;AUQ)1=M/.*B#X@2L'V,34!D\,7@7;9
MDD#E(7']JV!>.MG1"VTF?.F#F$8D^"M20KM09?B\CE,`L.VUBK[-,O-[G4//
MT-:MCKMB_LVKNW.IIP2/,>E-^G,9IN[RVOF]>T(<V,@^E)8&U..>O\6-D,OE
M38_\3_O02T':10(I72:X10)0-]J%*#]Z%`:-O*NB*4(-`#TH"3I$GCO6)*>5
MD\Y=WRS(>>5IGLD&!6UWA4BTN%(^\&E$#U@U@V.N`BW\4['>/4^=!8,R^DLM
MLIX2*B+9(\35Y"F2KW[0O4%2`-J6M'2H[;D?K03UI\BT`&(.]6*R6=0'.]5^
MP;TK275`;<5.,/MM.#[L']Z"Q,A8E)Y&_%.V7"%CD[[U'I>0L(=0J)D'U@4X
MM2T@)*E@R.]!,)<!`!['N)HR].F1S':D&G&H^0C4?6@XXLH)B4\30+,:6U&Z
MF83"AYBH1%T'>HRI)E+B")]*4OW5HM'2VHIT_-J!B(J+P90]>)NE*&WZ'RH+
M9]**0>*-$[_O0B@)$>E"E(\J%`>)VH!-'CM'UHVF@:7JDMV=RXXK2E+2B3Y;
M&O,YN'%-J:2)WT[&8]Z]']4,./\`3^29:!+AMU:0GDP)_I7FBU"+9MTN*Y6H
M@]XH']N2E"9Y(I]9.Z(@D+)F8J.:6E;J"DR@@0?2K`O'D6R%I2%2(B3-`X2X
M708N&T@;23`2?<F*;W+E_:%$/I=;!^4R""?<$TU9Z>9OY;NW%*^;8B1`]/*I
M[*XJW_R]`,*4VF-0V*O4^9H'G3F47?W+-M"DE,D[\FIG+7;]LYX!4A!2G[ZC
ML*JGP]EK)):6..)W,5;>KL4S=ZKI2%*TD),'8#VH&=C?6UR^DKZA8#Z1`;[5
M8[95RE&E%R+E*E"2.WTJIX;H[&*OOMJT`J4!J2#\JO($5;L?B+2P41;N.!"I
ME"E$CZ=Q0+784MAY*>2@B#Q]:9]*-VBEN(8O4N^&=P@;)([;]J=N.>%=AL$%
M+@T[4ZZ=Q35DVXZE,..*5)_U<_\`/*@EX'ES0([32A'D-ZY'%`2/3]:%*1]:
M%`H!S1X[UP>NU*#??]J!,CN!7F?X@XAS'YJ_LFD$)0\5M@?P*W'[UZ;($5E7
MQ@Q4&SS;2/\`UWH'U23^HH,CLE0ALQ$)`CRJ]X9].A)6-4C@U14P%&.QJQXR
MX*5($["@O35M:NI*@V0KT,5#Y]UFT82B1\TB.]+#(I8MB1Y3MWJCY/(7+]\M
MUV5)@A*0>*"V]&-:[[QAM)XK2$J3K5XJ0$GD'B*RKI+--,+&J$D=C5\1D[J\
MN&FVK`K:6/F<U!*4C^M!)V]M9/*AA(3!D:3'>G[S1;:AN"?,U0G;F\P>5T.$
MJME*_P"VOM[5<1D1<VR5`[D4#127%WR'`G4&AJ4KRJT6"5"R8U#YB@$^_/\`
M6JV@RBZ5(DZ1S[U;FTZ$)1_"`*#FG:0*X4]^*5CTHI%`2.(BA1M/?3-"@4`G
MGM71/![4;2-YWBA'I0%.VU,LOC;;+8]_'WB"IAY.E6DP0>00?,&G\2./UK@'
M%!A'7W15OTRQ:7=D_</M/.*0ZIV/E5$IX'E-5O'H*G$)!Y->A>J<,C.X*[QB
MH"W$ZFE'\*QND_G^]>>;4.6[RD.H*'V%E*T'D$&"*"R.LD(C[T"JFNZL_'4T
MZN%`\0:MK-VAW'`ZH<"B#42];@+UZ`I',$3%`ZP:<2M.EPIU<SM5\M<QC;9A
MMLND*B``)G\JK&&5;-0M%H@E0B0!5NL_LSZDN)MDI<&VL[D#RH(?.9%J\9+1
MLG2TI,H<4V0)[$33G!E:;30L\';SJ6RZ6UVR6BD;J'/E3-I/B7"&V-/B.J#;
M8)@306'`V%O<(-Z\A2E^(=(4HZ=N\<<U8X,4E9VJ;6U9MV]TMIB?,]S^=+QW
MWH"\BN1YT?3OOM0C?RH"0)H4?3^5"@.!OO0@S54Z@^(?1N`!3?9NW4[$AFW/
MC+/T3Q]:SG+_`.('%M%:,1@;FX5/RKN70VD_02:&MQ('>A!W.\>=>4<O\<>L
M[W4+-RTQZ#V89U*'^I4U1\KUEU1E@4Y'/9"X0?P*?5I_(;5<37L?,=7]*X8K
M&3S]@PM/+9="E?RB37GO-]16V>ZDR.9L6?"M'WR&Y$%82`-9'F8FL@"U$E1,
MDU>L(UX6'M"?Q))/U,T)5G1>!LA)(TJJP8UQIQHAPR`*HRU'2-_:G=MD'F4\
M$[1([U%:=A+:W<0%*)`![5<6VF&T2V8$<>?M608OJ/P4E*TN3Z"K!;=4NJ1\
MK2D^J]A06?*O(U):!!5.\'BJ)\0LH]C['')M75MW+EQXS:TG[H;@@_S$?E4[
MB&KK*78G4O6=_(_[52OB_<)_ZG:QB%`IL+5*%1QK6=1_330:/T[\8L)<M,,Y
MMA^QN2`E;R4ZVBKN=MP/I6CXK*XS+M%[%W]M>-CDL.!4>XY%>-5@^"3P0)!H
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M?!*5*4K>"=O?VIATY:.YJ^3:@+2RR`HDC:3W_H*UK$XQJR0E#:-I^8^=`[Q=
MI;8JR6ZO9+:"MU<<A(D_2!Q7ES*Y)S,Y6_RKWW[M]3OL"=A^45NGQ9ZNML%T
MZ_C6'`K(7[:F4)'*$$0I1^D@>]>?;<$-)$<"@45$`3S39(C;TI9T[C;]:3_&
M>-C0<Y!'UKOX8\C74QK@G;B@!R/.@X4Z@-4;;;T*,B#MYT*"&T[4D0#L*%"J
ME!:(%-R"3-"A1FNMC>KWT+=A*[FR7N`0H?44*%%Y7[P$I2%3S5"SO6=V77,=
MB'BW:ZH=<@@ND=O,#]Z%"HM2?2V:=;N$WK#KOVQK<AQ95*>Z)_A/KN($5NR<
MXV_A;?(VB3IN&0X@*[`CO0H45YTZ^N7;[J'Q'EE:RH[GTJ-;"@FA0H"K*C29
9F9/E0H4!9E4TOPOZT*%!P?*KCBA0H4'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g595336.jpg
<DESCRIPTION>G595336.JPG
<TEXT>
begin 644 g595336.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!!35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU!1$1)4T].7T)!4E)97U)!3D1?4$A/5$\N15!3_]L`
M0P`'!08&!@4'!@8&"`@'"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9
M&B4R)2@L+2\P+QTC-#@T+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN
M_\``$0@`AP"'`P$B``(1`0,1`?_$`!P````'`0$````````````````!`@,%
M!@<$"/_$`#D0``$#`P$&!0$'!`$%`0````$``@,$!1$A!A(3,4%1!R)A<8&1
M,D)2H;'!T105(_!R%D-$4V+Q_\0`%`$!`````````````````````/_$`!01
M`0````````````````````#_V@`,`P$``A$#$0`_`-A[(82\9*/=_P#U`@#!
M]/5%S"7NG/\`*+&&X0)`QHFYI8X6&2:0,:.KBCJ9XJ6!TTSL-:-5G%YO-56U
MDN<\$'=C9T;Z^Z"P7':EC2^*AC#R/^Z[D/A4^Y;2WJ;><VX-#`<"-@`&?HH6
MOJ9XBY_FRT;I(ZZ?=[*`=5UL#R8V@L/(DYU_TH)N:^WB(<0ULN^'`AID!!]M
M.B[Z;;Z^4LK3(]M0!SCD9C3W"J<DLLO^0-&0"<<]>RXJCB^5\H=ON'V.OMZ(
M-SV?V[M%U<R&?-%5..Z&R'+">P=_*MX"\O-=(]P?(X`M&@[+3O#_`&UE_JV6
M.\S`M<`VFJ)#J#T8X_H?A!JAY8)1=P=?=*QJAC'(90)Y9P@,)>--$`.Z!&/]
M*"41G3MV00.,R=2E;N0@!A*`ZE`DMRD[N.B>YA-S.$<,DGX6D_D@I.T=9Q:M
M\)F_QQ\F@8!4=26]A=Q7M+G8\K2?LC^4Q"755TE=D%@.0`,Z_P"]%<J"C9PV
MES?KW00C;32/CX;Z=FX3G5N57JG9^"GJY9(@'L<?L$:>ZTN6*-C,;H.B@*N-
MN^]V-#^2#/:VWT\>7<,@GF%!5E!"\>4D'NKU=8V$9`!56J6EN2<805S^A(F+
MM2<^;V]ERU3-PN=NO'KV_A=]3,(GDG08YINIX<T#3Q,'=R1O$DH-K\-KZZ^[
M-PF=[G5E*>!,7<W$#RN^1^:MP&G+Z+$/!ZOEI=IY;>2.!60.)&?O,U&/C*W/
M&@"!O!TR$"$[NE$0@:P-=$$X/U00*QIV1C"<(*`'H@2-%&;12F*T3N:<$Z9[
M*6Q@\]%#[5#%BJL-SIW04RQ0,BWG-&&<ACKZJVT<M.UH!F8'=MY9!4U=VN=3
M)!33"&EB=N-:#N[^.I*[J.&[PEG%E+FCFYISGT0:O*3(,`AP457[D,;G.(TY
MD]%&V2LK"R3C.S@^4$<@H_:JL+F&&,@O)[H."Y3P"-S]\#/<A5N26*1KFME#
MOG*X*^T7&1W$X>1W)59JJ*Y4\F\)-TM.NZ=?H@E:QK7;[7#/7W7)(`_>9C&&
MX83V10SOGBW9!AX]$RZ5S7;F@&",=4%A\/)32[<VHD-.9#'H?Q-(RO1X&%YL
MV+ASM79W"0M)J6@8'(KTL!H@+X22#R2L(80(QCT03F.R"!>,Z(!J7CICY2MU
M`C'=0NT,N]&VWOA+HZD;I=ZY`QZ*=(P?9<-V@E=%'44XS-3/XK6_C&#EOR"4
M&:ROHK573TT-/$Q[I"&D#><3G&!G4G*B;G?V0U)I'1N$XR"QS1D8YYQR^5V5
MH9/<9ZMKFF-SG.8]SL'4Y^J8CM\MPJ-]TN(SS<0-?<\R@EMG*AU5PF$`MD!<
MYY!\H`Y*,?411W*>2K#9MR3#&8Q@8YE6BTT4-!2RO8YSPX$-+AC3KCT5`N4;
MZB]DF1\<1>`]S<YP@F+Q=@RVR5[H!P68;Y&AH!QH-=?R6<UMPXX$DD;FLD)P
M7`+0;I1U#8"ZCJV30.'V202/JJ=/23/<X.C)/JW1!%24S(HV2"J:XO8UX:-1
MJ>0/<#FN&H\M0SS9#]-.ZD*JF%(]D>ZUV`=XCJ2>GIR4?.=Y[']6'("!4''$
MHJHII(S%]DM?ND'OHO0WA97U=RV-I)JZ5TLK9'QB1YR2T'3)Z\UYUA+VL<QQ
M):\''HO37A]:76?9*VT<@(F='Q9!V<[7""PX'9`CIE.$=AJBQR0(QZ?F@G,?
M*"!P#FEXZHAZZ)P:Z_H@;<WL%SU#A'3RO)P&L<<_"ZW#11U[#S9Z\1CS<!^!
MW.Z4%,M=!2R44?%8QP#<Y*-U;2,E%+31Q;XU)/)JJW_4'"MQW78\OT164D4<
ME769)J-2UPYMZ!!<W$RTTKWN:2T?=(6=5(B%QED?+AC>@/5,2W6DI&2P4,KH
M8LX#2XN!]E3+HV22J=//4E_4`:!H0:#:-HV-JG4,H#AS:3VY:J;N45/)"7NC
M;NGL%E5'74L67'+7#`)[JPQWN7^G$#G%[>0/5I['^4'!?&1M<2QH`"K;P-[W
M4A<JTF4QGF[HH]PP[T02VQ=F?>]K*"A#O(Z0/?O'1K&^9WY#\UZH`YX'PL@\
M#+32RBXWF1CC512"GB.=&M+<NT[K8P,=$""W3("(MZ\D[CT22$",<L802MWK
MNY00.`9Y]$8SR/1*W1KG7"&/1`DZ:))`.A`QR*<QD<OS18SA!@5;:BRX5]O<
M-WAS/:/KHN"Y_P!UD$%+`"[A09>&G&7#3/\`OJK]XCVYU!<HKQ"T\&I.[)V#
MP/W'Z*&MC6O;)*X9+AC*#/S9;M4XE90O(`U#=2,=QS7%4V6YAF'TTC6G0%XW
M03\^RU^DJJ"EC>9P-_D'@X+?10EUN%O,3FQD2.!)&\2<(,@J*"I9Y0T9/12N
MSM'4NFD=42ET40T;W.%)51-34;D`R,ZNQ^B[J:)L,,H&C@$%?GB$UU9H<-R4
MS7`1OW0G89<U<LO;\D5'2RW:Z,IH^1U>[\+>I0;KX)T[8=D'OR.)-4OD<.H&
M`&_D%HV#A89'M@-B9:$AC7T,T@BG@'VMP#[3?4?FMNH*JGKZ."NI)1+33L$D
M<C3HYI&A0.\PBQW2]W771#&O9`C`R@E[OT00+`UU0P<I>!T0QV0(('5``YTU
M2P$6,(.*ZVVFNE!/05C-^*5N#CF#T(]0LFDMU39:]]KJ]7`>1XT$K.CA^_8K
M5KM>;39HN+<[A3TC>G%>`3[#F50+MMGL]M7<*+9^T,EGK)I#PJIT>XR,@$GG
MJ0<8T"#CAI()&?YPW(^JX+A;J-K,AC<D]N:1/=#13RTU9$8:J([KXW#4.';T
M]5%5]]IYJ7B.)C:,Y`.IP@Y*AE+"'EK0'@8PJY67`4\<K<^9P1U5SS(Z4L(;
M]UO[E0+HZJOJ0&1N<]YT:`@3!QI7,IX&%\TKL!HZE:1L_:([30EI(=4/\TTG
M<]AZ!,[+;."@9QY0'5+Q@N_".P_E%M[=1:+0Z"%V*JH&XS',#J4&:[873^Z7
MF1T;B8(?)'^Y^JNWA)XD2;,3MM-V<Z6RS.T/-U,X_>'=O<?(67!N>:6&[H+L
M(/<])54M=3LJJ.HBJ()!ELD3PYI^0N@#F%XUV1VKOVRE6)[56.:PG,D#_-%+
MZ%O[C5>C-B?$^P;3!E-4/;;;D<#@3O&[(?\`X=R/L=4%]T&J"7TY:H(%'O\`
M1#&5Q7>ZV^RVZ:XW*I;3TT0U>[J>@`ZD]E@NV_BQ<;NV2AL;9+?1'1TN<32#
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M>GRK5;-C8;<WR1>8\W'4E:VX`C4+EG@803NA!GM73Q4%+)/,0R.-I<XGH`-5
MYWVHNLE\O$M6<\$>6)IZ-Z?)YK5?&O:)C9!LW1/\PP^L<T\OPQ_N?A8X&9*!
MAD9*,-WI-WHSG[I^0\&%S\9/(#N>B.&+<C`)R[F3W*!+6)6!U"<#4>Z@ONQO
MBEM!L[&VDJ'?W.WM&&Q3N\[.VZ_GCT*"H!;U00:MXY[02U^U#+)&YPI;<T;S
M>CI7`$GX!`^JS`G)P@@@4`$H]D$$!\@ML\`+>R*CO%YDP"\MA!YX:,N/[(((
M']H+@_;'^MG@J(J6"VR-DI"]LF_@!V9/*1C)^1@*U^&VT4MYM;J&N>'W*A#6
MRO:#NR,.=QV3UTP?;/5!!!=5![7WF/9_9VNNSV[SH68C;C.](=&@^F2,H((/
M(U=43UM9-5U4KI:B9YDDD=S<XG)*9#4$$'--_DK61?=B&\??HNG&B""`PCQU
*000)<.J"""#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g521797.jpg
<DESCRIPTION>G521797.JPG
<TEXT>
begin 644 g521797.jpg
M_]C_X``02D9)1@`!`0$!K@&N``#__@!!35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU77T%.3E]215E.3TQ$4U]02$1?4$A/5$\N15!3_]L`
M0P`'!08&!@4'!@8&"`@'"0L2#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9
M&B4R)2@L+2\P+QTC-#@T+C<J+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN
M_\``$0@`A@"%`P$B``(1`0,1`?_$`!L```$%`0$```````````````8``P0%
M!P$"_\0`.Q```@$#`P,"`P8#"`$%`````0(#``01!1(A,4%1!A,B87$4(S*!
MD;$'0M$5%C-28J'!\>$D-'*"\/_$`!0!`0````````````````````#_Q``4
M$0$`````````````````````_]H`#`,!``(1`Q$`/P#2X57VUX!X\5)15ZD?
M[5&A)]M?I7JZN/8MG/.XCX0.I-`W?7\-I"[E-Q`R/K0[-J3F>,WGP[L[<#A<
M8_K3-[=PO#[QE^%5(<%3TW9(QYJCUC6";A+F&#[J)@6D/*J#@<_6@(;N\56C
MC##VVRWPM@C`R?VJ3/K-O!92;)D+K@9(S@]L^1VXK+_5E\ZWDC0QXB$@W*W9
M3T_[^=4B:OO7%S[BE251L_&/(\'%!H=SZOCN[N*)X9L<;RN`I'.`2>@SR?I1
M+IQ%];F:*/*'AA(ARP_T]B/G6%S-8VK07MKJ(GD5PS)AQQ^?TZ5;MZE]0WKW
M6HV\C10;1$65CE4Z8`^9'./VH-@N8[2*1IIY(DFD4I;V\C`/C_,/F.OR'%,V
M<^@RHB:5=VQ=B6$K1,\DY/5LG@#Z"LCT#U!J-G>,T;BZ)7XE=0Q`\ECT\4YJ
M_J:>34@(K.*W,9*L000['K].H%!M#W[V-W';HS3W6!(F!M`^G]*LCJ'VK<)8
M0QSS&C#=GZ]OSH5]*:O%J^G2V>H6\,=V%)C<$B.3CH<$@4UIWJ.VM;M]/F"6
M]S"VUEPS#M^(XQ^=!I4MM&;11&WW8_!N'*_*J^6W,85^"C?A(Z5!AU26WB4V
MK">-FRZ'H!_I-7#$3",@GV7&03_*3Y_:@A;5!'%>-J_04_)&4+*W!4X--+CI
M0<*CIBE7KC`I4$:/\*C'-5NHZA;I$9)&^#<1D<\@XXJ8['VUQT;BL_U36U6T
M=?9=GAE/P-C:P4^>U!$U,F*Y)Q$L;,&R)#Q@YR!TZ$9%.7$MO:Z!]M:W`,N4
M(9F9<X/7'0']\4,:]JMQ?P0LR1)(796BCCX=?Y3D_H:AZ787.H7":=/*XE&=
MKYR@(/*D?D<4%A=ZC;7<3>_&R2Q$PJ63<)$(X#CKD#N*K)-)N;NV]W2MLC1C
MX88\-[@ZG`\_*C:[T.VAA2RO[=`@4,LRG:R\9Z^?K4#7((X;*&72X;:<ERKL
MF`2>/C/?B@#]%O4L[F&74MT-LK\QO`0Q\KM.*-6]<Z9*1"MM$4"[55;?8JJ?
M)\]J%9;.6[8_:V,EQ,&*&1R3D<#GJ.M-G0KB'>&;9&I'WC*2ISTX^?/%!K&E
MQ:)=Z8]Q%!:@,`%";<9`X/D_3%4NO>G=.;39[J")H[A`9"HQDK_F*$8_;K0U
MI!-BP>]BG$"$;9DE)13D[20!E1\QT[T2:7+;C4(V_MPM<.V^.)F92R^`P&UO
M_B10`FB:QJ.EWR0P2QNC95"R@HWCQ_6M3TK5+@^[-J8A@C+#:-N-W'09R?UH
M>]7^G=)C#7UA(;42,2\:_#&LF.&)(R,GCQS3&AF"6W^R/K3Z?>_A(N=K1O\`
M_8?]T!A!/9Q*0]Q,\,AW`,W)7/.!V%&EO<QV^DR!RTBJ00!UP>E9D]N^FRS1
M7NV1)%7_`-5M_'GN#SV[U*3U7'%/)(D@]K8=V5(#'L`:#2Q)'=V8N(6#@GKW
M![@C\JAGD\5%](ZOIU^DJ64JLX`8@?S'/_=65Q"(Y&*G`W$$'J*!DXP*5=*`
M@=_I2H*Q,-&`Q'(YK.M7GM;_`%+V),?=`INB(&2&)&?SK0)7]NV0<XZ9%9;J
MMM*+9RS);W,;,"2,%CQM8?7/ZYH):Z;%<6VGW\3NZ1-[LF>JJ@S@G'D5+@LE
MMYWN(74_&"C9`R9.Y/0<XY^=1HM4%E:0(`KV\D`$D;<$\'G]Z[87DL>TPC[5
M;LN`4.X%?#CJI'DT!9>))/9*ESMBF"!&W'EUQR#V[D?D*$]2].6L,37%I,JN
MN1M)VD]\@#O1?I<IO;6-)83A<?%S@^.M6.I6)ELV*V.Z->22`<'Y4&46VG.\
MJ8]P87*.1_,<?OY^E:1I5M=R62(D=L\CH>)H_B0X."01@G/'-*R@M3<2)-$/
M=*AE/D>#4RYGM_;CM8]R.I^&0')4^:"JTT_8KJ7^T;9521?:E25<KO'';@9'
M;&#QBE'H&C%9[2YC?V0Q:,-U`Z[D8<C'CY5<>T\LLI.U9,X)&<,/%,W=U9-:
M_9VN"+B,9SNP>/\`GF@H-C:3+LN[JYO+%R%BF0[MG@/@=#YZ5"UCTW#>3"^T
MN$01QHP=64*IY_%QD'J:N%`*A-2A@>7:5,I1@LJGH05X!\@UYN]*N880=&CM
MXWC&"O*AAU/G.>!S0`[:=>+-;Q6BS/;.1]T6)3=W..P[U7:];70]V15F,4+A
M0$CP.GXL?\UI>C/JUQ=F2XMH;=XOA;WHF4A>X&#@G_:INM:3;7,;R/$LDQ)/
M+8QD8Y_*@S3T)KMUI^I`1P%F+H"N[XBI(!^G7-;]9:C:3SB*1%)E'!QSGYUF
MVE:!I]O<+<6\.)MPS)_,<'Y4<PVWM21JG!4[@P[9[4$B52CE2>AI5(U!0)\@
M]1GIBE0"E^RG3\'!`QR?/6@'U$\M]-_[<^ZJ`%2QVYZ\41^I+FYCAM8;>;VS
MC>Q_S=JH)[TR!_<&P[>/;.0?IXH!NZW6T4;OAG4E'#+P/R_\T1?PRM(Y+[49
M2$=5V(`/S)H<O/\`#.Q3@$D!>@/G%7W\)KV-+O6!<R@;I(V!/\V`P./]OUH-
MNTZUB**=G;K5E);H\1CV\8-5NCZGITR[8;N%V'PE1(,_I5XC(>010!6K:'<+
M()+0*648'4''BJ:[T^^5!<BW:WG3)P4+@\<@8[UJ.Q?`KT%4\%0<T&8:'J<,
MMHWO03/-C'"$$M5;;:%J"ZX^JW$3Q6DR^VL+J/A(/#`^#SP1WK8EMX5;>(8P
MY_F"`&N3013J4F17![$4`1'91&+V9%4#&!D]OG0_>)=Z??)#;D_9WX#A=RJ?
MGW'[5J$=C:PD>W$H/G%9Q_$,7>GS?:+*:1`2"R(VTGGL:!HW=_=1-#<6IB`_
M#-'@AQCKCKGKP:EZ>D4SNK2E)#@[7)QCZ=J!_3]WJ`N(Y7NII(BQW+)(6;(!
MZGS6C[[>Y@60QJLH`ZC!%!'EAV3QI'\'\I8#]JMK5UF#!MH(7C-0<IN4/N*Y
MX)\XJ39N8IPOPE5...2:"7>E?NCDYV\XI5YNMLK+)$^5([]12H`37H%?3HIG
M&/989;N`>#_Q0;);!IB)IRRKVVD'Z&M'FMTNK&2VE&4D0J3X^=!.NV5WII5W
MN5]IAC+8)';KW%`/:D\8E]D.VP`ON!P`!X'SJ9_#"PL=0U#5C?-((X-A41R;
M1\6[.?TH;U"X]IOB(+<X&>O]://X,6BW%MKA&<M)$N2/DQP/UH/=RWI6.:>X
MTM-12*V/WUTGN-%%\R0#@=O-%7IOU4]L8H9Y#+9RLL:R$G=$S?AWJP#*#QU'
M?O5_;Z%;0Z9/IR1(MI-_BQ;?A?YGYU7R^GK&QLOL]K`L41_$!EBV.G)YH-!A
MR\:GBJ'U')+&@19GC#=U/)^E76G`K90JW78,YZYQ4?4;-;GE@"1T)%!F"7DZ
M:HON>I4@!)"QR1R,#@<_$`1_U6D:/>;T2.24NS#<D@D#I(.^UA^W6H=YH=M?
MQ6\-]`DJ0$&/:2FW!R,8J;::1:6K[K:)81QA5Z<=_KSU[T%L`2,]101_$!4%
MHCL!N]Q<'QS1L.G'Z4#?Q6MI9?3YN(<DPMDCRIX(H`.RL!.FWWC#<.[/&Y`V
MA@>,X[>?D:-5]V.WB!4*<#(!#=NF>XK---O1J>R`2-')-AK:3?@$KRRG'1NH
M^>`:/+&5IK4BYB9)<X)5CR/..Q\XH+-5/M;CL$K<+QR!7%E:WB:22,`[2.#R
M:9L9(EE<[B77JN<_2I5S=6TRBWD1`TA/P]R!U-`XCGVHV4X)&3BE7#M5548`
M`P`*5!6P_P"$HSV%4OJ+3KR\^.!8)(BFQXI1GKW^=7%N?NDSXYQ4E3GI081K
M_INXTLB1P@B?E73/P^5Y\4?_`,"I@D&IVT@Q*+E68,.2"O&?THEUC0K?55C$
MC!-C[QQGGS7?2WI^ST'4)IK>1W>Y8&0L0,D9Z`=.IH-)*H5R%&[%4VI;6*HH
MY9@#FK(7"[.HJG@GCN]03:X.#T/RH">$8B4=L5[V@\TEX`Q2;*J2!SVH&R`3
M@CG-.*,"HPN$:0IG#*<,I_>I0.1CKVH/!.!_6J#UB0=&E5EW!N,$9S\JOW&[
MI^=5FMVRSV+`H7"_$%7J<=!08=9Z(9KDM;J(ANRN3RWG'T\T3G6)+.&&W=5N
M&`P[,<L.@Y\T_P"HO[/T#2H%GN"E_?G;';GF3:>K`=E'<FLW_O#J&G7%Q8OI
MHANE9OQG.Y?(R/ITH-.@U&3VV]J/W#D;Q&`"OUJ;I44V)+B<`N6PG!^%?SH)
M]&7YU:^CN6MI+>>-MD@&=DO'!_*M'Z9QS0-.<8I5USX`I4%3!GVU\XY(Z5+7
MG'&#WJ);'[E<C!QTSG%24Z=*!\?K7B0'X<=FXKH/'-<SG(/2@>O/M"0(2S>T
M?Q,.<4S::5%J'L75K<,CJ0T<L3=OV(J]TYUEMGCP,`9%9W=:7=:=ZOAN+34;
MJUTNX=S>0PMP"5.R11@@8;KYH-6MK>^2-$N;H2\8)"[34VWMXXB63<2>N6)_
M>JG2;6X]B*1=8DGC<9!91G'RJR,80?>W<K'!X!QG]*!K4;%K@+-&^R9.C`?O
M36F7;R'VI0-Z]U/!IK4-,BU3[BYWBU#!B-Y#2$'."<\#Y5-M[6*`XB0*H&,"
M@E$#%>0,MS71P.M)>^<T&3?QGL7EN]*O%C]Q$BDC9=O/X@00>OFJ#[%_>/1;
M:<0E;NS=45@OXT\#YCQ6F?Q%M9)?3TMQ"@>2W^(C_1W_`*T'>FX)X[186DQ$
M""`>#DCQ0>?1UJ#//>0[%LMJI#MZNPSN9AV(Z8[<T5GC&*\:5IL.F:1#!$[2
M$NSN[=68G->V/F@:D/2E7)!SV_6E05L2E50`]OUI]<YIF)LJG`'`X\4\G/\`
MYH'-V3G'-+.:0&..E<XYH)5A<>S+@G"MQFN7T#&[CE#[6'1O/UJ-C(QYJPLY
MU<+%,`2.Y[T%O9JSQ(2J;EYXJXA0XR<`_*F+*.)8E(5?RJ<%&.!Q0><+XKR>
M`33C$"H,URAD]I&!;O@]*!_))ZG`_P!Z]BFXL[0",4Z!QTH.2(LL;1.`5=2I
M'RH7FTM;.))'$:HSG:J]5\<]Z*B,ML[D<_2O%S;174)BE&1V(_E-`)R2;@$&
M`HYXI@^:FWVG3VC?%EHNSC_]Q4(CQ0-.,XP`?K2KK]NII4%2CC8N1SBG%<$9
M&>.*5*@D1O\`"#YKNX<G'>E2H.JP)QCGO7H`,`1D$="#R*5*@L;75+FV0*P5
MU\YYJ=#ZE5YD@%JP=ER#NXI4J!R>\GF#_$5'3"G%,Z<^^;`7`'SI4J`@C4@4
MZ3M4M2I4'I5P#WS7<<@>:5*@ZRJRD,H(/!!H;U?35M\2PMA&;!4]J5*@II(V
))[?K2I4J#__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g633815.jpg
<DESCRIPTION>G633815.JPG
<TEXT>
begin 644 g633815.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`\35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU23UE?4U]23T)%4E137U!(3U1/+D504__;`$,`!P4&
M!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H
M+"TO,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_``!$(
M`(<`AP,!(@`"$0$#$0'_Q``<````!P$!`````````````````@,$!08'"`'_
MQ``[$``!`P(%`@4"!`0#"0`````!`@,1``0%!A(A,4%1!Q,B88%QH10CD;$5
M0L'1,C-3)$-$4F)RX?#Q_\0`%0$!`0````````````````````'_Q``4$0$`
M````````````````````_]H`#`,!``(1`Q$`/P#8>U"*/$U[I_\`M`0"#[>]
M><BCP9_O0CTQ0$`C:O#`!4HQ`W)X%>7+S-K;.W-PX$--)*EJ/05CF:<Y7&+7
M3C-HXXWA\0EN=U$<E5!=\9SM86#Q8MFQ=*&Q7JTH![=S56N<ZX^XZKR'FV43
M_@0T#]S5>L&@M&M:`93,GH9Z>]+(4C4I;K9G@)C95!+MYIS,M#BE8D9$F"@"
M-^.*<VOB%B5H^EF]MFKA$1J)TKGXVJ`.(VR04Q_/$]SW^_2HF^4D("U-I)5(
M]0]/M0;3@.:\&QM*1;W`:?/^Y>])^#P:GH^*Y7=NW+4J<87Y8)V`Z3O6D9#\
M1G_.M\+QDA;).A+ZSZD=!)ZB@V$\037G<'?ZT80>((Y!H1'`F@+Q,4!%'C;:
M@!WH"1_Z:%&(G;MVH4"HYF9HT;5X!%&`ZF@*4S10C<")I:)%(7MR+"PN[TC_
M`"&%N?H*#*/$K'W<0Q(9<P]2PRRK_:%#8+5_857K3!6$D:9U<FDL&)?=N;MT
MR\XLE2C]ZLK"`-$#G?:@:-X<$)&Y`'045UM*&SI1(ZU8$,@-DJ)`CCM3%]"-
M"MC%!3KRV25E0$3)J*OFRI!!4KZ$U:KEI.J8'TFH'$&QJ)`H*TY;[$$^_-1S
M[2V5^:E1VYJ9?V)BF;R0001,B@WSPEQQ6-9:\MYY3EQ:+#9*COI(]/\`45>@
M-N/TKG;P8Q!=IFUJTUG1<ZFE)U0#MM^U=&@;`4"<'8$4(I72:\(H$H&^U"E!
M^]"@-&W:O1%*$&@![4!1(J`STHIRABVGE36G]2*L40>=J@<\6RKC*>)MH2%$
M-A>YZ`@T&'9=6G26SSWJWV@C0O2#TJF8.RIIU4S/V'M5WPT(2TDON)0CW-`_
MW6C>2:8/MG224D">(J81>8.ALC\6%+`Z=*B7KE+KR4-G\L@^KVB@@+W8D@&)
MWJ#Q"5'@Q5M=+!94%*'I-0.(O6*6=1<'OO051Y)))Z4P?D$FI5]ZU=GRE[U&
M/C??K0&RE<FVS1AKZ21IN4;CIZA77$0HUR'EUM9S#AZ&CZR^B#''J%=?@$"#
M]*#SXHI!XHT4(H"1'M0I2.U"@/$[4`FCQTCYHVF@)'>D+UD/V=PPK9+C2D'Y
M$4Z(@_2D+YEI^SN&7E%+3C2DK(,$`@S0<_,-I;2ZI*`/+)$C?49YIP/X:M!_
MBF)>23P)Y]NYKVQ:<;=?9*TK<#D3$`]J-8-85AM\Y?7:RJZ*5()(D"=B(_K0
M5Z^O,):?4FP><)'^H@@FG.#WSUV]Y30U$;1VIDZWAPNW5M^;<K>4)#GYBEQ$
M"/CO5SRSA#-FAHMLZ'%J!4F)(Z\_:@J..7+UB%L+D*/.]0*2W<:?,6I9/"!N
M:M7B!;ZKE2DIWU3M4/@;UM8)4]^'4;E/^%1/I`(YXH(]:\,:6IO1#B#"O2?2
M?>F=RI*E2@RF)!IZIYDJ>0BV@.SK`63J_6F*[8M'9)2B>*!UE0LHS9A*GU^6
M@73<KZ#U"NMU<D*'6N1<">;M<Q89<.!)2W<M+@]86-JZ]@%1(ZT!(':@1TFE
M".PWKR.*`D>WWH4I'S0H%`.:/'6O![[4H-]_VH$U)["FUTT7;9YI.Q6@I'U(
MIX0(HA[T&!AARTQ1]A]$*\PF.^]7)NRM;JU1K::5M)UI!FHKQ&PVXPS$DW\J
M5;W"E:#.R5<E-0]IF0^4&@?5$106%=OA-I<`-6K8<(/J`B*5P[6\ZVA(]7`$
M<"JU;-.XA>!URX"8Z=)[4^7F:VPK$@T[:7+3R-M2T^@CV(YH(GQ`M5?BE.!,
M`<BJ;9.AET+5LD]")!J>SEF5A]3CBBD^PJC'%OQ;>@(2T`1!F307$*8!UI0F
M?I43B:@I)4J*8L7ZD@))!]YI.ZN?.!`ZT"N6\+_C&:L(PXDA#URD*4.B9W_:
MNN4I`$`;<"L+\"L"9O<3N\;>62;`A#3<?SJ2?4?H/WK>`(VB@+IVD"O"GKQ2
ML>U%(H"1Q$4*-IZZ9H4"@$\]*]$\'I1M(WG>*$>U`4[;44BE(D<?>O`.*"A>
M+MJ7<KHN4@S:W*5&.R@4G]Q6(),N>:DZ5`&NHL5P]C$\-N</N4RR^V4*]O?X
MYKF/%;&ZP;%;G#[M&E^W64*[*'0CV(@_-!*V5XYNTBZ80`>"H$QW^M*X@\FY
M;2GS/,4Y*6Y$E(GD_;[U$X#A5M<W3MRZ@+GOR/I5TPW+5BC4;ERZ\D00MIWU
M1/;KM/%!FF)X7YZU^8V4G@0#I$=)/-1+]@PT@AM/KTR2%;@S,Q6M7V"8`D7`
M8%W<%(_+#JS$[\S'M5,Q]>I3K+(;9MU`!3;8Z0-B>O%!3+=Y*W@V$ZAON.I_
MM3ETA!T)YX_O1VVTL^M(CM2386XZ-"2I:C"0!))H.@/`2S4SE>]NU)C\3>'2
M3U"$@?N36IP8JD^$F*X1B>2\/M\*.A5DV&KAA1]2'.23[*))!J\`=:`O(KR.
M]'T[[[4(W[4!($T*/I_2A0'`WWH09H\#I2%W<VUDPJYN[AIAE.ZG'5A*1\F@
M4('6O#M*B=@))/`K,,R>+F&6@<M\"ME7SXV#[@T-#XY5]JR?',V9BQU2V[_%
M'U,K,EAM6AL#MI']9H-RQ_Q(RUA0=;8N3B%VB0&K82F?=?`^)K%;RYQ;.&-W
MV(*;2Y<EE3Q9;Z-H`]*1U@'YWJO#9/:K9X87PL,]80M7^!Y:F"3_`-:2!]XH
M&N"O)2F4GU#8$'FG%WB.(6@4AITAN9T\@5=\]Y%NL*Q!W',"MR[8.$K?MFQ*
MF3U*1U3U@<?2JB,2M2QJ4TVMSCU`4%7N<9O%;+<!)YJ-<??N%0OCKMS4MB#M
MLMS=IL2)V`W-1[KS2$J5L(V`%!'7BXE/Q5P\.L$+JU8S<)_+;E#`(Y5U5\<5
M$99R\_C]Z'%A2+)!EQS_`)O8>]:IB!M\(P&X6TVEIFV85I2G@0-J#$<%S'B>
M5LPNXA@]R6EH=6DH.Z'$:CZ5#J*Z#RAXQY;Q=E#>,K3A-[_,')+*CW"^GT-<
MM*45**CRHS0$@\T1W?:7-K>VZ;FSN&KAA>X<:6%I/R*<`<BN',&QW&,&>\["
M\2N;18_T7"F?J.#6NY2\<;ZV2FWS-9"]1P+FWA#@^J>#\1170NPWH5`Y;SAE
MS,C*5X3B;+KL2IA9T.I^J3O^E"@S_-'B^D!3&6[343_Q5RF(_P"U']_TK*,9
MQO%<;N/Q&*WKURYR-9]*?HD;#XJ/VHI)Z4!I/;<T8".>:(D0032J1UF#0"?3
M1V+A=G<LWC1AQAQ+J3V*2"/VHBM_BO%00?<4'8F'W2+ZQMKUK_+?:2ZGZ*`/
M]:JF:/#O+V87'+EQI=I>+'J>MCIU'NI/!_?WI+PAQ+^(Y(LDJ5+EJ56ZOH#M
M]C5XH.4,ZY*QC+-P?/MW'K8F$7#4J0L>^T@^QH97R1>XJ3<XBCR+-LB6]0#B
MS'!'*=N^]:UFG$;3,-Q>,.WT6;#9-NS;H+CATR%.D`P!.P)Z5GBL5NLNWIO$
MMM.VI@D(D*>1UU;<C>#TH+S9V;-JPBWMV@TRV(2E(X%5#Q3OA;9=<M4F%/D)
M/TFM`2XP_:-7=LL+8>0'$+'5)$BL7\4KLOW*6Y]*3`_<_P!*#-HKV*4T30"=
MZ`FF-^]*!-&T2(HS8F0>10!M2T*!0HI4."#!%"E(%"B+%WHHYF*%"B@E04O3
M$$=.]*G8;\FA0H/)W`%&`$$=J%"@V+P`OSY>)X<HF-0<'[5HF?,8.#Y?>6U/
MXFX_)9(Z$C<_`FA0H*!AV5VV,!L,:<#[I<4&7+=IP)\U*U:8))XF*S[';9>)
MXBEAM2VFFX;\@D0@@D<]>WQ0H4&BX-:.8;E5+*S*&BH(WX!WC]:Q7/"_,Q!(
E/1.KY)_\4*%!5$#>*44CM0H4`B*(82Z`?YAQ0H4"X%"A0H/_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g304005.jpg
<DESCRIPTION>G304005.JPG
<TEXT>
begin 644 g304005.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@!"35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU724Q,24%-7T1?4TU)5$A"55)'7U!(3U1/+D504__;
M`$,`!P4&!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@
M&1HE,B4H+"TO,"\=(S0X-"XW*BXO+O_```L(`(<`AP$!$0#_Q``<```!!`,!
M```````````````'``$%!@(#!`C_Q``Z$``!`P,"!`,&!0,"!P`````!`@,1
M``0%$B$&,4%1$R)A!S)Q@9&A%".QP=%"4F*2\#-3<H*RX?'_V@`(`0$``#\`
M,/:E%.!!]/6FYBDD=*Q5I&ZB!\:C+[.8JQ)2_>M)4![LR:JV4]HV.M3HM6%W
M/4D;"H17M?M`LI.*=,;'\P`_I4SB?:;@KT`/^+:KY$.)D#YBKG892POT!=I=
MLO2)\B@:[`-NU.>1FEW'/XTN4Q2$4H_V:SB:?3_]IH,_S31M'2-Z@>(>(;7$
M,0E0<N"-D_V^IH7YGBZYOUJ;7<*2V?Z0HIJ%:6V]J+BW%?XGS>G.N9X)0U*6
M"C2=E`[DUQW+%N^A3CZ0IR0"KD?K_OK7&]9I9$H*H`D;ULL\A?8MX.6[[K+@
MZI5%%7A#VCH>#-GFTZ'%&$W"8TF>6H=/C1.;4E:0M,%)W!K+2.@FGC;:D!WI
MB)V[=JVCG,S64;4Q3-<>4NVK"Q>?4H%:$E03/,]!]:#G$*EI4Y=7BBMQPZB#
MR^'J*K.,QMQF\@BW8;"4$SLG8#THJ8[@JT9LR$R5Z8)CG4+D^'5-J4TEO4VD
M2!&]52XPCKBB`V05'85JOL<ZEE32&X1"1,;P*K.6M;D*+^D[&8ZUR6SRG$J6
MD01S,T7?9IQJ5K;P^0<F=F5D_:BX.0VVI0=I%(BF@;[5L`BL@.IK(<J&W'-\
MM629M]10TWYU`<BKI\Z&/$-\N[N=`G2%;2>=$[V9X?P,<+MU!\1T[`CD*)#3
M/E!(KEN6F]4%*3,Q(J"NL9;AS4E(Y;[5$WF.9*5#0`*H^<L6QK`2(Z4/'[?\
M%DT]&73!VY4\FTNBME12IM6I*AT->F.#\NG.8"TO@1K4B%@'DH<ZGM)-,13#
M]:RC;M3B*?D-^76@EQ2ZI_)W*P%I`6H@J,Q%5K#8YS(Y0!R4HD;=:]`X:T:M
MK5FW0`$H2(J6Z0/O7'=>4@SRWJ*>4"E?;]*B;HD)(G:JAETA4S'.:H^>M):6
M4QJ2=234`ZL/)"S[Q$'O-%7V(W2@B]M-8VTK`Y<]C1D&XF*8@\J:(]*V$&D!
MZ5D`)@\NM!'BM"6N(;Y"U:$3(_RG<`338%3!O&$-(@%P;CKOSHQ,E(3Y3O-;
MT/H*BD*2I0Y@&2*T7F@H))@@$U#H4E3A;7R4T5_I_-0U\]J=+0,Z!*HJL9'4
MX5$"JME0"A2.X-5"0F6U$`'K1(]B04G,Y!!,CPDDCY]*.0'>E%/':LXG:D$U
ME'>@W[3,>\GB`7GADMJ2E*O#,E//S1\_M47PBTXO.VR%`@)A9%$S*7+Z6V[2
MV64O.[:I]T=35$SEHJQUO,\2(2^=RF23]17)B,SQ`I?@KO57"#_2K?;N.M7O
M*^-CD6]ZX0$FV*#Z$@?Q0OO^++I;BVK-`4L\R!S^-1:[S+WG.Y;!_M#F]:O&
M?7J:N/?3Z557ED.K"C!22*+/L0MKIQ^[O$G\E*0@COO-&^!VYTB.DTH]/O6<
M=(^=9::1$'X53.(,<S=9Y27I_-;$'J`.U16+P#%CF1>-.J*H*%MJZ$=9JRWN
M,:N6]"Y`6(4H'<"J_E>$,>MIM272`D@J&H0L@D@GN1)IL)P[;I>_&3J93LD'
MDHCM67'5R$8K1,DC3':AC@\?;I?475>54[$;&L[G":7'7$J*RLSJZGE_%1R[
M<I4I"U:EH$3,S4$]AUW5TM0<"&RJ28FC!["VW!;Y<E/Y:5H0DQU$_M1:([#>
MFCE3Q\ZV`<ZSCK3*3V%0F;8TJ:O$I$I!23V]:KF/95;M:G#^8Y<+U>GN_P#N
MK+;K"O*0-,5S7S%D"'+A""!N=?*M2+U%RE*6%`M@0%$0-NU4OCNY:6T&0O?O
M5*QK@\?PU1)Y`]:G1:6ZD$DKCJD*BJ[DRV'E):;2VD;".M0P=4W=LP=EDB/W
MH_>S'&IQ_!]FH)A=V57"O^X[?8"K=IVD"F*>O*E'*(K,>NU;!OO^E,0(KGN6
M4O,.-&`%#KWJIWZ?#4AI2D!2-M']0^-;/Q(;//IM59XBOW+N[9L6E$N.*T@=
MAU)I\MCKQNXMC;7;K=LTB"A($*/K0_XC-ZI:D*>&Q("AN?I46VNX6&E*(#C9
M!U#::M#%ZE=L%3YHWJOWSNIQ1%:\9CGLI?VMC;I4I^Y6&A`]T$[GZ5Z>M;=N
MUMF;5H0VRA+:8'0"!6Z/2L2*;3UTS6P">?2G$\CTI';:L2*@>*F$BW:NDMH"
MT.:5+C>".]0QT^&M9$D)D52[2[M;.\7D[UT%Q:"0(G0)Y0/2IQOB!J^MDK:L
MWW&E#RN(02#55RKM@R'6E-.(=U$J*T$$'UJJOO6Z#"%#<]=JZ["73H&X6#'T
MKA>`"W"3L#%'K@/AS'8W$8Z_%DA&1=MDEQX^]YM_EL1-6Z#%+F*:.]*!-9Z1
MO.\4H]*42.7WI@.5:+ZU3=V;UJO8.)(GL>AJB)<6T-#J8=;);6#W&U:N'<>A
MO\0IY`*EJ46S'('I63K-K:!?G=MU3*2T8$_"JOGWOQ(.J_TR=1(0D&?I5%=L
M;=RX22I;Y1LDN&0-Y_>I6Q2W:6[ST>ZDA/QKEP^.?S.5M,8R)<N7()_M3_4?
MD)KTVAM*&T-MB$(2$I'H-A64==Z6G??:E&_:EI^E9@;[TH,TB!UI`&=MZ1`$
MD]JH&>MELY"X>5.ZPM7I(D']JZ<>\VY;@I@$"?@:U7MLW<(.H@'N4\JIN4Q*
M`M2BL*!](J`N[-#+"G$%(_FH3(7`4VW;-*\B>9[T9?9%AK2WP(S90%7EX5)U
MG?2VE4!([21)HA@4HWZ4Q'?K3@<Q3;#>LX'2E':D!2B*K'$V32,ACL$RN%W3
MZ/'*3NEO5R^<?2IC-XI.0:UH@/I!&_):?[3^U#M9?Q=TXW"@`2"@\P:Y;SB1
M*1H("/6.=5G)<1I=5`22GN=JK=_DEOIT@^6HU,K6`!*B8'QH\>RS,V[EBYPT
ML)1=8Y"5I'_-;5OJ^(5(/RH@QTI09I"`>]*.L4NGK61[_2E%+K58XDXJL\4E
MRVME)?OAL$#=+9_R/[4-6;]U.88R=RXI;HN$.K4KKYA-'8;[CE41G\';9=@A
M?Y=PD>1P=/0]Q0CXHP5Y;A:%(TOHY@GWAW!ZU2KG&W"1^8Y]*C'VRC8B#ZU+
M\.XQ9`R%PF$G_@I/_E_%<6;RE[@>*+'*XQ[P;MIK942")(@CJ"-B*-O"'M/X
M=S[;#%T^G'Y)8`4R^80I7^*^1^!@U?\`MZTH^E+X4OG3CE7!E<OC\4SXE]<I
M;)]U'-2_@.M#C.<<9&^#EO8(_"6ZMM<_F$?'I\JJ#3DJ,F3-9O#6VH<Y%&K@
MR_.2X:L+A9EP-^&O_J3Y3^E3E<&7QK&2MO"=2`M.[:XW2?X/44$.(;=&/R-S
M;NJ0%-GW">5<.&X:N\LLY*Y94FR!\I4(\4]AZ=ZF+QGP1IB`-@*%O&.I6<6#
MR2T@#[U!15JX9XWXEX?4D6.2=4P.=N^2XV1V@\OE%%7`^VBS>*6\[BG+975Z
MU/B)_P!)W'WHBX?BGAW,P,=F+5Y9C\O7I7_I,&IN/E0DR''&<NE0PMNT1')I
M,GZFJW<.NOO*?N'5NNJYK6J2?G6C5)/I7.R=^O.NG5Y>M$;V37FJTR./)/Y3
MH=3\%"#]Q]Z(#SJ&&7'G5:6VTE2C$P!03XM]H62RUS^$PGB6^+"M+CC:@A]\
M>A/N`_7UZ57K]IAQ#[C#@6?&UC4G1Y8,JY'<'IR/K71@^-\\G4RZZB\L$**4
MMNI`(3TTJ&Z=AUFI>YO&<BP+IB0A1(A0W21S%#/BIF<R\>NA'Z5!%OI3Z"/-
GVYUN0`1-;0GD>HY'M5KPW'?%>(:2S;99QQA(A+=P`X`/2=_O7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g583704.jpg
<DESCRIPTION>G583704.JPG
<TEXT>
begin 644 g583704.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`\35),3%]'4D%02$E#4SI;04)"3U14
M7TQ!0D]2051/4DE%4UU*3TA.7U)?5T%,5$527U!(3U1/+D504__;`$,`!P4&
M!@8%!P8&!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H
M+"TO,"\=(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_``!$(
M`(<`AP,!(@`"$0$#$0'_Q``<````!P$!`````````````````0(#!08'!`C_
MQ``\$``!`P($!`0$`@@&`P`````!``(#!!$%$B$Q!D%180<3(G$R@9&A%$(5
M(S-2<K'!T18D-6*2X;/P\?_$`!4!`0$````````````````````!_\0`%1$!
M`0````````````````````'_V@`,`P$``A$#$0`_`-AZ(62[71Y?_J!`%CV[
MHMPEV-_[HK6%D"0+:)#W-C89)'90-R4<TK(6^K5QV`W*B*ZO$3;W+I>HUMV:
M/ZH)1ID>-+1#JX7=;V7#7?A1$65<\LH.MB<H/R"8@%1+%<Q.N>3C>RC\0I*B
M0$E@!ZA!!XE5TK)#Y`RD;@IO"^*Y:![62MSP$ZCI[+FQ&BG=?/>_?55^L@<U
MI:^XUW"#9\-Q*CQ.`3TDH>.8YM]PNP!8+A>)8C@U8V:GD(`[Z'L0M2PCBV"K
M;$*J(PR.T+@;M06D[6)1=0=?=!CFO`<PAS3J"-4JUMA=`G:]D!9+MH@!U0(M
M_P"E!*(OITZ(('1O>]TJVB("R4!S*!);=(<&L:7OT:T7)/)/VN%&XN^S(Z?\
MLFKM>0Y?-!!XA7%F:K(=ZSEC%N7*PZIS#*-[RV:K8?-.H9>^7W[IJFA-16R5
MLUGY#EC['L.2L%)&,I)TMS*!Z)H`RC3V49B#;26%]N2FG!HV(7!6AA;ZB`1S
M053$('',X[;W55Q&,6N0-E>*L,<'=.2J.,,&5P&W1!5)V@BW(I=#*^!WE`G*
M=M?LCD81>XYIA^EC]$%QP'BN?#)1350=)3`ZM.[>X6FTE1#54T=1`X/BD&9K
MAS"PNM'^7AJ@.@/=7SPOQ!TD=9ACW$B(^9&">1*"^V.EP@0G<I1$(&K#71!.
M#^:"!5M.B,63A!0`[($BX4)B8,N*,A:;$Q6%^6NJGK6TO8*MXJ\QX]&XW#6Q
M@('Z>)K7MC#?2-5)Q?#<:"ZC*)PD>PWN.JE798HB][FM;?KS0,S2$.!'PCDN
M21GGONT@7WU0JZF$^IKQ<'8'=,4]5%H]SAJ+(.7$HQ'!<6.46M=4G$GA^;>Z
MLV)UXF<Z&.09M[]%`?H]\CKRN-CMH@KD[00=%'RZMZE3V*P"F;HYCCV.ZKKW
M$@D=4'96S-9A;(=W'3Z*9\,*AQXG8T$@/A<'#KHJO*3)N3E`5F\,X#_BR)P'
MI;&]Q^B#:_DDD'9*LA9`BUNR"<MT00+M?1`-2[<K?-*RH$6ZJO\`$\-O(G:"
M7ZL_LK&18^RY<2@;-22-R@N:,[;]1J@@O(?24T43-)0P%Q[G=5_&<5P>)KA5
M35M5)'HYD(<YK3W(L`K6US:J;?*',M<>RYQ%%14P@IPR*(:^IF:Y.Y[E!GE#
MC`JW1NH*>K8#J(IV:N]E<*FC$&$?C+'S'MN0[=IZ)^BHR^I\YH>(P<SY'-RY
MNP"<Q^8,PQPN;6-P@R6"L,]74/GAJ)F,=E8R/2Y7?551I3''^A*HE[2<\;\P
M;MH2=+^W1(PJS*IXL?6;_-3<[*B9N1CW6/4`H*C-5"9Q#&.:=BQVA:N9["TN
M:K7-A4$1;)(`YXUUYJMX@6MJ2!H$'+(VV9PTS*^>$E+*_$JRL<P^3'%Y8?;3
M,3LLXK:TQF&)K<Q.OOJM^\/8FLX0PPM@$3GQES@!\1+CZC[H+#8=$".5TX1T
M&J*VR!%NWW03EOF@@<`W2[<T0[Z)P:Z_R0-N;T";(TU&B?(%D@]4%?GI6T=>
MPL?:*0$M;^Z>?\UT/<P^H:V2L>81%!/;2.2Q]B%!XI7"CHG3.Y(.V:OC_8L-
MW@7-SL%#<3.(PHN;:]KFQ35#A\LV'RRU,DD=54^H.;O&.04!CF%8I34(BDKG
MS7%B2/B""K0U#J>0U.8%@=\'4*W4,\,\(FB<'-<%0AAU0Q\N=[[.W:3M_96+
M"GBG@$0T;;5`[B-46.RDFQ.AZ*LUSLTUU,8J2Z[@#INH2<@DDG0(.GAO!QBF
M,TE*`2ZHD#7']U@U<?H"O1D$,<$3(H6!D;`&L:-@!L%3O#KA>'"Z&'%)SYE;
M4Q!S>D3':V'<\RKR!R0(RZ7`1%O/9.V[))"!%MK602LO/+=!`X!??DC%]CR2
MLHUOK9"W9`DZ:))"<M<;?=$!L@YJVG%32RP;%PT/?DJ#C+/Q%)D<W5C@2WK8
MZK2"-%3N)Z%]/,9XV_J9S]'<Q\T$`S$L4GJ)'14)-/'JUY>!F^2*NQ.L?!GF
MPA[RWX<I!(4S1Q&.@9&[7JHC$L-JI0[R9`UO^XH*'B,V(OE?(::*._(N3>%_
MI!\QSOBR'H"IG$L-<QP;-*"1I8%<L;!`?5HT:(%8YE@B$>F9S!<CJJI4.]+A
MS(4OC56)YVM!]+0H9H,E1&T"Y<]H`ZW(0>H:)@924[```V)H`Z>D+HL;(PTY
M6BVPM9';GJ@3N$5NJ7EUUT0MKT0(L+H)>7Z((%@:ZH6-TNPY(6Z($$#F@`;Z
M:I8"*UD"<N^]U#<5P&;!Y`"1E>UVG+7_`+4AB>(X?A5*ZJQ&L@I8&BY?*\-'
MRZ_)9G5^(D'$W$.%<-\.LF$%35L%352-RYXF^IS6MW`(;8D\D#U+B,E/(::K
MY?"\;.".IQ>$!S+@$[ZKIXCP>2FJ'1D>EUW1/Y.'147&8)869W-<T#<A`6*X
MM')/F+A8'8%0==B+I/2W9<UO/<0S/?N%R3!T9LX>J^R`W/<ZY<=TNA8Z2NIF
MM)!,K;'I8WNF0#;U*T\/84YC/Q\[2'N%HFD;#][YH-IX-XCIN)<,DJ(V^554
MTI@JH2;F-X_H1J"K#;7DO)'$>,8QPIQ:ZOP6NEI))XF/>&'TOMI9S=B-.:OW
M#?CW&6,BXCPEP?L:BB.A[ECOZ%!O!'7FC`W"@^&^+.'>)(\^#XI!4.MK$3ED
M;[M.JGK<[($:#5!+Y=T$"MAJN>NK:*@A,]?5P4T0_//(&-^I7G[BCQJQ>N#Z
M?A^D;AL!T\^6TDQ]ORM^ZR^OKJ_$YS48C63U<Q-R^>0O/W0>D\?\7>$L++XZ
M2:7$YQLVE;Z+_P`9T^EUF>-^,?%&(.='AD5/A<&MBQOF26_B=I?V"S$-3K1;
M0(.NOKZ[$ZEU5B%9/53NWDF>7'[[+1O`;!YJSBN3&"VU-00N:'$;R/%@/I=9
M?V`%UZ4\"J)M/P-'4AMGU,[W$]0TY?Z%!H59205M.ZGJ&9F.^H/4="LVXGP:
MIPZX='YU&\V$EOL>A6HI$L4<T;HI6-?&X6<UPN"$&!24M/`]K0UMCLH+%*:-
MM9(\-)9LWN5K&*\/89'BC:6GQ6FB>7-_4U#Q=I=\+1S)/(*4@X6H<./GEOXB
MKM^VD'[/LP<O?=!E>!<,29VUF)19;:QP'^;O[*Q31V!5HJ:=K;V"A:J*Q*##
M/%+_`%NG;S;3B_\`R*HJM_B++Y_%%4`=(PV,?(?]JIEJ)0AEEAD;+%(YDC3=
MKFFQ!['DM0X6\:.*L&$<&(NCQ:D:`,M1Z9`.SQO\P5EMDL"Z#U9@'C-P;BD8
M%;/-A51;5E2S,SY/;<?6R"\J6*"*F@Q*L@@@,=D>PV000!OQ+U1X/"WAU@_M
M)_Y'(((+NJ_QMQ#'PSP]4XFYGF2@9(8^3I#M?MS/L@@@\O8]BE9+42U=1,^2
MLG)D,NSG'U7<#RM\K6%@MV\/>+W\5<-B2I!&(4=H:D\I#;TO'N!J.H*""":>
M,[C=1-9&,KWG9H)*""#R_P`0SFJQFMG/YY7'[J,<VX000(LA^>P000+L@@@@
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g206804.jpg
<DESCRIPTION>G206804.JPG
<TEXT>
begin 644 g206804.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`O35),3%]'4D%02$E#4SI;04)"3U14
M74U)3$537T1?5TA)5$5?4$A/5$\N15!3_]L`0P`'!08&!@4'!@8&"`@'"0L2
M#`L*"@L7$!$-$AL7'!P:%QH9'2$J)!T?*"`9&B4R)2@L+2\P+QTC-#@T+C<J
M+B\N_]L`0P$("`@+"@L6#`P6+AX:'BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN_\``$0@`AP"'`P$B``(1`0,1
M`?_$`!P```$%`0$!```````````````!!`4&!P,(`O_$`#H0``$#`P$&`P8#
M!P4!``````$``@,$!1$A!A(Q05%A$W&!!R(C,I&Q%$*A"!4S8L'A\!92<I+1
M@O_$`!8!`0$!```````````````````!`O_$`!<1`0$!`0``````````````
M```1`2'_V@`,`P$``A$#$0`_`-SU29[)/NE0+TT2:H2X0)ZI)'M8"][@UH&2
M2<`+A<*ZFM]))65DS8H8QDN/V`YE8KMKM=67N;\/%%+!0-.D&1F3'-V/M]T&
MFUVV%LAD\&F/XQW`^$X8"C_]65D[O@4\#>SLD_W]%F-N?*Z-F`?#=P!X>G^9
M5PM;7OB:R<Y</ED(P2X=>_=!:(MJ)6`">D!+C@/:="?Z*1BVAI=W?E8^/!P2
M-0#_`$5;'OTV2!O#1XQC>_S[J/EFEI9R&@.CSC+N8Z(-'I:J"JCWZ>1KVCH>
M"[^OU5`AN4=N@=5T\3G/T^$.Y&BFK7M%/5.S/0B-G\C\D(++JEY=%\1O9(QK
MV.RT\%]>J!>NJ.O-)]4'"!3WX(290@.7'5&O)'V2GH@3/9!X=$>B8WFH-/;Y
M7M.'N]QO7)T09WM?6U%\G^!&X45.XB,$:R.X%Q'(=%3X*.H\8F2-F1TT)5\N
M\.[#%3!Q8#QP=24TIXXLMC`R!U014-`S<<\1_"=_$8.(/4=_NK!;H=!'D.W@
M,.Z]"GT5'$1OM&/)?4-&^$AK&983D?RH"=C63`_DD&Z[L4RJZ-SLMW>V>@4V
M*?>RYYX\1C@E>QGAG`SGF$%==3[T;6NT(XE2UH!:0W)ZX!0(F^+\O'0DI]0P
M-$I&H'(H)FG/AM:X?*?F']4\7&!N8=UP&1H5TC.6#)0?25'DA`FB$>:$!U1Z
MX1W1E`#'-0.T4COQ-#`,[I<7'N>7W4^5`[4PDT\%:T^]"_!'9VB"%O4+0YTQ
MU)&!VPH6A.]*<8XJ8N]1&^BWB_@,#',J`M._XI!&<]4%NIG-.,-P,!/&D`:.
MX<%%TK)L#3ZE2#6.:,D9Y\4'?+=T]4'PPTC3'9-VLD>[)`POO<>!EQ;A!PE8
MUNN.)T(3JE;[P32I.?\`.2?4>'L!:=1R^R"5=((X`[/(#*2E<70-?R))'EE,
MI'^Z6C&,YQT3ZFW131AAT`"#KGHCS0A`%""4(%\DGJE&4F$!ZJ+VDCEDLU2(
M3[S0'XZ@')"E4PODYIK-7U#1ES('N`SSP@RZHJ'2TS)=[+&DY[E1-!772KFW
M[93.>QG!NC0[KDKO).V2&W4@]WQ!XCP#U_LG$^SSZJIBC;(UM*UV]X>N[(>C
ML<D$O0[1U,3W4]5;W->T:^&X.U]"3^BGK;>(*]F8CDC0M(U!Z85$EV2CM3JV
M=G@2&=A:R-D7\+.?EQTSUZ%/=EF?NZ1D>7Y=ESP3G)06^LN%12!N:9SLG`#"
M-569-H;G6U3H(VV^``XQ-6,:1Z9RIVOIXKI3OBD+L@Z8/!14VQM%=74K:QNX
MRF&ZT,:T9&"->IPXZ]T'8&Y4!9)+N302X+A'(7@'J-%.4-1A_P`V-,>>4UI;
M)!02O;2S%L3R7/8=6Y/,#@WR&`N5P<VFJ?<X<<=4$Q657A'<:,O=J`.94Q:B
M#01.:,;P+N.>)54_'0U7BQL>&U#6,=@CAG4:^:GMF9Q46]Y`<&ME<`".`SG"
M"9]4).^.*`@"<(1GLA`8QT1PXH2]^B!`HK:>-TNSMS8PDN,#B!UQJI7."$.:
MUX+",M<-TCL4&!/$L%W;)O8:[#V:?*W'!72S5$LH`B;D'BYRIUW<]M8P;I^&
MPL'?#B%8-FZJ04N1HT<T$[=Y&_ARZ2;=&-<JMVR037-@#\Z'!`_SHG-Z:ZM;
ME\XA:W7=YN\U#VB6II+E'(VF\9@!!<W4X/9!<Z>:."8M><`Z@'FI2FGII@X1
MO(=G4$\"H"JJ!4/:]L(:UH#'#&N?_4CH8Y=V>"5U/.S0/&N1T(YA!9)XI&P^
M+O#34*O5SS+*PGYN"<4]7/-"^GG]V5@WA@Y:]IY@^:X.C<Z(DG4'()0,HX)J
MBLADIY/#C@:/Q>!DO`<2QH5_V?A\&V1DLW7/)>1CJJU9G!^[3.`+'SX=N\0"
M`?Z*\#`P`,#&B`*!A&J.71`:(0A`N,HT2#@E0(ETSHDZ(*#,O:':::DN%%64
M\&XVJ<]LV''!?H>'+.2OG9>..1DU(X8D;P^JN^U=K_>UDJ*<#XS/BPG^=NH^
MNH]5G%@J3'5Q5`)#7-PY`PVG;6TMP:Z.#?IG?,6N(<S7IS"FK125D\!$%(*A
MH&2^&5I!&G+((XIQ=(F5L;P1J"2".2C[:)*25P(<'@8\2-Y82.AQQ06**BJ:
M:G+JJ.&EB>0,U4H;J>PST5;JC<KA.8+3*R&#@ZJ?%J[_`(`_<_12K&1U)8^2
M#Q).3Y7EY'UX*9H*1L(+N)(0<:2C--;8XI'F25K0PN/$]45+6Q4^"<9!3Z4;
MQ:QO$:E1US)<!&-<:GR02.QC(7LJYC$WQ6RAN_SQN\%:.BKNQ+"VURO(P9)W
M'(''``5C\T"=?)*CB@#J@,E"3*$`>8"`<H2X0&OHD/FA'H@74>BR;:FC_<]_
MGB:-VEJOCPG_`&D_,/K]UI5WNUMLMODN%UK8J2DC'O22NP/(#B3V&JSNDN<W
MM%L]UNU)3/CH:6I#+<Q[,22-8WXKCW<7#`Y;O5`EMKHW`LE.O=/(,5`(C@R!
MS*JK(9&G>8X@J;M]U=$P1398X:9P@GH&R0-),+<<3GBGK)P&[SAC70!1M-<1
M*7!NZ\)RW><0YVIY('#9,`N/S'BF<5-/7U7X>'YWG5Q_*.OD$]HZ2>KE\*)N
M<\3R;W*MMNM\-!#N1C>>[YY"-7?V09'M[>*WV=;6VFZ4OBS62O@%/5TA=D%T
M>`'LZ/W2#WQJM+LMWM]\ML-RM=2RHI91[KF\0>8<.1',%99^TJTFU6$;V@J)
MB6]?=;JL=V6VHO6REP_&6>I+6.QXU/)[T4P')P^Q&H1'L1+S[E9_LQ[5-E+Y
M'%'/6"UUS@-Z"K]UN]T;)\I'G@]E?F2,DC$D;VO8>#VG(/J$4N.NJ$80@7''
M`)ZJ"O&UFS%ER+K?J"F>/R.F!?\`]1D_HO*FT.V>UFT3S^]+U4&(Z>!`[PH@
M/^+<9]<JM>"UN<`9//"L2O35U]M^Q=$'"C%?<'@Z>#!X;3_]/(^RH5Z]OMZF
MWF6:S4E&W@)*AYF>.^-&_=8S,=2&_5<4A4UM#M'?MJ:YM3>;A+62C2-IT9'G
MDUHT'HO5_LFM3K3L!9J5XQ(Z,SN\WN+OL0O._LAV8.T>T,C'M+HJ6FDG=I^;
M&ZP?]B#Z+US24[*:FAIXQAD3&L:.@`P/LFBJW[9DR2R5M`W)<2Z2$<SS+?\`
MQ0E/01R\L%:8%7=I39[8UMRK;C3T!E?N?&)#978SIC7>\@5%1$-"(0"3IA2M
MNMDU:ULC/AP$_P`1PU</Y1S\^'FNFSS;;?(C6P7&&MI(W[GAPM(;O`9]XG4\
M1IH/-6H::#@@XTM-#2Q"*%FZT<>I/4KLE32Y5;*.CEG<X-W6DY/+N@\]?M!7
MB.MVEH[9$\%M#"0_7\[CD_H`%DQX<L*3VCN,EWOM=<"<MFE<6DZ^[G3]%&/)
MYX0,JD>\TM)!X*0LVTE_L,GB6BYU-*>.[&\AI\V\#]$RF((`W>!"^=SA@*LM
M/M'MOVII1NW&@H+BT?FP87_5NGZ(69-;H=4(=(.O)-YI"XB&,X)XE"$#-[2T
MD8QCBEB8Y[@!P'%"%1Z&_9II`*B^U.!@0Q1_5Q/]%NY"$++3Y/0+S?[2[@[:
MG;Z:UR5H@HJ',4!DW@QI&CCAH)+G.T]!R0A`]]E>T4FS>U\%A,T=3;Z]WA.?
M$PC#\X:[4`Z'(\BO1R$(!9/[;KU-2;./IH'%KZN00`CDW&7?4#'JA"#S?'O:
CXP>R)?=T(&4(0<'#(()&HZ+Z;'J.B$(C[8PGN3W0A"*__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g368266.jpg
<DESCRIPTION>G368266.JPG
<TEXT>
begin 644 g368266.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`V1$E32S`T-SI;,#5#2$DY+C`U0TA)
M,3`R.2Y/5510551=,3`R.5]015)&7T-(05)4+D504__;`$,`!P4&!@8%!P8&
M!@@(!PD+$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H+"TO,"\=
M(S0X-"XW*BXO+O_;`$,!"`@("PH+%@P,%BX>&AXN+BXN+BXN+BXN+BXN+BXN
M+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+BXN+O_``!$(`<\"H`,!
M(@`"$0$#$0'_Q``<``$!``(#`0$`````````````!P4&`@,$`0C_Q`!9$``!
M`P,!!`,+!PD#"04(`P`!``(#!`41!@<2(3$3%T$4(E%687&1E)71TA464U57
M@>(R.$)(4G:&H;(C<L,()#-B@I*3L<$E0U1SLS0U-C=C=:+A)F3Q_\0`&`$!
M``,!``````````````````(#!`'_Q``O$0$``@`$`@@&`P$!`````````0(#
M$1(A!#$4,E%A<9&AX1,B,T&!T5*QP?!"_]H`#`,!``(1`Q$`/P#](HB("(B`
MB(@(B("(B`B(@(B%!HVK]I%FTW=HK'%1W"[WJ1N_W!;8>ED8WGEW'APXXY]O
M)>C1NT"QZJI+C-$*BW5%L.*ZEKV"*2G''B[CC'>GCV8XX4YV67>SVK7VT1VI
M:^EHKT^X.(=62B/-.'.P&EQY?DG`[-U=&N;Q:=3[.==7[25C?`_I8Z:HN0B#
M371MD;ON:1Q+0W&<]A\Z#9I]MEA`GJZ.P:AK;+`_<ENL%'FG;QP3DD<.7/"V
M#56TO3>G--VS4<AJ:ZAN3@*;N-@<YXW2[.'%N`,8/:"M0N6M-%VK8DVGH+A1
M2B6T]R043)&F5TKH]TAS.8(<27$CP^%:+2V&JJ'Z`T3<(G=)0V.ON-1$[FQT
MPDZ,.'80=W@@NM]UW8[)HNFUA6&?N"IBBD@B8T=+(9`"UH!.,X))X]A6$JMK
M5BI].6*_?)5XECO4SX:.EBA8Z=Y:2,[N_P!IQC!)XA0M]XGOVSAEQG;(RU:8
MM;*"F8X<)Z^7O-\>$,C.1Y<'M6U76TW>37&SW2>GY*1E=8+,VK)K&N=$R4CO
MBX-X\VM^\A!5],[2K/?=0#3LMMO%HNSXS+%372EZ%TK0,DMXGL!Y^`KMOFT?
M3UFUG;M'U'=,ERK71MWHFM,<)><,#R2"">>`#P(6F7:VW32]?/M0V@7>AK*V
MUT;J>WT=OB,<9<[(`R[B22X^;)/9A2N\OO\`;=-T]_ONF+G!=I+[#=JFZS!H
MC.,AD;1G>``/`'W(/T3K3:!;-)W*VVN>VW2XU]P:]T-/;H!*\AN,]Z7`^'EG
MD5T:4VDV?45^FT^;==K3=8H>G[FN=,(7/9PR1Q/ASQQP4^OL=^U-MYG?IJOH
MZ6>PVM@;-50F5@,@R0&CM(E_DL7:*NLI[IM.U+JFJ%9J.PT1HH*B'#(6L>UP
M:&LP"#O`<23^4?.@I$6UW34NFY+^VFN/0&O-OIH!$UTM7,`#B-H<<CCS.%[-
M-;1J"\:@;IRNLUWLEVDB,T,%R@#.F8.9:03RP?05*+):M,2Z&T3H^\7&KLEZ
MJ(C>:"YLW61LD<YQ`+G$=]C=X<.3>*]\%[U2ZX:NTI/=:#4U516&>HH[O2P-
M$T+RW'1DMY.(<>`).<<4&Z7+;#9(JZLIK/9;W?8*$D557;:;I(8L<^^SQQ@\
M>7E6;GVCZ:9H-^N899JBU-W061L'2[Y<&[FZ2.^!/AY<>*TC93K'1>G-C]'/
M)=*.*2EBD=54QD:)GS;QR-SFXG@!PY8\"G=JMM9U<Z0T]4T_1G5&I15MA=V4
MS0T'AX#P/FP@O=1M$L,&SYFO"VI?:WL:X1L:TRY+]S=QO8W@>?'L6ULK8?DY
MMPG/<\'0B9YF(;T;=W)WCR&!S7YAOE+/;M0NV1B%W<%7J2GKJ0X[T4CP2YGF
M!Q_NN5AV\]V]5-]%`';VY'TFYSZ+I&[_`-V.?DR@QL^VRP@3U='8-0UME@?N
M2W6"CS3MXX)R2.'+GA;)J7:+I^PZ9MNI'=TU]#<I61THHV!SY"X$C#7$>`Y'
M//#"TRY:TT7:MB3:>@N%%*);3W)!1,D:972NCW2',Y@AQ)<2/#X5H;[#>)V[
M)]!,J76^Y1137225\0E-.2XR,)8<`ENZ1@]I06C3.T:GU!>8;5%I74M"Z0./
M3UU#T43-T$\7;WDP/*5O:UK2%HU-:^ZSJ+59OIEW>A_S%E,(<9WOR?RLY'/E
MA>[5O=GS5O7R<'&M[AGZ#<SO=)T9W<8[<H-)O&U^R4EQK:*TV>\WX4&>ZZBV
M4W210XYY=GCC!X\N'-9&OVH:9I=$TNLH^ZJJW5,S8(XX8QTO2$D%I:X@`C!S
MQ\V5I6Q[5NC-.;(89JFY4D%13],^LIW2-$\DN\<`,)RXENZ!_P#HK!:YJ;'-
M;MF;::SMT_IVY7;NV>*1C8VL`+`'.QP&\UQ//D@M&M=8VW1UFI[K<Z>JD9/.
MRGCA@:TR%[@2!@D#A@YXK%U>TNQ4NO8=#R4]<;E*YC.E:QIA8Y[-\-)WLYQY
M.U:9M$KZ#66T70NF+15P5\--5&XUQIY1(QC&8(WBW('`.'^T/"M`KZV)E5<M
MIDL3GQ0:UB:"WBYU/&QP('G!:@N.LMIM@TI?K?8:N"MJ[A6AI;'2,:[<WG;K
M=[+AC)SCGR\RRMJUC;;KJZ\:6I8*HU=I8Q]1.YK>BR[&&@YSGCX.PJ&VFW5E
MXVC:,J[Q'_VM>*B2_P!6QPST$#&XIHAY`&G_`'O(MAV0:@LM'>-H-XOUUHZ&
MOFNS^DBJ90QS8F%V,`\3S(X>!!O]1M)L4%=JFD?!6'YMPB6LE#&[CLC@QG?9
M+NSB!Q"V335Y@U#8:"]TL$\,%;$)HV3@!X:>60"1Y>:_+UPJJANR756H9AT4
MVK[\&0E_`NA:XOSYLAP^Y7Z@U?HNQ:89#3ZBM=3%:J`9BIJIDCRR-@'!H.3V
M#SD(.6M-H^GM'W:VVFY]TRU=<1NMIVM=T32X-#WY(P"2>6>17+7&OJ+1TL3*
MRR7NN8Z%TSYJ&EZ2.)H.._<2`.1/F7YVU#-J&ZZ2U-JB[Z5N8JKQ+!4PW([O
M0TM,QP,;&@G>P<\\<>]*LFUS40ZDI[E&[^TNM)3QQX//I=TN'^[O(/59ML%F
MNM/-61:>U%!014LU6ZLGI&MAW(VEQP_>P2<8'EX+)6+:99;U=K#:X:&XP37N
MC?64SIV,#0QI>,.PXG)Z,D8SP(6H;3F'2VP*DL<;"VHF@I:`-',O.'/].Z[T
MK#;1'P;.[]LSN\L;C!:Z">ED;'Q+G-A``^\N/%!4+QM#LEKO]RLDD%9--;+>
M^X5LT+&F.!@;D-)+@=\\,#'Z0\JURFVTVRJIXZFET=J^>"1N\R2.W!S7#R$/
MP5/]0T%9IO8C>;U=R3J/5M3$^I<_@6M>[?;'Y,,#CCLWL=BVO0\-=12V*UTV
MV>T55)!T4;;73TM,72,:!F)K@XNY`C//M06>FEZ>FBG,;XND8';D@PYN1G!\
MH6I:ZU_:M&5-LI*RAN-=57$O$$%!")'G=QG@2#^EV9[5N2A&KJ*[:KV\04%D
MNXM518;5THJS3-J.C>\\1N..,D2-'W(-MBVM6OY-NERK--ZDH*6WTXGD?648
MB$F7M8&,R[BXEW+P`K,6?:!:;KJ.BT\RCKH*RLMC+G&9FL#>C<`0TX<3O<>(
MQC@>*FVU^CO]+HJU:4O&H77NY7N]11,G[E93[L0QWNZWGAVZ<^5=6U:[1Z$V
MF6#4$,#BUMCGI((VC(>]N\(VGR9<S*"A7O:A8+17W^CEIJ^<6*!DU;/`QAC:
MY[FM;&"7#+R7#ARX'CP6,I=L%#5&'H-&:O<V8MW'_)PW2'8P<[V,<>:F.N+%
M+IG91:;/<J@1WW5%VCJ+G/.[&Z3EQWCX&DLSY=XJCZ*-P%\H*4;8;9?*:)I`
MM=+24S'RM:P@`%CB0!P/#P(*L]Q:QS@TN('!H[?(M.LFT73UUTK<M3DU%%1V
MV22*JCJFALD3VXX$`GB<@`9XDX7/3E=KVHNQCO\`8K51VW<<>EIZPR29_1&[
MCTJ1NTC3W_;CJ'38JY1IUCXKM<*)O!DT^ZW##Y"9"3]_D(#?JO;!9:2UV2OE
ML5^+KR9.XJ9E.QTTC&8[_<#^1WN':<9QC!66TKM"@U)=FVV+3&HZ`F-TAGKZ
M+HH@!V;V\>)SP4OU_.VOVWT5'3ZGH=,BQ6L&*LJ&1N9'([CNM:\AI):\>8#R
M+:CJZ?26C[W?*[7M'K"<.C@HHZ:"*,,G<#NL/1DYS^4<]C3A!M-5M'T]3Z]I
M]#_YQ)<IL`R,:TQ1O+2X,<<YWL#L!YA<=7[1;;IB_4EA=:+Q=+C4TYJ&0VVG
M$S@P$CB-X']$GS!0.3Y9TY%I*Y7K3=TH[@S4`K*^YU>[NU#Y",M&#D=ZWD?]
M;EE;H*?4FI-N.I[CIBX45')9J:*AZ6K@,K<$<0`.1W@_C[T%+T;M#L^JKM76
M:&BN=MNE&P22T=QI^BDW#CCC)\(Y^$+[KC7U%HZ:)E99+U7,="Z9\U!2])'$
MT''?N)`'(GS+2MB,%1<-3:ROU_F[JU)3UAMLU0P@1=&S&`QH`QQ8.?@'ESL.
MWNZ?)FRZ\[I(EJPRE8/#ON`</]T.0?--[6K+?GA[++?*&W]#).ZXUM*V.F8Q
M@)),@<1V8X=JQSMMUA##7MT_J)UB$G1F["B_S?GC.<YQG[_)V+"[6;76678#
M;[52LD:RF921U@9^P!EQ/^WA>S:+K#1T&R26V66NHZLU]&RCH:*G>'R=\`!E
M@XMW1QXCF,<T&VZJVDVG3L%'5?)5XNE'54O=;:JW4O2Q,B["YQ(`R./FYKIT
M;M.M^KKA34EOT]J""&=CGLK*FD#8,-!_3#CVC'#M6IZV%5I'_)UBM=7EM>^B
M@HG-SR<\C?;]S=X?<LU?KUU;[*+314D6_>74L-#0TX&7/J7-&3CMP23Y\#M0
M9VGVCZ>J=?/T-`*F2Y,#@Z8-;T(>UN\YF]G.\!SX<^"][M8VT:Y9HID-3)<3
M2=UOD:UO11L\!.<YY=G:%^?+6RX::O\`LW-QTW<K94Q7*5E775A:>[):@M#S
MP.>'E[%N6BK_`&/KCU]?KQ>;?1=$YEOINZJAD9<UAW7;N\>(S$/2@NZG%?M7
MMM/?+I9J+36I+K/;9>AJ)+=1"9C7><.R.1'$#D5OD-QH:BW"Y4U7#/1.C,K9
MXGA['-''((X$<%^<-GT6O7:1U1KC3UXMM%%7U%36R,J:8R2/W,G(<<@<W`9!
MXA!68-JVF)]#5NLXQ6&BHY1!/3F,"=LA+0&[I=C/?`\\8RO%0[7*.MJ*:"'1
MFKAW0]C62/MP#!O$`.)WN7'.?`HY?(;?'L>T=;*>H[FGU1=>ZJZIJI`1O-)8
M]Y/`!H):<>`<^U5_1$EP??Z6)^U^V:@IV,?FVTU)3L=(`W`.6.)`'`\/`@Z[
MEMJLMNN#:"ITQJALTLKHH`:$#IR#CO`7`N[.SM"RU%M/M=366&ADLE[I*N]5
M$D%/#4T[8WM#-W,CP7<&=]P(R>]/!:W??^W/\HBP4(!?!8[:^KD'[+WYQ_SC
M7FOUPHF?Y1=K-YJX:.EM]G<ZE?4/#&/D=O`\3PSASO\`=04>]ZQMMGU18]-3
M05,M?=R_H>A:TMC#>9?D@@<^0/(K5';8[2^6XBATOJ>X4]!-)#/54="V2(%G
M,[P=P&!GCC@M6J;S3W?:Y?\`5M%/'4VK2ECD:RHC.]&9BUQPTC@?RGC_`&5J
MNFJ3:!I_8O5Z@M-[MU+;ZELM9)"^FS.0YP82'GAD@`C@@L=?M7TO2:&I=:`5
MD]NJ9Q3LBCC;TPDXY:6EP&1NGM\V5D[WKRRVC3-JU&]E34TETDACIF4[6E[G
M2C+>!('#!SQ4>?8[15-V2Z*H:5[[?5M==ZN*=P>7`QAQWB`,Y[\<APPL788Z
MU^M-+[+:YCY&Z>OE15![OR7T[6B2(_U?<X(/U&B#DB`B(@(B("(B`B(@(B("
M(B`B(@(B("(B#7K_`*,TKJ&I;57JPT-94-&Z)9(AOX[!O#B0LM16V@H;>RVT
M5%!!1,9N-@CC#6!O:-T<%ZT0:M0[/]%4%Q;<J/3%LAJV.WF2-@'>'PM'('S!
M9D6>UB[OO(H*<7)\70.JMP=(8_V=[GCAR601!@_FGIKY)99_D.@^3F3=.VFZ
M$=&)/VL>'CS7LCLUJBO$M[CM].VYS1B*2J#!TCF#'>EW@X#T+((@QUXLMIO4
M<$5WMU-6QP2"6-D\8>&O')P![5SNUJMMYH7T%UH8*RD>070S,#FN(.1D'RKW
M(@QMOL5GMM94UU!;::GJJH-$\L<8#I`T8:">W"\TVE=.3-N3);)0O;<W-?6@
MPC%0YIR"_P#:P>*S:(,+=M+Z>O%NI[;<[-1U5'3`-@BDB!$0```;^SP`'!=E
M@TY8M.P/I[':J2@CD.7B",-+SV9/,_>LLB#59MGVB9KD;G+I>UNJR_I"\TXP
M7>$CD3]RS559K55U]%<*JWT\M919[FF?&"Z'//=/8L@B#&U-BL]5=Z:\U%MI
M9;E2MW8*I\8,D8X\`[F.9])60D8R1CHY&M<QP(<UPR"/`N2(-6H=G^BJ"XMN
M5'IBV0U;';S)&P#O#X6CD#Y@LRZS6IUX;>W6^G-T;%T+:HL'2!G[.]X.)601
M`1$0:M5;/]%5=R-SJ=,6R2L<_?=(Z`=\[GDCD3YPLQ>++:;W0?)]VMU-64F0
M1%/&'-!'(CP'RA9%$&#T_I33FG!+\AV6CH72C$CX8P'/'@+N9'D0:3TT+0;,
M+'0?)IEZ8TO0CHR_.=[=\*SB(/!\CVOY7%Y[@I_E(0]`*G<'2"/.=W/@\BP]
MVT'HZ\7!UQN6F[=4U;CE\KX1O//^MC\K[\K9T08:YZ8T]=:*FH+C9:&II*7_
M`$$$D+2R+ACO6\APX+%MV=:%:'!ND[0`X8<!2MXC.<'[P%MJ(/)5VVWUMN?;
M*JC@EH7LZ-T#V`L+?V<>#@%XZK3=AK+72VBJM-)-;Z4M,%,^(&.,M&&X'9@$
MX671!C[O9K5>601W6WT]8R"431-G8'!CQR<,]JZ[UI^R7T0"\VJDKA3N+XNZ
M(@_<)QDC/+D/0LHB#&7NPV:_4\=->K92U\$;]]D=1&'M:[!&0#VX)6.MNAM'
MVNMAK[=IJV4M7"=Z.:*G:US#C&0?,5LB("Q]+9K527.KNU-;Z>*X58`J*AC`
M'R@<MX]O(+((@Q]PLUJN5715E?;Z>HJ:%_24TLK`YT+N'%I[#P'H75==/V2[
MU-)572U4E9/2.WJ>2>(/=$<@Y:3RX@>A95$&(ONF[#J#H/ENT4=PZ#>Z+NF(
M/W,XSC/+.!Z%YK1HW2MEK6UUIT_;J*J:TM$L$#6.`/,9"V!$!8^DLUJH[C67
M.EM]/#75F.Z*AC`'RXY;Q[<+((@UNY:'TA=*Z:ON.F[955<Q!DFFIVN<\@8X
MD^0!?:?1&D:9D#(-.6V-D$_=$36T[0&2\._`_:X#CY%L:(,?>+/:[W2"CNU!
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M"V-M4-'"R@;%T(IVMPP1XQNX\&."ZJ2R6BCLYLM+;J:&V%CXS2LC`C+79WAN
M\L')SYUD40:Y5:)TC5TE'156G+;-34;7-IHGP-+80XY(:.S)XKLLVC]+V.L[
MMM%@M]%4[A9TL$`8[=/,9'9P"SZ(,?#9[7!=ZB\PT%.RY5#!'-5-8.DD:,8!
M=VC@/0O+J#2VG=1B(7RS4=>8O]&Z:,%S/"`>8'D6:1!A:32^G:.S362ELM%#
M;)@1+3,B`9)GGO#]+ES*]+[):)+,+&^VTSK6(Q%W(8QT>X.3=WEC@%D408J#
M3]DIZVDKH+72QU5)3BEIY6Q@.BB')C3V-XG@N?R%9Q>C?1;:7Y5+.C-7T8Z3
M=QC&]SQA9)$!$1`1$0$1$!$1`1$0:K5U>JJZZW&FLS;?14M"61MEKX))#52%
M@>=W=<W=8-X#>[XDYX<./AM^I[OJ&.V066&EHZF>B%;5S53'31P-+BQK6-:6
M[Y<YCR"2!NMSVX7BU%=77*\UUGN;+S1V2G(B?'16VHD?<,M!=F6-A#8N.[AI
MWG$')`X'T]W4]EOL%[905<=AKK9%2M,5%)FE?"]Y8UT0;OL:6R$#O<`M`.,A
M!VMU/>#$+1W-1C49N#J$\7=S@"(3=/C.]N]&0=W.=X[N>U92RW.ZLOE38;XZ
MDEJ&T[:JGJ:6-T;98][=<"QSG;KFNQR<00X<N*U-L=<VYC6YME;W(;J][J?H
M'=.*0TS8!+T6-[.\P.W<;VZ>6>"S]FG-]UA)?*6"I9;:6@[DBEJ('PF>1\@>
M_=:\`EK0QHSC!+CC.$&X(B(&4RH7M!T_2ZJVXVJQW"IK(J-]D,I[EFZ-V\V2
M3''BLUU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=
M(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94
MEZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05
MK*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O
M?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^L
MM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$
MZ1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7O
MPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66
MH/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=
M(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94
MEZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05
MK*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O
M?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^L
MM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$
MZ1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7O
MPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66
MH/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=
M(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPIU$Z1^LM0>O?A05K*94
MEZB=(_66H/7OPIU$Z1^LM0>O?A05K*94EZB=(_66H/7OPK`Z.TY1Z1V[FRVV
MJK9:0V)T^*J;I#O&0`]@\`07A$1`1$0$1$!$1`1$0$1$$DN?YQUH_=]_]<BK
M:DES_..M'[OO_KD5;0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`1$0$1$!2/\`62_AS_$5<4C_`%DOX<_Q$%<1$0$1$!$1`1$0$1$!$1!)
M+G^<=:/W??\`UR*MJ27/\XZT?N^_^N15M`1$0$1$!$1`1$0$1$!$1`1$0$1$
M!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$
M!$1`1$0$1$!$1`1$0$1$!$1`1$0%(_UDOX<_Q%7%(_UDOX<_Q$%<1$0$1$!$
M1`1$0$1$!$1!)+G^<=:/W??_`%R*MJ27/\XZT?N^_P#KD5;0$1$!$1`1$0$1
M$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!2/]9+^'/\`$5<4C_62
M_AS_`!$%<1$0$1$!$1`1$0$1$!$1!)+G^<=:/W??_7(JVI)<_P`XZT?N^_\`
MKD5;0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$)`XGD@(M=N^LM-VG
M+:FYQ.E'_=0GI'>AO+[UJ<NT6YW21T.EM.5%2<X$TP)`\X;P'WN5].'Q+QG$
M;>2B_$X5)RF=^[=3D4M=IS:#?@77B^,M\1'""%WHR&8_F2N%/J?4^CIV46JZ
M1];0D[K*V/B<?WN3O,[#O.I]&SVI:)GL5]*RWO68CM_[DJJ+'V>\6V]4HJK;
M5LGC[=W\II\#AS!\ZR"S3$Q.4M43$QG`B(N.B(B`B(@(B("(B`B(@(B("(B`
MB(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("D?ZR7\.?XBKBD?ZR7\.?XB"
MN(B("(B`B(@U#6\MZIY[-+27&&"@==*..:)L+NEE#I0"W?WL!IR,C=XX(SQ7
MEUK-5SWZUVV"&^30BFFGECM4W0.>[>8U@=)O-``R\X+N/#@5L&IK9/=*>@CI
MW1M,%PIJIV^2,MCD#G`8[<#@NB\QZBI[G#<+,*>MIS"8IZ"HG,(SG+9&/#7<
M>)!!'$8XC'$-7IZZ*N@M-AM=?>J;NRNF97.K)WFLIQ%'ONBWG$EI),?%I_)<
M2T\05F[/'+9M72V..KJZBWU-#W7"RJG=,Z![)`QX#WDN+7![#@DX(..:\+M,
MWP.^7VRT)U"+AW;T&7"G+.A$)@W\;W^C`._N_E`'=QP65LEONT]]J-07N"FI
M9NYFTE-2T\YF$;-[>>YSRUN7..[P`P`T<3E!LR(B"27/\XZT?N^_^N15M22Y
M_G'6C]WW_P!<BK:`B(@(B("(B`B(@(B("(B`B(@(B("(NN>>"GC,M1-'%&.;
MY'!H'WE!V(M+N^T?3-O#FQ53ZV4<-VF;D9_O'`_F5@OG7KB_DMT]I_N2`\IZ
M@9^_+L-]`*T5X;$F,YC*._9GMQ6'$Y1.<]VZGR/9&PO>X-:.)<XX`6K7?7NF
M+7O-?<&U$K><=,.D/I'`>E:VS9_?+PYLNJ=232CF8(27`?><-'W-6TVC1&FK
M5NNAMD<LH_[RH_M7?SX#[@NZ,"G6MGX?N4=>/?JUT^/ZAJKM<ZGO9Z/3&FY`
MP\!43C>'G[&CTE!HS5]][[4NHW11.XFGISO#S8&&C^:IX:&@```#D!V+ZG2=
M/TZQ'K/J=&U?4M,^D>C4+1L]TQ;-UW</=<K?TZH[_'^[^3_);9%%'#&V.*-K
M(VC`:T8`^Y<T5-\2]YSM.:^F'2D95C(754005,+X*B%DL+QAS'M#FN'E!7:B
M@FFMXV?5%!5&ZZ-KGT54WCW.7X:[R`GL\CLCS+E9-H3Z6I^2M7T;[?6-X&?<
M(8[RD=GG&1YE2%C+W9+9?*7N:Y4C)FC\EQX.8?"UPXA:HQXO&G&C/O\`O[LD
M\/-)U8,Y=WV]GO@FBGB9-!(R2)XRU['`AP\((YKL4IGT[JK14KZO3-2^X6W.
M\^CD&7`?W1S\[<'R+9=+:\M%\+::8]PW#.Z8)C@./@:[M\QP?(HWX><M=)U1
M_P!SA*G$1GHQ(TS_`-REN*(BSM(B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@
M(B("(B`B(@(N$DC(VE\CVL:.9<<!8:MU9INAX5-ZHVN'Z+9`\^AN5*M;6Y1F
MC:]:]:<F<1:#6[4M-0$MIQ5U3NSHXMT'[W$+']8-_N'"RZ0J91V/EWB/Y`#^
M:NCA,:=YC+QV43Q>#&T3GX;J<BF._M5N9X1T=LC=_<!']17WYAZGN/\`[ZUA
M.6GG'"7D?\P/Y+O1ZQUKQ_;G2+3U*3^=E`K+K;*$$UEPI:?'TLK6_P#,K7:W
M:'I.D!_[2Z=P[((W/_GC'\UC:/97IV$A]5+65;^W?D#`?]T9_FMBH='Z9H2#
M!9:3>'Z4C.D/I=E,N'K]YGT,^)MRB(]6J3;4Z69_1VFQ5]8[LS@?R;O%:GI:
MY7&Z[?C5W.VNM\QL!#87`YW>D&#Q`/:?0KG%#%"P,AC9&P<FL:`/Y*3?K)?P
MY_B*&)?#F,J5R_*>'AXD3G>V?X5Q$14KQ$1`1$0$1$!$1`1$022Y_G'6C]WW
M_P!<BK:DES_..M'[OO\`ZY%6T!$1`1$0$1$!$1`1$0$1>:X5M+;J*HKJR414
MU/&9)7D$[K0,DX'$_<@]**57K:F)10?->C[J?*]W3QU<,C'A@X#=:..3SX\A
MV9Y:UK#:!K.C:PUMOK[12R8/24]`]VZT]I>1_(8*T5X:^6=OECO9K<53/*OS
M3W+C6UU'00F:MJH:>(?IRO#1_-:9==INGJ0]'1=/<)CR$+-UI/\`>=S^X%3G
M351LVOL[9KOKPU=8X\8ZHNIN/@WI.)^XA6>P6C3M'"V:R4M%N$<)H</+O]OB
M3Z5W+`ISF;>D?MS/B+\HBL><_II/RUM%U"/^RK3':J9W*:88=CSO_P"C5VP;
M-JFX2BHU/J"IK9/V(R<#_:=G^0"IB)TJU?IQ%?#GYG1:SOB3-O'EY,%:-)Z?
MM&Z:*V0"4?\`>R#??_O.R?0LZB*BUK6G.TYM%:5K&58R$1%%(1$0$1$!$1`1
M$0%JVJ=$V;4(=+)'W-6]E3"`''^\.3OOX^5;2BE2]J3JK.4H7I6\:;1G"3LN
M>K]".;%=XG76RM.&U#226#^\>(\SN'@*H&G]1VF_P=+;JIKW`9?$[O9&>=O_
M`%Y++/8V1CF/:'-<,$$9!"G^H-G<#Y_E/3-2ZUW!AWFM8XMC)\F.+/NX>1:-
M>%B]?Y9[8Y?F&?1BX/4^:.R>?XE0D4QMFN[I9*MMKUK021/Y-JXV<'#PD#@X
M>5OH5&HJREKZ9E515$<\#QELD;@X%58F#?#Y\NW[+L+'IB<N?9]WH1$52T1$
M0$1$!$1`1$0$1$!$1`1$)`0$6OW;6&G;3O-J[I"91_W41Z1_H;G'WK4IMI-9
M<9'0:8T]4UC^0DE!('G:W_J0KJ</B7C.(V\E%^)PJ3E,[J:O)67*WT0)K*ZG
MIP/I96M_YE3D67:+?^-TN\=JIG<XH3AV/,S_`*N7NHME5BC(?755962_I$O#
M`?0,_P`U/X.%7KW\MT/C8MNI3SV9>MV@:3I`<W5LSAV0,=)_,#'\U@I]JE#(
M_H[59J^L?V<FY^X;Q6ST6C-+T1!ALM*YP_2E;TA__+*SL$$%.S<@ACB9^RQH
M:/Y)JX>O*LSXSE_1HXBW.T1X1G_:;#4VT.Y<+=I9E*QW)\[3P_WBW_DGR)M,
MN7&MU!!0L/Z,+L$?[C?^JIR)TG+JTB/QG_9T;/KWF?SE_2:1[+FU+A)>=15U
M8[M`X?S<7+,T.SC2E*!O4#Z@CMGE<[^0P/Y+<D4;<5C6VU?XE7A<&O\`Y_UC
MZ&S6F@`[BMM)!CMCA:#Z<+((BIF9G>5\1$;0(B+CHB(@*1_K)?PY_B*N*1_K
M)?PY_B(*XB(@(B("(B`B(@(B("(B"27/\XZT?N^_^N15M22Y_G'6C]WW_P!<
MBK:`B(@(B("(B`B+SUM;1T,/35M5#3Q9#=^5X8,GD,E!Z%X+Q>+99:-U9=:Z
M"DIQPWY78R?`!S)\@XJ?WS:8)*FKM6G;?-4U)'1T]4,/:Y_[36#)<!Y<9\W%
M>&@T-J;4CJ6JU?=)6QPY,<;MUTPWN?(;K,_>>`'8M->&F(U8DZ8]?)FMQ,3.
MG"C5/IYNF_[4[A7S=P:2MKV%YW6U=5$7/=_Y<(X_>_']TKHL>SK4%YJI+GJ6
MY543YP.E,LF_/(T'(;C\E@\``X>!52Q:>M%BAZ*VT;(B1ATA[Y[_`#N/$K++
MOQZX>V%'YGG[(_`OB;XT_B.7NP]ATY9[#%N6VC9&\C#I7=](_P`[CQ^[DLQA
M$6:UIM.<SFTUK%8RK&37[UHW2M\WOE;3]NJGGG(^!H?_`+PP?YK$6G9MIW3]
M+>HM-"IM,UT@Z%TT,[GNAYX<S>)P1G//L"W=%Q)H=79M=VG2UOMVG=04MQN<
M$Q=45=X829HR3AO>YXC(XY[.?%<=7:PU1IV[B*GT+77FT]$UQK**4%^_^D.C
MP3@</`M^1!+J#;;HJ684UT=<++4]L5QI',P?.W/\UOEEU#8KZPOLUXHJ\`9<
M*>=KRT>4`Y'WKU5]NM]QBZ&X45/5Q?L3Q-D'H(*P5+H32U!#=([5:8K:ZYTY
MIJB2C_LW;A!'>]C3Q/((-H1:%4Z+O=MTE26+1^K:N@J*:H,O==<P53Y&G/\`
M9G/`#B.SL7S5UUVCVJY1OT]INWWJU-@;T@-1T4YDX[Q&3C'+A@H-^125NV2*
MVNZ/5NC=06-PYR.I^EB'^UPS]P*W/2VN]*:K$HL5XAJ7PQ]+)&6N8]C?"0X#
MAY4&SHN$4L<T;9(I&R,<,AS2""/.%S0$1$!$1`1$0$1$'CN=MH;I2NI+A2QU
M$#N;7C.#X1X#Y0IS6Z-OVF*E]RT;7221$[TE%*<EP\''@_[\'RJI(K</&MA[
M1R[/LIQ<"F)O//M^[1--;0[?7RB@O,9M=Q:=US9<B,N\&3Q:?([TE;T"",CB
M%@=2Z4L^HHB*ZG`G`PRHC[V1OW]H\AR%HICUCH$DQDWBQ,[#G,3?YEG\V^96
M_#P\7Z>T]D_Y*KXF)@_4WCMC_85E%KNF=76;448%'/N5.,NII>#QYOVAY0MB
M6>U+4G*T92TTO6\:JSG`B(HI"(B`B+S5M?1T$1FK:J&GC'Z4KPT?S2(SVAR9
MB-Y>E%HEVVFZ=HR8Z,SW";DT0LPTG^\[_H"L3\O[0K__`.Y[*RVT[N4TXXX\
M[_\`HU:(X7$F,[;1W[,]N+PXG*N\]VZG2RQPQNDED;&QO$N<<`?>5JEVV@Z7
MMN\TU_=4K>!92C?_`/R_)_FM?BV<W&YO$VJ-1U%4[MBB)('WNX>AH6UVC1FF
M[5NNIK7$Z5O*6;^T=Z7<ON7=.!3G,V\-O67->/?JUBOCOZ0U(ZWU5?,LTSII
M[8W<!43C>'GSP;_,H-&:OOIWM2:D=%$[B:>G.\/0,-'\U3P```!P"^ITG3].
ML1ZSZG1M7U+3/I'HTZT[.],6X-<ZB-9*/TZIV\/]W@W^2VV&&&",101,CC')
MK&AH'W!=B*F^)>\YVG-?3"I2,JQD(B*"8B(@(B("(B`B(@(B("(B`I'^LE_#
MG^(JXI'^LE_#G^(@KB(B#3-JVH+CIS1\U9:#&RX33PTL$LHRV)TCPW?([<#*
MTJ\:DVB1WH:2TS4VRNK[):V55UK:R/`J)2,[@`X-)''LY\QA;SM3GT[3Z$NT
MFJH99K3N-$D</^D<XN&YN>!V]C!Y>'@HU:;AH:@TA=+=;=3W;2EWN%1&*V>\
MQ&6L?%NG``:/R2TG!&.?F07;1%_;JC2=KO[8>A-9"'NCSG<<"0X`]HR#A9Y:
M]H&FLU)HZSTVGZDU-KCIVB"<@@RCCEQ!`XDY/);"@(B("(B`B(@DES_..M'[
MOO\`ZY%6U)+G^<=:/W??_7(JV@(B("(NFKJJ>C@?454\<,+!ETDC@UH^\H.Y
M=-954]%32557,R&"-N\^1[L-:/*5/+WM)8^I90:5HG7.J><;Y8[=_P!EHXN\
M_`>=>.CT-J#453\H:ONDL;''>%+$_):/!^RS[LGRK3'#3$:L6=,>ODRSQ,6G
M3A1JGT\WV^[39JFH-NTG;WU,[CNMJ)8R=[RLC'$^=V/,5Y+=L^OVH*IMRU?<
MI03Q$1<'R`>`?HQCR`*F6:QVJR0=#;:**`?I.`RYWG<>)637?CUIM@QEWSS]
MCH]L3?&G/NCE[L79+#:;'!T-LHHX<COGXR]_G<>)641%FFTVG.6FM8K&4"(B
MXZ(B("(B`B(@(B("(B#X6M<"T@$'@0>2Q1T[8MVN#+321.KH3!4R0Q"-\K""
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MS20O]E;`SI)8)PVIZ3CO'=[1RX!OA04%%,K/MGT;5SBCNLE98:[DZ"Z0&+!_
MO#(`\^%1:&NHKA3MJ:"K@JH'<I()`]I^\<$'H1$0$1$!$1!H^IMGMMN<AKK8
M\VRX@[XDA&&.=X2!R/E&#YU@Z35NHM*5$=OUA125%,3NQUL7$D>?D[^3O.JH
MNFKI::LIWTU7!'-#(,.9(T.!^XK17B-M.)&J/6/"6:_#[ZL.=,^D^,//:;K;
M[O2MJ[=51U$)[6'BT^`CF#Y"O<IE=M!5]IJG771==)33#B:5S^#AX`3P(\CO
M2%UBS;1[^/\`M.[1VJG<,&.(X=CS,_ZN4IP,.?FK>,N_FC&/B1\MJ3GW<O-O
MUTOMGM+2ZXW&GIS^R]XWCYF\SZ%IEPVH6XR=SV2VU=QG/`8:6-/W<7'T+T6O
M9A8*9_2U\E1<9B<DROW6G[AQ/WDK<[?;:"W1"*@HX*:/&,1,#<^CFN9\/3MM
MZ1^W<N(OV5]9_2=;^TW4'Y#(;)3.[3WK\?S=_P`EZ*+9?2RRBIOUVJ[C.>)&
M\6C/G.7?S"I")/%7C:F5?#]\R.$I.]YFWC^F*M6GK):`/DZVT\#OVPS+_P#>
M/%95$6>;3:<YEIK6*QE$"(BXZ(B("(B`B(@(B90$3*90$7!\T3&&1\C&L'-Q
M<`!]ZZ9Z^BIXFS5%9!%$[\E\DC6@^8DH/2BQOR]9/KB@]99[UPI=1:?K*AE-
M27RVSU$APR**JC>YQY\`#DH,JBQ[;S:'=V;MUHG=Q`NJL3M/0`9R7\>]Q@\_
M`5XZG5FF::U17B>_VYEMEDZ*.J[H:8GOX]Z'`X)X'T%!G$6H/VE:!:TN.KK1
M@#/"I:3Z`N%+M,T'5U,-+3ZHH))YGMCC8UQRYQ.`!P\)0;DI'^LE_#G^(J##
MJFPS:CJ--17%CKQ3Q]++2AKMYC<`YSC')P[>U2G3NH+/J3_*#=<+)7,K*5M@
M,1D8UP`<)!D<0/"$%Q1$0:+MCL]UONA*R@LM'W96]-!*R$/:W>#)&N/%Q`Y!
M2RHU=)!M#?J?7.SNZ45,;4*'!I14L:\2EQ?O$`8+3CM*M.OZ_45LTM6UVEK=
M'<+K%NF.G>TN#F[PWB`""2!D@`^E0:;6VNKRRT-@U];Z6:ON<-OGH*2AZ.HI
M'29!<YL@WB`1C@<>5!^A]+5]JN>GK?7V2)L5MGB#Z=C8NC#6^#=[/,LLL9IV
MWU-JLE%;ZRX27"I@CW9*J1NZZ5W:XC)QZ5DT!%U5%3!3-8ZHF9$U[VQM+SC+
MG'#1YR2`O+=[Q:[-3MJ+K<*>CB<[=:Z:0-WG>`9YGR!![T7@^6+3\E?+'RE2
M?)N[O]U],WHMW.,[V<<^'G2T7BUWFG=46JX4]9$UVZYT,@=NN\!QR/D*#WHB
M())<_P`XZT?N^_\`KD5;4DN?YQUH_=]_]<BJE95TU%3OJ:NHC@A8,NDD<&M'
MWE.9,Y<W>NFJJJ>C@=454\<,+!ESY'!K1]Y4]NVT<U-2;=I.W2W&K=P$I8=P
M>4-YD>4X"\])H6]W^H;7ZSNLCNUM)"X=[Y,CO6_[(^]:8X?3&>+.G^_)EGB=
M4Z<*-4^GF]5XVD,EJ/D[2M!+<ZQW`2;AW/.`.+O/P'E7DI=$7_44[*W65UD#
M`<MI(7#O?)P[UOW9/E5!M%GMEG@Z"VT45.P\]P<7><\S]ZR"[TB*;8,9=_W]
MG.CVOOC3GW?;W8ZSV6UV:#H;;114[2.^+1WSO.X\3]ZR*(LTS,SG+5%8K&4"
M(BXZ(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B#'7BR6>]TYI[O;*2NBQC
M=J(FOQYL\ON6L6_9Q8[#27MNDC+9:NZ0"+NB-[I.@(SAS&N/`\?#X%O"(-$G
M&O\`3VG[/24#:?5-P;,6UU34O%,3&3P+0#S`(\)X=N5\U#M1TOIO4<EBOIKJ
M)S6M(JWTSC3O)&<!PR3C/'AA;XNBLHZ2N@=35M+#4P._*CF8'M/G!X(/'9;]
M9;Y`*BSW2DKH\9S3RA^/.!Q'WK)J:7G8SHNNG[LMU/4V.N!RVHM<YB(/]WBT
M?<`O9:;+K?2VGKNV&_NU37]Y\FQ5[1%N8_*#WYR[.>T]@Y90;^BTFIUN^R4V
MG(=36:LIKG=R(G14;.GCIY<@!KG@]N\.6>WP+9(KY9IKG/:HKK1ON$!`EI1,
MWI6$C(RW.>109)$1`1$0$1$!$0D#F@(M?O&L]*64.^5-0VVF<WFQU0TO_P!T
M$G^2Q5/M'T]<K!=KUI\5EZCMCFMEAHZ=W2/+L8W6NQGGG[B@W5%I=7J#5E30
MZ>KK%I-SXZX[U=%6S""6B9D<VG&3C>]`X<5CM3Z?VDW>]U0MFLZ6S6,EO0M@
MI!)/C=&]DD#MSC!Y(*(YS6@EQ``YDK$U6I+%2V^NN,MUI32T(!JI(Y!)T/\`
M>#<D*>MV,4-<[I-4:LU%?'=K)JHLC/\`LC)'I6Z:;T/I735%545GLT$-/5M#
M:ACRZ7I@,X#M\G/,^E!C[EM#M-/:+-=K90W*\TEVE,=.^@IB[&#@EP."`./9
MV%>35EYVDQWJ:W:5TI034;6M+;C6U8#'$CB-P$'@<CM6^000T\3(8(F11,&&
ML8T-`\P"[$$D&F-K]XQ\KZ\H+1$[B8K52;Q'DWG`'^:V/3NA:BU4%UI*S6&H
M+F;C3]`Z6IJ<N@X.!=%SW7=]Y>06\(@T6MV=45;I*ETS/J"_F&GJ#.*ONL=T
M/)WN]<\MXM[[ECL"YZKV<VC5%7#4U]SO,+HJ=M.&4M9T;'-!)R1@Y/'FMW1!
M*(MAFCV/WG5M]D'[+J\X_DT+8=*;-M.:6N;KE;'7`SNB=">GJW2-W7$9X'MX
M!;LB#2J79II&ETS<-,PT,PM=?*V:HC-2\ES@6D'>)R/R1R7.Z[-M'7>U6FU7
M*U&HI+5$8:1KJB1IC:0`1D.!/Y(Y^!;DB"=P[&MFT6<:9B=G]NHE=_S>LG9M
MFFA[)<Z>Z6O3\%-6TY+HI6R2$M)!'(N(Y$K<408.ETGIREENLM/9Z5C[J'"N
M.[GN@').]GGG>/I7"31^EY;/#99+!;W6R&0RQTI@'1L><]\&^'B?2L^B#5X=
M`:'A:6QZ1LN"<\:*,_\`,+U4VCM)4D[*BETQ9X9F$%LD=%&US2#D$''!9Y$'
MC9;+<RO?<64%*VN>W=?4B%HD<.'`NQDC@.WL"E-+2TU)_E'=%2T\4$?S=SNQ
M,#1GI.>`K$I'^LE_#G^(@KB(B`2.U3W:=H735\ME7?:NFEI;K00.J(J^B=T<
MX,;2X<>3OR>&>780MGU=IVBU58YK-7S5,,$KF/Z2FDW)&N:X.!!P>T*77G9I
MJ>SV>O=:MIUS9;&T\G3P7*,U#>BW3O<<G]'/)N4%!V8W"KNN@;#<*ZIDJ:F:
ME:Y\T@`<\Y(R<=O!;6M0V401TVSO3T$-7#5QLI&AL\(<&2#)X@.`=Z0"MO0:
M3M`ME')-8KF]LIJH;Q0B,]._<;F8`G<SNYPXC.,KV1-CGVCU1J,%]+:(33`_
MH])+*)"/*>CC!/D"SEUME/<XZ>.I+PV"IBJ6;AQW\;@YN?)D+QWJP17.JIJ^
M&NJ[=<:=KHV55(YH<8W8WF.#VN:YI(!P1P(R,(-(CCB^?@M71M^3A?I*AL>.
M\Z?N!DF/!^4YS\?M<5LS0R':41!AIJK.7U`;^D8Y@(R?+A\@SX!Y%V_,ZV_(
MXMW=%:)FU/=@K^F_SGNCZ7>QC>P<8QN[O>XQP7MLEACM=355LM=5W"OJ0UDE
M55N:7;C<[K&AK6M:T%SC@#B22<H,RB(@_/6UK4=1I7;-;[M34SIY&V(L`;&9
M-W>DD&]@>!8"76EFJ:^"IU]-J3I)FB6"E%%N;\9_)<W+AAI[-T?>J3<_SCK1
M^[[_`.N14^NMENK]WNZ@IJG=Y=-"U^/2%=AXUL.,J[=_W4XF!7$G.V_=]DGM
MFU?0UEK/D"WZ9O\`2UQ>&&B;;<3N>1D`M+MXG'A6<I]K%MJ213:3U=,6G!$5
MJ+\'[G+:IM(Z:FOC+_)9*,W9CQ(*L1XDW@,`DCGP\*PMNV8:1M==<;A:Z.HH
MZROIY:>6:.J>7!LGY1;O$@'/'/8JIF9G.5L1$1E#S':;`.>B-;CSV1_O7SK.
MI_$K6OL5_O7"@V;2VBQW:UV;65_@DKW1%E5//TKZ;<))#.6-[."ODVF=HE%I
MRDH+1KF.HN<=2^66LKZ4'I8R,-CQWV,<\]JXZ[.LZG\2M;>Q7^].LZG\2M;>
MQ7^]?+W/M7H*:U,L])8;K(VF`KWS.=&7S9XE@RT!N,+UU6I-7T^LH[.W14M1
M99)8X_E5E4`&@M!>\LP3@$D8R,X0>7K.I_$K6WL5_O3K.I_$K6WL5_O7;:=H
M@K;Q<+;6:6OUO91QS2NJZBF(A>R//$'@>(X@87VR;5=&7BV7.YPU\T%);1&Z
MJDJ*=[.C#W;K.PYR>P(.GK.I_$K6WL5_O3K.I_$K6WL5_O6Q46LM*UMM9=(-
M06_N&28P,GDF$;72`9+`78XXXX6:@J:>HBCFIYXY8I!ECXWAP</"".:#0^LZ
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MQZ``O6@B%=K_`%A6SZ>J(+'J6V,B#77>E9I]\PG=EI+(W'B`>^&<@\EA-006
MG4E[J[C>;=M5FI9W[S*".WO9!$,`8`R>'#LQS7Z*1!`[/3;-K3NFGV2:JE>/
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MM;>Q7^]:?IR]-OW^4":YEMN5O`L!CZ&XTQ@EX2`YW3V<>?G5R4C_`%DOX<_Q
M$%<1$08/6-#=[A89Z>Q7D6BX!S7QU;HP\,#7`D$'L(!"C<][VH5-+7V*FN^C
MM5]T020/%%6,94-#FEI.[EHSQ\!6[;?G5C=F5S[E,HB=)"VJ,7Y0@+QO_=RS
MY%KU\V?[+ZG0DUYL1IJ+N6F-12W2EJB'L>UN\TN.]Q.<9!XYY8*#?]EUOK;5
ML_L-NN-.^GJZ>E#)8G\V.R>!6V+4]EUVKKYL_L-TN3BZLGI@97D8+R"6[Q\X
M`/WK;$!$1`1$0$1$$DN?YQUH_=]_]<BK:DES_..M'[OO_KD5;0$1$!$1`1$0
M%YJF@H:N&6"JHZ>>&7'21RQ-<U^.(R"../*O2B#6KAH;2-PM;+34Z>H>X&3&
M=L$4?1-$A&"X!F...U874&RC2-[I[;3RP5=+';H3!2BEJ7,Z-A.<<<YX]I6_
MH@T:MT)//JZGU%3ZLOE+%&^$NMT<_P#F[VQ@#<(\!QQSG.2N%MT[KJAU)65\
MVM6UUKEZ=T5!+2!HB<[)C&\,DM:2.1'`+?$03BV.VM4%KN\ET98;G7LB9\GQ
MTQ,;9'EW?;Y.[@!O+DOIUEK*VZ8;<KSH&KDN?=I@-#;Y>F/1;F>FR`[AGAA4
M9$$ZN6U>Q6:VV>MOMNNUO=<H72B)],7.@#7;N'X/`GL_Z+/2ZZTG!>8+'47J
M"&YS",LII0YKCT@!8.(QDY'#.>*V8M!&"`1Y5C:JP6.KN$5RJK/035T3FNCJ
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M8"V&@N5ON,'=%OKJ:JASCI()6O;GP9!0>M$RB`B(@(B("(B`B(@(B("(B`B(
M@(B("(B`B(@(B("(B`B(@(B("(B`B(@(OA(!P2L:^_61C*E[[O0@4L9FG_SA
MG]DP<W.X\!Y2@R:+4:C:+HR"SU5Z^7J>:WTTS8)9H&NE#7N_)'>@YSZ%BKCM
M8TU2V*VWNEIKI<J2XOEC@[CI27%T9`<"'$$<_P"104-%/KOKV[TU;:X;7H2]
M7*GKJ6&I,[!N"`//Y+^!`>WM!*];KOKXZT;;V:5I&Z;$VZZXFK:7NCW?R@S(
M(.<#&#R/G0;LBGUF@VJ3U5T%ZK+!34SZ66.B=1L<YT<Q/]F]P<.(''(RNJAT
MEKJHL%RH+WK^9U=4R1/@K**G$3J8-)WF@#=R'<$%&7EJKA0TCFMJZRG@<[\D
M2RM83YLE:'4[+Z>Y:>H;-?-47ZN-)/)+W3W3NR2A^.\<3O9:,<%[*[9;HVY?
M)9NENEK9+;2,I())JE^]T;#EN]ND9.2>/E09Z;5FFH+U'8I+W0BZR/$8I!*#
M+O$9`+1Q'#PJ66*^VJ__`.43/56BK%3#!8WTTCPQS<2-E&\.(&<9Y\E4W:3T
MT^]F_/L="^ZE[7]UOA#I`X``$./(@`<0IU!3P4_^4@YM/#'$UVGBYPC:&@N,
MO$G':@L*(B#`:XOELTYI6Y7>\0]/10Q8?!NAW3;QW0S!X')('%?F]]IT[22P
M7_4^R*ZVK3\SVO=-37%\D<;7'@Y\6`0.(X9;Y!V*\[7--W+5>AZVS6GH>[))
M(GL$S]UIW7AQ&<'L"T2_ZHVDMT_<K/J39FZJCJJ22G[HMDW3-&\P@$L&\<9P
M>806:U=PFV49M@B%`86=S]$,,Z/`W=WR8QA>M:;LCCGAV;:<BJ8Y(YF4;6N9
M("'-P2,$'DMR0$1$!$1`1$022Y_G'6C]WW_UR*MJ27/\XZT?N^_^N15M`1$0
M$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0%Q>QCP6O:'`@@@C.0N2(,'/I334]-6
MTK[%0"&M8UE2V.!K.F:#D!Q:`3@\5@*W99HZHT\_3]/0S4-`^K%:6TL[FNZ4
M-W0<G/9V<EO:()W=-G-4ZU6BV6#6=[LT5MCD8UT<N^9MYV<OXMWB.('@7IN-
MFVAC4=#46K55$VR1B%E12U-*'2/#<=(X.W2=YW'M&%O:(-%H[AM'9JRJAN%D
MM3M-ATSH:BGE/3[@!,8+2[BXG=!X8&5X;1M,D-ONU;JC2EVT_';(6RSOJ&;[
M'!S@T!AP"XY/8%2%Q>QCVECVAS2,$$9!0:]8]:Z6OMK%UMUZIG49F[GZ24F$
M=+C.YW^.^QQPMB:YKFAS7`M/$$'(*UN_:'TK?K6+5<;-3FC;,9Q'"#"!(1@O
M[S''!6NW?9M4]RVFFTKJZZZ>BMD'0110GI(W@N+B7#(WCQ[?0@HZ+1:OK)I]
M90=R"S56EI)(V/Z3(J86!HWW=@))SRSS'!>:U[0ZU]PNM-?M'W:STU!3S51K
M)AO0OBC/,'`[XC&`,H*&BU73>OM):CM]1<+9>8#3TQ8)W3@P]$7YW0[?`''!
MPMGBDCEC;)$]KV.&0YIR#]Z#FB(@(B("(B`B(@(B("(B`B(@(OA(',K7Y-9:
M8;555%%>J2HK*6"2>6GIY!+(UK!EW!N>(\'-!L**;4.TQ^H;'=KAH_3-RN%1
M1&$0Q5+>@;5;[L$L=QR&XR>2^U,.U._Z;HS'4V[2]U,\@J6AHJ/['`W"T]\`
M[GGCZ.2"CD@#).!X5@I-7::9?([!\M4;[M(YS&TC)`Z3>`)(('(X!X'"UFZ;
M,:74$]HK-1WZZU=304L43VP3=#%/*PYZ4LXX<3X#V!;3!I73<%ZFOL5DH1=9
M7[[JLP@R;V,9#CR/FP@U.T;3X=1Q7=NF-.W6LJ*&E=-%W1%T,=0\.`Z-KN.'
M<>1\!2*OVKW+3-1*RRV>T7KNIO0QU$W2LZ`M[XDM)[\.Q[E1@`!@#`\"^H)U
M<;%M-N5CM$+-7T-JND?2_*$M+2B1DV79CW`X`C`X'ES7==-#7FY7:W7"77=Z
MIV4L,+)::D=T<<\C/RGD9QWW:,+?T0:3#LYL46M#K#NFY/N/2OE#'U.8FES2
MT@-QRP3PSVKNL>S?15B=6NMMBAC[MA=!4!\CY&R1N():0YQ&.`6X(@PUNTOI
MRV4LE);[%;J:GD<'21QTS`UY'(D8XD9[5EHXXXF".)C6,')K1@#T+FB!A$1`
M1$0$1$!2/]9+^'/\15Q2/]9+^'/\1!7$1$!$1`1$0$1$!$1`1$022Y_G'6C]
MWW_UR*MJ27/\XZT?N^_^N15M`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`1$0$1$!$1`7P@$$$`@]B^H@P-VTCIJ[VVJMM=9Z5U)5/;).R-G1=(YO
M)Q+,$D>%:M<-F,<-CM]ITEJ.YZ<90RRRQNIY"\2.D(SOY(+@,<!GM5'1!/;K
M#M0MUPM4=CGL]SM<4$,-4ZMRV>1XX22\,#B..`3YEZ*;6UT.M)=.UVC;K2T?
M22-ANN-Z![&-+M]QP`T''#B>86])A!I^E]H^CM3Q5,EKO$?^:Q]+4"=CH>B9
MG&\2X`8SVY6UT]1!4Q-FIYHYHG?DOC<'`_>%C+AIJPW&EKJ6KM-*Z*N8&5.[
M&&.F:#D!SFX)X^5:E/LNMU)IU]DTK=[EIYKZWNTS4DQ<\OW-W=))SNXXXSS0
M45%-KM0[4;+;+1!IRXVR]OI87-K)+F"R6J>79!&#@`#A^5Z5[JO6=ZM^KZ;3
M]7HVY2T<[X8F76F&]!ON:-XD8[UK23Q)SPY(-[1:A8MHND;Y=JJT4%U::^E,
MHEBDC<S`C.'.WB-T@>'*[+GK_25OM%?=_EFGJZ2@<QE0ZB=TYC<\X:#NYYE!
MM:*:U>T.\7/3]!=M%:/KKL:R:6'<J7"GZ'=QASN8W79X'(7?>*':==ZNU3VZ
M\6ZPT1IH7UM.Z(3RMFSE[`[!!;R&01VH*$7``DG`'$DK5ZO7FDZ>EN51'>J:
MK%MAZ>J91O$SHV9QG#<]I7@I]GM(S6TFKJF^7BIJ!(]\%+)49@A#FEI:&^#B
M>&0%F-/Z-TOISI39;'1T;Y6ELCV,RY[<YW2XY)&>SD@U=FT>KO>F);QHS2MQ
MNDS*L4PIZG%.2TMSTH/$%O(<POESH]J=^M=G?27.WZ8J7QO^48A&)W,?O=[N
M'O@1N\^(5)P,8PB#0Z[9Q17/5=+J>YWJ[35=,Z&6*G9/N4[)(P.^#,'`)&2,
M]I6>M6D-,6FY5%UMUCHX*^=[WR5+8\R$O.78<>(!SR&`L\B#X``,`<%]1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0%(_UDOX<_Q%7%(_UDOX<_Q$%<1$0$1$!$1`
M1%A;Y?#:ZJCHX+76W&JJA(YD5*8P0UF[O.)>YHQWS1SSQ09I%K\^HW4MMBJJ
MRRW"GJYY^YZ>@<8G33O(R-W=>6@8#B27#`:2<+NLE]^4:JIM]7;JFW7&F:R1
M]/4%CMZ-V=U[7,)#FY:1X01Q'+(9I$1!)+G^<=:/W??_`%R*MJ27/\XZT?N^
M_P#KD5;0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1
M$!$1`1$0$1$!$1!CJJR6BJ=4OGMM*Z2IA=!-)T0#WQN&'-+AQP?.O%I[2.FM
M-P2P62S4M&R;=Z7<9DR8Y;Q.2<9.,K/(@8"(B`B(@(B("(B`B(@(B("(B`B(
M@(B("(B`B(@(B("(B`I'^LE_#G^(JXI'^LE_#G^(@KB(B`B(@(B("TZ_4-DN
M>KZ2DNE96QU'<$G0P,J'01S-,C2_#F$.<X%K,MSC!!X]FXKQ72U6R[P-I[K;
MJ6MA:[>:RHA;(T'P@$<"@FM#5MI;[;99;E)5V*WWF>AIJVHFZ3=,E,,-,A_*
MW9=^(.))R0TDE;5%+'5;27FF<V1M':3'4N80=Q\DS71M..W#'G'@(\*V)UNM
M[K>;:ZAIC0%G1]S&)O1[O[.[C&/(OELM=MM-/W-:Z"FHH"[>,=/$V-I/AP!S
M0>Q$1!)+G^<=:/W??_7(JVI)<_SCK1^[[_ZY%6T!$1`1$0$1$!$1`1$0$1$!
M$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!
M$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`4C_`%DOX<_Q%7%(_P!9+^'/\1!7
M$1$!$1`1$0$1$!$1`1$022Y_G'6C]WW_`-<BK:DES_..M'[OO_KD5;0$1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$
M1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!2/]9+^'/\15
MQ2/]9+^'/\1!7$1$!$1`1$0$1$!$1`1$022Y_G'6C]WW_P!<BK:DES_..M'[
MOO\`ZY%6T!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!
M$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!
M$1`4C_62_AS_`!%7%(_UDOX<_P`1!7$1$!$1`1$0$1$!$1`1$022Y_G'6C]W
MW_UR*MJ27/\`..M'[OO_`*Y%6T!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`
M1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`
M1$0$1$!$1`1$0$1$!$1`4C_62_AS_$5<4C_62_AS_$05Q$1`1$0$1$!$1`18
M+4MSK*1]NMMK$'RC<9C%$^=I<R%K6E[Y'-!!=@#`&1DN'$+SV2X7:"^U%@O<
M]-53=S-JJ:JIX3#TC-[=>US"YV'-.[Q!P0X<!CB&RHB())<_SCK1^[[_`.N1
M5M22Y_G'6C]WW_UR*MY\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G
M]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_
MH0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/
MG]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\
M_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3
M/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9
M\_H0$3/G]"9\_H0$3/G]"9\_H0$3/G]"9\_H0%(_UDOX<_Q%7,^?T*1_K)?P
MY_B(*XB(@(B("(B`B(@U;5\-33UUDO\`34D]6VVSR=T00-WI##)&6.<UO-Q:
M=TX'$@'&3P759I)KUJZ6^QTE73V^FH>XX755.Z!T[WR![R&/`<&@,8,D#))Q
MR6W(@(B(-!UKLQL^K[[!?*RZ7:BK(:84S30SMC&X'./:TG/?'M6#ZD;+XUZK
M]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7J
MOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->
MJ_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XU
MZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC
M7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^
M->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+
MXUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J1L
MOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&
MR^->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD
M;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J
M1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.
MI&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$
MZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@
M3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^
M!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OC
MX$ZD;+XUZK]?'P*M(@DO4C9?&O5?KX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^
M/@3J1LOC7JOU\?`JTB"2]2-E\:]5^OCX$ZD;+XUZK]?'P*M(@DO4C9?&O5?K
MX^!.I&R^->J_7Q\"K2()+U(V7QKU7Z^/@68T=LMLVE-0F_TMUO%;6&G=3_Y]
M.V0;A(/[(/9X50D0$1$!$1`1$0$1$!$1!YKA6TMNHIJZNG;!30M+Y)'\FA=-
MWN]NLU*VJN54V"-SQ&S(+G/>>36M`)<>!X`$\%K.U:UV^MT;=:NKI(IIZ6F<
M^![QDQNR#D>7("]6J&5E-?K)>J2A^4!3,J(9*2.1C9MV0,/21AY`<YNY@C(.
MZ\X\!#)TFI;%5VNINL-RA%'2DBHDDS'T!`R0\.`+3@C@0.87RS:ELMYFEI[?
M6[\\3!(^*2-\3PP\G;KP"6_ZP&%.Z\7:ZZGO-7%:V4[X8[55LH:F9C'3NCGE
MPR1P):U[A^2,G&ZS..SOU7+<M0WVTT@MM19F3T5RIG2UKF=)AU/@NPQS@&-=
MN9)/$D8':@W:WZPTY<*^.@I+I')/*7"'O'-9,1S$;R`U^,'\DGD5L"EFHKG=
MZG3UHI#IF2WS05]O_M72Q.A#A/&`("UQ+\C.,AN&YSCDJF$!$1`1$0$1$!$1
M!X+Q=K=9J3NRYU3*>$O#&EV27O/)K6C)<X^``E>:@U+8Z^WU=PI[C#W-2$BI
M=+F(P8&3OM>`6<./$#@NC4S[/0R6^\W0RNFHY7-HXH@7OEED86[K&#BYQ&<8
MY#)X#*U"\4EPDD9>[Q2LHX[G=;;3OH]X/,=/'*XLZ5PX%[I'C(&0!NC)XE!N
MUFU)9;U-)!;JT231L$CHGQOC?N$X#@UX!+2?TAP730ZMT[7W%MNI+G')4/<Y
MD?>N#)7-SO!CR-UY&#D-)Y'P+5]JDDD!HYZ-SFUOR?<V@L/?;G<KG'E_KMC^
M_"R>IF446D+1W`(^CAK+;W%N]G]O$&[O^R2/,2@RM;JW3M#<'6^JN<4<['-9
M)WKBR)SL;K7O`W6$Y&`XCF/"L\M"L#*6;9K<C6[A;*+@:TN[7]+*)-[S8(^X
M+9]*/GETO9I*HN-0^A@=+O<]XQMSG[T&61$0$1$!$1`1$0=%95TU#2S5E941
MT]-"TODEE<&M8T<R2>06,LNI['>JF2EMU;OU#(Q*89(GQ/+"<;X:\`EN>T9"
M[-30VJ:S3?+<K8[?"Z.HE<]^ZT=&]KQGR9:.';R6E:E-SO=NNFHXZ.>WT=NM
M-:+>)@65,[Y(^,A;SC8`T;K3WQ)R0W`!#;:'5NG:^XMMU)<XY*A[G,C[UP9*
MYN=X,>1NO(P<AI/(^!*W5NG:&X.M]5<XHYV.:R3O7%D3G8W6O>!NL)R,!Q',
M>%8K4S**+2%H[@$?1PUEM[BW>S^WB#=W_9)'F)7EL#*6;9K<C6[A;*+@:TN[
M7]+*)-[S8(^X(-TKZZEM],:FLF;#"'-9ONY;SG!K1YR2!]Z]*F>HK?35NSZQ
M7:XTK9;I"RVD32#+XWF:'>(\![YWI*I@0$1$!$1`1$0$1$!:]1:QTU77".WT
MMUBDGE>YD1W'".9PYM9(1N//`\&D\CX%FZN".II9J:4N$<L;F.+3@@$8.#V<
MUH\`COT=IM%@I=S3ELG@>;A(,-EZ!P+(X!S<-YH!DX-QD-WB>`;!6ZMT[0W!
MUOJKG''.QS629:XLB<[&ZU[P-UA.1@.(YCPKNO6I++9)HX+C6B.:1AD$3(WR
M/W!P+RU@)#?]8\%K.GFTT^S.XFOW")FUYK2[M?TDO2;WFP1]P7S9E(Z=]VFK
M'.-Q+*!LF^>^W.XXG#[M]TI\Y*#:*[4=DH;=2W&HN,/<M7N]S/CS(9\C(W&M
M!+^''@#PXKT6:[VV]TAJ[95,J(6O,;B`06/'-KFD`M<.'`@%:+8Y[/:Z.*Z5
M,4LTU-<;G26JGIF;[Y6OJ"2V-@Y_D8SP#0#D@<5LVE;?7Q3W2\76*.GK;G,R
M1U-&_?$#&,#&-+N3GX&7$<,\!D#)#8T1$!$1`1$0$1$!:]7ZQTU;ZZ2AJ[K%
M'-$YK)3NN,<+G<A(\#=83D<'$<QX5L*T*X=%)37726EJ3NBHJY9_E"KEXP4C
MIB72%[OTWX?PC&3^3O%HXH-EO6I++9)HX+C6B.:1AD$3(WR/W!S>6L!(;_K'
MAY5RKM166AMU-<I[A%W)5;O<[X\R=/D9&X&@E_#CP!X+"Z.IX*6^ZGI@]SIJ
M>>E@87NR[H6TL>YQ\&\9#YR5K^BNC.JX82&]RP1W7N$?HAO=^'[OF&Z/-Y$&
M\PZDL<UFEO3+E!\GQ$MDF<2WHW`X+7`\0[)`W2,Y(&.*Y6;4%IO3IF6ZKZ26
M'!DB?&^*1@/(ECP'`'!P<8."M8IXK5)KJ\0UI86]U4,U.USB`:P0RGLX%W1L
M:>/@!Y@+LMWRE#M`;)?F4W2U%!+';WT9.X(V2,=()`[OM_OHR#^3@'D>8;PB
M(@(B("(B`B(@+#7K4UDLD\=/<:WHYWL,@BCB?*\,'`O+6`D-SPWCP696J72K
MHK->ZIUMH9[CJ*Y11GN6-V`(X]X-<]QX11@EW$\SG=#CP09.KU)8Z6V4MTEN
M4+J.JQW/)%F3IR1D!@:"7'`)P`>17V#4=DGL\MZ9<H!;X=X2S/.Z(R#@M<#@
MM<#PW2,\1P6IZ=MDMIU;:K?7R12S,M574M,;=V,32U37S;@/(#>:!V[OG*\%
MS,(V@F!SL4;[O0/F'Z)G[EJ"W/ERR`^<-0;[9=06F]NF9;JOI)8-TRQ/C='(
MP'D2QX#L'!P<8."O0ZZ4#;NRS&J9\HOIS4BG_2Z(.#2[R#)`_P#\*U75-?':
M-5T%TCIY:A\-HKGS10,+Y)6-?`6``9)[\X'G/E6MZ=NML;KJT335$\]UKZ.J
M[KE[AG8TRN?3[D;2Y@_LV!I:">`YG!=Q"MHB("(B`B(@(B(/)=;?2W6W5-NK
M6%]-4,,<C0XM)!\HY+S7RQT5ZB@;4F:*:GDZ6GJ:>4QRPOP02UPY9!((Y$'!
M!641!K\.DK*RTUMLFAFJHZYP?535,SGS3/&-UQDSD%NZW=QC=P,87*TZ7MUN
MJ)JI\M97U4L70.GKZAT[A%G)8,\`TGB<#CPSG"SR(-9MNC+1;ZNEGCDKIHJ,
MYHZ6HJWR0TIP0-QA.!@$@9SN@X&%LR(@(B("(B`B(@(B(,+?M.T-\GHJBJEK
M(9Z,O,,M+4OA<W?`#N+2.P8]*ZH=+6T4%;;ZN:ON%+6-#98ZZLDGP!RW2XY:
M<\<C!R`>P+/H@P-HTO06VK?6NJ*ZOJW1&`35]2Z=S(R02QN>`!(&>&3@9)PO
M-;]%V>@JZ::)]=)3TC^DI*.:J>^GIG8(!9&3@8!.,YW<\,+9T0:Q7:*LU;5U
M,SWUL=/5R=+5T4-4]E/4O[7/C!P<X&\!@.[05LX````P`B("(B`B(@(B("(B
M#&WZS4=]MYM]<9A"9&2YAE=&X.8X.:0X<>!`/W+R6S3=-;ZKNAMQN]3WI88Z
MNX2S1D'PM<2"LZB#6+?HNST%7331/KI*>D?TE)1S53WT],[!`+(R<#`)QG.[
MGAA*[15FK:NIF>^MCIZN3I:NBAJGLIZE_:Y\8.#G`W@,!W:"MG1!X[G;J2YT
M1HJN,N@+V/W6N+>+'A[>7E:%[$1`1$0$1$!$1`1$0=%=2Q5U%4450'&&HC=$
M\-<6G=<"#@CB.!YK7[?HZAM[J7N:YWP1TQ;T<+KG,Z,!N,-+2<%O#&.2V=$&
ML5VBK-6U=3,]];'3U<G2U=%#5/93U+^USXP<'.!O`8#NW*]%WTO07*M;7MJ*
MZAJ^C$+YJ"I=`Z6,$D-=N\P"3@\QDX(R5GT0:S4Z+LLK;<VG-;1?)\#J>G-'
M5R0EK'$%P):<G):"2>)PLI9K3%:8Y8XJROJ1(X.)K*M\Y;PQ@%Q.!Y%DD0$1
M$!$1`1$0$1$!:HS0]LB=-W-<KY3-FE?,YD%TF8W?>XN<0`[ADDE;6B#7KGI6
M@KZF.L%5<:.K;"V!]11U;XGS1CDUY'Y6"20>8R<$9*^U6D[/-;K?0P1340MW
M_L<U),Z.6#(P</YG(Y@Y#NW)6P(@UUFD+*+3);7QU$@DG%4^I?4/-09QC$O2
MYW@X8`!!&`,#AP7?9M.45KJY*_IZVLKGQ]$:FMJ'3/;'G.XW/!HS@G`&<#.<
M!9M$!$1`1$0$1$!$1`6MUVD+=5W6JN@K+K2U-4&"8TE?+"U^X,-X-('`?\RM
MD1!K]7I6WU5!1TTM3<.GHG.?3UO=;S4QEV=[^T)R00<$'((QPX!(])65MFJ+
M3)%-/%4R]/---.]TTDHQB0R9W@\;K<$$8W1C&%L"(,+9-.T5IJ)JQL]965LS
M!&ZIK:ATTFX"2&`G@UN23@`9/$Y7ODM]-)<J>YN83500R0QNWC@,>6EPQRYL
M;Z%ZT0$1$!$1`1$0$1$!>"_5S[98[E<HV"1]+2RSM8XX#BUA=@^A>]836G_P
M??\`_P"W5'_IN02^Q:^VK7ZTTUWM6S^WU%#4M+HI.[VMW@"0>!<".(*R'SGV
MS?9Q;_:3/C6<V&?_`"ITY_Y+_P#U7K?T$D^<^V;[.+?[29\:?.?;-]G%O]I,
M^-5M$$D^<^V;[.+?[29\:?.?;-]G%O\`:3/C5;1!)/G/MF^SBW^TF?&GSGVS
M?9Q;_:3/C5:)`!)P`.U8NSZALEZMTMSM=SIJFAA<YDD[']XPM&79)Y8!R@G/
MSGVS?9Q;_:3/C3YS[9OLXM_M)GQK=M/ZXTEJ*NFH++?:2LJHFESHF$@EHYD9
M`WAY1D+C:M>:/N]Y=9;;J"BJ;@"0(6./?$<]TXP[D>1*#2_G/MF^SBW^TF?&
MGSGVS?9Q;_:3/C5"9J6Q/LU5>VW.`VVE<]LU0,[K"PX<#P["OD.I[!->8K)%
M=*=UREA$[*<$[SHR-X.'DQQ03[YS[9OLXM_M)GQI\Y]LWV<6_P!I,^-;Y)J_
M34=7=*-]XIA46N(S5L>3F!@QDNX>4+T4NH['5W*&UT]SIY*Z:F;5QP!W?/A=
MR>!VA!._G/MF^SBW^TF?&GSGVS?9Q;_:3/C5`?JG3S+56W9]WI64%%,Z"HG<
M[#8Y&G!:<]N2!A?--:JT]JB"6:PW6GKFQ$"01DAS,\LM(!&?,@T#YS[9OLXM
M_M)GQI\Y]LWV<6_VDSXUNE_UUI73]TIK5=[Q3TU7/QW7NX1-P2'//)H.,#/A
M^]9NHN5OIG4C:BL@C=62"*G#G@=,X@D!OA.`3P03#YS[9OLXM_M)GQI\Y]LW
MV<6_VDSXUO\`4ZKTW2WR*P5%[H8KK+C<I72@/)/(8[">P<RGSKTU\O?-[Y;H
M?E?EW)THW\XSC'AQQQS0:!\Y]LWV<6_VDSXT^<^V;[.+?[29\:IMQNMNMLE%
M%75<<#ZV<4].'_\`>2$9#1Y>"\,.J].SVJNN\-WIGT%`]T=5,UV1"YO,.[1S
M0:!\Y]LWV<6_VDSXT^<^V;[.+?[29\:H]!?K/<)*Z*CN$,KZ'=-2T'_1!S=Y
MI.>PCBL)4[2-#TL5-+4:EH8V5472PN<XCI&;Q;O#ARRUP^Y!J?SGVS?9Q;_:
M3/C3YS[9OLXM_M)GQK<:O:!HVCL]->JC4%&VWU+W,@F!)Z5S3AP:`,G!Y\."
MY5FO='45OH;E4ZAH8Z.N#C33%^6R[I`=C`["0".Q!IGSGVS?9Q;_`&DSXT^<
M^V;[.+?[29\:VUNT;1#K?)<6ZDH31QRMA?+O'=:]P<6MY<R&N/W+E3[0]%5-
M#65\&HZ*2EH]SNB5KCB/?.&YX=IX(-0^<^V;[.+?[29\:?.?;-]G%O\`:3/C
M6_:>U9IK4CY8['>J.NDB&9&0R9<T>$CGCRKNU'J.QZ9HVUM]N4%#`YVXUTIX
MO=X`!DD^8()W\Y]LWV<6_P!I,^-/G/MF^SBW^TF?&MZAUEI>?3TFI(KU2/M$
M3@V2J#N]820,.X9!R1P([0LA)>[3'5VVC=7P]T7-KGT;`[/3M:T.);X0`04$
MU^<^V;[.+?[29\:?.?;-]G%O]I,^-5&Y5]%:Z*:ON-5%2TD(S)-,X-:P9QQ)
M\I"Q]_U3IW3I@%[O-'0NJ/\`1-GE#2_PD#P<>?)!/OG/MF^SBW^TF?&GSGVS
M?9Q;_:3/C5+J[Q;*1M`Z>LC#:^9L%*6]\)GN!<T-QG.0"<\L+QV;5FFKY6U%
M#:+W0UM53YZ2*&8.<`.!/E'E&0@T#YS[9OLXM_M)GQI\Y]LWV<6_VDSXU4:6
MX4-74U=+354,L](\,J(V.!,3B,@.'8<'*PE;KC25!"9JV_4=/&*F2EWI7[N9
M6'#VC//=)`)'`>%!I/SGVS?9Q;_:3/C3YS[9OLXM_M)GQK?+OJ_2]F%&ZZ7^
MWTK:QH?3F2=H$C3R</\`5_UN7E7ONMYM=HMWRE<JV*GHLM'3//>Y<0&\1X20
M@FGSGVS?9Q;_`&DSXT^<^V;[.+?[29\:I/RW:?EE]C[OA^4V0=TNIL]^(LXW
MO,L8S7&DY*9M4R^4I@=3/JP\$X,+'[CG\N0=P0:3\Y]LWV<6_P!I,^-/G/MF
M^SBW^TF?&MNM^T71%RJV4=#J2AGJ'AQ;&QQR0UI<>SL`)^Y91VI;$RS4M[=<
MX!;:IS&PU''=>7G#0.':4$]^<^V;[.+?[29\:?.?;-]G%O\`:3/C5(OU]M&G
MJ$5]ZKX:*E+Q&)93@;QS@?R*\=HU?IB\T=766N]T=7!1L+ZAT4F>B:`3EPY@
M8!X^1!H?SGVS?9Q;_:3/C3YS[9OLXM_M)GQJAVK4ECN]3W-;;E!43=SQU.XP
MG/1/_)?Q'(KIH]7:;K9X8*6[TTLL[IFQ-:3WYB_TF.'Z.>*#0OG/MF^SBW^T
MF?&GSGVS?9Q;_:3/C6X6K:#HJ[UT5!;M2V^>KF.(XA)ASSX!G&3Y$NVT'1=H
MN$]MN>HJ*FK("!)#(XAS20#QX>`A!I_SGVS?9Q;_`&DSXT^<^V;[.+?[29\:
MH=OU+8;C7LMU%=*>:LDI65C(6N[YT+@"UX':""/2O#5ZZTC1T$=PJK]214DD
M[Z=LKB0#(S\IO+F$&E?.?;-]G%O]I,^-/G/MF^SBW^TF?&J#;-4Z<NMKJ+M;
M[U15%!3`F>=DHW8L#)WOV>''BO/IK6>E]3S3P6&\TU;-`-Z2-A(<!G&<$`D9
M[1P0:-\Y]LWV<6_VDSXT^<^V;[.+?[29\:WG4&M-+:=K&45[O=)0U+XQ*V.9
MQ!+22`>7A!]"X5.N-)4UGIKU-?Z%MMJ9#'%4B3+'/`)+<CMX'@4&D_.?;-]G
M%O\`:3/C3YS[9OLXM_M)GQK<J/7VCJZEFJZ34%'-!#+%#(]CB0U\A(8#P[2#
MZ%E*;4%EJJFYTM/<8)*BV?\`MD8=WT'`GOAY@?0@G/SGVS?9Q;_:3/C3YS[9
MOLXM_M)GQJA6G4UAN]2REMMS@J)Y*9M6UC"<NA<<!XR.6>"QU;M`T90QB6KU
M#111F>2G#G..#)'C?;RYC>&?.@T[YS[9OLXM_M)GQI\Y]LWV<6_VDSXUN3=?
MZ-=99[XW4-$;;#*(7SAQP)",AHX9)QQP`5QZP=%_(T5[^<5$+=+,8&SEQ`Z0
M#.Z1C(..."$&G_.?;-]G%O\`:3/C3YS[9OLXM_M)GQK;8-HNB*BDJZR'4E"^
MGI`PSR!QQ&'.W6YX=IX+E1;0]%5T=7)2:CHIFTD!J)RQQ/1Q@@%QX<LN`^]!
MJ'SGVS?9Q;_:3/C3YS[9OLXM_M)GQK>;#K32FH:MU'9K]0UE2UN\88Y._P`=
MI`/$CS+8D$D^<^V;[.+?[29\:?.?;-]G%O\`:3/C5;1!)/G/MF^SBW^TF?&G
MSGVS?9Q;_:3/C5;1!)/G/MF^SBW^TF?&O9H;76J;KKBKTGJ?3M+:JF"@[LQ%
M4=*2"YH`R"1R<?0J>I);/SCKO^[[/ZXT%;1$0$1$!$1`1$0$1$!836G_`,'W
M_P#^W5'_`*;EFUA-:?\`P??_`/[=4?\`IN0:WL,_^5.G/_)?_P"J];^I]L.>
MP;*=.`N`/0/YG_ZKUO\`TD?[;?2@Y(N/21_MM]*=)'^VWTH.2+CTD?[;?2G2
M1_MM]*#2-K]ZJ+1HBLAH`772YN;;J)C3ASI9>]X>4#>/W*46.,Z3^=&DKWIZ
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MO;NN)`[X>`^$(/RY04-13-UG7UQ)KKOI"6YU`)Y.FF<X#[F[H68DM%RN&L+;
M<+&\B]VC2E!74;=[`F<TX=$?"'L+F^<A?HLQTCBXED)WF[AR!Q;X/-Y%]:VF
M8_?:(FNW0W(P#CP>9!^9-/UD=18;+J:Z4KVZ>BU?5U5PB>TO$&^UO1N>,<FN
M)R?>M^TIJ6ENNV6LCH#9*Z":W2;MQH(Y0\L:]N[$]Q?N/<`020WM`R.2K@92
MMC=$&PB-^=YH`P<\\A<*>GH:9K64T-/"UF0T1M:T#//&$'Y[VGUEOM>NKW64
M=SBH[BYC'5EOO%*V2FKV"ED##&0=X@C,9'[3O(L[=[=2R7_95J'N":@K:R>)
MCZ,S/,=,T0#$;6$X;C'8`?"K'5T-LK*FEJJJG@EGI7E\#W@$QN(()'W$KTO[
MG>YCG]&XL.6DX.#Y$'YPU!+!':->6"HDC&JZS544M#`?]/*PR1F)[!S+0P/X
MC@,^7CQZ:G^1?FZZ2,ZR^>W3&`#^W+NEWNF\.YN?I<L+]&NAHGU+*IT4#JA@
MW6REK2YH\`/,!.AHNZNZ^B@[IW=SI=UN_N^#//""?[5__>^S_P#>.#^ERB-3
M27&R:`U%J"@9+/;;O4UEON<.]PB>)LPS@>EA_O!?K)_0/+2_HW%IWFYP<'PA
M<>CI.B=#N0]&XY+,#!^Y!^=MH,MQTU6TT]KBD>=8:?AM@W#C%4W<:UQ/_EOP
MNW5$<.D=H]FMM/J"VV6&CTO%3-J;A2]/&_$SN]#<COB079\Z_0KVTS]S?;$[
M<.6Y`.Z?)X%QEBHYG!\L<#W`8RYH)Q]Z"%7RZ6VHK=*W./6T%ONL5)4"GO8H
M&&V5.9")(MUQ[QXP/3SR0NVUUC+GL4UM(^V6V%M.:UD=301N;!5G=!,T8=Q&
M3X.&1PQR5MEI;?-!W/+3TTD&<]&YC2W/FY+M#:80]`&Q"+=W=S`W<>#'@00[
M:48Z/9IL\J(YZ>B+;A;GNJ98PYD>('=^]OZ0',A8W5MZAN&S:_;^J[/>W0U=
M"]QM]'W.(6],/RN)SG'W8*_04C*62-L<C(7L;R:X`@?<N`IZ`-<P0TX:[&\-
MUN#CD@DAN=@U-M8TK6:,?%4OH8ZEUTJZ6,B-L+F88Q[L8)+N0[%[M8U=#9-K
MMAO>I7LBLAM<M/25,PS%3U?29))Y-)9P!*J,3::$%L+8HP3DAH`_Y+Y4,I:F
M)T-0R&6)W-D@#@?N*#\VZVGH[G:=J-ZL(:ZP5#;=$)HQNQ5-2V9G2.9V'`."
M1SRLK:Z2YV':[HG2%8)):"V&NEME6\\9*66$[L9_UF%KF^;'D5\;%1MIQ3-C
M@$`&!&`-T#S<ES<*=TC9'",O9^2XXR/,4$K_`,HJT4E7L]K+K,9^Z:$Q="&S
MN:S+IF`ES`=UQP3@D<.Q8S:E>].6[4SJ$&A&H+C:NY9:NZ2?YK0TQ).=W!+G
MN).&CG@$\.=GDZ"5A9)T;V'FUV""NN6"BE?ORQ0/=C&7-:2@C^GJ>UULU)2T
M-1->=/Z2L!#9*<X?55$\9!#.([X1-<`,@CI!Q6-L%39;OM`TK3V.LAK+,;/4
MQ4])1@Q3V>,QM!$SVN)<XG(&2""<\3Q-S@BHZ??Z".&+?.\[<`;O'&,G'/@%
M\@@H:>262"&GB?*<R.8UK2\^$D<T$7TE54NAZ3:A/1->YM#<`VECDD,CI)71
M@1M)=DDE[@.T\5X[M;(="W;3LLUQM`JQ89J6ICO#GL@>YSR^:5CPTASRY[LL
MX%P(`YJZ/AHI`X210.#GAYWFM.7#D?.,<TJ8:*J:UM3%!,UK@YHD:UP!'(C/
M:@_,%H9-INT4D]TK;6RHN&F'P/IKRU['1T_2O+.A[TB1Q:1F+(.2...*K4.G
MJZY[!HK!<HWBO=96AL;QWS9&MWHP?*"&A46>&BJ'1.J(H)71.WHR]K7%A\(S
MR*[NDC_;;Z4'Y.FO%R?9SM69%,*NKFDLVX#R8:(1M=_QFERIVF[*RQ[2=*6-
MS&_YMI%T4C2,@OZ4;_I=E5[HJ/HA#T</1@Y#,#&?#A<ST!D$IZ/I`-T.X9QX
M,H)+HJ&$0[4GB)@<R[U@:=T9:.A'+P*?OMNI(]DVDZZIU-'/9WU5%T=M%`UA
MCS+P_M=[)QYN.5^F6BG;O[HB&^<NQCOCY?"OFY2]$V+<AZ-N-UF!@8Y<$$WV
MZSP4VG;%453VLIXK_1OE<_DUH<XDGR86IWZOLNHM8UUUT<Z.>EI=.5\=UJZ:
M,MB?O1GHF%V`'.!X^8>17644\S=R412-SG#L$9^]?&,I8XS&QL36'.6@``_<
M@_-]VKJO1VEM!ZWH(GO=4:?=:)MS@=YT1?`?N?D_<L_26(Z:U!LVLSQB:"S7
M%T__`)KHPY__`.1*N+HZ1T38G,A,;<;K2!@8Y8"Y.%.Y[9'",O:"`XXR`>:#
M\PT]WTU<]B-GTO0NBK-7N+&T=/3QET\4W3EV]D#O0&YR<\EE:N[NM>TC6S'Z
MOLMD>^HIMX7"A[H,Q$`R6\1@`_\`,+]"Q0T4+MZ**"-V,9:UH/\`)?'T]#(\
MO?#3N>>;G-:24$$NU%77':/7:DTY.*FZ6FST%?2=#WD=;&0>DCQX'L)Q]RP&
MG[M;XK'H>\W&1E+0'4];/(Z;E&T@GCZ5^GF-IF.WF-B:[=#<@`'`Y#S+K,%"
M6!AAIRP$D-W6X!/:@_/][FTY>[SK:]6N"METF^RPTMPJ+7!_I*GI@1(P'`?N
M-&7'P9\*RNA;PY^T.RT+;O9=6,?02L;=:.F,-311-`+6R[IW=T\!@\<^#MN#
M!3QL$;.C:P?HC`'H752T]!2;_<L%/!OG+NB:UN\?"<<T$GU-!>ZC;G$RPOM;
M:H:;!=\I0OECW>Z3R#7`[V<<<\LJ<U$K:+25HDDJJ:W5\&MI^[YY(P^F@G#3
MES8^&(P-WO3Y5^H_[#I.E_L^DQN[W#./!E=;H:)X(=%`07;Y!:TY=X?.@@>H
MKM'=-$2ANI[3?)8KS;RY]NI.YQ$TR'`<,G.2#CS+PW"DN-NU)M"UE:&2SR4%
M?)35]*UV!/1R0C>/]YCL/'F*_1+8*%K2UL-.&D@D!K>)')=@;3#I,"(=)^7C
M'?>?PH/S9-6U&D-%;/-?TD3WF*VS6RI#.9#VO=%]P>"5SOMN?H^GV54\UUI+
M55,AKIZFLK8>FCCEE8QS]]N1O<7;H^Y?H\QTCH1"60F(<F$#`^Y)HZ2;=Z9D
M,F[RWP#CTH(1?+K:KC8K%/5:T@-5379[Z>_6VW-%'23",;K)XW'M!.#_`-`5
ME-!W'Y4IM>P30V>O$,8>Z\VV$LBK7F%_,'(WVCF6\./WFP&GH3"^`PTYB?\`
ME,W6[KO..17*".DIX1!`R&*$#`C8`UH^X<$$!O;(XO\`)GM,K>CB>64>](6C
MZ<<3X5V7B^1W+0VLJ<ZRL=\E%L<]L5OH.YWQ@/:"XG)R.(&%>S'2&$0%D)B'
M)F!N^A<&T]"T.#8:<!PPX!K>(\!01"KNNGM27;9W2Z3EAJ[[0UD$M5-2Q'_-
MZ5L>)0]^,`'@,'M\ZO(Y+HA92PYZ%D,>>>X`,^A=O21_MM]*#DBX])'^VWTI
MTD?[;?2@Y(N/21_MM]*=)'^VWTH.2DEL_..N_P"[[/ZXU6>DC_;;Z5)K60?\
MHZ[X.?\`^/L_KC05M$1`1$0$1$!$1`1$0%Y[C1PW"@JJ"H#C!4Q/AD#3@[K@
M0<'S%>A$$F&P;0(``AN6!_\`W'>Y?>H?0/T-R]==[E6$02?J'T#]#<O77>Y.
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M!HS9EI?1MUENMECJVU,L!@<9J@R#=)!Y'RM"WA$!$1`1$0$1$!$1`1$0%UU$
MS*>"6>3.Y&PO=CG@#*[%\<`X%K@"#P(/:@GXVKZ7(!W:[C_]$?$OO6MI?]FN
M_P""/B6Z?)EN_P#`4O\`P6^Y/DRW?^`I?^"WW+3KX?\`C/G[,NCB/Y1Y>[2^
MM;2_[-=_P1\2=:VE_P!FN_X(^);I\F6[_P`!2_\`!;[D^3+=_P"`I?\`@M]R
M:^'_`(SY^QHXC^4>7NTOK6TO^S7?\$?$LKIS7-DU#<3;[>*D3",R?VD8:,#&
M>T^%9_Y,MW_@*7_@M]R[(:*D@?OP4L,;\8WF1AIQ]RC:V#,?+6<_'V2K7'B?
MFM&7A[L!M!U#4Z<TX^KM\,<]TJ)HJ2@@DSNRSR.#6@X(X<R>/(+0[OM/NL6B
M]-7>F%MH[A77$V^X=V1O?%2R-#@\[K7!V`6YYG@5O&L-%V_5U=:7WB:62WT#
MY)31-):V9[F[K7.<""-WCC'A6M2[):*!O162]5=K@BN;+I21LC;**:9L>X<;
M^<@\#QSR5#0UB3:QJ)NFZ^O8^PROIKU!;F5T<4O<[V/:2YYC+M\;N!QSQXXS
MA>NBVKWEEIU-/-%:+K+;YJ6FH9Z`2113S3<`US7DN`;X>1P0%G:G92RJIZV6
MIU-7RWBLKZ:NFN+H8@[?@:1&!&`&@#>\'%>EVR^DKX+X[4%\K[I7W:.*-]86
M1PNA$1WHRQK&@`@\<_=X<AY9=0:[M6HJ#3%SFL4];>:>5]OJXJ:5L44T0#GL
MD9OY<W=SAP(.<9"Z-)7_`&DZD%ZZ*ITO`;9<9;<=^CG.^^,MR[A)R(/+FMBL
M.BJJFO\`!J#4.H:B^W&DA=!1NDIV0,IV._*.ZS\IYY%Q]"RFD],P:;^6>@J9
M)_E.Y37%^^T#<=)C+1CL&$&N[+M0:MU-!4W*].L[:&.::E;'202-DZ2-X;O$
MN>1NGCPQGDLKH'4E;J+YR=VQ0,^3;U46^'HFD;T<>[@NR3WW'LP/(O=HW34.
MEK7-;X*F2H;)535)>]H!!D=O$</`M>M^@KO:;E<JFS:TK:*FN%PDKYJ444$C
M2]YR1O.:78P`.?8@\=LVB5=7M*FL#Z2`:?DFFH*2M`.^^LA8Q\C2<XQWQ`X<
MPM0H-K>I)Z^EC,VG973WCY/%N$,T<^YTA;O](7%@X>'_`/2VVDV.Z>HZ6W2T
MU14LO='5LJ_E0O+I)9`_>.\PG=P>1P.2XQ[*":=UKGU7<'V)]>:Y]N;3Q,#G
M[^_CI,;^,X[?0@\=1K76=;:]0:LLL-I;8[/431MHZB.0SU<</^D?OAV&$\<#
M=/+CY<7>MJ]V%WKV6^Y:<ME!%;::OIFW:.4RU'2Q"3<&Z\<1G'+M"VFNV9.E
M?=*&AU/74.GKM.ZHKK9'#&X.<_\`+#)"-Z-KL#(&5F:/0MLI+E?:N*1P@NM!
M#0&FW!N0QQQE@W<\^![?`@U'4NTR^V_3>FZ^@LD3KG6T1N=PI)=X]!2,:#(X
M<003O#=S]X*]VNM5:NM4UCKK#/89K1>ZVFHZ3NBGE=(TRMR'N+7@%O#D!GBN
M5!L?T]F'Y>FGO+::ABH*9LQ,0AC9GEN.&<EW:LE'L]@&G-,6*6[U,L=@N$59
M!*YC=Z01EQ9&[R`.QD=@"#'27_6]QU)+I2U366"NME%'/<:V6GD?$^63.XR-
MF^"&XXDDGWZS4;6+Y)\@TXDL-GJ*A]93W":XMD?#%-`YH[TAS3AV>&>TX[..
M_:@T74UFH':CL&H*BQW2:G%-4R1T[)V3Q@Y;EC^`<.QW@739-G%KLMQT_6T=
M94N=:&5.>EPYU3)/C?D>[PY\"#6M/;2;[<8]-&>FMQ;<;W46V2H@8_HJB*-N
M1+#DY`)R..>16-T#M1O^I)[>*FXZ?$U0Z3-LAH:D3NW0XAK92XQ@G=SD\./A
M6Y4FS:BI+A2U<5QGW::]SWB.(QMP'2M`,8\#1C(\Z\^F]G=SL%OI[-3ZUN#[
M)%OM=0FDA:'L>27MZ0#?&=X\0<CL0870.T'4%\U#1T%QJK*V6?I!5VIT4M+5
MT)&2T#I#B;EQP.'/L5A4YM&S>:ENUFJ[IJBLNM)9'.=;J>:"-KX\C`WY1WS\
M#S<E1D!>>OJX*"AJ:ZI<6P4\3I9'`9PUH))QV\`O0OC@'-+7`$$8(/:@T*@V
ML:)K[+=;U37&9U#:^B[J>::0%G2.W68&,G)'8DFUC1,>G8=1.N,PMLM4ZD9)
MW-)DRAN\1NXSR[5N[:.D:QT;::$,?C>:(Q@XY93N.DZ,1=S0[@.\&]&,9\.$
M&D77:SHFU45LK:VXS,@N4!J*9PII';S`<9(`X<?"O57;2M)4&IJ;3-372MNE
M0Z%D<0IWD$R@%G?8P,[P\RVUU'2/:UKZ:%P8,-!C!P/)P7UU+3.E$KJ>(R#&
M'%@R,<N*#5+7M&TK=-5S:4HZZ5]WBDEB?$8'@!T>=_OB,<,%=.U#4MVTS:J&
MIML$;8IZIL5572T\D\=%%C)D=&SOCX/`MQ;34[)3,V")LAR=\,`/'GQ6"U=I
MN:_-H)Z&\U5IN-!,9:>I@`>W)&"U\9X/:1V%!/ZO:1=*300O<USL$CW71E&V
MXTI=+&8#Q=+T&\'[[1Q,><XX\EVW?:+?*31NE+D'V2BN5SK&4M<ZL)=#2;S"
MX.<`\%G>[CL$\`[[U[X]E701"LIM1SLU`:V6L?<74<3F.=)'T;V]`>\#=W[\
MDI:=D=LMM%;K<RYSST-#=&7-D4T$9WWAFZYKB``6GGRX<N2#);-M85VHXKY'
M<C;I_DNI$3;A;"XTU2TMWLLR2<CD>)YA:7;=K-YCLU;>KP;:W=H):NFMHH:B
M"63$@8S$KSN/`R-[='#/D*M+*.GBI'4E/$VGA+2T-@'1[N>T8Y'RA3N398VX
M[\6I=3W&]T\5'-1T0J&,:^G;)C>>YXXR/[UN'.\')!B*K:%K&VWEFD+A0V=^
MHZR6E%'40B04S8Y0XN+VEV]ENX1@'CGL[=GL&KKG6Z/U)75U+2QWBQ2U=+.V
M+>,,DL+-X.:"<AI!'#.>:QO5;),9+E7ZHJJG4C9J>6ENIIHVFGZ$$,:(QWK@
M0YV]GGE;%8]&P6O2UTLCZ^:IJ+HZHEK:U[`U\LLP(<_='`<,8'D0:+2;6+C!
M?-)T]VHZ46NZV:GK:VHB:YO<LLLAC:[)<0(][=''B-[.5QM^T'65ZKK+;;8R
MR055PJ+C&Z2I@E<QK:=PW>#7@Y()SY5M-!LSM,$M.:JIEJX([`+$^&1@#9(@
M_>WSX'9]'-8FW;)3:(+,+/JJNHZJU.JC%4]SQ2.<)R-X$.!'(8Y=J##7C:GJ
M.WVIL53!::*[4M\^2:Z62.6:F#3&7B5C6D/QPY<3Z5E&:]OT.DSJONRRW>W4
M5>([CW%2SP.;3D-!+!*[)>TN!QR(..!"R,VRVG^3*.&EU!7Q7.&Z&[27)[(Y
M99JC=(WB"-W`SP&,<%[:C0M?=645-J;557>:&GJVU3Z:6EAB;.6CO6/W`,M!
MXX(XH,KH&\7;4%@9?+G!3T\5<\S44$0.\RG/Y'2')!>1Q.,`9`6SK7-&:99I
M2BJ;;25TTUN=4/EI:>4#_-6N.3&T]K<DD9Y96QH"ZZB:*F@EJ)GAD432][CV
M`#)*[%QD8R1CHY&AS'`AS7#((\"#0>N#9OXTTW_"E^%?>N#9OXTTW_"E^%;)
M\T]+>+=H]1B^%/FGI?Q;M'J47PH/%5:]TE26BVWFHO,3+?<GEE),8WXE<#@@
M#=R.7;A>YVI[$W4K-+NN#!>GQ]*VEW7;Q;@G.<8Y`]J],ECLLM+3TDMHH'TU
M.<PPNIF%D1\+6XP/N7<;;;C<!<S04IKPW=%3T+>E`QC&_C./O0:=/M:V>4\\
ML$VIJ=DL3RQ[3%)P<#@C\GPA9;3.N=*:IJY:.P7B*MJ(H^E>QC'MW6Y`SWP'
M:0O8_2VF7O<]^G;2Y[B7.<:*,DD\R>]7JM]EL]ME=-;K30T<KF[KGT].R,N'
M/!+0."#4-J6JKMIAEI[A;#3455,]M9=*BEDJ(J)H`+<LC(/?$XSR&%K5XVE7
M2WZ%M=WFN%A;455<^F=6TI-3$8VM<[I&PAP=DD-!;GO<Y*WW5NF*F]5-ON-L
MOM5:+G0EXCFB8)8WM>,.:^)W>N'#AX%J3=DD5/0Q"WZBJ*>YN?5.JJM])%(V
MH%0&B5O1$;K1W@QCEQYH.K4FT*]4-!H[H:BPVZKNQDCN$EP>7PT4K(VN<TEK
MQND$XP3PR`LUH+6E9?-,7JZ7**D>^UU$\/=-!O&GJVQMWNDCWLG!Y<RO)9]E
M%KM@L=/W?+4T5GK)ZFGAG@C.^)6`%CR`-[!&0<9[.P+?YZ""2V36V'?I89(G
M1`TIZ)T8(QEA'Y)&<@CD4$:M^U2_QV*IKKD;5)<GTD$M+;&T512R;\TC6-<7
M2'$D8+N)9V]JR4FO]6P7B31DU':':H[OAIXZEK9!2=$^)TO2%F]O9`:1C/$\
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M`#C@2%QC[,^;AS66TIM&KKSJ>Z4-11T\5KEAJ)K)4M!S5-@>62;W'CQ&1@#A
ME>BR[/+[9;/%9*#7UPCMD43XF0=PT_>AV<]]N[V<N)SE?*#9%INU/LE59WST
M5?;3A]2UQ>:EI86/:YI.!O9).`$&5T=?;_JG9O;[Y3?)U/>JR(N;TD3S3M<)
M"WBT.WL8'AYK1AK_`%[#IC5U_J1IYT=@JY:'HXZ:8&25CV-WN,GY/?\`+FMT
MT5HFZZ59044.L*VJL]&US6T$E'`UK@<GB\-W^#CGG_)<9]G5'+IG5-@-QG$5
M_KY*Z67<;O1.>YKBUH[1WG;X4'ALVTJEOVN;18K+/3U-%44$L]4\PR,>R5N,
M`%V!CB>P^=>F\:AU/<M9UVEM*NMM+\FTD=15U5?$^4.?)^1&UK7#`P,EW'S<
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M$:*2V:CK*&>AN557TTK*>-_1&<`%@:X%N!@XX=JW;3MON=MHGP76^SWB<R%S
59YH(XBUN!WN(P!V$YY\4&61$0?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g674535.jpg
<DESCRIPTION>G674535.JPG
<TEXT>
begin 644 g674535.jpg
M_]C_X``02D9)1@`!`0$!L`&P``#__@`P35),3%]'4D%02$E#4SI;04)"3U14
M75)%0UE#3$5$7S-0245#15],3T=/+D504__;`$,`!P4&!@8%!P8&!@@(!PD+
M$@P+"@H+%Q`1#1(;%QP<&A<:&1TA*B0='R@@&1HE,B4H+"TO,"\=(S0X-"XW
M*BXO+O_```L(`%<`D`$!$0#_Q``<``$``P$``P$`````````````!`4&!P$"
M`PC_Q``Z$``!`P0!`P(%`P`&"P`````!`@,$``4&$1(3(3$'010B,E%A%2-Q
M%C,V0F*A0U)35')T@8*1L;/_V@`(`0$``#\`_2-*4I62]2\NBX9B4V[.K3\2
M4EJ(T3W=>(^4?P/)_`-1O2/*!EF"6RXNR`].;1T)G^L'4=B3^2-*_P"ZMMNF
MZ;INFZ;I2E*4I2E<\RY-M7EC[U\?DIMD"QKEK2U*=9`(=[JTA2=G0UWK\QKS
M!^\RKP(^-KG2)22U;T.NO2Q`;5V6$H45;4I/E7G?C53_`$Q8DXYFEMMF3LRH
MD6Z+#3D(R'8[B.79#JDH4"GOH#EY"B=:[UUR[0'8N3R+3:+;)N!7<U-!MZYR
M1TF$1XJU:4'AH;>6=GE[#1W67C9*E=F1-<L)^(45J2U^IS$\T<&%HU^\?/64
M-[[Z'8=Q4YV>XNV,W6-!CICR(\5Y#;L^;S3UY*F0"3(">W'9V0.^MC6ZO;*W
M'N-]O]G1#0^["AO.Q^C<YFPX@I2D.#K'LLJV-$=@>Y\UG,>O[.0O-MQ+*J,E
MQY+*5OW&:?K:?=;5H/#8XLC?\U(AST2Q$B/VUQM<RWHE?$Q[C+`:+D%^0E("
MGB>0+:1X(UR\=J[SC3BW<=M3KJU+<7#94I2CLDE`V35G2E*4I2N7>H\.-/N&
M019;ZV6%8NZ5.)&RG3V]_P"5?GVU7RX1(2+<YZAR,;BA((8CV];>_;8+/U=O
M<G9]Z^+3=E+SB,9D7&ZR4+2_.ODQOI:TK:&VD;)Y+6$C:B5$]@`-UVS,LPNV
M$QKS.@PXSTEZ]LQWI,I"UM1A\#'Y*5P[]S_Z/8^*@1?4O)[RBR6G';)CTB^R
MX[TE]PK*HP;;)">(!VE1X_2H[';[[%"/6S)'(@#F+VYPW)D-VMM#"E)4^ET)
M6A?S?,.Y(`T=E/WW6]]0\TOV#HQIIJ%:53;A%D*G$,*"0XTTE0"-*!X[)'??
M:L-`]<+G+A03&M=H1,3"F/2VRPK276FU*;*/F[)*=>=_W@#6@PK/;SGUMOKA
MAVF';K=:2)`2V2^X^IE8VCYOD;'?6P3H:WW.NPXM_9FS_P#),_\`S35K2E*4
MI2L=>V;O%R]%VA6-VYQ7+:8JTM/M(*5=7EW#BAL$?:L5>\*9N3B78N!W6U.<
M0E7P<V$6W-#0Y-.*4@G7;>@=:&Z]\?Q%VSW"/<'<0OMQ?BJYQDRI\)++"]:Y
MH:;4E`5KW()I?;#DUZ<N2EV2^VY3]Q3-9<@W"*#H,--E#B2YQ6-M[T?Q^16=
M;]+GHD2`+99LEM]QBEWE<&)\-+CH<^I)`<``]AKV)WNKF-A;T2/B4:'B5X:;
MQR2J2SN;#4J0M1!5S/4[;(]JGY[CUTS23;)$S%[Q%,!#Z$!F7$5SZJ0D[VY[
M:K,.^EI48;C>-7MIUBVKMRUHDPOWTJ0I'44.IV4`K7YT*FVO`[E8Y3DRRXY>
M67'+2JW/L&5##4H],I#B].=E;XDZ]Q^374\95?8R8EJGV=IF'&AH0)B)07R6
MD!/'AK8\$[WJM)2E*4I2E*53Y5?8N-V*7=Y:5.)93IME'UO.$Z0VD>ZE*(`_
MFLJQC&2W&+^J9%FUVMDIQ/47$M:VFH\1.M\-J0HJX^ZB>_>LSA=GR?)HTR_0
M/42^L6E;RT6KJ])Y;B4'B77`4@$%0.D:!UK9K48IZ@Q'WXV-Y&XW%RU,E<-Z
M&TA1ZBTIY=5.O#:DZ4">W?7M70*4I2E*4I2E*5R[-;DF%G]JFY5$E,8K;D=6
M)+0CJ,&:KMS>*=E'$'2=C6R3NIV7ST9;-@X79I:78<UH2[K*CN!240M]D!0_
MO.GY1_A"C6<PV]3<>O\`D+3.%Y'%QN2\E^''3;5J4V[K3A2E/9*%:!`WY_FK
MRU&$K(KIZC9+&198S+8@P/U!L,.);'UNKWWY+4>*1Y"4_FNDI(4`I)!![@CW
MKS2E*4I2E*4KG'J@[>_U+'8&.Y'+@W*X2@S\(RAM25LCYG725))3P3[]_(&J
M^65-7C"XD?(7,EN=XM+#P1<X<\,J"HR_E4M'!M)*DDA6N^P#6PQC'\=LC,A_
M';?%BLW!29#ACC27.W8CV`UX`[=S]ZMY0>^&>^%Z8D<#TRZ"4\M=MZ[ZWK=<
MRP>Q6_+[<N]Y:IZ[WE"W8<J),`#-O<&TN--M#Y4]M:6=J((.ZN/3R;(M[L[!
M[HZIR=90GX9Y?F5"5_5.?R-<%?E(^];JE*4I2E*4I6"RTIL.<V'+)"0J`\TJ
MT2G%#?PQ<6%-.#[`K'!1_P`0K*9O<&\LRM5K?QN\WW%[.5MR&[<A)2_.*=<5
M$K3V;2H^#]1_%6=KS&+AF,QH3F%YA'M4%*6A(F-,JZ:2O2>2@[X!4`.WC56?
MJO>[\Q;VL>P]MQW))Z%NH#1`4RPWKFYL]@22E(WY*OQ5+"N.4V[,YEZA8%?!
M;[E&2)T93L??Q"-!#J/W-=T_*KQX2>]3,8N<S+O4=V["SR+5'L,1VWR.NM"E
MO/NJ0OI[02G2`@$]]@J%=0I2E*4I2E*5!O=KA7NTS+3<&@[$EM*:<3^#[C[$
M>0?N!7-\.O$?T]LHQC)K;<8ZH;CG3N3$%R0Q.2I94'.3840L@_,%=^U0O4G.
M,=R#"[C:+2Y/?G2"R&FS;)*.1#R"?F4V`.P/DU<WVYP\(SJ=D-^6?TJ\0T--
M2R@J,9UD*/0&O[JP2H?=0(^U?6[9\[<(2X&(V>[OWJ3^U&5*MKS#+)/^E<6M
M(`2D=_N>P]ZU6(8_'QFP1;3'6IU38*WGU_4^ZH[6XK\E1)_\#VJ[I2E*5S+*
M?4Q^PWJ\POT:*_$M/PQ?<5<0T^X'0#^TT4'F1OQR&ZNY>>6@W)%MMSZ'I+=T
M:MTH.MNMI;6HD%*5<"E2^WC>O?8JNN?JQBL>RS[C;GGK@[%CJ?2PF.ZWU4I6
M$**5*1H@*.B1O7O5XWG.,KNC5J5<%-3'"E/%V.XA*5E',-J64A*7./?@2%?B
MH5B]0+1D&5-V.SA4AA4!R8910ML?*XE`"4J2.23R)"@2.U3V\VQER\KLR+D#
M-0XMK71<Z:G$#:VTN<>"E@>4@D_BO.-9KC>32%1K-/4^\&$R`E<=QKDT3H+3
MS2.0WVV-Z-9%OU1>7>UP3:(*F$WA5JX-70*F$ASAU!'X`E/O]78;/M6D9]0L
M.>3-6F](2W#:4^XXMIQ"%MI7P*VU%.G$\OEVC?<C[U5WS(<`S"S/V:YS%*BN
MI>6M#K#K*VBP$N+/S)!0I(*5:/<@]MC=6\;/,5?N$.V,W)1E2@V&4JCN)3R6
MCFA"E%/%*RGOQ)"OQ5=9_4RP2;39)=T<5;Y-T9;=2P&W'4M<UE".3B4<4[4-
M`JU7QA>IUHD1+HEQLLW6%\<40U\P'Q&*M\7"@))(2"4C92#5G9\_QVXNVV$Y
M+Z%QFMM'HEM9;0ZXV'`UU>/#GQ/T[V?M51F?J))QR\7&"U:84ABWP&YSSC]Q
M$=:TJ*P4MH*#S4.![;&]@5?LYSCCEV9LYENMSW4[#2X[@'+I]0HY\>',)[E.
M]U#B>I>%RXKTEF\'IM--O:7&=0IQ"U<4EM)2"YM7R_*#W[5)1GV*N?I@;N*U
MKN3SC$9M,9TK+C9`6E2>.T%)4-\@-#OXKZ1\.M"<HN>1RH[$N7,+!07V$*,8
MM(X@H41L;\_]*A?T$B?[^]_:#]=^@?UG^S_X?SYJK<]++>Y8X]G5=)/29MTJ
M`%A"=D/.I<*OY!2!KW%>4^EUO7D:KW,N+D@O.)D2&51FOW'^GP*PO7)`/GB#
MY\'53L2P,X[=HD]=_F7!$*WJML5E]IM(:8YI4!M(!41P`V:]6/3UAJ[)D?K$
MQ=L9F/7"/;5)1P9DN!04OGKD0.:R$DZV?>IF,X5&L$ZVRVISSRH-G1:DI6D`
M*0E?/F?S[:J&?3JU]/DA[4L7LW@2NBGJ!1=YEK?GCW*?/BJ:)Z-V6/%FQ/U&
M267&BU%4EEI#D8=5+@/,)Y+(4A/GMH=Q[UYS+`[O>K9:;8_<I=UD*N?6EW%Y
M;;/P\=2"AU"4)`^52"4\1[G9-:.)ARX.12KG!OTZ-;Y4D2W[:VE'3<>"`C?+
M7()(2-IWK8%9I?I##5'ML;];D*:@QX[*`Y';64EIPN`H)[M\C]7'SH=_:IR?
M3%E4B0J3?YKT8F>Y&C=)M*8[DH+2XK8&U:"R`":];5Z56RVWZ)=6[@ZXAA;+
MQ87':/)YML("@L@J2#Q!*0?/OKM6C>P^T2LHDY%.C,3'G8S+#;<AA"PSTU+4
M%))!()Y_Y"J&1Z<MJRES)1=7GI`E.2VVW64*4"MHM]/J_5TQOY4^!^?-4%F]
M)%S,8M[.27:6;DQ`8C,("6BF#P6'"D:&G/F2!\V]CM^:U>/8!"LLVT36YJW'
7H'Q:E:80VEY;_#D>*0`G73`'^9-?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g560613.jpg
<DESCRIPTION>G560613.JPG
<TEXT>
begin 644 g560613.jpg
M_]C_X``02D9)1@`!`0$!(`$@``#__@`E35),3%]'4D%02$E#4SI;04)"3U14
M75)%0U1!3D=,12Y%4%/_VP!#``<%!@8&!0<&!@8("`<)"Q(,"PH*"Q<0$0T2
M&Q<<'!H7&AD=(2HD'1\H(!D:)3(E*"PM+S`O'2,T.#0N-RHN+R[_P``+"``E
M`+4!`1$`_\0`&``!`0$!`0````````````````8'!03_Q``P$``!`@8!`@()
M!0$``````````@,!!A95D]($!0<1$A,Q,S=A<G6QP2)"0V*!D?_:``@!`0``
M/P"T[?RM+_4I'Z!U#G]-1R>7R.$VX\\XZY%2U1]<8_J]9143*ED9RN["B94L
MC.5W843*ED9RN["B94LC.5W843*ED9RN["B94LC.5W843*ED9RN["B94LC.5
MW843*ED9RN["B94LC.5W843*ED9RN["B94LC.5W843*ED9RN["B94LC.5W84
M3*ED9RN["B94LC.5W843*ED9RN["B94LC.5W843*ED9RN["B94LC.5W843*E
MD9RN[$7W$E[HW2T=-5T[@PXT78NP7Z-UR'F\/)X?N^,?^E;VP]W,K_3FOR50
M`````````!GW=;V72/F?^S9U^V'NYE?Z<U^2J``````````,^[K>RZ1\S_V;
M.OVP]W,K_3FOR50`````````!GW=;V72/F?^S9Y>W<RHXTAR]QX\%2_1\%M/
MF@]X>/\`GE*2K$6Y>>&HJQ%N7GAJ*L1;EYX:BK$6Y>>&HJQ%N7GAJ*L1;EYX
M:BK$6Y>>&HJQ%N7GAJ*L1;EYX:BK$6Y>>&HJQ%N7GAJ*L1;EYX:BK$6Y>>&H
MJQ%N7GAJ*L1;EYX:BK$6Y>>&HJQ%N7GAJ*L1;EYX:BK$6Y>>&HJQ%N7GAJ*L
>1;EYX:D1W(F!/+1TR$.&I'D4]_+X^/C!']?@?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
